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ABSTRACT 
 
Background: When analysing relationships between breast cancer risk and vitamin C 
intake, few prospective studies have included vitamin C intake from supplements, or 
excluded general supplement users in dietary only analyses. For the first time these 
relationships are explored in UK women, and from diary recordings. 
Methods: The UK Women’s Cohort Study was used in prospective breast cancer risk 
analyses examining exposures from: general supplement use; fruit and vegetable 
intake; and dietary only vitamin C intake recorded at baseline using FFQs and 
additional questions for 33,000 women (~1,000 cases); vitamin C contained in 
supplements recorded by diaries at phase 2 for 11,000 women (239 cases); and total 
vitamin C intake from diet and supplement recorded by diaries in pooled UK nested 
case-control studies (851 cases 2727 controls).  
Results: There was no evidence of dose-response relationships between breast cancer 
risk and vitamin C intake from diet, supplements or both, or from fruit and vegetable 
intake; risk estimates were non-significant and generally close to unity. There was 
some evidence that risks differed by menopausal status and supplement use. There 
were no significant associations for non-users of supplements or post-menopausal 
women by continuous estimate or intake category. Risks were raised for pre-
menopausal women who were: frequent users of supplements containing low vitamin C 
(1-60mg/d) (HR=2.37; 95% CI: 1.32, 4.27; p=0.004); daily multivitamin users (HR=1.51; 
95% CI: 0.90, 2.54); or general supplement users (HR=1.14; 95% CI: 0.91, 1.43), 
compared to non-users of these supplements. Women with a history of breast cancer 
were significantly more likely to be high dose vitamin C users (≥1000mg/d).  
Conclusion: There was no evidence of significant associations between vitamin C 
intake per se and breast cancer incidence, even at high doses. The increased risk for 
pre-menopausal women taking supplements containing low dose vitamin C may be due 
to other ingredients.  
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CHAPTER 1 
1 Introduction and Objectives 
Breast cancer is the most common cancer in women in the UK, and in many other 
western countries.3 4 The cumulative risk of being diagnosed with breast cancer in the 
UK was 6% by the age of 65, and 11% over a lifetime, based on cancers diagnosed 
between 1994 and 1997.5 The latest estimate of life-time risk increased to 12.5% (.i.e. 
1 in 8) based on breast cancers diagnosed in UK women in 2008.6  
Whilst age, genetics, hormonal and reproductive factors are established breast cancer 
risk factors, there is evidence that lifestyle factors such as diet, weight and exercise 
can also contribute to risk (as discussed in chapter 3).7 Initial research using 
retrospective recall methods indicated that fruit and vegetable intake probably reduced 
the risk of many cancers, including breast cancer.8 Subsequently the 5-A-day fruit and 
vegetable initiative, based on the World Health Organisation (WHO) 
recommendations,9 was introduced in the UK in 2001 to encourage healthy lifestyles 
with a view to reducing cancer risk in general, as well as the risk of other chronic 
diseases. Since then, however, an increasing number of null associations between 
breast cancer risk and prospective recordings of fruit and vegetable intake have been 
published; consequentially overall there is no convincing evidence of a protective 
effect.7 10-13 Similarly, studies of antioxidant intake have often produced conflicting 
results between observation methods.7 Furthermore, a recent Randomised Control 
Trial (RCT) using several types of antioxidant supplements found no significant 
associations with breast cancer incidence.14 Although media reporting of conflicting 
studies may have caused many people to ignore dietary advice relating to cancer 
risks,15 many health conscious women remain interested in such information. For 
instance, a study of UK women who were sufficiently health conscious to attend 
mammography screening for breast cancer, reported that the majority were interested 
in obtaining dietary and exercise advice at these clinics; many of these women were 
interested in advice about how to reduce risk of serious diseases.16  
In addition to maintaining healthy lifestyle behaviours, many health conscious women 
tend to take supplements, moreover levels of use in general continue to rise in the UK 
(section 2.1) and Europe, as well as in the USA. Even though the majority of women 
are likely to use supplements for reasons other than specifically reducing their cancer 
risk, research is needed to determine whether some supplement types may increase 
the risk of cancers. The 2007 World Cancer Research Fund (WCRF) report has 
systematically reviewed research on cancer risk and diet and supplement use.7 Some 
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of these and more recent studies are discussed in section 3.6, particularly in relation to 
vitamin C which is a common ingredient in supplements and a common micronutrient in 
fruit and vegetables. The majority of research on supplements has been undertaken in 
the USA; however it is important to evaluate the effects of supplementation on different 
populations, with different diets and levels of food fortification. No published research 
has assessed the effect of supplementation on cancer risk in the UK population.  
The aim of this current research is to explore associations between the risk of 
developing breast cancer in UK women and intake of vitamin C from diet and 
supplements, and dietary supplements in general. Associations with any supplement 
use (chapter 7) and with vitamin C supplementation (chapter 8) one of the most 
popular supplements, are assessed in relation to breast cancer risk. The analysis of 
vitamin C intake from all supplement types categorised in relation to recommended 
daily allowance and high doses of vitamin C (see section 2.2.1 for definition) leads onto 
a brief analysis of risks relating to the use of multivitamins (chapter 8).Total vitamin C 
intake, which includes both supplement and dietary intake, is assessed (chapter 10) as 
is dietary vitamin C intake sub-analysed by users and non-users of any supplements 
(chapter 9). The analysis of non-users provides a clearer picture of the effects of 
dietary vitamin C intake on breast cancer risk, without the influence of the variety of 
different supplement types taken by many of the women. Breast cancer risks in relation 
to fruit and vegetable intake, the main source of vitamin C, are also explored in chapter 
9. 
Since UK women generally obtain sufficient nutrients from their diet, it is hypothesised 
that women who maximise their intake of vitamin C by taking high doses of this water-
soluble supplement on a daily basis may have a higher risk of breast cancer due to 
pro-oxidation mechanisms or to the reduction of beneficial apoptosis. These 
mechanisms are discussed in more detail in section 2.2.4. Conversely, women who 
have a low vitamin C intake may have an increased risk of breast cancer particularly if 
they have high levels of damaging free radicals and generally have a low antioxidant 
status.17 Consequently, the analysis of a population with a wide intake range may 
produce a U-shaped risk curve. It is also possible that vitamin C or other micronutrients 
could increase breast density which has been linked to breast cancer risk. 
The analyses use pre-gathered prospective cohort data incorporating a wide range of 
intakes enabling important vitamin C dose-response relations to be examined, which 
would not be possible using RCTs where only one or two doses can be evaluated at a 
time. The thesis is original since no research on any of the above associations has 
been conducted on the UK population. Furthermore, the total vitamin C analysis utilises 
both supplement and dietary vitamin C intake recorded by diary as opposed to 
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questionnaire methods used in previous research in other countries. Evaluation of 
vitamin C intake by diary method in comparison to the questionnaire method is covered 
in chapter 5. Fruit and vegetable intake is also evaluated here. 
Chapter 6 explores cross-sectional associations between taking supplements 
containing vitamin C and a personal or family history of cancer, primarily to identify 
whether these women are more likely to frequently take high dose vitamin C. Women 
who reported a family history of breast cancer, who may have had different health 
behaviours and cancer risks compared to other women, were identified and excluded in 
some sensitivity analyses of risks. Unfortunately numbers were too low to power risk 
sub-analyses by family history or by those estimated to be genetically at raised risk or 
high risk of breast cancer (defined in section 4.7.6.3 and 0). Other potential 
confounding characteristics of women are discussed in sections 3 4.7.5 and 4.7.5.2.  
All the analyses use data from the UK Women’s Cohort Study (UKWCS), either from 
the baseline FFQs (35,000 women), phase 2 diaries (12,500 women) or phase 2 
questionnaires. The relationship between the available data and the thesis objectives 
are shown in Figure 1 of this introduction. Further details of the cohorts and tools used 
to capture the intake data can be found in sections 4.1 to 4.6 of the methods chapter. 
Unfortunately total vitamin C intake (diet plus supplements) could not be analysed for 
the full UKWCS cohort members at either phase; at baseline details of supplement 
types used were not electronically captured, and at phase 2 dietary intake recorded 
from diaries were only electronically captured for a small nested case-control analysis. 
However, total vitamin C was analysed by pooling nested case-control data from the 
UKWCS and two other UK cohorts: EPIC-Norfolk and EPIC-Oxford which are part of 
the European Prospective Investigation into Cancer (EPIC) and are also discussed in 
the main methods chapter, chapter 4. 
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1.1 Objectives 
1. To evaluate vitamin C intake in UKWCS (Chapter 5): 
a. To compare the frequency of vitamin C supplement use in the UKWCS 
recorded by diaries with that recorded by the follow-up phase 2 
questionnaire.  
b. To compare the baseline dietary vitamin C intake with fruit and 
vegetable intake in the UKWCS.  
c. To compare ascorbic acid blood plasma levels in a sub-sample of the 
UKWCS with derived vitamin C intake from diary recordings and also 
from Food Frequency Questionnaires (FFQs). 
2. To determine what characteristics of women predict vitamin C supplement use 
at phase 2 in the UKWCS. To determine whether women who have a history of 
breast cancer are more likely to use high dose vitamin C supplements (Chapter 
6). 
3. To determine whether there is an association between any supplement use and 
breast cancer risk at baseline in the UKWCS and whether the associations are 
modified by sub-factors. To determine whether the risk is different for long-term 
users: women who have taken supplements at both baseline and phase 2 of the 
UKWCS (Chapter 7). 
4. To determine whether there is an association between vitamin C intake from 
supplements and the risk of breast cancer at phase 2 in the UKWCS, 
categorised in relation to the European Recommended Daily Allowance 
(60mg/d) and high dose (500mg/d) use (Chapter 8) 
5. To determine whether there is an association between dietary vitamin C intake 
and the risk of breast cancer at baseline in the UKWCS, and whether it is 
modified by supplement use of any type (Chapter 9). 
6. To determine whether there is an association between total vitamin C intake 
(supplements plus dietary) and the risk of breast cancer in the UK Dietary 
Cohort Consortium using pooled nested case-control data from UKWCS, EPIC-
Norfolk and EPIC-Oxford (Chapter 10). 
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UKWCS 
Baseline  
N=35,372 
Less exclusions 
Cases=982 
 
UKWCS 
Phase 2 
Combined BLQ 
& P2Q 
N=14,271 
Plus P2 diary 
N=12,453 
Less exclusions 
Cases=239 
UKWCS 
Phase 2  
Diary nested 
case-control 
Cases=186 
Controls=785  
 
BLQ: Taking any supplements (y/n)? 
(supplement details not extracted) 
BLFFQ: dietary vitamin C intake  
 
P2D: supplement vitamin C dose 
 
 
 
 
Pooled diary nested case-control 
data from UKWCS Phase 2, 
EPIC-Norfolk and EPIC-Oxford 
Supplement vitamin C dose & 
Dietary vitamin C intake  
 
BrC = Breast cancer    
Vit C = vitamin C   
BLQ= Baseline Health & Lifestyle questionnaire 
BLFFQ = 217 item FFQ   
P2D = Phase 2 diaries  
P2Q = Phase 2 Health & Lifestyle questionnaire 
 
 
Chapter 7 
Any supplement use & BrC risk 
Chapter 9 
Dietary vit C & BrC risk 
Sub-grouped by: 
Supplement users & non-users       
 
 
Chapter 7 
Long-term use & BrC risk: users of 
any supplements at BL & P2 
 
BLQ: Taking any sups at BL (y/n)? 
P2Q: Taking any sups at P2 (y/n)? 
 
 
 
 
Chapter 6 
Supplement vit C dose & history 
of BrC 
Chapter 8 
Supplement vit C dose & BrC risk 
Categorised by non-users, 
recommend intake, high dose 
 
Chapter 10 
Total dietary + supplement vit C 
intake & BrC risk 
 
UK Dietary 
Cohort 
Consortium 
Cases=851 
Controls=2727 
Figure 1 Flow chart of datasets, assessment tools & intake data available for use in risk analyses   
             Datasets                Available dietary & supplement intake information       Analysis chapters  
 
                        Datasets                                  Dietary & Supplement info available                     Analyses (in 
section 8)
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The UKWCS and two of the other cohorts in the UK Dietary Cohort Consortium are 
some of the largest population-based prospective studies in the UK which were 
designed for examining associations between diet and chronic diseases, and are ideal 
studies to investigate the objectives above. Their large size increases the power of the 
analyses. Another major strength of these studies is their prospective nature which 
minimises reverse causality and recall bias (responder bias) which can affect results of 
retrospective case-control studies. Additionally the studies have captured many 
important health and lifestyle factors which may be potential confounders and can be 
adjusted for in the analyses. Furthermore, the majority of the analyses in this thesis use 
previously unexploited supplement data. 
The UKWCS, used in all the analyses, has an extensive database of supplements used 
and covers a wider range of vitamin C intakes than most studies which have reported 
on similar objectives. Women from baseline and phase 2 in the UKWCS were followed-
up for cancer incidences for over 11 and 7 years respectively, which is comparable to 
or better than most studies reviewed in section 3.7.  
The UKWCS, instigated through the World Cancer Research Fund, in general 
comprised of health conscious women. The results are therefore directly applicable to 
similar women; who would be interested to know how lifestyle choices could affect their 
risk of breast cancer, and who may be prepared to alter their behaviours. In addition, 
the UK Dietary Cohort Consortium of other UK studies provides results that are more 
generalised to the UK population as a whole, as well as providing an opportunity to 
examine total vitamin C intake in relation to breast cancer risk using diary data. 
First, supplement use and vitamin C in particular will be discussed in chapter 2, and 
then a review of literature about life-style factors affecting breast cancer risk, including 
diet, will be described in chapter 3, before systematically reviewing articles which 
examine the influence of vitamin C intake on breast cancer risk. Chapter 4 then 
describes the methods used in this thesis, which is followed by the results chapters (5-
10) and the summary discussion in chapter 11. 
  
 7 
 
 
CHAPTER 2 
2  Supplement use and vitamin C  
Supplements are proactively marketed in the developed world in a multi-billion pound 
industry, retailed through shops, mail order and the internet. One of the largest 
producers and consumers of supplements is the United States (US). Annual sales in 
the US since 2004 are estimated to have been over $20 billion per year, about 1% of 
the US health expenditure, providing employment for about 200,000 people directly 
and over a quarter of a million indirectly.18 The number of different types of 
supplements marketed in the US may be between 29,000-50,000.18 
Both in the US and Europe supplements are classified as food rather than drugs. In the 
US the Food and Drug Administration (FDA) regulates the supplement industry, with 
powers to take action relating to quality, unsafe levels, and false claims or misleading 
labelling. Although US manufacturers are allowed to make general health claims, any 
claims relating to treatment, prevention or cure for a specific disease or condition would 
be considered illegal.19 Regulation has been similar in Europe under the Food 
Supplements Directive 2002.20 However, the European Food Safety Authority (EFSA) 
has implemented regulations for approving or rejecting general health claims made on 
foods and supplements based on whether these claims are independently verified by 
research studies.21 Additionally, safe or tolerable upper limits have been set by the 
EFSA for many supplements,22 but many high dose products do not state warnings on 
their packages as required. 
2.1 Supplement use in the UK  
Sales of supplements in the UK in 2009 were estimated to be £396M.23 Vitamin 
supplement use reported by UK women increased from 17% in 1986/1987 to 41% 
reported in 2008/9.24 25 A 2008 UK survey reported users were most likely to be women 
above 55 years and of higher socioeconomic status.26 An analysis of the UK Women’s 
Cohort Study (UKWCS) found that users were significantly more likely to lead healthier 
lifestyles; to be more physically active; have a lower alcohol intake; a lower body mass 
index (BMI) and eat diets which met recommended dietary intakes.27 Therefore they 
were less likely to need supplements than non-users.27 Further support for this ‘inverse 
supplement hypothesis’ has been found in the UK,25 28 29 and elsewhere.30-35 Moreover, 
those classifying themselves as high strength supplement users in a recent UK survey 
were particularly health conscious.26 
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An exploration of reasons behind supplement use in a UKWCS sub-sample of 303 
woman, incorporating the theory of planned behaviour and other potential predictors,36 
found supplement-taking was predicted by an individual’s value of health and their 
perceived ability of supplements to reduce susceptibility to illness.37 Supplement use 
was associated with a perception that supplements were particularly able to reduce 
development of colds, flu, arthritis and rheumatism, and also to have a protective effect 
on the development of heart disease, anaemia and menstrual problems. 
General health and well-being was the most common reason (57%) given for taking 
supplements in the 2008 UK Random Location Omnibus Survey.26 Ten percent of the 
801 sample of both men and women were taking them to ward off colds, 11% of full 
time workers were taking them because they believed they had an unbalanced diet, 
26% of over 45 year olds were taking them for a specific health reason, and 17% of 
women were taking them due to advice from a health practictioner.26 High strength 
supplement users in particular considered the health implications of what they ate, 
actively looked for information about how to stay healthy and believed that they needed 
vitamin and mineral supplements to feel and stay healthy.26 Additionally they were 
more likely to take other supplements than those not taking high strength supplements 
(52% vs. 43%). Thirty eight percent of those surveyed, an estimated 15% of the 
population, reported taking high strength supplements.26 Sixteen percent of users 
bought supplements because of their high strength content; however only 68% of these 
users were fully aware that high doses may cause adverse side effects.26 Only 6% of 
high strength users were likely to report they were in excellent health compared to 25% 
of non-users.26 
The most commonly taken supplements in the 2008 UK survey were multivitamins 
(36%), cod liver oil (35%) and vitamin C (24%).26 In the EPIC-Norfolk study only 4.7% 
of women took single supplement vitamin C, the most popular supplements being cod 
liver oil (24.5%) and multivitamins, with or without minerals (10.4%).38 The percentages 
of women reporting daily use of supplements by questionnaire in the UK Women’s 
Cohort Study (UKWCS), the main study in this thesis, are detailed by type in Figure 2. 
This shows vitamin C, the focus of this thesis, is one of the most commonly taken 
nutrients in supplements both as a single supplement and in combination with other 
nutrients.  
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Figure 2 Percentage of women reporting daily supplement use in the UKWCS phase 2 
questionnaires by supplement type 
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2.2 Vitamin C 
Vitamin C (C6H8O6) exists as ascorbic acid (the reduced state) and dehydroascorbic 
acid (DHA, the oxidised state) in both food and the human body. Humans are one of 
only a few species that cannot synthesis vitamin C, and therefore obtain this 
micronutrient from fruit, vegetable and other plant food. It is widely present in plant 
tissues, for instance in peppers, oranges, lemons, strawberries, grapes, brussel spouts, 
broccoli, cauliflower and tomatoes.39 The storage, processing, and cooking of foods 
can reduce vitamin C content substantially therefore fresh or steamed produce is 
recommended. Although natural and synthetic forms are chemically identical and have 
similar bioavailability, the added benefits of other bioactive components from food are 
lost if vitamin C is obtained predominately from supplements.  
Vitamin C has a number of functions in the body, and supplementation is often 
necessary in malnourished populations such as the chronically sick and the elderly, as 
well as in developing countries. Low doses of vitamin C, 10mg/day, are needed to 
prevent scurvy,40 and doses of 20mg/day are necessary for optimum wound healing.41 
Symptoms of scurvy, which is now uncommon in developed countries, include bleeding 
gums, easy bruising, impaired wound and fracture healing, joint pains, fatigue and 
depression.39 Vitamin C acts as a cofactor for enzymes in the synthesis of collagen, 
carnitine, tyrosine and the neurotransmitters by maintaining metal ions within the 
enzymes in a reduced state.42 Collagen is the main protein found in body structures 
such as skin, bones, teeth, cartilage, tendons, blood vessels and eye lens and cornea. 
Carnitine is involved in the transport of fatty acids into mitochondria for energy 
production. There is evidence that vitamin C suppresses the oxidation of low density 
lipoproteins (LDL) which are implicated in atherosclerosis.43 Through electron donation 
ascorbic acid acts as a reducing agent i.e. an antioxidant, by scavenging oxygen and 
nitrogen free radicals and also regenerates the fat-soluble vitamin E antioxidant (α-
tocopherol). The oxidised form of vitamin C, DHA, is recycled back to vitamin C by 
several enzyme systems within cells. Additionally vitamin C supplementation is found 
to increase the absorption of non-haem iron from plants, probably by reducing iron to 
its ferrous state (Fe2+).44 
Pharmacological uses of vitamin C, though not necessarily evidence based, include 
protection against cardiovascular disease, reducing histamine, boosting immune 
function, aiding iron absorption, protecting against cataracts, as well as use with the 
aim of reducing symptoms of the common cold and prolonging survival in cancer 
patients.40 Ascorbic acid (E300) and its esters are also added to food as browning 
inhibitors, reducing agents, flavour stabilisers, dough modifiers and colour stabilisers.42  
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Suggestions that vitamin C is able to reduce the incidence of colds have been 
unsubstantiated in randomised controlled trials.45 Additionally, food and supplement 
manufacturers often make claims for vitamin C in relation to protection of cells from 
premature ageing, antioxidant activity, antioxidant content and antioxidant properties, 
protection of DNA, proteins and lipids from oxidative damaging. However, the EFSA 
has recently reported that no evidence has been provided to them to establish that 
having antioxidant activity/content and/or antioxidant properties exerts beneficial 
physiological effects on humans.46 In future manufacturers should not make these 
claims.  
2.2.1 Vitamin C recommended intake 
Table 1 shows current recommended vitamin C intakes, primarily to prevent scurvy and 
for optimum wound healing, and recommended safe upper levels set to minimise 
gastrointestinal disturbances.47 Most supplements sold in the UK quote doses as a 
percentage of the EU Recommended Daily Allowance of 60 mg/day for adults. A meta-
analysis indicated that daily intake of 60mg vitamin C would produce average plasma 
levels of ascorbic acid of 42.4 µmol/L.48 A higher recommended daily allowance of 100 
mg/d has been recommended to maintain average plasma concentrations of ascorbic 
acid at 50 µmol/L,48 49 which has been suggested as optimum.50  
Table 1 Current recommended vitamin C intakes 
 
Recommended daily intake 
 
Recommended safe upper 
levels  
UK RNI 40 mg/day51  None set: insufficient data52 
Europe RDA 60 mg/day53 None set: insufficient data22 
US RDA 75 mg/day for women 2000 mg/day47 
RNI = Reference Nutrient Intake 
RDA = Recommended Daily Allowance  
RDA = EAR + 2 SDEAR (EAR: Estimated average requirement; SDEAR: Standard deviation of the EAR) 
 
The most clearly defined side effect of taking large doses of vitamin C is abdominal 
pain and osmotic diarrhoea due to unabsorbed vitamin C being metabolised by 
intestinal bacteria.54 Although vitamin C does not accumulate to toxic levels like fat 
soluble vitamins, high intake may increase the risk of renal stones in some at risk 
individuals due to the increased excretion of the vitamin C metabolite oxalate. A recent 
review of clinical trial evidence concluded that doses of 2000mg/day are safe for most 
adults,55 other than those genetically at risk.56 Individuals with genetic iron disorders 
are at risk of iron overload and development of haemochromatosis or thalassaemia if 
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they consume high doses of vitamin C since it aids the absorption of dietary non-haem 
iron.56 Rebound scurvy has been reported anecdotally, and was thought to occur after 
abrupt cessation of long-term high intakes of vitamin C due to established accelerated 
metabolism or disposal of ascorbic acid, but the results appear to have been 
misinterpreted,41 and systematic conditioning appears to be minimal.57 Evidence shows 
that plasma ascorbic acid concentrations do fall in well-nourished individuals in such 
circumstances, but to within normal levels.57 
 
In its 2004 review of adverse effects of vitamin C, the EFSA suggested an upper limit of 
1000mg/day,58 however both the EFSA and the UK Expert Group on Vitamins and 
Minerals currently believe there is insufficient data to set an upper limit.22 52 The EFSA 
acknowledged there was conflicting and insufficient evidence to set limits relating to 
breast cancer and vitamin C intake and welcomed future research on its safety.22 58 
2.2.2 Vitamin C bioavailability, absorption, transport and excretion 
The bioavailability of vitamin C is the effectiveness with which it is released from the 
source into the tissues of the body. Natural and synthetic vitamin C are chemically 
identical and the bioavailability of vitamin C from food sources and from supplements 
have been reported to be similar.59 ‘Slow release’ or ‘time release’ vitamin C 
supplements and those which also contain bioflavonoids are promoted as having 
increased bioavailability, though evidence for this is lacking. 
At low doses ascorbic acid is actively transported by sodium ions at the brush border 
membrane in the small intestine60. DHA, the oxidised form, diffuses into cells facilitated 
by glucose transporters, and is immediately reduced to ascorbic acid, creating a 
concentration gradient which drives the movement of the former.60 At low doses of 
about 20mg/day absorption of vitamin C is about 98%;61 at normal intakes of between 
30-180mg/day absorption is about 70-95%.54,62 Absorption falls to 50% at doses of 
1.5g/day, 25% at 6g and 16% at 12g/day.63 In plasma, vitamin C is transported mainly 
as water-soluble ascorbic acid, normal levels being about 30-70 µmol/L.  
Vitamin C is stored in the body, although not to the same extent as fat soluble vitamins 
which have stable reserves and associated toxicities. Ascorbic acid is stored in white 
blood cells and is also distributed to all tissues of the body. Body stores can be more 
than 100 times greater than plasma content, the greatest concentrations being found in 
the adrenal and pituitary glands,64 and the largest amount in the liver.60 The ascorbic 
acid content of a range of leukocytes types generally reflect body stores, whereas 
plasma levels reflect recent vitamin C intake which fall more rapidly in depletion 
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studies. The maximum body pool of vitamin C has been estimated to be about 1500 
mg.62  
The bioavailability and therefore plasma levels of vitamin C as water-soluble ascorbic 
acid are determined by the rate of intestinal absorption and of excretion.60 The 
relationship between vitamin C intake and plasma ascorbic acid is S-shaped; between 
doses of 30-100 mg/day plasma levels and increases linearly with increasing intake in 
healthy women, with plasma and circulating cell saturation occurring between 200-400 
mg/day.65 Excretion from the body in urine starts at intakes of about 100mg/day before 
tissue saturation is reached,61,54 and continues to increase steadily if dosage is 
increased. However, oral doses of 500 mg and 1250 mg are not entirely excreted in 
urine by women;65 most likely due to a decline in intestinal absorption at high doses.63 
Therefore, it appears that intakes as high as 200-400 mg/day are utilised in the body by 
healthy women, but whether these levels have optimum health effects is unknown. 
Urine excretion as well as absorption limitations means intakes above these levels may 
not be utilised and may be unnecessary. 
Due to the body’s limited ability to store vitamin C, measurements of plasma 
concentrations are thought to represent intake only in the preceding few weeks.66 
Another measurement problem is that it is unstable in blood and rapidly deteriorates if 
not stabilised by chemicals such as metaphosphoric acid and stored at low 
temperatures.67 
2.2.3 Characteristics associated with vitamin C plasma 
concentrations 
Low ascorbic plasma concentrations have been associated with older age, smoking,48 
high blood pressure and in women with high cholesterol.67 Cross-sectional analyses of 
the EPIC-Norfolk study have reported inverse associations between plasma vitamin C 
and BMI, waist-to-hip ratio (WHR), diabetes, prevalent undiagnosed hyperglycemia and 
HbA1c plasma levels (a measure of blood glucose levels).68 69 Low plasma 
concentrations may reflect increased antioxidant requirements in those with higher 
oxidative stress, associated with abdominal obesity.68 Furthermore, the increased 
blood glucose levels in those with hyperglycaemia and diabetes may inhibit the uptake 
of DHA by glucose transporters;70 DHA may metabolize and be excreted if not taken up 
by cells. In addition, plasma vitamin C has been inversely associated with the 
inflammatory marker C-reactive protein (CRP),71 though an ability to reduce 
inflammation is inconclusive.72 In addition supplement use in general is also positively 
associated with ascorbic acid levels.67 Lifestyle factors may explain the link between 
plasma vitamin C levels and adiposity, HbA1c and CRP plasma levels.68 69 Indeed, high 
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levels of plasma vitamin C may be a marker for healthy diet, lifestyle and socio-
economic position across the life course which appear protective of a range of 
conditions; factors such as exercise, low fat and high fibre diets, housing conditions 
and education have been associated with increasing vitamin C plasma 
concentrations.73  
Furthermore, in the UK low ascorbic acid plasma concentrations have been associated 
with increased mortality from all-causes, from cardiovascular disease (CVD), ischaemic 
heart disease in men and women, and cancer mortality in men but not women.67 The 
latter difference between sexes may possibly be due to the lower baseline antioxidant 
status of men. The associations remained after excluding diabetics and cigarette 
smokers, and after excluding supplement users (except for ischemic heart disease in 
women). Unfortunately, it was not possible to adjust for socio-economic status (SES) or 
physical activity which were likely to confound the results.67 Associations between 
cancer risk and ascorbic acid plasma concentrations are given in section 3.6.4.1. 
2.2.4 Potential mechanisms of vitamin C and other antioxidants in 
relation to cancer 
Sales of supplements such as vitamin C, vitamin E, vitamin A, selenium and other 
antioxidants have been promoted by focusing on their ability to eliminate free radicals 
which cause DNA damage and thereby increase risk of chronic diseases.74 However, 
their mechanisms in relation to cancer have only been partially elucidated.75 As 
discussed below antioxidants may exert different influences at different stages of 
cancer development. This can be split into three stages: initiation where DNA damage 
and repair occurs; promotion where cell proliferation, involving the mutation of tumour-
suppressor genes and the formation of oncogenes, can be reversed by programmed 
cell death; and progression which leads to the change of cells from benign to malignant 
and involves angiogenesis (the increased supply of blood vessels to the tumour) and 
metastasis (the spread of the cancer to other areas of the body).76  
Vitamin C, as ascorbic acid, can readily donate electrons to suppress activities of free 
radicals such as reactive oxygen species (ROS).  High levels of ROS such as super 
oxide (O2
.), hydrogen peroxide (H2O2), the hydroxyl radical (OH
.) and nitric oxide radical 
(NO.) are thought to initiate cancer through oxidative damage to DNA. ROS are 
produced internally by the release of electrons from mitochondria, white blood cells, 
peroxisomes and the detoxification enzyme cytochrome P450.76 It is possible that 
antioxidant supplementation may prevent DNA damage during the initial stage of 
cancer in individuals with high levels of ROS which are not eliminated by endogenous 
antioxidants such as superoxide dismutase.76 77 Salganik et al. (2001) suggest 
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populations may need screening to identify those with high and low innate levels of 
ROS in order to determine appropriate supplementation.77 However, levels of 8-OHdG, 
a marker of DNA damage, do not appear to reduce with vitamin C supplementation, 
except for individuals with very low intakes.78 Higher baseline levels of 8-OHdG have 
been found in individuals who had lower serum ascorbic acid levels, those who did not 
use antioxidant supplements, or had low fruit and vegetable intake, or did not exercise 
regularly.79 However, two months of supplementation with vitamin C (500mg/day) or 
vitamin E (400 IU/day) in this US RCT did not affect levels of 8-OHdG.79 These results 
may indicate that supplementation may need to be prolonged to be effective or that 
high vitamin C intake or high serum ascorbic acid levels may be a marker of a good 
diet and healthy life style rather than a true protective factor against the initiation of 
cancer.79  
One study has found a moderate but significant increase in breast cancer risk in 
women who had short telomeres and who had low dietary and supplement intake of 
antioxidants.80 Telomeres protect genes from degradation, but appear to be 
detrimentally shortened by oxidative damage; therefore it may be possible that 
antioxidant activity could protect telomere length.80   
Conversely, antioxidants may decrease protective functions of ROS which are 
necessary to suppress the promotion or proliferation stage of cancer which leads to the 
formation of preneoplastic cells.76 As part of our immune system, phagocytes require 
ROS to enable them to destroy invading microorganisms and cancer cells.  Excess 
ROS induce beneficial apoptosis, programmed death of damaged cells, without which 
uncontrolled cell division may lead to the progression of cancer.29, 77, 81 The inhibitive 
effects of antioxidants on programmed cell death may be one reason why some studies 
have not shown antioxidant supplementation,7 or vegetarianism to be protective of 
cancer.82 In individuals who are constantly exposed to carcinogens such as tobacco, 
antioxidants may eliminate ROS preventing beneficial apoptosis whilst the carcinogen 
is left to promote cancer cells.77 This may explain why the antioxidant β-carotene, a 
form of vitamin A, increases the incidence of lung cancer in smokers, but decreases 
the incidence in non-smokers.7 83  
On the other hand, vitamin C appears to beneficially modulate the expression of 
tumour suppressor genes such as p53 and p73 which initiate apoptosis of damaged 
cells.84 Therefore the effect of vitamin C at the proliferation stage of cancer may 
depend upon the balance it offers between the detrimental elimination of ROS required 
for apoptosis and its beneficial promotion of suppressor genes.  
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Some anticancer drugs such as cis-platin generate ROS and eliminate cancer cells by 
mediating apoptosis. It has been reported that the antioxidant alpha-tocopherol, a form 
of vitamin E, can reduce the amount of ROS and apoptosis produced by cis-platin in 
breast cancer cells, thus reducing its effectiveness.77. Although vitamin C can 
regenerate vitamin E and may inhibit apoptosis itself, research on cell-lines have 
shown it can increase the sensitivity of cis-platin.85 However, a recent systematic 
review of antioxidant supplementation during chemotherapy indicated in general they 
improved survival times and tumour responses, and also reduced toxicities to the 
chemotherapy.86 Mixed results were produced using high dose vitamin C 
supplementation on terminal cancer patients.87-89 Results of trials using intravenous 
vitamin C for cancer therapy also produced mixed results.39 
It is unclear whether ascorbic acid and other antioxidants can inhibit processes in the 
final stage of cancer development involving angiogenesis and metastasis, although 
mechanisms have been proposed.84 Since vitamin C promotes collagen formation this 
may help maintain the extracellular matrix and prevent tumour cells for spreading. On 
the other hand, collagen formation will support the growth of new blood vessels needed 
for tumours to develop.84 
Vitamin C as ascorbic acid can also act as a pro-oxidant by reducing ‘free’ transition 
metals such as copper and iron, which via the Fenton reaction with hydrogen peroxide 
leads to the formation of highly reactive and damaging hydroxyl radicals (Fe(II) + H2O2 
→ Fe (III) + OH. +OH-).76 77 84 Potentially high intakes of haem-iron in red meat plus 
ascorbic acid could initiate cancer;90 indeed this combination was associated with an 
increase risk of lung cancer in the Iowa Women's Health Study.91 However, since free 
iron or copper are not normally available in vivo because they are bonded to proteins 
such as ferritin, transferrin and metallothioneins, this hypothesis is controversial. 
Nevertheless, Kabet and Rohan (2007) propose that high levels of stored iron, 
particularly found in menopausal women, can be released by mechanisms involving 
infection, inflammation, high alcohol intake and oestrogen metabolites which via the 
Fenton reaction could increase breast cancer risk.92 Conversely, since both iron and 
copper are more abundant in cancer cells than in normal cells, this pro-oxidant 
mechanism could be used to target the apoptosis of tumour cells, particularly since 
ascorbic acid has been found to mobilise copper ions.93 94 
As discussed above, the overall effect of various mechanisms involving vitamin C or 
other antioxidants on the development of cancer in general is still unclear. With regard 
to specific cancers, vitamin C may reduce the risk of gastric cancer by suppressing the 
formation of nitrosamine compounds; however its effect is reduced when infection by H 
pylori is present.95 96 A meta-analysis of RCTs, however, did not find a significant 
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protective effect of antioxidant supplements on gastric cancer.97 The influence that 
vitamin C may have on breast cancer specifically is less clear since, as seen in the 
next chapter in section 3.5, this cancer is predominately influenced by hormones. 
Vitamin C may have a greater influence on non-hormonal cancers, including non-
hormonal breast cancers. Nevertheless, as seen in section 3.4.2, vitamin C may affect 
breast density which is associated with breast cancer risk. 
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CHAPTER 3 
3 Literature review of breast cancer risks 
3.1 Introduction 
The main approach used for the time-to-event analyses in this thesis is based on the 
lifestyle model, and in particular on the assumption that lifestyles during mid-life may 
affect the risk of developing adult chronic diseases. Later chapters in this thesis use 
recordings of diet and/or supplement intake during one time period in mid-life to 
estimate their influence on cancer risk seven or more years later. Other lifestyle factors 
measured at mid-life which may affect breast cancer risk, such as exercise and alcohol 
intake, are discussed in sections 3.5 and 3.6 of this chapter and most of these are 
taken into account in the analyses. Some factors highlighted in the life course approach 
to chronic diseases which may also influence breast cancer risk can also be controlled 
for in the analyses, such as age at menarche or age of first birth; these are discussed 
in section 3.5. This combination of approaches has been used in the majority of studies 
evaluating diet and cancer risk discussed in section 3.6. Cancer processes which may 
be affected by diet are also mentioned in section 3.6. 
Cancer can take decades to develop and may be due to independent cumulative 
exposure effects or may be due to a chain of linked events. Within the life course 
approach there are models which emphasise critical periods such as gestation, 
childhood, adolescence, young adulthood as well as adult life.98 Interaction effects 
between exposures in different critical periods may also occur.98 Exposures during 
gestation, childhood and adolescence may, for instance, influence hormonal 
mechanisms linked to breast cancer risk, as discussed in section 3.5. Such data have 
not been gathered in studies used in the current analyses. Indeed, few longitudinal 
studies have recorded information from the pre-natal stage, though famine studies and 
animal studies may illuminate hypotheses based on pre-natal programming of adult 
cancer.99 100 Long follow-up studies on humans are expensive, time consuming and 
prone to attrition, and as yet there is no intermediate breast cancer end-point that can 
be easily employed. 
Cancer occurs both through genetic modification to the DNA sequence and epigenetic 
modifications, i.e. changes in gene expression which occur without altering the DNA 
sequence. DNA sequence mutations occur due to damage from external factors such 
as sunlight and radiation, and from internal factors. Damaging reactive oxygen species 
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(ROS) are produced by a variety of normal intracellular processes, some of which are 
mentioned in section 2.2.4. Furthermore, there is substantial evidence that ROS 
become elevated as a result of intense exercise101 or hyperglycaemia102 
Epigenetic changes are manifest in DNA methylation, histone (chromatin) modification 
and non-coding RNAs (ribonucleic acid). Such alterations are transmitted to daughter 
cells during cell division and appear to be involved in most steps of tumour progression 
and development.103 Although currently unclear, maternal diet and other exposures in 
utero have the potential to cause epigenetic changes to the foetus, such as mammary 
gland development, which may increase susceptibility to breast cancer.99 Twin studies 
show that epigenetic changes can also accumulate over the life course, with older 
twins showing greater differences in DNA methylation and histone acetylation levels.104 
Environmental and dietary factors such as tobacco smoke, ionizing radiation, UV 
radiation, alcohol and folic acid may contribute to the accumulation of epigenetic 
changes during aging which cause cancer.103 Moreover, there is evidence that 
epigenetic changes originating in utero in animals can be passed on to future 
generations.105 Unlike genetic changes, epigenetic changes are reversible which 
means new cancer prevention and treatment strategies could be developed in the 
future.103  
This chapter will review the literature relating to breast cancer risks. Rather than 
reporting individual studies which can produce conflicting results it focuses in general 
on larger or more recent pooling studies and reviews, particularly systematic reviews 
and meta-analyses. Many articles referenced in this chapter appear to be influential, as 
evident from their large number of citations. Methodological issues including study 
design, measurement tools employed, measurement error, confounding factors, bias, 
length of follow-up and the initial health of study members, can all affect results. In 
relation to nutrition, conflicting results may arise due to dose effects, and to interactive 
and synergistic effects of nutrients. First, a brief description of breast cancer types and 
a summary of incidence rates, trends and survival are given. 
3.2 Classification of breast cancer  
Lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS) are non-invasive 
or pre-invasive cancers, sometimes termed pre-cancerous, which have not spread 
elsewhere. Respectively they describe cancer cells present in the lobes in the breast 
glandular tissue, and cancer cells present in the milk ducts between the nipple and the 
lobes. LCIS does not cause symptoms and usually does not show up on 
mammograms.106  
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If cancer cells do spread outside of the lobe it is called invasive lobular breast cancer. 
Similarly if the cancer cells have spread outside of the ducts it is called invasive ductal 
breast cancer; 70-80% of breast cancers diagnosed are of this type.107 When cancer is 
also found in the lymph glands, such as those in the armpit or surrounding the breast, 
then cancer is likely to spread to other parts of the body via the lymphatic system; 
nevertheless this is still classed as early stage breast cancer. Secondary breast 
cancer, also called metastatic breast cancer or stage 4 breast cancer, is a term for 
cancer that has spread to other parts of the body.  
Rare breast cancers include inflammatory breast cancers which occur when the lymph 
channels become blocked, and Paget’s disease which starts at the nipple area.  
Breast cancers are also classified according to the presence and type of hormone 
receptor or oncogene. If the breast cancer cells have oestrogen receptors present then 
the tumour is said to be oestrogen receptor positive (ER+). Other receptor statuses 
relate to the presence of progesterone receptors (PR) and Human Epidermal Growth 
factor Receptor 2 (HER2). Triple negative cancers do not have these receptors; this is 
often found in basal type cancers which are associated with women who have BRCA1 
germ line mutations. 
Treatment decisions are based on the TNM stage and the grade of each breast cancer 
case. The TNM stage classification system describes the size of the tumour or whether 
the cancer remains in situ (T1-4, Tis(DCIS), Tis(LCIS)), whether cancer has spread to 
the lymph nodes (N0-3), and whether it has spread anywhere else in the body i.e. 
metastasized (M0 or M1).108 The grade of cancer describes whether it is a slow or fast 
growing cancer. Fast growing cancers are more likely to spread and return after 
treatment than slow growing cancers.  
3.3 Breast cancer incidence, trends and survival 
Breast cancer is the most common cancer in women and the second most common 
cancer overall in men and women worldwide.4 Globally, there were an estimated 
1,383,000 cases of malignant breast cancer in women in 2008, making up 10.9% of all 
cancer cases and 22.9% of all female cancers (excluding non-melanoma skin cancer).4 
The world age-standardised incidence rates (ASR) in 2008 for female breast cancer 
were 39 per 100,000 and the cumulative risk to the age of 74 or more was 4.1%.4 
Breast cancer incidence is substantially higher in more developed countries (except 
Japan) compared to less developed countries (ASR = 66.4 vs. 27.3 per 100,000). In 
Northern Europe in 2008 it was 84.0 per 100,000 and the estimated cumulative risk to 
the age of 74 was 8.9%.4 Figures for North America were 76.7 per 1000,000 and 8.4% 
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respectively.4 The higher incidence in developed countries may be partially due to 
better procedures to detect breast cancer cases earlier e.g. through surveillance, as 
well as better procedures to accurately record cases. Some African and Asian 
countries submitted no data at all to Globocan for the global cancer estimate, and their 
estimates were based on data from neighbouring countries,4 though the accuracy and 
quality of the latter may not be good. 
 
In 2008 there were an estimated 332,770 breast cancer cases in the European Union 
and 45,570 in the UK. The European age standardised rate (EASR) for breast cancer 
incidence in the European Union (EU) countries in 2008 was 103.7 per 100,000, and 
the EASR for the UK was 119.1 per 100,000; the UK has sixth highest rate of the EU 
countries (Figure 3).3 In the UK, 31% of all female cancers were breast cancers, 
making it the most common cancer.3 The lifetime risk in 2008 in the UK has been 
estimated as 1 in 8. 6 Figure 4 shows that breast cancer incidence rates have more 
than doubled in Britain since the mid 1970s.109 Rates increased substantially after 
breast screening was introduced in 1988, which found previously undetected 
cancers.110 HRT use during the 1990s is also believed to have contributed to the 
increased rates.111 Figure 5 shows that the sudden increase in rates was mainly 
confined to the  50-64 age group who were invited to join the breast screening 
program.109 
 
The estimated deaths (458,000) attributed to breast cancer in women globally in 2008 
was substantially lower than incidence rates, being 12.5 per 100,000. Globally 13.7% 
of female cancer deaths were attributed to breast cancer, it was the most common 
death from cancer in females and the fifth most common overall in men and women.4 In 
2008 there was an estimated 332,800 breast cancer deaths in the European Union and 
89,800 in the UK; 16.6% and 16.0% cancer deaths in the EU and UK related to breast 
cancer.3 
The percentage of women still surviving five years after their first malignant invasive 
breast cancer diagnosis varies widely between countries. Survival rates at 5 years, 
age-standardised to the International Cancer Survival Standard weights, for women 
diagnosed between 1990-1994, ranged from 80% or over in North America, Sweden, 
Japan, Finland, and Australia to less than 60% in Brazil and Slovakia, and below 40% 
in Algeria.112 Most European countries were in the 70-79% range, however the UK 
survival rate was 69.7%.112 The five year survival rates have improved in England over 
the last thirty years, from 52% for women diagnosed in the early 1970s to 82% for 
women diagnosed between 2001-2006.109 Five year survival rates are lower the later 
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the stage at diagnosis, ranging from 98% for very early stage to 18% for metastatic 
breast cancers in Europe.113 
 
Figure 3 Estimated European age-standardised incidence and mortality rates in 2008 
by EU country3 109 
 
Figure 4 European age-standardised breast cancer incidence and mortality rates for 
Britain between 1975-2008109 
 
Source: Cancer Research UK. Cancer Statistics - breast cancer 
http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/  
0 20 40 60 80 100 120 140 160 
Greece 
Lithuania 
Romania 
Latvia 
Poland 
Estonia 
Slovakia 
Bulgaria 
Hungary 
Portugal 
Spain 
Cyprus 
Slovenia 
Czech Rep 
Austria 
Malta 
EU-27 
Germany 
Sweden 
Luxembourg 
Italy 
Finland 
UK 
Denmark 
Ireland 
Netherlands 
France 
Belgium 
Rate per 100,000 females 
Incidence 
Mortality 
0 
20 
40 
60 
80 
100 
120 
140 
1
9
7
5
 
1
9
7
7
 
1
9
7
9
 
1
9
8
1
 
1
9
8
3
 
1
9
8
5
 
1
9
8
7
 
1
9
8
9
 
1
9
9
1
 
1
9
9
3
 
1
9
9
5
 
1
9
9
7
 
1
9
9
9
 
2
0
0
1
 
2
0
0
3
 
2
0
0
5
 
2
0
0
7
 R
a
te
 p
e
r 
1
0
0
,0
0
0
 p
o
p
u
la
ti
o
n
 
Year of diagnosis/death 
Incidence Rates Mortality Rates 
 23 
 
 
 
Figure 5 Age-Specific breast cancer incidence rates for Britain, 1975-2008109
 
Source: Cancer Research UK. Cancer Statistics - breast cancer 
http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/  
 
3.4 Major breast cancer risk factors 
3.4.1 Family history and genetics  
Most women who have a family history of breast cancer do not develop cancer 
themselves. A 2001 meta-analysis estimated that women with one first degree relative 
(mother, sisters, daughters) who developed breast cancer have about double the risk 
of developing breast cancer compared to women with no affected relative.114 Increased 
risks may be due to shared genetic and/or environmental factors. Risks are estimated 
to be nearly four-fold for women who have three or more affected relatives;114 these 
cancers are more likely to be inherited. Risks were higher the younger the relatives 
were at diagnosis, particularly if diagnosis was before the age of 50.114  
Risks are very high in women who have certain rare germ line mutations such as 
BRCA1, BRCA2, TP53, PTEN, STK11 and CDH1. These high-risk alleles are rare 
(~0.1% of the population are carriers) but account for about 16% of familial breast 
cancer risk,115 and about 5% of all breast cancer cases. Women with BRCA1 and 
BRCA2 mutations have a 10- to 20-fold relative risk and a 30-60% risk of developing 
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breast cancer before the age of 60 compared to 3% in the general population.115 0 
describes the criteria the NHS use for defining people at high risk. These genetic 
mutations are also linked to high risks of developing other cancers; for instance BRCA2 
is also associated with ovarian and pancreatic cancer as well as prostate and breast 
cancer in men.116  
Other rare mutations, such as ATM, BRIP1, CHEK2 and PALB2 confer moderate risks 
of two- to 4-fold of developing breast cancer; together these may only account for 2.3% 
of familial risk of breast cancer.115 These are involved in biological pathways relating to 
BRCA1 and BRCA2 genes. Additionally, the genome-wide search of hundreds of 
thousands of single-nucleotide polymorphisms have found common low-risk alleles 
associated with increased breast cancer risks of less than two-fold. Although the 
frequency in the population of some of these alleles may be as much as 50%, those 
discovered so far are likely to account for only a small percentage relating to familial 
risk in total.115 It is unknown how these may interact with the high-risk alleles. 
3.4.2 Breast density  
Breast density, distinguished by non-fatty mammary tissue, is strongly and 
independently associated with increased breast cancer incidence, and shows a dose-
response relationship.117 A 2006 systematic review estimated that dense breast tissue 
in more than 75% of the breast increases risk of breast cancer by over four fold 
compared to densities below 5%.117  Mammographic breast density is also associated 
with other risk factors such as age, menopausal status, parity and body weight, and to 
a lesser extent family history, race, alcohol consumption and diet. 118 High saturated fat 
intake has been associated with lower breast density.119 One study found an inverse 
relationship between breast density and fruit and vegetable intake, vitamin C intake, 
and also with olive oil.120 Conversely, another study reported total vitamin C intake and 
supplement vitamin C intake was positively associated with breast density in 
premenopausal women, although not in post-menopausal women.119 There is evidence 
that density can be altered using combined oestrogen-progesterone hormone therapy, 
although the evidence relating to the effects of endogenous hormones and growth 
factors is inconsistent.121 Twin studies have demonstrated that breast density is 
heritable,121 nevertheless it has been reported that carriers of BRCA1 and BRCA2 
genes have a similar breast density to non-carriers.122 It has been suggested that 
breast density should be incorporated into risk prediction models,123 however it is 
unknown whether breast density is predictive in young women when high density 
breast tissue is more common.117   
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3.4.3 Previous diagnosis 
Benign breast disease  is a risk factor for malignant breast; women with proliferative 
breast disease without the production of abnormal cells (without atypia), have double 
the risk compared to the general population, whilst those with atypical hyperplasia have 
a more than four-fold increased risk.124 Women with a previous in situ tumour (DCIS 
and LCIS) have double the risk of invasive breast cancer in the same breast compared 
to the general population.125 
Previous invasive breast cancer can increase the risk of contra-lateral breast cancer by 
as much as 5-fold, although the spread of the initial cancer to the other breast within 
the first two years probably inflates this figure.126 Contra-lateral breast cancer 
diagnosed two years after the primary breast cancer is linked to tumour size and age; 
being more common if the first cancer was diagnosed before the age of 40.126  
3.4.4 Thoracic radiotherapy 
Women who were treated with moderate to high dose chest radiation for childhood, 
adolescent or young adult cancer have a substantially increased risk (13- to 15- fold) of 
developing breast cancer at a young age.127 Exposure to lower doses of radiation in 
infancy has also been associated with increased breast cancer risk; risks increased 
linearly with increasing dose.128   
3.4.5 Risk prediction tools 
Various models have been developed to estimate life-time risk of breast cancer in order 
to help clinicians decide whether surveillance is necessary for particular women; these 
include Gail-2; Claus Model; Claus Tables; BOADICEA; Jonker Model; Claus-Extended 
Formula, and Tyrer–Cuzick.129 In addition to breast biopsy history, family history and/or 
genetic test results, parameters often included in these models are age of menarche; 
parity; age at first child; menopausal status; menopausal age; BMI; ovarian status; age 
at ovarian status; HRT use.129 These will be discussed below. Whilst the models aim to 
calculate the risk for an individual, the risks used in the models for these various risk 
factors are based on population risks from epidemiology studies. 
3.5 Hormonal and related factors affecting risk of 
breast cancer 
3.5.1 Hormone lifetime exposure 
Hormonal and reproductive factors such as early onset of menarche, late age of first 
birth, low parity and late menopause are established risk factors for breast cancer.130 131 
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Hormonally induced changes in mammary cells during pregnancy may provide 
protective effects.132 In contrast, it is believed that early onset of menarche and late 
menopause increase risk via their influence on women’s lifetime exposure to 
endogenous oestrogens. High energy diets during childhood have been associated 
with early menarche thereby increasing exposure and risk.133 134 Risk increases rapidly 
during the reproductive years but then increases at a slower rate during menopause, 
which is reflected in the reduced production of oestrogen by the ovaries.131 Due to 
fluctuations in hormone levels in the menstrual cycle of pre-menopausal women, 
lifetime exposure to oestrogens cannot be measured, therefore hormonal and 
reproductive events, plus the use of contraceptive pills and Hormone Replacement 
Therapy (HRT) that contain them are employed as proxy covariates in risk analyses. 
3.5.2 Exogenous hormones in HRT and contraceptive pills  
Oestrogen production from the ovaries diminishes as women approach the 
menopause, which can cause numerous problematic symptoms that can often be 
alleviated with Hormonal Replacement Therapy (HRT). However, there is substantial 
evidence that HRT increases breast cancer risk during its use, with increased risk 
disappearing about five years after cessation.135 136 It has been estimated that risk 
increases by 2·3% for each year of use in current or recent HRT users; this compares 
with an increased risk of 2.8% that would normally occur for each year that menopause 
is delayed.135 The increased risk has been reported to be more pronounced in women 
with lower BMIs.135 Post-menopausal oestrogen-plus-progesterone replacement 
therapy has been found to increase breast cancer risk to a greater extent than 
oestrogen alone replacement therapies;136 137 Additionally, there is evidence that 
mammographic breast density, which is linked to increased breast cancer risk, 
increases during HRT.138 
 
In addition to oestrogen and progesterone, ovaries also produce testosterone in normal 
pre-menopausal women. Testosterone combined HRT has been used to treat women 
with removed ovaries, as well as to treat menopausal symptoms in normal post-
menopausal women.139 Adding testosterone to HRT has been found to inhibit the 
stimulatory effects of oestrogen on breast cell proliferation in monkeys.140 However, 
there has been little research relating to women and this is inconclusive: although one 
study reported no increased breast cancer risk in women using the testosterone 
combined HRT,141 another study reported increased risk.142  
 
A modest increase in breast cancer risk was reported in a large meta-analysis of 54 
studies relating to current or recent use of oral contraceptives (containing oestrogen 
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and progestin); this increased risk disappeared within 10 year of cessation.143 There is 
evidence from an unadjusted meta-analysis of case-control studies that risk is more 
pronounced in multiparous women who used oral contraceptives before their first full 
term pregnancy than women who started use later.144 Newer formulations of oral 
contraceptives have reduced oestrogen and progestin content; results of some studies 
indicate that the risk of breast cancer from the use of these may be lower than that 
from the older type of contraceptive.145  
3.5.3 Endogenous hormones  
There is consistent research evidence to show that high serum concentrations of 
endogenous oestrogen are associated with increased breast cancer risk in post-
menopausal women; additionally there is evidence that androgens, prolactin, insulin 
hormones and insulin-like growth factors (IGF) may also influence risk.146 This section 
describes the evidence that links serum concentrations of these hormones to breast 
cancer risk, much of which is from seminal work on the pooling of thousands of cases 
in nine prospective studies. Pooling not only increases the power to detect smaller 
effect sizes, but in contrast to meta-analyses ensures uniformity in analysis methods. 
The following sections describe how these hormones are related to lactation, body 
fatness, physical activity and height which are also associated with breast cancer risk. 
 
The pooled analysis of nine prospective studies showed that post-menopausal women 
with the highest fifth of oestradiol serum concentrations had twice the relative risk 
compared to the lowest fifth for this endogenous oestrogen.147 Other prospective 
studies such as EPIC have reported similar results.132 148 149 Free oestradiol levels, 
including non-SHBG bound oestradiol which were free to enter breast cells had a larger 
effect than total oestradiol on risk.147 Evidence suggests that oestradiol and other 
oestrogens stimulate mammary cell proliferation, thereby promoting cancer.150 
Oestradiol has been found to have a strong and significant association with oestrogen 
receptor positive breast cancer in post-menopausal women in some studies,149 151 
although in other studies the increase was not statically significant. 148 152 Although 
there is some evidence of an increased risk relating to higher oestradiol levels in pre-
menopausal women, it is inconclusive, probably as a result of large fluctuations in 
levels during the menstrual cycle.146 Despite the fact that some genes are associated 
with an increase in oestrogen levels there is no evidence they have a large enough 
effect to significantly increase breast cancer risk.146  
 
The pooling of nine prospective studies also found breast cancer risk was more than 
doubled for post-menopausal women with testosterone concentrations in the highest 
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fifth compared to the lowest fifth.147 Testosterone is more abundant in post-menopausal 
women than oestrogen, and is converted to oestradiol by aromatase; thereby indirectly 
increasing risk via increases in oestradiol. Nevertheless testosterone was found to be 
independently associated with breast cancer after adjustment for oestradiol, though 
rates were slightly attenuated.147 A positive association was also seen in pre-
menopausal women in four prospective studies.146 Positive associations between other 
androgens with breast cancer have also been found.147 In addition to being an 
oestrogen precursor, androgens can act directly on breast cells by binding to androgen 
receptors and may stimulate cell proliferation.153 Conversely, other researchers 
propose that androgens such as testosterone are protective in respect to breast cancer 
risk,139 154 since some studies found an inverse association; differences in results may 
depend on the methods for measuring testosterone, the calculation of free testosterone 
as well as oestrogen status.139 Hypotheses have been proposed which may explain 
some, but not all of the inconsistencies in results: in the absence of oestrogens, for 
instance in post-menopausal women, androgens may stimulate growth of breast 
cancer cells via binding to oestrogen receptors; alternatively in the presence of high 
oestrogen concentrations, androgens may act as anti-oestrogens to inhibit oestrogen 
stimulation of growth of breast cancer cells via binding to androgen receptors.155  
Furthermore, in vitro androgens have been shown to stimulate or inhibit breast cancer 
cell proliferation depending on the breast cancer cell line.155 In post-menopausal cancer 
patients, high testosterone levels have been significantly associated with positive 
oestrogen receptor status, large tumour size and high BMI.156 Although this supports 
the original androgen excess theory,156 the association in cross-sectional studies could 
also be explained by the tumours’ effect on androgen production. The mechanisms by 
which androgens affect breast cancer risk remain unclear. 
 
Serum levels of sex-hormone-binding globulin (SHBG) have been inversely associated 
with breast cancer risk,147 157 risk reduced by approximately a third in a high verses low 
analysis of nine pooled cohorts.147 SHBG not only reduces the bioavailability of  
oestrogens and testosterone to cells, but may also act directly on breast cancer cells 
by inhibiting oestradiol induced cell proliferation.158  
Prolactin, the luteotropic hormone, was associated with a moderate increase in breast 
cancer risk in a pooled analysis of two prospective studies.159 No difference in risks 
between pre-menopausal and post-menopausal women was found, probably since 
prolactin declines only slightly during the menopause.159 Risks were higher for women 
with ER positive tumours. 
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In a large pooled analysis of seventeen studies insulin-like growth factor-1 (IGF-1) 
showed a significant association with breast cancer risk, in particular oestrogen 
receptor positive cancers (OR = 1.38 (95% CI 1.14-1.68), for both pre-menopausal and 
post-menopausal women.160 Results of an earlier meta-analysis showed associations 
were limited to pre-menopausal women,161 however this analysis did not include four 
large recent studies included in the pooled analysis. The association in the pooled 
study was independent of levels of oestradiol and testosterone, and was not modified 
by these.160 IGF-1 was positively associated with height and age at first pregnancy and 
inversely associated with age at menarche and years since menopause,160 which are 
risk factors for breast cancer. Dietary factors associated with increased IGF-1 are dairy 
protein and calcium.162 
Other reviews have suggested a possible link between insulin or C-peptide (a marker 
of pancreatic insulin secretion) and increased breast cancer risk, although some 
studies showed no association.163 164 Hyperinsulinemia has also been associated with 
increased breast cancer risk.165 Insulin may affect tumour growth indirectly through 
increasing bioavailability of IGF-1 and decreasing sex-hormone-binding globulin 
(SHBG). Insulin and IGF-1 may also have a direct effect by increasing breast cancer 
cell proliferation, though this has only been demonstrated in vitro.158 
 
Despite evidence that the combined oral contraceptive containing oestrogen and 
progesterone confers more risk than oestrogen alone, the evidence for the influence of 
endogenous progesterone on breast cancer risk has been inconsistent and does not 
provide support for an oestrogen-progesterone hypothesis.  
Shift work may affect breast cancer risk through hormones levels; a meta-analysis 
showed that shift work increased breast cancer risk by about 50%.166 It is hypothesised 
that reduction in melatonin, which occurs in artificial light, may increase levels of 
hormones such as oestrogen, additionally melatonin may have a direct effect on  
tumour suppression.166  
3.5.4 Pregnancy and lactation 
In addition to a 7% reduction in breast cancer risk for every birth, a woman’s risk is 
further decreased by 4.3% for every year in total that she breast-feeds.167 This 
evidence is provided by a pooled analysis of 47 epidemiological studies from 30 
countries.167 The mechanisms involved remain unclear, however hormonal influences 
are likely to be involved, relating for instance to delayed ovulation and increased breast 
cell differentiation.168  
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3.5.5 Body fatness 
Body fatness is an established risk factor for post-menopausal women, whereas a 
probable inverse relationship with breast cancer exists for pre-menopausal women. 7 169 
Several hypotheses involving hormones such as insulin, insulin-like growth factor and 
oestrogens that were discussed in previous sections have been proposed to explain 
the former. There is no clear mechanism, however, to explain the inverse relationship 
for pre-menopausal women. Waist circumference and waist to hip ratio are positively 
associated with breast cancer risk in postmenopausal women. 7 169  The 2008 WCRF 
continuous update report stated that abdominal fat is a probable cause of post-
menopausal breast cancer, as is adult weight gain.169 BMI, which is derived from 
readily obtainable height and weight measurements, is often used as a marker of body 
fat and is associated with breast cancer risk. The updated meta-analyses of cohort 
studies in the 2008 WCRF continuous update report showed a 7 per cent decreased 
risk per 5kg/m2 for premenopausal women and an 8% increased risk per 5kg/m2 
increase in BMI for postmenopausal women.169 Obese post-menopausal women in 
particular (BMIs over 30 kg/m2) are at increased risk of breast cancer. Additionally, 
obese patients tend to have larger sized tumours, their cancers are more likely to 
metastasize due to lymph-node involvement and they generally have a poorer 
prognosis for survival.170 171 Weight loss is recommended for survivors and gastric 
bypass surgery improves cancer outcomes in obese patients, for both pre and post-
menopausal women.172 There is some evidence that women genetically at high risk 
could reduce their risk by avoiding weight gain post-menopausally.173  
 
Levels of oestradiol are higher in obese post-menopausal women, which appear to 
explain why the risk of breast cancer is greater in post-menopausal women with high 
BMI; indeed controlling for oestradiol concentrations in a prospective study reduced the 
risk towards unity in the association between breast cancer and BMI.174 The 
association between oestrogen production and obesity related breast cancers is further 
supported by the fact that these cancers are more often ER+,175 and particularly in 
women who were not currently taking HRT. 176 Weight gain during adulthood is also 
associated with an increased risk of post-menopausal breast cancer,169 and is also 
stronger in women who were not currently,176 or previously using HRT,177 or who had a 
later menarche.176 Therefore the effects of weight gain on risk appear to be obscured in 
women who had early menarche or used HRT which would increase their cumulative 
exposure to oestrogen .176 
Adipose tissue becomes the primary source of circulating oestrogens during 
menopause when the ovaries cease production. Aromatase in adipose tissue, mainly 
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found in breast, abdomen, thighs and buttocks, convert androgens to oestrogen.158 
Aromatase inhibitors are recommended to reduce peripheral production of oestrogens 
in women with advanced (or metastatic) breast cancer.178  
Alternatively insulin resistance and IGF-1 concentrations associated with metabolic 
syndrome, together with the action of oestrogens may explain the link between breast 
cancer and obesity.158 Since high levels of insulin are inversely related to SHBG, the 
bioavailability of oestrogens and testosterone are also likely to increase.175 179 180 Intra-
abdominal adipose tissue, in particular, influences the production of insulin and other 
hormones; waist circumference being a reasonable measure of abdominal adiposity. 
Hyperinsulinemia may also promote the synthesis and activity of IGF-1.158 However, 
despite IGF-1 being positively associated with weight in overweight women, lower 
levels of IGF-1 are found in obese women and therefore cannot explain the increased 
risk of breast cancer in obese women.160 181 Insulin resistance and hyperinsulinemia are 
seen in the early stages of type-2 diabetes, and both hyperinsulinemia and type-2-
diabetes are associated with an increase in breast cancer risk.163 165  
 
A third hypothesis proposes that various cytokines, polypeptides and hormone-like 
molecules secreted by adipocytes may influence risk via their autocrine, paracrine, and 
endocrine functions.158 Since the majority of cells in the breast are adipocytes, their 
autocrine and paracrine activities are likely to affect breast epithelial cells. The 
adipokines secreted by adipocytes include leptin, adiponectin, necrosis factor-α (TNF-
α) and interleukin (IL-6); the latter two being a marker of inflammation along with C-
reactive protein. Furthermore, tumours stimulate the production of aromatase and 
oestrogens locally via the autocrine and paracrine actions of TNF-α and IL-6.158 
Chronic inflammation has been implicated in various steps of tumour formation 
including cell proliferation, angiogenesis and metastasis, and suppression of apoptosis 
has been associated with increased risk of breast cancer.182 In vitro evidence suggests 
leptin may also promote cancer in a variety of ways including breast cancer cell 
proliferation, and via effects on ER and insulin signalling.158 Additionally, case-control 
studies have reported an association between leptin and breast cancer.164 Leptin 
suppresses appetite, and although high levels are found in obese individuals it is likely 
they develop leptin resistance.158 Adiponectin is inversely associated with insulin 
resistance and obesity, and is also inversely associated with breast cancer.183 
Inflammation, which is linked to abdominal obesity, is also associated with increased 
reactive oxidative species which can cause damage to DNA. 
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3.5.6 Physical activity  
There was sufficient evidence in the WCRF 2007 and 2008 reports to suggest that 
physical activity probably protects against breast cancer in post-menopausal women, 
whereas the evidence for pre-menopausal women is inconsistent and limited.7 169 For 
post-menopausal women meta-analyses showed a 3% decrease in risk per 7 MET 
(Metabolic equivalent task) hours of recreational activity per week (equivalent to about 
2 hours brisk walking).7 Since physical activity is difficult to measure this may explain 
some of the inconsistencies in the evidence base. There are a number of biological 
mechanisms involving hormones whereby physical activity may reduce the risk of 
breast cancer in post-menopausal women, though they remain unclear.  
In a recent review Neilson et al. proposed a biological model which links the influence 
of physical activity through BMI, oestrogens, insulin resistance and chronic 
inflammation, and also through less commonly considered biomarkers such as 
leptin.164 Physical activity can reduce adiposity which will then result in reduced 
amounts of circulating oestrogen produced from the conversion of androgens by 
aromatase found in adipose tissue. Fat loss from exercise will also lead to a reduction 
of inflammatory markers, such as TNF-α and IL-6, and also leptin, which have been 
associated with breast cancer risk.158 Physical activity also reduces insulin levels;184 
since this is inversely related to circulating SHBG the bioavailability of testosterone and 
oestradiol is also likely to decrease.175 179 180 Additionally, regular physical activity can 
sustain insulin sensitivity and reduce the likelihood of developing type-2 diabetes,184 
which is associated with breast cancer. 
3.5.7 Hormonal exposure in utero and childhood development 
Increases in birth-weight above 4000g compared to below 2500g are associated with 
increased breast cancer risk, and most consistently with pre-menopausal breast 
cancer.185 A 2007 WCRF meta-analysis showed an 8% increase in risk per kg increase 
in birth weight.7 Trichopoulos hypothesised that in utero exposure to oestrogen 
influences the risk of breast cancer,186 because oestrogen levels are at their highest 
during pregnancy and high maternal levels have been linked to high birth-weight.187 188 
IGF levels during pregnancy also substantially regulate foetal growth,189 and may play 
a role in increased breast cancer risk.185 These and other in utero factors may directly 
affect breast development, for instance by inducing epigenetic changes to the 
expression of oestrogen receptors, mammary stem cells or gland morphology.99 
Alternatively they may mediate breast cancer risk through other changes which 
increase risk in adult life; their mechanisms are as yet unclear.190  
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Birth length, adolescent height and adult height have been positively associated with 
breast cancer risk.191 192 Meta-analyses from the 2007 WCRF report showed for every 
5cm increase in adult height there is a 9% and 11% increased risk of pre-menopausal 
and post-menopausal breast cancer respectively 7 Factors that lead to adult height may 
influence breast cancer risk. Birth length, which is associated with adult height, may be 
a proxy for exposure to oestrogen and growth factors in utero. Birth length has also 
been associated with age at menarche; one study showed that girls who were long and 
light at birth had earlier menarche, which is associated with an increased risk.193 Early 
growth spurts in adolescence are also positively associated with early menarche, 
though it is unclear whether early growth spurts are an independent factor in breast 
cancer risk.191 Nutrition may influence age at menarche via rapid post-natal growth,193 
or through diet during childhood.133 134 Despite being linked to earlier onset of 
menarche, body fatness during childhood has been inversely related to breast cancer 
in later life.194 One hypothesis is that early breast differentiation induced via oestrogen 
by body fat may reduce breast malignancies later in life.195 Additionally, as mentioned 
in section 3.5.3 IGF-1 concentrations have been positively associated with increased 
height and with breast cancer risk, but are inversely associated with age at 
menarche.160 Furthermore, despite adult height being positively associated with breast 
cancer risk, taller women tend to have had a later menarche which can reduce breast 
cancer risk.191 Despite some inconsistencies in these explanatory mechanisms, early 
life and adolescence are critical times for maturation of the hypothalamic pituitary 
ovarian axis, which regulates production of oestrogen and other hormones linked to 
breast cancer risk.191  
 
3.6 Diet and breast cancer risk 
The risk of breast cancer varies internationally; possible reasons for this, in addition to 
differing provisions for recording breast cancer incidence, include differences in 
genetics, environmental pollutants, and lifestyle factors such as reproductive events, 
exercise and diet. The observation that the risk of cancer for populations who migrate 
alters from their country of origin to their country of residence indicates that, at the 
population level, it is changes in lifestyle or environment which have a large influence 
on risk rather than genetics. Ecological evidence relating to breast cancer is apparent 
from women of Asian origin settled in the US whose breast cancer risk is substantially 
above that of their country of origin.196 Given that one of the biggest changes in lifestyle 
for migrants is diet, this area of research has been given considerable attention. 
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On the whole the role of diet on cancer risk of individuals has been assessed using 
cohort or case-control studies, the latter being prone to recall bias and selection bias 
which may explain the frequent discrepancies in results between the two types of 
studies. Furthermore, self-reporting of food and supplement intake is prone to reporting 
bias in all types of studies, as well as measurement error, the latter being likely to 
attenuate any associations. Few dietary studies have used a RCT design, one 
weakness being the difficulty for randomised participants to adhere to new diets for a 
substantial length of time, although this is less of a problem with interventions using 
supplements. Conformity within the non-intervention group may also be poor, since 
motivated members may easily alter their dietary or supplement intake towards the 
intervention if this is known to them.  
Several approaches have been used to assess the role of diet on cancer risk focusing 
on dietary patterns, individual or groups of foods, or individual nutrients. The majority of 
the analyses in this thesis uses the individual nutrient approach, assessing the impact 
of vitamin C from diet and supplements in chapters 8 to 10 using cohort designs. The 
effect of fruit and vegetable intake, the main source of vitamin C, is also analysed in 
chapter 9. Sections 3.6.4.1 and 3.7 of this chapter review the previous research on 
vitamin C. First the evidence of breast cancer risk in relation to dietary patterns and 
some foods, focusing in particular on fruit and vegetable intake, will be discussed in 
sections 3.6.1 and 3.6.2. Then evidence relating to macronutrients that have been 
linked to breast cancer risk will be discussed in section 3.6.3  
3.6.1 Dietary Patterns  
The advantage of this over the individual food or nutrient approach is that dietary 
patterns incorporate interactions between foods or nutrients which are likely to occur in 
the body. Because of the difficulty of characterising dietary patterns, research in this 
area is not as extensive as other approaches. A dietary pattern constitutes a variety of 
dietary components which may typify the intake of a population or sub-population. 
Some of those that have been examined are traditional diets such as the 
Mediterranean and the Asian diets, which are viewed as healthy in contrast to the 
Western diet. The Mediterranean diet, characterised by seafood, poultry, fresh 
vegetables and olive oil, has been associated with a lower risk of breast cancer in US 
women,197 and in pre-menopausal women in the UKWCS, though the latter was non-
significant.198 Associations between a variety of healthy diet indices, based on healthy 
eating guidelines, and breast cancer risk have also been assessed.199 The alternate 
Mediterranean Diet Score (aMDS) and also the Alternate Healthy Eating Index (AHEI) 
and the Recommended Food Score (RFS) have been inversely associated with risk of 
post-menopausal oestrogen receptor negative (ER-) breast cancers.200 Inverse 
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associations between the Diet Quality Index-Revised (DQI-R) and also the Canadian 
Healthy Eating Index (CHEI) and BRCA cancers indicate that some dietary patterns 
may be protective for women at high risk.201  
3.6.1.1 Healthy and unhealthy dietary patterns 
Some studies have used factor analysis, principle components analysis or reduced 
rank regression to derive healthy and unhealthy dietary patterns; although these 
methods are less subjective than using diet scores, an element of subjectivity is still 
required during categorisation. A recent systematic review and meta-analysis of 18 
case-control and cohort studies found a small decreased risk in breast cancer for 
women in the highest compared to those in the lowest categories of prudent/healthy 
dietary patterns.202 No association was found for Western/unhealthy dietary patterns 
when both case-controls and cohorts were included, although a significant and modest 
increased risk was seen when only case-control studies were use; these however are 
prone to recall and selection bias.202 The Western unhealthy dietary patterns were 
characterised by high intake of red and/ or processed meat, refined grains, potatoes, 
sweets and high-fat dairy. Conversely the prudent/healthy dietary patterns was typified 
by high intake of fruit, vegetables, poultry, fish low-fat dairy and whole-grains.202   
3.6.1.2 Vegetarian compared to meat consumption dietary patterns 
Compared to meat consumption diets, vegetarian diets are low in energy and protein 
and have been associated with lower levels of IGF-1;203 increased levels of the latter 
have been positively associated with breast cancer risk as discussed in section 
3.5.3.160  Vegetarian diets also avoid the high temperature production of heterocyclic 
amines produced during the frying, grilling or barbecuing of muscle meats which are 
thought to increase cancer risk.204 On the other hand, it is possible that nitrates and 
nitrites found in vegetables may be converted in the body into carcinogenic 
nitrosamines compounds.205 These are also formed in meat during curing.205  
There is evidence that Mediterranean diets are anti-inflammatory;206 and as mentioned 
in section 3.5.5 this may influence breast cancer risk. In particular, there is some 
evidence that magnesium, dietary fibre, omega-3, polyunsaturated fatty acids, 
monounsaturated fatty acids, flavonoids, and carotenoids from food are associated with 
decreased levels of inflammatory markers in serum.206 Additionally, there is evidence 
from cross-sectional studies that vitamin C is associated with the anti-inflammatory 
marker C-reactive protein, however there are conflicting reports from RCTs.71 72 
A dietary pattern high in consumption of raw vegetables and olive oil, determined via 
factor analysis in the Italian ORDET cohort, was found to be protective against breast 
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cancer, particularly relating to HER-2 positive beast cancers or lean women of BMI 
below 25 kg/m2.207 Although vegetables are major components of the Mediterranean 
and prudent/health dietary patterns which are inversely associated with breast cancer, 
there was no evidence in the EPIC-Oxford cohort that a vegetarian diet free of meat or 
fish reduces the risk of breast cancer in UK women.208 The non-vegetarian comparison 
group in this cohort also had relatively high intakes of fruit and vegetables and this may 
have reduced the ability to find a significant association. There was also no evidence of 
a significant association between breast cancer risk and vegetarians in the fully 
adjusted model for pre or post-menopausal women in a UKWCS analysis of dietary 
patterns, when comparing them to women who ate red meat at least once a week.209 
Vegetarians were defined pragmatically as women who consumed red meat, poultry or 
fish less than once a week. In contrast, an earlier UKWCS analysis using a stricter 
definition of vegetarians who ate no meat, reported that vegetarians had a lower breast 
cancer rate than women who had medium to high intakes of red or processed or total 
meat.82 However in the analysis of pre-menopausal women, low meat consumers were 
found to have a 32% lower risk than vegetarians, even after adjusting for the different 
characteristics of these groups.82 The authors suggest that the vegetarian group may 
consist of a larger proportion of women genetically at high risk of breast cancer who 
started a vegetarian diet in the hope that it may be protective.82 Alternatively, 
vegetarians may lack dietary components that are protective, particularly if some foods 
are consumed in moderation. Dose-response relations relating to fruit and vegetable 
intake are mentioned in section 3.6.2.1 on food groups.  
 
In the UKWCS, compared to women who ate red meat at least once a week, a dietary 
pattern of eating fish at least once a week (excluding the consumption of red or white 
meat once a week or more) was inversely associated with breast cancer incidence.209 
A reduced risk of 40% was found for post-menopausal women, but there were no 
associations relating to pre-menopausal women. 
3.6.2 Foods 
On the whole the WCRF 2007 report on Food, Nutrition, Physical Activity and the  
Prevention of Cancer focused on food rather than dietary patterns or individual 
nutrients, and reasoned that micronutrients may be simply markers for particular foods 
which contain other constituents that are associated with cancer development and 
progression.7 Despite extensive systematic literature reviews and meta-analyses 
limited conclusions were reached about the influence of the foods considered in the 
WCRF 2007 report (summarised in Appendix A) and in the 2008 continuous update for 
breast cancer; evidence was limited due mainly to conflicting results from different 
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studies.7 169 Whilst retrospective case-control studies have produced evidence of 
protective effects for some foods, results from cohorts are often mixed. There was, 
however, convincing evidence that alcohol increased breast cancer risk in both pre- 
and post-menopausal women and suggestive evidence that fats increased risk in post-
menopausal women. A review of prospective observational studies by Michels et al. 
(2007) relating to intake of fruit and vegetables, dairy products and macronutrients 
such as fats and carbohydrates found no consistent, strong or statistically significant 
evidence of an association between diet and breast cancer, other than through being 
overweight and gaining weight.11 The evidence relating to breast cancer risk and the 
amount of fruit and vegetables and dairy products consumed are discussed in more 
detail here. Dietary constituents such as fats, carbohydrate, fibre and alcohol are 
discussed in the following macronutrient section. 
3.6.2.1 Fruit and vegetables 
Theoretically, there are various mechanisms by which fruit and vegetables could 
reduce cancer risk. As low energy-dense foods, they may help to reduce weight gain 
and obesity, which as seen in section 3.5.5 has been linked to increased breast cancer 
risk. Additionally their fibre content may help to regulate and increase the excretion of 
endogenous oestrogen,210 thereby reducing exposure to one of the main hormones 
associated with breast cancer development (section 3.5.3). A diverse intake of fruit and 
vegetables can also provide a variety of vitamins and mineral including carotenoids, 
folate, vitamin C, D, E and selenium. Other bioactive compounds such as 
phytochemicals found in fruit and vegetables are non-essential components for 
humans but provide colour, flavour and preservation. Many of these bioactive 
compounds are believed to protect against cancer, for instance via their antioxidant 
properties. Unfortunately, storage and cooking processes usually reduce the nutrient 
content of fruit and vegetables, particularly in the case of vitamin C which is destroyed 
by heating or exposure to air by chopping; additionally, it is lost into the cooking 
water.39 However, processing can also increase the bioavailability of some nutrients for 
absorption within the intestine; pureeing and adding oil increases the bioavailability of 
fat soluble lycopene found in tomatoes,211 and chopping some foods can release 
enzymes that help the formation of other nutrients. Growing and transport conditions in 
addition to the timing of harvesting can also alter the nutrient content of foods.  
The 2007 WCRF report judged that there was sufficient evidence to show that high 
intakes of fruit and non-starchy vegetables probably reduce the risk of cancers of the 
digestive track, such as mouth, larynx, oesophagus and stomach.7. However, a recent 
EPIC analysis found only a very small inverse association between intake of total fruits 
and vegetables and total cancer risk.212 Furthermore, there is no conclusive evidence 
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they are associated with breast cancer, whether this be grouped as total fruit, total 
vegetables or fruit and vegetables.7 11-13 Meta-analyses which included mainly 
retrospective case-control studies reported a reduction in breast cancer risk with 
increasing intake of total fruit and vegetables by as much as 25%.8 213 However, results 
of a subsequent pooled analysis of cohort studies showed that fruit and vegetable 
consumption was not significantly associated with breast cancer risk.12 The 
susceptibility of case-control studies to recall bias and selection bias may explain the 
discrepancy in results. Furthermore, the pooling of studies is superior to meta-analyses 
since it ensures a standardised approach to coding, grouping of intake categories, 
analysis and adjustment by confounders. Nevertheless, a limitation of both designs is 
that dietary measurement may vary systematically between studies, even if similar 
measurement tools are used. One aspect of measurement error for the FFQs is that 
recorded intake of fruit and vegetable tends to increase with increasing numbers of fruit 
and vegetable items on the FFQs. This was evident in the pooling of eight studies from 
Northern Europe and North America where fruit and vegetable items varied 4-fold 
between the studies.12 A pooling of eight European cohort studies by EPIC attempted 
to overcome differences in FFQs by calibrating the FFQs used in all the studies with 
the same 24-hour recall instrument; furthermore the measurement errors of the tools 
were likely to be independent.13 This analysis, however, also found no significant 
associations, although this may have been limited by the median follow-up of only 5.4 
years.13 A strength of this pooling project was the wide range of fruit and vegetable 
intakes found throughout Europe, which increased the power to detect a significant 
result.  
 
The EPIC pooling project also examined specific vegetables in relation to breast cancer 
risk, but found no inverse associations.13 Subgroups examined were: leafy vegetables, 
fruiting vegetables, root vegetables, cabbages, mushrooms and garlic and onions. 
Other groups of vegetables were examined in the pooling project of studies from 
Northern Europe and North America, but no associations were observed for green leafy 
vegetables, eight botanical groups and 17 specific fruit and vegetables.12 Although 
preparation of brassica/cruciferous vegetables (broccoli, cauliflower and cabbage) 
produces isothiocyanates and indole-3-carbinol which may be anti-carcinogenic, 
evidence of a protective association between breast cancer and this type of vegetables 
has only been observed in case-control studies.214  
 
Daily grapefruit intake, which is high in vitamin C content, was associated with a 30% 
increased risk of post-menopausal breast cancer in a US cohort study, where higher 
risks were observed for non-users of HRT 215 However this was not supported by 
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results of a second study.216 Grapefruit, nevertheless, has been found to increase 
plasma oestrogen concentrations,217 possibly through the inhibition of the CYP3A4 
enzyme which is involved in the metabolism of oestrogen. 
 
There are indications from cohort studies that the relationship between fruit and 
vegetable intake and breast cancer risk may be modified by hormonal receptor status. 
Fruit and vegetable intake, and healthy dietary indexes which recommend high intakes 
of fruit and vegetables amongst other items, have been inversely associated with risk 
of oestrogen receptor negative (ER-) breast cancers.200 218 In a cohort study of African-
American women significant associations between a prudent diet and specifically 
between frequent vegetable intake and oestrogen/progesterone receptor negative (ER-
PR-) breast cancers have been observed.219 220 There is also evidence that high 
consumption of raw vegetables can potentially reduce HER-2 positive beast cancers by 
up to 75%.207   
3.6.2.2 Dairy products 
Dairy products have been associated with IGF-1 levels in children in the UK.221 US milk 
used in dairy products is likely to have higher levels of IGF-1 since, unlike milk in the 
UK and Europe, it is contaminated with bovine growth hormones which increase levels 
of IGF-1, as well as being fortified with vitamin D.11 As discussed in section 3.5.3, IGF 
is positively associated with breast cancer,160 therefore associations between breast 
cancer and dairy products in US studies may differ from European studies. However, in 
one review no differences in results were found from cohort studies by region;11 many 
studies showed an inverse association between dairy products or milk and breast 
cancer risk, some being significant.11 169 The 2008 WCRF continuous report, however, 
judged that no conclusions could be reached on whether dairy products influenced 
breast cancer risk, or on whether vitamin D did so either.169  
3.6.3 Macronutrients and breast cancer risk 
3.6.3.1 Fats 
Fat intake has been the focus of many studies. In the 2007 WCRF report and its 
detailed breast cancer systematic literature review, meta-analyses of case-control 
studies showed weak but significant increases in breast cancer risk with increasing 
total fat, saturated fat intake or mono-unsaturated fat intake.7 Conversely, inconsistent 
results were found for cohort studies, though a meta-analysis of 4 cohort studies 
showed a weak increased risk for saturated fat in post-menopausal women.7 Since 
then a large EPIC pooling study of over 300,000 women from European cohorts 
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reported a significant 13% increased risk of breast cancer with increased saturated fat 
intake.222  
In comparisons of dietary tools used, an initial analysis of EPIC-Norfolk found a 22% 
significant increase in breast cancer risk per quintile increase in energy adjusted 
saturated fat intake using 7-day diary data, but not using FFQ data when analysing the 
same women.223 Bingham et al. (2003) suggest that measurement error may be the 
reason why many studies using FFQs find no associations. 223 Similarly the nested 
case-control analysis of the Women’s Health Initiative Study (WHI) found a significant 
positive association using 4-day diaries and a non-significant association using 
FFQs.224 Results of a recent pooled analysis of additional UK studies using diary data, 
however, did not support these findings.225 Although diary recordings may be more 
detailed, they are not without their limitations, the main one being their short-term 
episodic nature. Additionally, since they are very time consuming, participants may 
alter their diet in order to record less items, furthermore the quality of recording may 
reduce over the diary time period; nevertheless this is the same for both cases and 
controls. 
An RCT using an intervention group target of reducing dietary fat intake by 20% and 
increasing fruit and vegetable intake to at least five portions, and grain intake to at least 
six portions, did not find a significant reduction in breast cancer incidence overall after 
an average follow-up of 8 years.226 Although there was a significant difference in fat 
intake between the groups, very few in the intervention group achieved the target of 
reducing fat intake by 20%. However, women in the intervention group who were in the 
highest quartile for fat intake at baseline showed a 20% significantly lower risk of breast 
cancer compared to similar women in the non-intervention group.226 The intervention 
group also had a lower risk of developing progesterone receptor negative breast 
cancer. A recent review of studies of intentional weight loss supports the hypothesis 
that intentional weight loss can substantially reduce cancer risk.227 Weight loss is 
associated with decreased endogenous oestrogen levels and increased levels of 
serum levels of sex-hormone-binding globulin (SHBG),227 which have been consistently 
linked to breast cancer risk in menopausal women (section 3.5.3). Weight loss is also 
linked to decreased inflammatory markers,227 which as discussed in section 3.5.5, is 
another mechanisms by which body fatness may be positively associated with breast 
cancer risk.  
3.6.3.2 Carbohydrates 
Carbohydrates as an energy source are available as complex polysaccharides such as 
starch found in breads, rice, peas, beans, root vegetables, potatoes and bananas, or 
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as simple carbohydrates i.e. sugars which are found in many processed foods and 
drinks, and also in fruit and vegetables.  
 
A meta-analysis of cohort studies in the 2007 WCRF report, produced evidence of 
borderline significance of a positive association between carbohydrate intake and 
breast cancer risk in post-menopausal women (pooled RR per 50g/d=1.09; 95% CI: 
1.00, 1.18).7 The four studies included in the 2008 WCRF/AICR continuous update 
report relating to energy from carbohydrates and breast cancer risk provided 
insufficient evidence of an association.169 Nevertheless, there was evidence of a 
positive association between percentage energy from carbohydrates with a high 
glycemic index (GI) and breast cancer risk in an Italian prospective study, not split by 
menopausal status.228 Results for low GI food were not significant.228 Glycemic Index 
(GI) is a measure of the effect of carbohydrates on plasma blood sugar levels, and 
glycemic load (GL) is the measure per 100g serving. Simple and refined 
carbohydrates, such as white bread, release sugar quickly and have a high GI, 
whereas whole grain products tend to have lower GI. Although GI and GL are positively 
associated with insulin levels, and insulin resistance and hyperinsulinemia has been 
positively associated with breast cancer incidence,163 research into GI and GL have 
produced null or unexpected results with breast cancer incidence.11 229 230  
3.6.3.3 Fibre  
Fibre, the indigestible content of foods such as non-starch-polysaccharide 
carbohydrates which are present in some fruit and vegetable, cereals and legumes 
may also influence risk, via possible affects on hormone levels.231 However the weak 
inverse association with fibre found in the 2008 WCRF meta-analysis of cohort studies 
did not reach significance for post-menopausal women (pooled RR=0.96,95% CI: 0.91, 
1.01).169 Results for pre-menopausal women were also inconclusive in the WCRF 
continuous update.169 However there was some evidence of a reduction in risk with 
higher fibre intakes in an earlier analysis of pre-menopausal women in the UKWCS 
(high versus low RR= 0.48, 95% CI: 0.24, 0.96); fibre from cereals and possibly fruit 
appeared protective.231 A very recent meta-analysis of 10 cohort studies, which 
grouped together both pre- and post-menopausal women, reported a 11% reduction in 
breast cancer risk from total dietary fibre which was significant.232 Evidence, however, 
was limited about whether specific food sources of fibre, i.e. cereal, fruit or vegetable, 
were protective.232 
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3.6.3.4 Alcohol 
The majority of cohort and case-control studies report a positive association between 
alcohol intake and breast cancer risk.7 Meta-analyses and pooling studies estimate the 
risk to increase linearly by 7-10% per 10mg/d increase in ethanol intake.7 169 This 
evidence was judged as convincing in the 2007 WCRF report and in the 2008 WCRF 
continuous update report for both pre- and post-menopausal breast cancers.7 169 A few 
cohort studies have reported increased risk for hormone receptor positive tumours but 
not for ER-PR- breast cancer with increasing alcohol intake,233-235 indicating that 
alcohol interferes with oestrogen metabolism. Additionally, it has been observed in 
some studies that high folate intake attenuates the association between alcohol intake 
and breast cancer risk.236  
3.6.4  Micronutrients and breast cancer risk 
Initial research using retrospective recall methods in case-control studies indicated that 
fruit and vegetable intake probably reduced the risk of many cancers, including breast 
cancer.8 Subsequently the identification of the active component in fruit and vegetables 
has been the focus of many studies. Micronutrients such as vitamins, minerals and 
antioxidants in these foods have been considered to be potentially protective against 
cancer, indeed the meta-analyses of retrospective studies indicated some 
micronutrients were protective.8 Possible protective mechanisms of vitamin C and other 
antioxidants have been put forward, which have been discussed in section 2.2.4. 
Furthermore, the 2007 second WCRF report judged there was convincing or probable 
evidence from prospective studies that some micronutrients were associated with 
specific cancers (summarised in Appendix B).7 For instance, it reported that the 
antioxidant selenium was associated with a reduced risk of lung, stomach and prostate 
cancer,7 although more recent results from the SELECT trial do not support the 
latter.237 Conversely, there was important convincing evidence that supplementation 
with the antioxidant β-carotene increased the risk of lung cancer in smokers.238 
However, prospective studies assessing dietary and/or supplement intake in relation to 
breast cancer incidence have produced many null or conflicting results. The 2007 
WCRF report judged that the evidence was limited or non-conclusive, therefore no 
conclusion could be reached regarding the intake of micronutrients and breast cancer 
risk.7 The 2008 WCRF continuous update report for breast cancer which reviewed 
studies published to the end of 2008 also made the same judgement.169  
In relation to antioxidants and breast cancer risk most prospective studies have 
reported no associations for carotene, vitamin A or vitamin E intake,239-246 although the 
Nurses Health Study reported protective effects for vitamin A, vitamin E intake and α- 
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and β-carotene for pre-menopausal women with a family history of breast cancer.169 247 
Similarly there was no overall convincing evidence of associations between the intake 
of vitamin C and breast cancer risk; these studies are discussed in sections 3.6.4.1 and 
3.7.  
In general, the 2007 WCRF report recommended that nutritional needs should be met 
through diet alone, when possible, rather than through supplementation. Furthermore, 
most studies published since the WCRF reported no reduced risk of cancer from 
micronutrient supplementation or reported evidence of harm.14 248-254 A meta-analysis of 
four antioxidant RCTs published to October 2007 showed no association between 
antioxidant supplementation and breast cancer risk (RR=1.0; 95% CI: 0.90, 1.11).255 A 
more recent factorial designed RCT based in the US using daily 500mg vitamin C, 
600IU Vitamin E every other day and 50mg beta carotene every other day reported no 
effects of these on breast cancer incidence as well as on total cancer.14 The French 
SU.VI.MAX trial used low dose antioxidant supplements (120mg vitamin C; 33iu 
vitamin E; 100µg selenium) and reported a reduced risk of total cancer in men but not 
women, which may be due to the lower baseline antioxidant status of men.256 Breast 
cancer risk was not reported in this trial.  
Most studies evaluating the relationship between supplement use and breast cancer 
risk have focused on individual supplements. Only a few studies mentioned in the 2007 
WCRF review examined general supplement use in relation to breast cancer and these 
were case-control studies which may be prone to selection and recall bias.257-259 No 
associations were found in the Danish and US studies reported in the 2007 review,257 
259 whereas a significant protective effect of supplements on breast cancer was found 
in a Taiwanese study (OR=0.40, 95% CI: 0.3, 0.7). Taiwanese women may generally 
have lower intake levels of nutrients than western women and therefore may require 
supplementation to reduce their risk. 
A recent meta-analysis of five cohort studies found no evidence of a significant 
association between multivitamin use and breast cancer risk.260 This included a 
Swedish study which reported an association between multivitamin use and increased 
risk of breast cancer.261 The authors suggest that folic acid in the multivitamins may 
have promoted cancer, since there is no mandatory folic acid fortification of food in 
Sweden. Conversely, the US does fortify food with folic acid and the four US studies 
have not found an increased risk of breast cancer with multivitamin use.250 251 262 263  
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3.6.4.1 WCRF systematic literature review of vitamin C intake and breast 
cancer risk 
Over thirty-five studies published to the beginning of 2006 relating to vitamin C intake  
and breast cancer risk were systematically reviewed in the 2007 WCRF report;7 most 
were retrospective case-control studies, 12 were prospective cohort studies and 5 of 
these were nested case-control studies (the individual cohorts are detailed in Table 3 in 
section 3.7.2). The meta-analysis of 14 retrospective case-control studies of dietary 
vitamin C intake provided significant evidence of a protective association for breast 
cancer not split by menopausal status (RR=0.88, 95% CI: 0.84, 0.92 per 100mg/day), 
though heterogeneity was high (I2 = 85%) between the studies. Meta-analyses of pre-
menopausal (RR=0.90; 95% CI: 0.82, 0.98 per 100mg/day), and post-menopausal 
analyses (RR=0.86; 95% CI 0.79-0.93 per 100mg/day), supported this, as did the 
analyses comparing high verses low intake categories. In contrast, as seen later in 
Table 3 in section 3.7.2, cohort results were inconclusive; this was the case for 
analyses assessing dietary vitamin C only,239 240 242 243 245-247 264-267 supplement vitamin C 
only,241 242 245-247 267 or total vitamin C intake.239 241 242 245 247 In the 2007 WCRF report no 
significant associations were produced for dietary vitamin C in the post-menopausal 
women meta-analyses of three cohort studies (HR=1.15; 95% CI: 0.92, 1.43 per 
100mg/d), 7 245 246 265 or in the high versus low intake analysis of two US studies.242 247  
One study included in the WCRF cohort meta-analyses did find substantial evidence 
that breast cancer risk increased with increasing vitamin C intake in relation to dietary 
only (RR=2.06; 95%CI 1.45, 2.91, per 100mg/d), supplementation only (RR=1.06; 
95%CI: 1.01,1.13) and total vitamin C intake (RR=1.08; 95%CI: 1.02, 1.15).245 This 
Danish nested case-control study is compared with the other studies later in this 
chapter. 
A prospective nested case-control study included in the 2007 WCRF report assessed 
the relationship between vitamin C plasma levels and breast cancer and found no 
association.268 Whether or not plasma levels are a better indicator of vitamin C intake 
than data from FFQs or diaries is discussed in section 5.4 in the evaluation chapter. 
Differences in findings between study types may be due to recall bias in the 
retrospective case-control studies or to differences between assessment methods; 
FFQs were used in the cohort studies and interview-administered diet histories were 
used mainly in retrospective case-control studies. No relevant studies were published 
between the search for the 2007 WCRF report and that for the 2008 WCRF continuous 
update, although results are now clearly tabled in the latter.169 The studies from the 
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WCRF reports are tabled and compared in section 3.7 of this thesis with the studies 
found from the new literature search undertaken in 2011 for this thesis. 
3.7 Updated systematic literature review of vitamin C 
intake and risk of breast cancer 
The purpose of this systematic review was to search for and evaluate cohort studies 
and RCTs relating to vitamin C intake and breast cancer incidence in women with no 
previous breast cancer. Only studies that were published since the beginning of 2006 
until June 2011, and that were not included in the 2007 or 2008 WCRF, report were 
considered. New case-control studies were not evaluated since it was clear from 
previous meta-analyses that these types of studies show an inverse association 
between retrospectively reported vitamin C intake and decreased breast cancer risk; 
these findings may be due to recall bias. 
3.7.1 Criteria for considering studies 
Types of studies 
Included: Cohorts, prospective nested case-control studies and RCTs. Reported in 
English. 
Excluded: Retrospective case-control studies, cross-sectional studies 
 
Types of participants 
Included: women whose dietary or supplement vitamin C intake has been estimated, or 
who were part of an RCT vitamin C supplementation study and whose cancer status 
was known at time of dietary recording/intervention and at censor date. No age limit, 
any country 
Excluded: women with previous breast cancer (i.e. cancer patients or survivors) 
 
Types of exposure 
Included: dietary or supplement vitamin C intake estimated using dietary assessment 
tools such as FFQs and diaries or intake provided in the intervention of a RCT 
supplementation study 
 
Types of outcome 
Included: incident invasive breast cancer  
3.7.1.1 Search strategy for identification of studies 
OVID MEDLINE (Jan 2006-June 2011) was systematically searched for relevant 
articles using the key words which may appear in the title, subject headings or abstract 
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of articles. These key words were: vitamin C; ascorbate; ascorbic acid; antioxidant in 
conjunction with vitamin; micronutrients in conjunction with fruit and vegetable; breast 
in conjunction with cancer, neoplasm, tumour, malignant, carcinoma and 
adenocarcinoma. The search was restricted to extract articles relating to diet only 
studies using key words: food, diet, intake, nutrient, supplement, nutrient surveys, 
dietary supplement, and dietary record. It was also restricted to include only those 
articles published during and after the last year of the WCRF 2007 search i.e. from the 
beginning of 2006 to the beginning of June 2011. Search criteria were also applied to 
restrict the search to epidemiological studies using terms recommended by the BMJ.269 
The full search strategies can be found in 0.  
The initial search criteria found 62 articles, six of which were duplicates. The title, 
subject headings and abstracts for all the articles were downloaded into a reference 
database and labelled according to their relevance. Eight articles at this stage 
appeared relevant, relating to the study of the association between breast cancer risk 
and vitamin C intake.244 270-276 Five were case-control studies and were excluded,271 272 
274-276 two of these were sub-analysed by genotype.272 276 This left three cohort studies 
for the main review,244 270 273 which are tabled in Table 2. 
Articles citing or cited by relevant articles which were identified above or in the 2007 
WCRF report were manually screened to determine whether they were also relevant. 
No further cohort studies were found; however, one RCT was identified which analysed 
vitamin C supplementation and breast cancer risk, though ‘breast cancer’ did not 
appear in the title or abstract.14 Figure 6 shows the flow diagram of the studies included 
in this current review. A limitation of the search criteria was that articles with breast 
cancer analyses included in the main body would not be identified if only ‘cancer’, but 
not ‘breast cancer’ had been included in the title or abstract. Furthermore, articles that 
did not contain key words related to vitamin C in the title or abstract may have been 
missed. As described at the end of 0 some work was undertaken to check the latter, 
but no additional articles that were found met the full inclusion criteria.  
Later, during a follow-up manual search for citations, a meta-analysis of vitamin C and 
breast cancer risk was found which was published online in July 2011. This review by 
Fulan et al. (2011), which had searched for publications to March 2011, found no 
studies in addition to those found in the search undertaken for this thesis.277 
Furthermore, it did not report finding one study (Roswall et al. 2010)273 which was 
found in the current search. Nevertheless, since this recently published review had 
searched the PubMed, Embase and Cochrane databases, it was decided not to extend 
the current search to other databases.277 
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3.7.2 Search results summary 
The four recent studies identified in the current search relating to breast cancer risk 
and vitamin C intake are summarised in this section and shown in Table 2. In later 
sections these are compared with the studies that were included in the 2007 WCRF 
report and the 2008 WCRF continuous update which are shown in Table 3.7 169 
Two out of the three cohort studies retrieved undertook separate analysis for dietary 
vitamin C intake, supplement intake and also diet plus supplement i.e. total vitamin C 
intake in postmenopausal women.270 273 Both of these studies also sub-analysed by 
hormone-receptor status of the cancers, the results of which are discussed in section 
3.7.3.1.3. One was an analysis by Cui et al. (2008)  of the Women’s Health Initiative 
study, a large US cohort following 84,805 women over an average of 7.6 years with 
2879 cases which did find an increased risk of breast cancer with intake.270 The other 
study by Roswall et al. (2010) followed 26,224 Danish women over a median of 10.6 
years with 1072 cases, and did not find any evidence of an association with vitamin C 
intake. 273 A previous analysis of this Danish cohort by Nissen et al. (2003) found an 
increase in breast cancer risk with dietary, supplement and total vitamin C intake, 
however this was a nested case-control study and therefore was subject to potential 
selection bias of the controls, and incidences were followed-up for a shorter period.245  
The third study retrieved was an EPIC pooled analysis of cohort data from 10 
European countries following about 520,000 women over a median of 8.8 years 
resulting in 7502 cases.244 Only dietary vitamin C was considered in this analysis. It 
was substantially larger than any previous study undertaken relating to breast cancer 
and vitamin C intake, and had sufficient power to sub-analyse by supplement use, 
alcohol consumption, hormone use and smoking status, as well as by menopausal 
status. To account for differences in questionnaire design and follow-up procedures 
between the cohorts, a stratum method of Cox proportional hazards was used. This did 
not find any significant associations in the main pre- and post-menopausal sub-
analyses. 
The RCT, the Women’s Antioxidant Cardiovascular Study (WACS) mentioned earlier in 
section 3.6.4, was based in the US and had a factorial design with intervention groups 
using 500mg vitamin C daily, 600IU Vitamin E every other day and 50mg beta carotene 
every other day for 9.4 years. Women who were at high risk of cardiovascular disease, 
post-menopausal and over 40 were recruited. The study reported no effects of the 
supplements, either individually or together, on total cancer, including breast cancer 
incidence or mortality.14  
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Figure 6 Flow diagram of studies identified in current literature search
62 articles indentified from 
Ovid Medline using original 
search criteria 
6 duplicates 
8 articles relating to breast 
cancer incidence and 
vitamin C intake published 
since 01/01/ 2006 
5 case-control studies 
excluded (2 genotype 
case-control)  
46 non-relevant studies 
excluded 
2 relating to mortality or 
recurrence in survivors 
excluded 
3 cohort studies 
1 RCT 
1 RCT found from 
manual searching 
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Table 2 Studies identified by a search for articles published after the 2007 WCRF report and 2008 WCRF continuous update    
Author, 
year 
Study Design 
Baseline 
date & age 
Follow up & 
cancer 
incidence 
Meno-
pausal 
status 
Vitamin C risk ratios Additional 
sub-group 
analyses 
Roswall 
et al 
2010
273
 
Diet, Cancer 
and Health 
Cohort 
Denmark 
Prospective 
N=26,224 
1993-1997 
Age 50-64 
Median 
10.6yrs 
1072 cases 
Post High vs. Low intake 
Total            1.11 (0.88-1.40) ptrend = 0.38 
Dietary         1.15 (0.92-1.44) ptrend = 0.96 
Supplement  0.96 (0.77-1.21) ptrend = 0.41 
ER and PR status 
Histology 
Nagel et 
al 2010
244
 
EPIC 
Europe wide 
Prospective 
pooled cohorts 
N=520,000 
1992-2000 
Age 35-70 
Median 
8.8yrs 
7502 cases 
 
Pre 
 
 
 
Post 
 
High vs. Low intake 
Dietary         1.12 (0.92-1.46) ptrend = 0.37 
Non-supplement users  
                    1.15 (0.88-1.51) ptrend = 0.69 
 
Dietary         0.98 (0.87-1.11) ptrend = 0.79 
Non-supplement users  
                    0.92 (0.77-1.10) ptrend = 0.69 
Alcohol 
consumption, 
hormone use, 
smoking status 
Cui et al 
2008
270
 
Women’s 
Health 
Initiative  
US 
Prospective 
cohort 
N=84,805 
1993-1998 
Age 50-79 
Av 7.6yrs 
2879 cases 
Post High vs. Low intake 
Total             1.18 (1.04-1.34) ptrend = 0.009 
Dietary          1.06 (0.92-1.22) ptrend = 0.23 
Supplement  1.16 (1.04-1.30) ptrend = 0.03 
 
ER and PR status 
Lin et al 
2009
14
 
Women’s 
Antioxidant 
Cardio-
vascular Study 
US 
RCT 
Factorial design 
N=7,627 
Age >=40 
Av 9 yrs 
135 cases 
Post 500mg/d supplement group 
compared to placebo group  
                      1.11 (0.87–1.41) 
 
600 IU/d vitamin 
E 
50/2d β-carotene 
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Table 3 The WCRF reported studies on vitamin C intake and breast cancer risk 
Author, 
year 
Study Design 
Baseline 
date & age 
Follow up & 
cancer 
incidence 
Meno-
pausal 
status 
Vitamin C risk ratios Additional 
sub-group analyses 
Cho et 
al. 
2003
239
 
Nurses’ Health 
Study II 
US 
Prospective 
cohort 
N=90,655 
1991-1999 
Age BL 26-46 
8yrs:  
714 cases 
Pre High vs. low intake 
Total   0.98 (0.75-1.21) ptrend=0.72 
Diet    1.30 (1.00-1.69) ptrend=0.16 
 
Smoking status 
 
Nissen 
et al. 
2003
245
 
Danish Diet & 
Cancer Cohort 
Prospective  
nested case-
control 
1993-1997 
Age 50-64 
Mean 4.7yrs: 
418 Cases 
394 control 
Both diet & sup: 
228 Cases  
246 controls 
Post Per 100mg/d (vit C sup users) 
Total   1.08 (1.02-1.15) 
Diet     2.06 (1.45-2.91) 
Sup     1.06 (1.01-1.13) 
 
Non-vit C 
supplement users 
=1.54 (0.08-2.96) 
Zhang 
et al. 
1999
247
 
Nurses’ Health 
Study 
US 
Prospective 
cohort 
1980 
N=83,235 
Age 33-60 
14yrs: 
2697 Cases 
Pre 784 
Post 1913 
 
 
Pre 
 
Post 
 
Not 
split 
High vs. low intake 
Total  1.01 (0.81-1.26) ptrend=0.59 
Diet    1.01 (0.81-1.26) ptrend=0.82 
Total   0.99 (0.85-1.14) ptrend=0.77 
Diet    1.06 (0.91-1.22) ptrend=0.57 
Supplement >1300mg/d vs. none 
           1.04 (0.77-1.42) 
HRT use, 
Family history of 
breast cancer, 
Alcohol  
Kushi  
et al. 
1996
242
 
Iowa Women’s 
Health Study 
US 
Prospective  
cohort 
1986 
N=34,387 
N=18,910(sup) 
Age 55-69 
Av 7yrs: 
879 Cases 
(sup 570) 
Post High vs. low intake 
Total   0.88 (0.70-1.11) ptrend=0.46 
Diet    1.06 (0.77-1.47) ptrend=0.88 
Sup    0.77 (0.50-1.17) ptrend=0.20 
Supplement only 
Graham 
et al. 
1992
265
 
New York State 
Cohort 
US 
Prospective 
cohort 
1980 
N=17401 
Age 50-107 
8yrs 
344 Cases 
Post High vs. low intake 
Diet    0.81 (0.59-1.12) ptrend=0.20 
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Table continued - The WCRF reported studies on vitamin C intake and breast cancer risk 
Author, 
year 
Study Design 
Baseline 
date & age 
Follow up & 
cancer 
incidence 
Meno-
pausal 
status 
Vitamin C risk ratios Additional 
sub-group analyses 
Li et al. 
2005
266
 
Shanghai Breast  
Self-
examination 
Trial 
Prospective 
Nested case-
control 
1995-2001 
Age 35-60+ 
Cases 130  
(who also had 
proliferative 
fibrocystic 
breast conditions) 
Controls 1070 
Not split High vs. low  
Diet     0.8 (0.2 - 2.6) ptrend=0.6 
 
Horn-
Ross et 
al. 
2002
240
 
California 
Teachers’ Study 
Prospective 
Cohort 
1995-1996 
Age 21-103 
2 years 
Cases 711 
Not split High vs. low  
Diet    1.1 (0.8 - 1.3) ptrend=0.5 
 
 
Michels 
et al. 
2001
243
 
Swedish 
Mammography 
Screening 
Cohort 
Prospective 
Cohort 
1987-1990 
Age 40-76 
130 months 
Cases 1271 
Not split High vs. low  
Diet    0.94 (0.78 -1.14) ptrend=0.99 
 
BMI:  >25 vs. ≤25 
kgm
-2 
 & high 
linoleic acid intake 
Verho-
even et 
al. 
1997
246
 
The Netherlands 
Cohort 
Study on Diet 
and Cancer 
Prospective 
Nested case-
control 
1986 
Age 55-69 
4.3 years 
Cases 650 
Controls 1066 
Not split 
(but 
likely 
post) 
High vs. low  
Diet    0.77 (0.55 -1.08) ptrend=0.08 
Vit C supplement  yes vs. no 
           1.06 (0.79-1.43)  
Low/High 
polyunsaturated 
fatty acids 
Rohan 
et al. 
1993
267
 
Canadian 
National Breast 
Screening Study 
Prospective 
Nested case-
control 
1982 
Age 40-59 
6 years 
Cases 519 
Controls 1182 
Not split Diet  per 119 mg/d 
           0.99 (0.83 -1.17)  
Supplement >250mg/d vs. none 
           1.46 (1.05-2.01) ptrend=0.98 
 
Giovann-
ucci, et 
al. 
1993
264 
Nurses' Health 
Study  
 
Prospective 
Nested case-
control 
1986 
Age 30-55 
2 years 
Cases 392 
Controls 786 
Not split High vs. low  
Diet     1.27 (0.82 -1.95) ptrend=0.25 
 
Hunter 
et al. 
1993
241
 
Nurses' Health 
Study  
 
Prospective 
Cohort 
1980 
Age 34-59 
8 years 
Cases 1439 
 
Not split High vs. low  
Total   1.03 (0.87-1.21) ptrend=0.67 
Supplement >1300mg/d vs. none 
           1.12 (0.75-1.69) ptrend=0.98 
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Table 4 Factors controlled for in the vitamin C studies published since the 2007 and 2008 WCRF reports 
Author, year Exclusions Hormonal factors 
controlled for 
Dietary factors 
controlled for 
Other factors controlled for  
Roswall et al. 
2010
273
 
Cancer diagnosis 
No lifetime menstruation 
Missing covariates and 
micronutrient intake 
HRT 
Parity 
Age at first birth 
Alcohol intake 
Total intake of 
vitamin E and B-
carotene 
Dietary or 
supplement 
vitamin C intake 
mutually 
adjusted 
Age (used as the underlying time scale for 
hazard ratio rather than adjusted for it as 
a covariate) 
BMI 
Education 
Nagel et al. 
2010
244
 
Missing non-dietary data  
Top & bottom 1% energy 
intake 
Age at menarche 
Age at full-term birth 
Parity 
Hormone therapy 
 
Energy from 
protein and 
carbohydrate 
Saturated fatty 
acids (SFA) 
MFA, PFA intake 
Alcohol intake 
Age (1 year intervals) 
Centre (stratified) 
Weight 
Height 
Smoking status 
Physical activity 
Education 
Cui et al. 
2008
270
 
History of breast cancer 
Implausible total energy 
intake <600>5000kcal/d 
 
Age at menarche 
Age at first live birth 
Parity 
Age at menopause 
Contraceptive use 
HRT use 
Hysterectomy 
Bilateral 
oophorectomy 
Energy intake 
Alcohol intake 
Dietary folate 
intake 
Dietary vitamin C 
Age 
Ethnicity 
Educational level 
Smoking 
Family history of breast cancer 
History of benign breast disease 
Lin  
et al. 2009
14
 
Self-reported cancer 
diagnosis (other than skin) 
Unwilling to avoid vitamin 
A,C or E use 
Randomised Randomised Randomised 
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Table 5 Factors controlled for in the studies included in the 2007 and 2008 WCRF reports  
Author, year Exclusions Hormonal factors 
controlled for 
Dietary factors 
controlled for 
Other factors controlled for  
Cho et al. 
2003
239
 
Post menopausal. 
Cancer (other than skin) 
Implausible total energy 
intake 
Missing >70 items on FFQ 
Age at menarche 
Oral contraceptive 
use 
Age at first birth 
Parity 
Menopausal status 
Calorie intake 
Animal fat 
Alcohol 
 
Age 
Height 
BMI 
Family history of breast cancer 
History of benign breast disease 
Smoking status 
Nissen et al. 
2003
245
 
Previous cancer diagnosis 
Pre-menopausal 
Missing items on FFQ 
Missing potential 
confounders on lifestyle 
questionnaire  
Age at first birth 
Parity 
HRT duration 
 
Intake of 
vitamin A & E 
(tested for total 
energy intake)  
Alcohol intake 
 
Cases and Controls matched on age 
School education 
History of benign breast disease 
BMI 
Zhang et al. 
1999
247
 
Previous cancer diagnosis 
Implausible total energy 
intake <500 or >3500kcal/d 
Missing >10 FFQ blank 
Age at menarche 
Age at first live birth 
Parity 
Age at menopause 
HRT use 
Alcohol intake Age 
Height 
Length of follow up 
BMI & BMI @18 yrs 
Weight change from 18yrs 
History of breast cancer in mother or sister 
Kushi et al. 
1996
242
 
Post menopausal. 
Full or partial breast 
removal 
Cancer (other than skin). 
Missing >30 items on FFQ 
Extreme total energy intake 
Age at menarche 
Age at first live birth 
Parity 
Age at menopause 
 
Energy intake 
Alcohol intake 
Age 
Educational attainment 
BMI @ BL & 18yrs 
Waist/hip ratio 
Family history of breast cancer among first 
degree relatives 
Graham et 
al. 
1992
265
 
Previous cancer diagnosis 
 
  Age 
Education 
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Table continued - Factors controlled for in the studies included in the 2007 and 2008 WCRF reports  
Author, year Exclusions Hormonal factors 
controlled for 
Dietary factors 
controlled for 
Other factors controlled for  
Li et al. 
2005
266
 
Energy intake >4000 kcal/d  Fruit & 
vegetable 
intake 
Age 
Matched on year of interview 
Horn-Ross 
et al. 2002
240
 
Previous cancer diagnosis 
Energy intakes <600 or 
>5000 kcal/d 
Age at menarche 
Age at first live birth 
Menopausal status 
 
Energy intake 
 
Age 
Race 
Family history of breast cancer  
Physical activity 
BMI 
Michels et al. 
2001
243
 
Previous cancer diagnosis 
(other than skin) 
Energy intakes <417 or 
>3729 kcal/d 
Missing or unreasonable 
covariate data 
Parity 
Age at first live birth 
Energy intake 
Intake of 
alcohol, fibre 
and mono-sat 
fatty acids 
Age (5 year categories) 
Family history of breast cancer  
Height 
BMI 
Education 
Verhoeven 
et al. 1997246 
Baseline self-reported 
cancer (other than skin) at 
baseline 
Incomplete FFQ (>60 items 
blank) 
Age at menarche 
Age at menopause 
Age at first live birth 
Parity 
Energy intake 
Alcohol intake 
Vitamin A 
Age 
History of benign breast disease 
History of breast cancer in mother or sister  
Rohan et al. 
1993
267
 
History of breast cancer 
No mammogram in 
proceeding 12 months 
Age at menarche 
Surgical menopause 
Age at first live birth 
Energy intake Matched on age (+/- 1yr, screening centre, 
date of enrolment) 
Age 
Years of education 
Family history of breast cancer  
History of benign breast disease 
Giovannucci, 
et al. 1993
264 
Energy intakes <500 or 
>4000 kcal/d 
  Matched on age 
Hunter et al. 
1993
241
 
Follow-up cases not 
confirmed by records 
Age at menarche 
Age at first live birth 
Menopausal status 
 
Energy intake 
Alcohol intake 
Age (5 year categories) 
Length of follow-up 
History of breast cancer in mother or sister  
BMI 
History of benign breast disease 
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3.7.2.1 Quality of studies  
The overall quality of the three cohort studies was good, with only some limitations. 
Quality was very good in relation to outcome measures which used methods employed 
by previous cohort studies: in two of the recent cohorts breast cancer incidence was 
provided from cancer registries;244 273 and in the other cohort and RCT, self-reported 
cases were independently assessed from medical records.270 Follow-up for the RCT 
was 93% complete. The average length of follow-up was between 7.6 and 10.6 years 
which is comparable with the previous cohort studies, the longest being the analyses of 
the Nurses’ Health Study (14 years). A limitation, however, is that these follow-up times 
may not be long enough to detect the development of cancer which can take decades.  
Quality was good in terms of controlling for confounding factors: similar to the majority 
of previous studies the cohorts adjusted for many known hormonal and non-hormonal 
factors linked to breast cancer as discussed earlier in this chapter, and seen in Table 4. 
There was additional adjustment for some dietary factors though these varied between 
cohorts and from previous cohorts. All of these, and previous studies, adjusted for 
alcohol intake and the majority adjusted for energy intake though this was not done in 
the main analysis of the Danish study;273 the previous nested case-control analysis of 
this cohort made adjustment for energy in sensitivity analysis.245 (A discussion of 
reasons for controlling for energy intake can be found in section 4.7.5.3.) The Danish 
study also adjusted for other antioxidants examined. In the supplement-only analyses 
adjustment was made for dietary vitamin C in the Women’s Heath Initiative and the 
Danish studies,245 270 273 but other supplement-only analyses did not do this.242 247 267 
Despite the adjustment for a large number of factors, residual confounding is still likely. 
The RCT was superior in this respect since potential confounding factors were 
randomised between intervention and non intervention group. However, there is no 
information on whether steps were taken to avoid subversion by staff during 
randomisation. Furthermore, some women in the non-intervention group may have 
consumed vitamin C supplements since they are readily available, even though they 
would have been asked to avoid using them.     
There were some weaknesses in relation to exposure which is common to all cohort 
studies in this research area: the vitamin C dietary and supplement intake of 
participants of all the cohorts may not be very representative of women in the 
populations they were recruited from. Women who were prepared to complete the 
FFQs (which in general comprised of between 100-200 items) were likely to be more 
health conscious that the average woman, and therefore more likely to have a higher 
intake of vitamin C. Since all cohorts used FFQs, the ascertainment of intake is 
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reasonably comparable between cohorts though there were some differences between 
types used. However, there are limitations with the self-reporting nature of FFQs, the 
general ability of the FFQ to record average intake and the conversion of food intake 
into nutrient intake, some of which are discussed further in chapter 5. In relation to 
exposure the RCT was limited to 500mg/d supplement intake, meaning it may be less 
able to detect the most effective dose than cohorts. Compliance, defined as having 
taken at least two thirds of the study supplements, was 76% at 4 years and 68% at 8 
years (average73%). Outside use of the supplements for at least 4 days per month was 
not different between the supplement and the placebo group, which ranged from 2% to 
13% at both 4 years and 8 years.14  
The results from the four recent studies for breast cancer risk in relation to vitamin C 
intake are discussed separately in the following sections by dietary, supplement and 
total intake (Table 2) and are compared to results of studies that were included in the 
2007 WCRF report and the 2008 WCRF continuous update (Table 3).7 169 
3.7.3 Dietary vitamin C intake 
3.7.3.1 Post-menopausal women 
All three of the recent cohort studies found no evidence of a significant association 
between dietary vitamin C intake and post-menopausal breast cancer risk.244 270 273 As 
seen in Table 2 risk ratios for high versus low intake for all three studies showed weak 
but non-significant increases in risk. There was also no significant evidence of trends 
across the intake groups neither in the three studies, nor for the risk per 100mg/d 
increases calculated in two of the studies where risk ratios were close to unity.244 273 
Similarly, three earlier analyses found no evidence of significant associations for post-
menopausal women in the New York State cohort, the Iowa Women’s Health Study 
and the Nurses’ Health Study.242 247 265 The analysis of women aged 55-69 in the 
Netherlands Cohort Study, likely to be of post-menopausal status, reported a small 
non-significant reduction in risk with increasing intake of dietary vitamin C (high versus 
lowest fifth OR= 0.77; 95% CI: 0.55, 1.08) and a significant trend in intake.246  
In contrast, Nissen et al. (2003) in an earlier nested case-control analysis of the Danish 
Diet, Cancer and Health cohort  (418 case and 394 controls) did find a significant 
doubling in risk per 100mg/d increase in intake for post-menopausal women (OR=2.06; 
95% CI: 1.45, 2.91).245 Unlike other studies mentioned, this was restricted to women 
who consumed vitamin C through both diet and supplements; women who did not 
consume vitamin C supplements were excluded.245 This nested case-control study 
followed women for 4.7 years; a shorter period than the other studies. Unlike the other 
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studies in the WCRF meta-analysis, Nissen et al. (2003) adjusted for intake of the other 
antioxidants vitamin A and E. Other possible reasons for the difference between the 
results of two analyses of the Danish cohort could be due to selection bias of the 
controls in the earlier nested case-control study, or that both cases and controls may 
not have been representative of the whole cohort, or that the more recent analysis 
used age as the underlying time scale for the hazard ratio calculation rather than 
adjusted for it as a covariate.245 273   
This risk ratio of 2.06 from the Danish study was used in the 2007 WCRF cohort meta-
analysis of dietary vitamin C intake for postmenopausal women,7 even though the other 
studies in the meta-analysis did not restrict their analysis to women who consumed 
vitamin C through both diet and supplements. Combined with the New York State 
Cohort and the Netherland Cohort,246 265 a non-significant increase in risk per 100mg/d 
increase in dietary intake for post-menopausal women was produced in the meta-
analysis (RR=1.15; 95% CI: 0.92, 1.43).7 Updating the meta-analysis to include recent 
studies may produce results closer to unity; the risk ratio was close to unity for the 
EPIC pooling project, and since this was a very large study it would have a much 
greater weighting than the other cohorts. Indeed, the recent meta-analysis of dietary 
vitamin C by Fulan et al. (2011) produced non-significant odds ratios close to unity for 
post-menopausal women (RR=0.97; 95% CI: 0.81, 1.06). However this calculation 
included case-control studies as well as cohort studies.277 Although it included the 
recent large EPIC pooling project and the Women’s Health Initiative,244 270 Fulan et al. 
(2011) had  not included the Roswall et al. (2010) Danish study273 in any of their meta-
analyses.277 Rather than continuous estimates, the Fulan et al. (2011) pooled high 
versus low results of the studies even though the cut off points for each study were 
different; this was an additional limitation of the meta-analyses.  
3.7.3.1.1 Non-supplement users 
Supplement users in general have healthier behaviours than non-users,27 therefore 
excluding all types of supplement users from analyses will reduce potential 
confounding and provide a clearer picture of associations between dietary vitamin C 
intake and risk. The exclusion of all supplement users in the EPIC pooling project, 
which had sufficient power to undertake sub-analyses, did not produce any evidence of 
associations and the hazard ratios did not change substantially in the pre or post-
menopausal analyses.244 
Excluding vitamin C supplement users in the Danish nested case-control study 
reported by Nissen et al. (2003) did reduce the association substantially from a 
doubling in risk  which became non-significant (OR=1.54; 95% CI: 0.80, 2.96 per 
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100mg/day).245 The more recent analysis of the Danish study, however, did not exclude 
supplement users from the analysis.273 An additional analysis of the Iowa Women’s 
Health Study excluded women who took antioxidant supplements A,C and E and this 
increased the point estimate in the high versus low calculation from a non-significant 
decrease (HR=0.88; 95% CI: 0.70, 1.11) to a non-significant increase in risk (HR=1.06; 
95% CI: 0.77, 1.47). Unlike the EPIC study all supplement users were not excluded. 
3.7.3.1.2 HRT use 
In the EPIC pooling project, post-menopausal women using exogenous hormones who 
were in the highest fifth of dietary vitamin C intake had a lower breast cancer risk than 
those in the lowest fifth (HR=0.88; 95% CI: 0.72, 1.07), though this was not significant. 
However there was evidence of a significant trend of decreased risk per 100/mg 
increases in intake, though the hazard ratio was close to unity and it was only 
marginally significant (HR=0.989; 95% CI 0.979, 0.999; ptrend 0.05).
244 This does not 
provide strong evidence of a protective effect. No other study appears to have 
undertaken this sub-analysis 
3.7.3.1.3 Hormone receptor status 
Both the Women’s Health Initiative and the Danish Study undertook sub-analyses by 
hormone-receptor status of the cancers.270 273 They found no association between 
dietary vitamin C intake and breast cancer risk of ER+PR+, ER-PER-, ER+PR- or ER-
Pr+ cancers. 270 273 Results of analyses with supplement intake and total intake are 
found in sections 3.7.4 and 3.7.5. 
3.7.3.2 Pre-menopausal women 
Only one of the recent studies analysed dietary vitamin C intake for pre-menopausal 
women which was the pooled EPIC study of 10 European cohorts; this found no 
evidence of a significant association.244  
Results included in the 2007 WCRF report from the first and second phase of the 
Nurses’ Health Study produced some conflicting results; the first phase analysis found 
no associations,247 however the second phase reported significant evidence of an 
increased risk between high and low intake (mean 200 vs. 69mg/d; HR=1.30; 95% CI: 
1.00, 1.69) but there was no significant trend, the highest risk being in the middle intake 
group.239 
Pre-menopausal women with a family history of breast cancer in the analysis of the 
Nurse’ Health Study reported by Zhang et al (1999) did have a substantially reduced 
risk (high vs. low intake HR=0.37;  95% CI: 0.17, 0.80), however the number of cases 
in this sub-analysis was low (90) which may have influenced the results.247  
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3.7.3.2.1 Smoking status 
The recent EPIC study and the Nurse’ Health Study II were sub-analysed by smoking 
status.239 244 Although Negal et al. (2010) mentioned that the results of their study 
suggests pre-menopausal former and never smokers have a higher risk of breast 
cancer at higher vitamin C intakes, neither study has produced strong evidence that 
smoking status modifies risk.239 244 
3.7.3.3 BMI 
None of the recent studies examined whether BMI modified the relationship with dietary 
vitamin C and breast cancer incidence. However the RCT did assess this for total 
cancer incidence and cancer death in relation to supplement intake; this is mentioned 
below in section 3.7.4.14  
As tabled in the 2008 WCRF continuous update report,169 a Swedish study of 59,036 
women attending Mammography screening produced evidence of an inverse 
association between breast cancer incidence and dietary vitamin C intake in women 
who were overweight (>25kg/m2) (high vs. low HR=0.61; 95% CI: 0.45, 0.82; ptrend 
0.004).243 Conversely there was an increase in risk with increased intake for women of 
normal or lower BMI (≥25kg/m2) (high vs. low HR=1.27 95% CI: 0.99, 01.63; ptrend 0.02). 
This analysis was not split by menopausal status, though the women were aged 
between 40-76 years old therefore the majority would have been post-menopausal at 
the time the FFQs were completed.243 
3.7.3.4 Menopausal status not specified 
None of the three recent cohorts report risk un-stratified by menopausal status. As 
listed in the 2008 WCRF continuous update for breast cancer, there were six previous 
cohorts which reported risk un-stratified by menopausal status. 240 243 246 264 266 267  As 
seen in Table 3 none of these reported a significant association between dietary 
vitamin C intake and breast cancer risk. The recent meta-analyses by Fulan et al. 
(2011) for cohort studies which was un-stratified by menopausal status produced a 
relative risk close to unity (RR=1.01; 95% CI: 0.95, 1.08) comparing high versus low 
intake; the heterogeneity between cohorts was low.277 
One study (not tabled) compared dietary vitamin C intake in adolescence with breast 
cancer incidence between the ages of 40-65, and found no evidence of an association. 
278 This nested case-control analysis of the Nurse’s Health Study gathered the vitamin 
C data retrospectively; possible recall bias, and also the short 24 item food 
questionnaire were limitations of the study.   
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3.7.4 Supplement only vitamin C intake 
Mixed results were produced in the three recent studies (the Women’s Health Initiative, 
the Danish Diet and Cancer Cohort and the Women’s Antioxidant Cardio-vascular 
Study RCT),14 270 273 as well as in previous studies that assessed supplement only 
vitamin C intake.242 245 247 267 
There was no evidence that supplementation with 500mg/d vitamin C had an effect 
overall on breast cancer incidence in the US double-blind RCT of initially cancer free 
post-menopausal women over the age of 40.14 Additionally, in sub-analysis by BMI no 
evidence of significant risks of breast cancer were found. However, the sub-group 
analysis of women with normal or low BMI (<25kg/m2) in the vitamin C supplementation 
group had a significantly increased risk of cancer death (RR=2.00; 95%CI: 1.12, 3.58), 
whereas there was no evidence of a significant association for overweight women (BMI 
≥25kg/dm2).14 The author believes the results may be a chance finding due to small 
numbers involved (44 supplement group: 17 placebo group). An alternative explanation 
is that normal weight women may have a lower level of reactive oxygen species (ROS) 
than overweight women; ROS required for apoptosis of damaged cells may be 
suppressed by antioxidants in normal women.  
Recently Cui et al. (2008) reported a significant trend (ptrend = 0.03) of increasing risk 
with increasing vitamin C intake from supplements for post-menopausal women in the 
Women’s Health Initiative; there was also significant evidence of a weak positive 
association in the high versus low intake calculation (HR=1.16; 95% CI: 1.04, 1.30).270 
Conversely, in the recent Danish analysis Roswall et al. (2010) reported no evidence of 
associations for post-menopausal women.273   
However, in the Danish nested case-control analysis, Nissen et al. (2003) did report a 
significant but weak increased risk with increasing vitamin C intake from supplements 
(OR=1.06; 95% CI: 1.01,1.13).245 Kushi et al. (1996) however, reported no significant 
associations in the Iowa Women’s Health Study.242 Neither was there evidence of an 
association in the Nurses’ Health Study for pre-menopausal, post-menopausal or total 
women.241 247 Information about the doses examined in these studies can be found 
later, in chapter 8. Only the Danish nested case-control study and the Iowa Women’s 
Health Study were included in the 2007 WCRF meta-analysis per 100mg/d increase in 
supplement vitamin C which produced a risk ratio close to unity (RR=0.99; 95% CI: 
0.98, 1.01).7 
Rohan et al. (1993) reported evidence of a moderate increase in breast cancer risk in 
the Canadian Breast Screening Study for women consuming more than 250mg/d 
(OR=1.45: 95%CI: 1.05, 2.01) compared to women with no vitamin C intake from 
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supplements.267 Results split by post-menopausal and other women were not 
statistically significantly different.267   
In comparisons between total vitamin C users and non-vitamin C users no associations 
with breast cancer risk were found in the Netherland Cohort Study.246 Duration of use 
was also not associated with risk in the Nurses’ Health Study.247 
Sub-analyses by hormone-receptor status for the recent Danish study and the 
Women’s Health Initiative produced no evidence of significant associations for vitamin 
C intake from supplements. 270 273  No other studies have examined this relationship by 
hormone-receptor status. 
The results of the above studies are detailed further by dose category in chapter 8 
which determines whether breast cancer incidence in the UKWCS is associated with 
consumption of supplements containing vitamin C. 
3.7.5 Total vitamin C intake 
Two of the recent studies assessed total vitamin C intake.270 273 A significant trend (ptrend 
= 0.009) of increasing risk by increasing total vitamin C intake was found in the 
Women’s Health Initiative for post-menopausal women; there was also evidence 
between high versus low intake of a significant weak positive association (HR=1.18; 
95% CI: 1.04,1.34).270  However, in the Danish study there was no significant trend 
(ptrend = 0.38) and although the high versus low intake risk ratio showed a weak 
increase in risk this was not significant (HR=11; 95% CI: 0.88-1.40).273 
Nissen et al. (2003) in the earlier nested case-control analysis of the Danish cohort 
found significant evidence of a moderate increase in risk comparing high versus low 
intake (OR=1.69: 95% CI: 1.12, 2.57) and also a weak increase in risk per 100mg/d 
increase in intake for post-menopausal women (OR=1.09: 95% CI: 1.07, 1.39).245 
The Women’s Health Initiative 270 was the most elderly cohort (average 64 years, oldest 
79) of all the previous cohorts assessing total intake 239 242 245 247; the positive 
associations could indicate that high intake of vitamin C may promote the progression 
of cancer in older people or at later stages of the disease. In contrast, the Nurses’ 
Health Study, an equally large study, which had the longest follow-up (average 14 
years) found no association with total vitamin C intake for women below the age of 
60.247 
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3.7.6 Conclusion 
The three recent cohorts and one RCT published since the 2007 WCRF report7 
produced mixed results; though on the whole they showed a tendency towards a weak 
increase in breast cancer risk with increased vitamin C intake, this was not statistically 
significant. These results, together with those from previous cohort studies detailed in 
the systematic literature review of the 2007 WCRF report and the 2008 WCRF 
continuous update report,169 do not provide substantial evidence of associations 
between breast cancer risk and vitamin C intake. This is the case whether the 
relationship is examined as dietary intake, supplement intake or total intake. 
3.7.6.1 How the current thesis may address areas where further research 
is needed 
As seen from section 3.7.4 of this review, mixed results have been produced in 
analyses relating to vitamin C intake from supplements and breast cancer risk. The 
UKWCS phase 2 data provides an opportunity to assess the association between 
breast cancer incidence and vitamin C intake from supplements for this thesis. In 
chapter 8 this is assessed in relation to the European Recommended Daily Allowance 
(60mg/d) and high dose (500mg/d) use, as well as by continuous intake. 
Characteristics of women that predict vitamin C supplement use at phase 2 in the 
UKWCS are described first and an analysis determines whether women who have 
history of breast cancer are more likely to take high dose vitamin C supplements 
(Chapter 6). 
As mentioned in section 3.7.3.1.1, previously very few studies have excluded 
supplement users from the dietary vitamin C analyses; these women generally have 
different health behaviours from non-supplement users, so their exclusion reduces 
confounding. The baseline phase of the UKWCS provides an opportunity within this 
thesis to sub-analyse dietary vitamin C intake derived from FFQ recordings by 
supplement users (58% of women) and non-supplement users (42%).  
Other sub-analyses may be enlightening. Few of the previous cohort studies have sub-
analysed by pre-menopausal status, one reason being there are less pre-menopausal 
than post-menopausal women. This thesis produces results by pre-menopausal status; 
however the power to find an effect may be limited in some analyses. Sub-analysis by 
hormone-receptor status could not be done since this information was not available for 
the UKWCS. Even though there is evidence that smoking status is associated with 
plasma C vitamin concentrations,48 so far only the Nurses’ Health Study II and the large 
EPIC pooling project have sub-analysed the relationship with dietary vitamin C by 
smoking status. 239 244 However, since only 11% were current smokers in UKWCS, 
 63 
 
 
there was limited power for sub-analysis, and this was not undertaken. HRT sub 
analysis has been undertaken in only one previous study,244 and BMI has been sub-
analysed in two studies.14 243 Similar sub-analyses have not been undertaken in the 
UKWCS for this thesis, but with accumulating breast cancer cases there may be 
sufficient numbers in the future for these sub-analyses.  
As mentioned in section 3.7.2.1, and discussed further in chapter 5, there are some 
limitations with the general ability of FFQs to record average vitamin C intake which 
have been used by the three recent cohort studies and previous cohorts. The UK 
Dietary Cohort Consortium, described in the methods chapter, provides an opportunity 
to assess vitamin C intake in relation to breast cancer risk using an alternative 
measurement method: diary data. It also provides an opportunity to assess total intake 
which has only be analysed previously in 5 cohorts (by 7 analyses). The current 
analysis and results of this are discussed in chapter 10 of this thesis. 
The next chapter describes the methods relating to the UKWCS and the UK Dietary 
Cohort Consortium, and also describes the cleaning of vitamin C supplement data and 
discusses the choice of covariates used. 
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CHAPTER 4 
4 Methods 
4.1 Study design, study populations and datasets 
All the analyses in this thesis used pre-gathered data from some of the largest 
population-based prospective studies in the UK which were designed to assess 
associations between diet and chronic diseases. Figure 1 in chapter 1 illustrates the 
datasets and the dietary tools used in the analyses. The majority of these analyses 
used previously unexploited vitamin C supplement data, results of which are reported 
in chapters 6, 8 and 10. Data from the UK Women’s Cohort Study (UKWCS) was used 
in all the analyses, and was part of the consortium of UK nested case-control studies 
described below in section 4.1.2  and chapter 10. 
For the first time these datasets have been used to explore breast cancer risk in 
relation to:  
 any supplement use, and also dietary vitamin C intake from FFQs (split by 
supplement users and non-users) at baseline in the UKWCS 
 vitamin C contained in supplements at phase 2 of the UKWCS 
 total vitamin C  intake (from diet and supplements) from diary records in the UK 
Dietary Cohort Consortium 
The phase 2 UKWCS data also provided an opportunity to determine whether women 
who have a history of breast cancer were more likely to take high dose vitamin C 
supplements. Note that total vitamin C intake could not be assessed using the full 
UKWCS cohort because both dietary and supplement vitamin C intake had not been 
captured electronically at either baseline or phase 2. Instead, pooling of nested case-
control data was required.  
A major strength of these studies is that their prospective nature minimised recall bias 
and responder bias, which can affect results of retrospective case-control studies. 
Selection bias, however, may have been present in the prospective nested case-
control studies, though this may have been minimal.  
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4.1.1 The UK Women’s Cohort study (UKWCS) 
4.1.1.1 Baseline dataset 
The UK Women’s Cohort Study was formed from about 500,000 responders to a direct 
mail survey from the World Cancer Research Fund (WCRF), targeted towards women 
living in England, Wales and Scotland.279 The overall response rate to the initial mailing 
was 17%, and 75% of these were willing to participate further.279 Sixty one thousand 
women aged between 35-69 years old were then invited to take part in the study. Since 
the cohort was originally designed to compare disease incidence in vegetarians, fish-
eaters and red meat eaters, all eligible women who stated they were vegetarians or 
non-red meat eaters were asked to take part, but only a portion of the red meat eating 
majority were invited to do so. For each vegetarian, the next non-vegetarian in the list 
aged within 10 years of the vegetarian was selected for the cohort.279 This structure 
provided a wide range of fruit and vegetable intakes, and as well vitamin C intakes, and 
helped to identify the effects of high consumption. The type of women recruited via the 
WCRF willing to complete long forms, in addition to the inclusion of a large proportion 
of vegetarians, meant that in general the cohort was likely to be more health conscious 
than UK women on average. This reduces the generalizability of the results.  
 
In total 35,372 women (58% of those invited) provided data for the baseline; between 
1995 and 1998 these women completed a 217-item Food Frequency Questionnaire 
(FFQ) and also additional demographic, health and lifestyle questions, totalling 24 
pages (see 0).279 The cohort was mainly white, well-educated, middle-class, middle-
aged, married women.279 Although 28% stated they were vegetarian, a more accurate 
but pragmatic definition classified 18% as vegetarian if they ate meat or fish less than 
once a week. At baseline 62% took some type of dietary supplement; however, the 
details of supplements taken were not captured electronically. 
Baseline UKWCS dietary vitamin C data derived from the FFQ is evaluated in section 
5.3. The risk of breast cancer risk in relation to any supplement use at baseline is 
reported in chapter 7 and in relation to dietary vitamin C intake at baseline is reported 
in chapter 8. 
4.1.1.2 Phase 2 ‘follow up’ dataset 
All the initial participants were re-contacted between 1999 and 2004, on average four 
years after recruitment; 14,172 (40%) completed a follow-up health and lifestyle 
questionnaire similar to that used at baseline and 12,453 (35%) also completed a four 
day food diary.  
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Answers to questions on the health and lifestyle questionnaire relating to 17 different 
types of supplement were electronically captured for all phase 2 women (see section   
4.5.2). More detailed supplement use was recorded in the 4-d diaries at phase 2 (see 
section 4.5.3). The cleaning of the vitamin C supplement data derived from supplement 
use detailed in the 4-d diary recordings is explained below in section 4.5.3.3. Phase 2 
UKWCS supplement vitamin C data is evaluated in section 5.2 and the breast cancer 
risk in relation to supplement vitamin C intake at phase 2 is reported in chapter 8. 
Unfortunately, the effects of dietary vitamin C intake could not be assessed for the 
whole cohort at phase 2 because FFQs were not included at phase 2 and in addition 
the dietary intake entered in diaries was only captured electronically for a small 
proportion of women in the nested case-control datasets (see section 4.1.1.3).  
4.1.1.3 Phase 2 nested case-control dataset 
Diaries provide an alternative method of measuring dietary intake; comparisons with 
FFQs relating to vitamin C intake are discussed in chapters 5 and 10. However, coding 
of diaries requires a large amount of resources. To reduce the amount of coding 
needed to examine the risk of breast cancer in relation to dietary intake recorded by 
diaries it had been necessary to create a nested case-control dataset within the phase 
2 cohort. This initial UKWCS dataset comprised roughly 200 women from the total 
cohort women who had developed breast cancer after completing the diaries and these 
were matched to four or five controls. To increase the power of the analyses, the 
UKWCS nested case-control dataset, comprising 186 cases and 785 controls, was 
pooled the with four other UK nested case-control data by the Centre for Nutritional 
Epidemiology and Cancer Prevention (CNC) based in Cambridge to form the original 
breast cancer dataset of the UK Dietary Cohort Consortium. More information is given 
in section 4.1.2 about this consortium, and chapter 10 reports the results of breast 
cancer risk in this consortium in relation to dietary and total vitamin C intake recorded 
by diaries. 
Note that, due to potential selection bias, 144 cases and 583 matched controls from the 
UKWCS, which were coded using DINER (Data into Nutrients for Epidemiological 
research), a system developed at Cambridge, were dropped from the dataset used for 
the published manuscript.2 These controls were considered not to be a random 
selection since they were more likely to be meat-eaters and less likely to be 
vegetarians than the cohort as a whole. This did not change the overall results from 
those reported in chapter 10. 
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4.1.1.4 Laboratory analysed dataset 
An additional 303 UKWCS women who completed phase 2 diaries and questionnaires 
also provided blood samples for laboratory analysis of micronutrient levels in a prior 
study.280 This dataset was previously used to assess the impact of high non-starch 
polysaccharide intake on serum micronutrient concentrations.280 Information on these 
women and the methods used to collect the plasma vitamin C data can be found in 
section 5.4.2.1 and 5.4.2.3. As described in section 5.4, this dataset was used within 
this thesis to compare plasma vitamin C concentrations with vitamin C intake derived 
from FFQs and with intake derived from diary data.  
4.1.2 The UK Dietary Cohort Consortium  
Breast cancer nested case-control data was pooled by the Centre for Nutritional 
Epidemiology and Cancer Prevention (CNC) at Cambridge to explore associations 
between breast cancer risk and dietary intake recorded by diary data from the five 
prospective UK cohorts described below. Information about the number of cases to 
controls, the mean time to diagnosis and the number of diary days for each cohort can 
be observed in Table 6. Data from all five cohorts were used in the analysis of dietary 
vitamin C intake and breast cancer risk. Only EPIC Oxford, EPIC Norfolk and UKWCS 
case-control datasets had detailed vitamin C intake from supplements and were pooled 
for the total vitamin C analyses. The risk of breast cancer risk in relation to dietary 
intake and total intake (supplement and dietary vitamin C) recorded by diary is reported 
in chapter 10. 
4.1.2.1 Oxford arm of EPIC 
A nested case-control group of women was taken from the EPIC Oxford study which 
was originally established to compare fish eaters, meat eaters, vegetarians and 
vegans.281 In total, 65,429 men and women aged 20-79 years had been recruited 
during the 1990s using several methods: by direct mailing of the general public using 
GP listings in Oxfordshire, Buckinghamshire and Greater Manchester; by mailing 
members of The Vegetarian Society of the UK and also all surviving participants in the 
Oxford Vegetarian Study282; and by a small portion by GPs recruiting patients attending 
GP surgeries in Scotland.  This resulted in a wide variation in intakes of major nutrients 
over the whole cohort.  
4.1.2.2 Norfolk arm of EPIC 
A nested case-control group of women was taken from the EPIC-Norfolk study which 
was made up of 23,003 men and women aged 45-75 years recruited between 1993 
and1997 from people registered with 35 Norfolk GPs.283  
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Table 6 Characteristics of the five cohorts in the UK Dietary Cohort Consortium included in analyses of vitamin C and breast cancer risk 
Cohort Participants Diary 
days  
Years when 
food diary 
completed 
Last follow 
up date 
Mean time 
to 
diagnosis 
of cases 
Cases Controls Mean(sd) 
dietary  
vit C 
intake 
Mean(sd)  
total 
 vit C 
intake 
EPIC-Norfolk General population in 
Norfolk 
7 days 1993-1998 31.12.2006 6.0 yrs 365 1329 91 (50) 118 (167) 
EPIC-Oxford General population and 
vegetarians in the UK 
7 days 1993-1998 31.12.2004 3.5 yrs 194 194 111 (61) 233 (436) 
UK Women’s 
Cohort Study 
(UKWCS) 
 
Middle aged women in 
the UK 
4 days 1999-2003 31.12.2006 2.4 yrs 186 785 117 (61) 239 (361) 
Whitehall II Civil servants in the UK 7 days 1991-1993 30.09.2005 7.8 yrs 70 275 101 (51) _
a
 
National 
Survey of 
Health and 
Development 
(NSHD) 
Nationally reprehensive 
cohort of women who 
were born in one week 
in March 1946 in 
England, Wales and 
Scotland. 
5 days 1989 31.12.2006 10.8 yrs 36 144 66 (37) _
a
 
a
Whitehall and NSHD did not have detailed diary data of vitamin C intake from supplements 
 69 
 
 
4.1.2.3 The UKWCS  
The UKWCS women who were included in the UK Dietary Cohort Consortium have 
previously been described in section 4.1.1.3. 279  
4.1.2.4 The Whitehall II Study 
A nested case-control group of women was taken from the Whitehall II study which 
recruited 10,308 male and female civil servants aged 35–55 years working in the 
London offices of 20 Whitehall departments in 1985–88.284 People from a wide range of 
grades and salaries were recruited, including clerical and office support staff, middle-
ranking executives, and senior administrative grades. The cohort was originally 
established to determine the extent to which psychosocial factors at work and outside 
account for social class differences in mortality and morbidity.  
4.1.2.5 The National Survey of Health and Development 
A nested case-control group of women was taken from the National Survey of Health 
and Development (NSHD); consisting of a nationally representative cohort of women 
born during one week in March 1946 in England, Wales and Scotland. 285 
4.2 Ethical considerations 
Ethical approval was granted at the initiation of the cohorts; 174 local research ethics 
committees were contacted and permission to carry out the baseline UKWCS study 
was obtained.279 Participants had consented to the use of information gathered at 
baseline, future phases and from cancer registries for research purposes provided that 
confidentiality was maintained. 
4.3 Measurement of cancer outcomes 
The cancer outcome in the analyses was incident malignant breast cancers. These 
were identified by codes 174 and C50 of the 9th and 10th versions respectively of the 
International Statistical Classification of Diseases, Injuries and Causes of Death (ICD). 
Cancer diagnoses are registered under ICD codes by local cancer registries and 
collated by the National Health Service Central Register (NHSCR). Cancer and death 
registrations for women in UKWCS are extracted quarterly by the NHSCR and made 
available to the University of Leeds at least once a year. This information is then linked 
to the UKWCS identification codes and any personal identifying information is deleted 
before the rest is made available for data analysis. At this time the distribution of the 
cancer dates are checked to ensure that a typical number of cases have been recorded 
and that a large number are not missing, particularly in the most recent months. 
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Research showed that the NHSCR for England and Wales missed about 10% of all 
incident cases of malignant disease, relating to diagnosis in 1971–1989.286 However, 
incident cases for the analyses in this thesis were gathered after this time, and may 
well be more accurate. Cancer registration is currently about 18 months or more behind 
cancer incidence; the latest cancer incident dates used for the time-to-event analysis in 
this thesis were July 2008. 
4.3.1 Censor dates 
The censor date (follow-up date) for the UKWCS baseline dataset used in this study 
was 01/01/2008. The median time to cancer incidence or time to censor date from the 
questionnaire was received was 11.2 years. 
At phase 2 of the UKWCS the censor date for the dataset used was 01/07/2008.  The 
median number of years follow up was 7.4 years from phase 2 diary dates. 
The breast cancer censor dates and the median follow-up dates differ for each cohort 
in the UK Dietary Cohort Consortium; these are shown in Table 6. 
4.4 Exclusions 
In all time-to-event analyses women were excluded who had any registered malignant 
cancer (except for skin cancer) prevalent at FFQ date (for UKWCS baseline analyses) 
or at diary date (for UKWCS phase 2 and UK dietary Cohort Consortium analyses).  
Women diagnosed with breast cancer within 6 months after the FFQ or diary dates 
were also excluded. This was done to ensure that latent disease not formally 
diagnosed was not present; otherwise disease suspected by participants could have 
influenced their dietary habits.  
Women with extremely high or low total energy intake (more than 6000kcal and less 
than 500kcal/d) were excluded in the baseline UKWCS dietary vitamin C time-to-event 
analyses.  
4.5 Assessment tools used for recording dietary and 
supplement intake in the UKWCS 
4.5.1 Baseline FFQ and Health and Lifestyle Questionnaire 
At baseline the mean daily dietary vitamin C intake for all women who had completed a 
FFQ had been previously calculated from the list of simple and mixed food items on the 
FFQ using DANTE (Diet and Nutrition Tool for Evaluation), a Microsoft Access program 
developed by the University of Leeds Nutritional Epidemiology Group. The vitamin C 
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intake for each food item had been calculated by multiplying an assumed standard 
portion in grams by the number of portions consumed per day, then multiplying the 
product by the grams of vitamin C contained in 100g of the food item as listed in The 
Royal Society of Chemistry Food tables, version 5 and supplements in the 5th Edition of 
McCance and Widdowson.287 This was then converted into mg/d. Standard portions 
had been calculated by averaging three data sources: portion sizes from a pilot study 
of the weighed food diaries of vegetarians and from published 1993 and 1994 national 
survey values.288 
The baseline FFQ, shown in 0, was developed from one used by EPIC UK studies,289 
290 by adding extra vegetable composition dishes to accommodate the higher 
proportion of vegetarians in the UKWCS to produce a 217 item FFQ 279. Thirty one 
vegetables (excluding potatoes), 19 fresh fruit and five dried fruit items were listed in 
the FFQ. Nine of the fresh fruit were seasonal; no canned or frozen fruits were 
specifically listed. For each item participants chose from 10 pre-coded frequency of 
consumption categories ranging from never to 6 or more times per day, on average 
over the past year (an example is given in Figure 7). Vitamin C content was also 
derived from mixed food items listed including casseroles, lasagnes and curries. An 
evaluation of fruit and vegetable intake is given in section 5.3.3.1. 
 
Figure 7 A section from the baseline FFQ relating to intake of seasonal fruit 
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Whether women were supplement users or non-users at baseline had been 
electronically captured from yes/no responses to the question: 
 Q29 Do you take any vitamins, minerals, fish oils or other food supplements? 
 
Women who did not answer this question but recorded information about the type of 
supplements taken on the questionnaire were also classed as supplement users. Full 
details of the supplements, however, were not captured electronically, thus vitamin C 
supplement use at baseline was not available. 
4.5.2 Phase 2 Health and Lifestyle Questionnaire 
Dietary vitamin C intake could not be calculated from the 20 page Health and Lifestyle 
questionnaire at phase 2 since it did not include a full FFQ.  
General supplement use at phase 2 question could be ascertained from yes/no 
responses to the following questions: 
Q14 Have you taken any vitamins, minerals, fish oils or fibre or other food supplements 
in the last year 
Q15 Do you presently use any dietary supplements? 
 
General supplement use at phase 2 for the analyses in chapters 6 & 9 was determined 
using answers from Q15. Additionally, if participants did not answer yes to Q15 but 
provided further details of the type of supplements taken weekly or more frequently, 
then these women were designated as being current supplement users. 
 
If participants answered yes to Q15 they were asked to note which supplements they 
took from a list of 17 and to indicate how often they used them. As seen in Figure 8 
these included vitamin C, selenium, iron and antioxidants; although antioxidants, 
vitamin A and vitamin E were not listed separately. Frequencies of use were 
categorised as: more than daily; daily; weekly; monthly; and less than monthly. For 
each of the different types of supplements the percentages of women taking them daily 
were calculated, these percentages are displayed in Figure 2 in section 2.1. 
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Figure 8 Questions relating to supplements on the phase 2 questionnaire 
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4.5.3 Phase 2 Diary 
4.5.3.1 Supplement intake captured from phase 2 diaries  
At phase 2 over 13,000 participants completed food diaries for 4 days with a separate 
page for each day to record individual supplements taken: Brand; Name; Amount 
taken; Dosage (the example provided to participants is shown below in Figure 9). 
Between 1999 and 2004, upon return of the completed diaries, this information was 
captured onto a Microsoft Access database of supplements taken by participants, and 
was matched at entry via a drop-down menu against supplements listed in a 
supplement ingredient database. This enabled the allocation of ingredient amounts to 
the supplements taken.  
After cleaning (as explained in section 4.5.3.3), the daily vitamin C intake from all 
supplement types was calculated for each participant, and was averaged across the 
total number of diary days that vitamin C was taken.  
 
Figure 9 Phase 2 diary supplement recording example provided to participants 
 
 75 
 
 
4.5.3.2 Supplement ingredient database 
The supplement ingredient database is a Microsoft Access database created by the 
Nutritional Epidemiology department at the University of Leeds between about 1999 
and 2004. In total there were 3,996 different marketed supplement types listed in the 
database and each was given a separate supplement identification code. This 
contained brand name, supplement descriptions, ingredient composition and units 
(normally milligrams (mgs) for vitamin C) which were obtained from product labels 
provided by participants, suppliers’ websites or provided directly from manufacturers 
upon request. A small proportion of vitamin C supplements contained ascorbate 
buffered with metal irons such as magnesium, calcium, zinc or potassium; the 
milligrams for the whole compound had been recorded in the ingredient database and 
a conversion factor was later applied to establish the ascorbate content (this could be 
found online or calculated using relative atomic mass of the elements). No adjustment 
was made for ‘slow release’ or ‘time release’ vitamin C supplements and those 
containing bioflavonoids which are promoted as having increased bioavailability, 
although evidence for this is lacking. Additionally it was assumed that the bioavailability 
of vitamin C in tablets, capsules, powder and liquid form was the same.    
The supplement ingredient database was inspected to determine the common types of 
supplements containing vitamin C in relation to the recommended daily allowance (EU 
RDA = 60mg/day53) and in relation to 500mg doses which are usually classed as high 
dose. As summarised in Table 7, a large proportion (46%) of supplements containing 
vitamin C up to the EU recommended daily allowance (EU RDA 60mg/day 53) are 
branded as multivitamins in the UK. Supplements which include more than the EU RDA 
but less than 500mg/day are often named multivitamins (26%) or antioxidants (14%). 
Vitamin C supplements containing high doses of 500mg or more are usually single 
ingredient (68%), and only a small amount are name as antioxidants (6%) or 
multivitamins (1%). 
 
Table 7 Percentage of supplements containing vitamin C in the UKWCS supplement 
ingredient database that are multivitamins, antioxidants or single vitamin C 
supplements, categorized by vitamin C content  
 Supplements categorised by vitamin C content  
 ≤60mg/d >60<500mg/d ≥500mg/d 
Branded as N=561 N=408 N=219 
Multi %(n) 46% (256) 26% (105) 1% (3) 
Antioxidantsa  %(n) 13% (72) 14% (56) 6% (13) 
Vitamin C (only)b  %(n) 3% (16) 10% (40) 68% (150) 
a
or selenium with vitamins ACE 
b 
names indicated supplements contain vitamin C only 
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4.5.3.3 Cleaning vitamin C supplement data in the database of 
supplements taken by participants 
Although details of supplements recorded by participants in the 4-day diaries had 
already been entered into the database, over 15% of all supplement entries had no 
ingredients or doses allocated to them because no supplement identification code had 
been selected during entry. From participants’ descriptions it appeared that the majority 
of these supplements did not contain vitamin C. In addition, it was unknown what 
proportion of supplement identification code allocations had to be deduced at entry 
because participants did not fully describe supplements used, or how many of these 
may have been incorrect. (Note that EPIC-Norfolk reported only 11% of their 
participants’ supplement descriptions were direct matches to their supplement 
ingredient database at the point of coding and a substantial amount of allocations 
(41%) required an assumption38).  
Any supplements listed in the UKWCS database of supplements taken by participants 
that were likely to contain vitamin C were checked and cleaned. Entries which indicated 
supplements containing vitamin C were found by systematically searching the  
participant database for the following descriptions: ‘vitamin C’, ‘vitamin’, ‘ascorb’, ‘anti’, 
‘A C E’, ‘glucosamine’, multi’, ‘meno’, ‘A-Z’, ‘50+’, ‘gold’. The participant’s description 
captured in the database was compared with the description of the supplement 
allocated from the ingredient database; if different these were compared with the 
entries in the physical diaries. Over 400 diaries (3% of the total diaries) were checked 
as part of the cleaning process.  
New fields in the database were created for corrected doses of vitamin C, or corrected 
or new supplement identification codes. New codes 9001-9007 were created to input 
mean doses for seven types of commonly taken supplements likely to contain vitamin 
C when dose and/or brand information was missing (see Table 8). The mean doses 
were calculated over the whole database by averaging complete entries which had 
supplement descriptions and identification codes relevant to these common 
supplements, and these were weighted by the number of women taking these types. 
(Note that EPIC-Norfolk also created generic supplement identification codes using 
weighted means, though these were more numerous and more specific38). 
After this initial cleaning, the allocated vitamin C amount per day per participant was 
calculated by the database manager using the Access databases. This was checked 
and then uploaded into STATA. This diary-gathered data was then compared with 
participants’ questionnaire answers relating to frequency of vitamin C use. The diaries 
of women who had no vitamin C dose captured were checked, if questionnaire answers 
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indicated they took vitamin C supplements daily. This cross-checking of assessment 
methods identified a further 400+ diaries which were manually checked; this resulted in 
vitamin C supplement intake recorded in diaries being identified and captured for an 
extra 87 women. (Detailed results of further comparisons between the two assessment 
tools are given in section 5.2). 
 
Table 8 Mean dose of vitamin C by supplement type in the UKWCS supplement 
databases 
 
Supplement type 
Mean 
vitamin C 
dose 
 
New 
code 
 
Observations 
corrected 
Selenium plus vitamins A, C and E 
Antioxidants 
Multivitamins 
Multivitamins and minerals 
Multivitamins and iron 
Vitamin C (no strength indicated) 
Vitamin C high strength (suggested by 
description*) 
90mg 
153mg 
75mg 
71mg 
57mg 
609mg 
743mg 
9001 
9002 
9003 
9004 
9005 
9006 
9007 
48 
19 
71 
62 
34 
65 
16 
*Note: ‘high strength’: those described as ‘with bioflavonoids’ or ‘time released’ or slow 
released’, or if most of the suppliers products were 500mg or over. 
 
A final check of 63 diaries (half a percent of the phase 2 dataset), randomly selected by 
computer and inline with the National Audit Office statistical sampling guidance,291 
indicated that 95% (+/-5%) of diaries have supplement usage correctly captured in 
STATA (both correct number of days and satisfactory doses). A 5% error has the 
potential to slightly reduce a true relative risk of 2 to an observed relative risk of 1.9.292 
4.5.3.4 Dietary intake captured from phase 2 diaries  
At phase 2 in the UKWCS, food and drink intake had also been recorded in the 4-d 
diaries. The front pages of the booklet detailed instructions on the information required, 
and included suggestions about using household measures such as tablespoons and 
cups if weight scales were not available. Participants were asked to describe food and 
drink consumed each day as shown in the example in Figure 10, and to list recipes and 
details of ready meals used and the portion consumed by the participant. Due to 
resource constraints only about a 1000 cases and controls in total were coded into the 
DANTE system developed at Leeds, or later into the DINER system developed at 
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Cambridge. These produced a dietary vitamin C intake per day per participant. DANTE 
had previously been validated against DINER using 100 diaries which showed 
excellent agreement; geometric mean energy intake from DANTE was just 2% lower 
(95% CI, 0%, 5%) than from DINER. 293 
In addition, dietary intake of micronutrients was also calculated by DANTE for 274 
women who had plasma micronutrient levels laboratory analysed. Vitamin C intake 
derived from the UKWCS FFQ and also the phase 2 diaries are compared with plasma 
vitamin C concentrations in section 5.4 
Figure 10 Phase 2 diary food and drink recording example provided to participants  
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4.6 Assessment tools for dietary and supplement 
intake in other cohorts of the UK Dietary Cohort 
Consortium  
4.6.1 Dietary intake recorded by diaries  
In the EPIC studies, the diaries allowed for the recording of the description, preparation 
and amount of foods eaten at main meals, snacks and between meal times over seven 
consecutive days. Detailed instructions on the information required in describing and 
quantifying each type of food or drink were printed on the front pages of the booklet.283 
Seventeen sets of colour photographs were included to help the participants describe 
the portion size of the food they consumed, as small, medium or large. The diaries 
were coded using DINER.  
The Whitehall II study also used 7-d diaries, containing instructions and pages to 
record foods eaten during seven time periods (before breakfast, breakfast, mid-
morning, lunch, tea, evening meal, later evening). Fifteen sets of black and white food 
photographs were included, showing three portion choices for a common food item.294  
For the National Survey of Health and Development (NSHD) a 5–d diary was used. 
The instructions contained 66 examples of how to describe foods in terms of their 
preparation and quantity. The main part of the diary comprised of seven spaces for 
each day in which to record meals and between-meal snacks, a reminder section about 
any other snacks and drinks and a space in which to write recipes.295 Fifteen sets of 
black and white food photographs were included, showing three portion choices for a 
common food item. The diaries were coded using DIDO. 
4.6.2 Supplement use recordings in EPIC-Oxford and EPIC-Norfolk 
Both cohorts used similar diaries to record supplement intake. Participants were asked 
to record their supplement use in a 7-day diary by answering an open-ended question, 
however this only provided room to record one supplement per day.  
Please name any vitamins, minerals or other food supplements taken on each 
day of last week.  
Headings: Brand name; Amount taken 
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In a later version of the diary more space was given for participants to list a number of 
supplements used and an example was provided.38 
Please name any vitamins, minerals or other food supplements taken on each 
day of last week.  Please write down all the details from each packet/container, 
and enclose label(s) giving ingredients and individual amounts where possible. 
Headings: Brand; Name; Amount taken per day – number of pills, capsules or 
teaspoons; Tick box(es) to show which day(s) supplements was taken last week 
–M T W T F S S. 
Using data from diary records and their supplement ingredient database, EPIC-Norfolk 
calculated the average vitamin C intake from supplements over the seven days of the 
diary for each participant in the nested case-control dataset. These averages were 
provided by Cambridge for pooling with the UKWCS and EPIC-Oxford. 
The supplement use diary recordings for each participant in the EPIC-Oxford nested 
case-control dataset were photocopied and transferred to a spreadsheet. If details 
given did not state doses, then vitamin C amounts were allocated based on information 
from the UKWCS ingredient database. Although this database was established at the 
end of the period the Oxford diaries were completed, many of the supplements in the 
UKWCS ingredient database would have been available in this earlier period. The 
EPIC-Norfolk database was not available for use for this task. 
4.7 Statistical methods 
This section details the statistical methods used that are common to many of the 
following chapters containing results; for example time-to-event analysis, the selection 
of covariates for adjustment, coding of menopausal status, exclusion of outliers in 
sensitivity analysis, etc. Although conditional logistic regression is only used in one of 
the following chapters (10), it is appropriate to explain this here as an alternative to 
Cox’s regression analysis.  
Kappa statistics and Bland Altman plots are explained in chapter 5 which are used to 
evaluate diet and supplement vitamin C recordings in the UKWCS. In addition 
restricted cubic splines are explained in chapter 9 which are used to determine whether 
there are non-linear relationships between dietary vitamin C intake and breast cancer 
risk.  
All statistical analyses used Stata SE version 10 and all tests calculated two sided p 
values and 95% confidence intervals.  
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4.7.1 Time-to-event analyses 
Time-to-event analyses (also known as survival analyses) using Cox proportional 
hazards models were used in chapters 7 to 9 to determine whether dietary or 
supplement vitamin C intake were associated with breast cancer risk. The analyses 
measure the time from FFQ or diary completion date to breast cancer incidence or the 
date the participant was lost to follow-up because they died of other causes or, for 
women who did not develop breast cancer, the time to censor date (as detailed in 
section 4.3 for each dataset).296 This enables the analysis to deal with recruitment 
which occurs at different times throughout the study. Therefore before running any risk 
analyses, a variable containing time to incidence or to censor date for each participant 
was created in Stata from FFQ completion dates for the baseline analyses, and for 
diary completion dates in the phase 2 analyses. Additionally a variable was required 
which flagged cancer incidence after the FFQ / dairy completion dates. As stated 
earlier women who were diagnosed with any cancer (except skin) before FFQ / diaries 
were completed, were excluded.      
The proportion of women who did not have breast cancer at any time since recruitment 
can be plotted in a Kaplan-Meier curve. Two or more groups of women can be 
compared using this technique as shown in Figure 22 in chapter 7 
This method produces an approximate estimate of a true time-to-event curve if both of 
the following assumptions hold:  
1. Participants who are censored have the same risk of subsequently developing 
breast cancer than those who were not censored 
2. The observations are independent of each other 
Hazard ratios for time-to-event analyses in this thesis were calculated using Cox 
regression, also known as proportional hazards regression. Hazard ratios compare the 
hazard of one group with another group e.g. supplement users with non-users. In 
simple terms the hazard is the probability that an individual in the study with no 
prevalent breast cancer is diagnosed with breast cancer at any given time. The 
distribution of the hazard over the length of the study is called the hazard function. The 
hazard can change over the study period so to be more precise, the hazard function is 
the instantaneous risk (i.e. the probability over a small interval of time) of breast cancer 
for an individual given that the individual has been breast cancer free up to a particular 
time.297 The analysis uses a conditional likelihood estimation procedure where at each 
point in time that an event occurs the value of the exposure variable, e.g. supplement 
use, for a participant who has incident breast cancer is compared to the value of 
exposure variable for all those without the disease.296 Although the Cox regression 
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method makes no assumptions about the shape of the curve, the hazard ratio between 
the two groups should be a constant proportion over time. This proportional hazard 
assumption was tested using the cumulated hazard by plotting the minus log of minus 
log time-to-event against log of time. The curves should approximately be a similar 
distance apart all the way along or they should at least not cross. In addition there 
should be about ten cases per variable in the model.298 
4.7.2 Conditional logistic regression analyses 
The risk of developing breast cancer in the pooled nested case-control studies was 
calculated using conditional logistic regression. In this type of logistic regression 
method breast cancer cases are only compared to controls within the same matched 
set, making it conditional on matching.296 Controls were randomly selected from women 
with matching variables who were still breast cancer free at the end of the study, 
representing the population at risk of the disease. They were matched within study 
centre by month of diary completion (± 3 months or as close as possible), so that 
follow-up times were comparable, thereby dealing with the varying recruitment dates. 
They were also matched on age (± 3 years). As an aid to this analysis each matched 
set had been numbered and this had been added to the dataset as a variable. It was 
also possible to control for variables other than those controlled through matching by 
adjustment in the model. Using between two and four controls for matching increased 
the likelihood that controls were representative of the cohorts.  
Wacholder et al. (1992)299 explained that overmatching, which can cause bias or 
reduce efficiency (the ability to demonstrate expose-outcome relationships) compared 
to an unmatched study, can occur in a number of situations if a matching variable is: 1) 
an intermediate on the causal pathway 2) is a surrogate for or a consequence of the 
outcome; or 3) is closely related to the exposure variable but not related to the 
outcome. It is unlikely that any of the matched variables would cause overmatching. 
For instance, age does not meet the first two points and, although age is related to 
breast cancer risk, as seen in the analysis of the nested case-control study in chapter 
10 it is not closely related to dietary vitamin C intake.  
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4.7.3 Evaluating interactions 
An interaction occurs between the effects of two exposures if the effect of one 
exposure on the outcome varies with the effect of the other. This is also called effect 
modification; for instance menopausal status has been found to modify the effect of an 
exposure on the incidence of breast cancer, examples of which can be found in the 
literature review chapter. Additionally, since supplement users are likely to have 
different health behaviours than non-users this variable was tested for interactions and 
split into strata in datasets when possible.  
Other variables suggested as modifiers were defined a priori: BMI; amount of exercise; 
family history of cancer; and dietary group. Socio-economic status and HRT use was 
considered later. Chapter 7 tests whether these modify the effect of supplement use at 
baseline on breast cancer risk and analyses incorporating interaction terms were 
reported. However, these variables were not tested in relation to levels of vitamin C 
intake due to limited power and the possibility of spurious findings from multiple testing. 
4.7.4 Coding of menopausal status 
Menopausal status used in the time-to-event analyses relates to status at the time of 
exposure (dietary or supplement intake assessment) rather than time of diagnosis or 
censor date, due to difficulties of determining status later. This means that some 
women in the datasets who developed cancer when they were post-menopausal have 
been defined as pre-menopausal at baseline or phase 2 assessments. The questions 
used at baseline and at phase 2 to determine menopausal status are shown in Figure 
11. The flow diagram in Figure 12 shows the rules used for coding menopausal status 
in the UKWCS for this thesis, which is similar to that used in the UK Dietary Cohort 
Consortium. For women who did not specify on the questionnaires whether they still 
had periods, it was assumed they were post-menopausal after the age of 50. The 
mean age (46 years) at which women were assumed to be post-menopausal after 
removal of ovaries was based on research by Farquhar 2005.300 A peri-menopausal 
category was not used for the UKWCS analyses. 
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Figure 11 Questions used to determine menopausal status (phase 2 questionnaire) 
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Figure 12 Flow diagram of coding for menopausal status in the UKWCS 
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4.7.5 Adjustments by potential confounders 
Unlike RCTs, where behaviours and characteristics which may influence the risk of 
developing breast cancer are randomised between intervention groups, in cohort 
studies these potential confounders can seriously affect the results of risk analyses if 
they are not statistically controlled for. Therefore their selection was carefully 
considered for this thesis. 
4.7.5.1 Model building 
Potential confounders are variables that may be associated with both the exposure of 
interest i.e. vitamin C and the outcome variable i.e. breast cancer incidence. Univariate 
analyses were performed to examine the association of each potential confounder with 
breast cancer incidence and with vitamin C intake. Variables that were significantly 
associated with vitamin C as well as breast cancer incidence in the datasets were 
considered for adjustment. Those that did not meet this criteria but where there was 
strong prior evidence from previous studies, as detailed in section 2.2.3 and chapter 3, 
suggesting they were confounders, they were still considered for inclusion. These 
potential confounders were assessed by visual methods using diagrams called 
Directed Acyclic Graphs as detailed in section 4.7.5.2. Covariates which appear to be 
on the causal pathway between vitamin C intake and breast cancer should not be 
included, since these mediators are not true confounders and controlling for them 
would attenuate the effect of vitamin C.301  
Confounders that had a substantial proportion of missing observations were not 
included in the main adjusted analyses (e.g. waistline had 7500 missing entries at 
baseline), particularly if other closely related variables were available e.g. BMI. For 
instance socio-economic status rather than education was controlled for at baseline 
since it had fewer missing observations. Important confounders which had a high 
proportion of missing variables in the UK Dietary Cohort Consortium analyses were 
considered for inclusion in sensitivity analyses i.e. cumulative breast feeding and age 
at menarche. 
4.7.5.1.1 Assessing linearity with outcome  
Continuous variables, such as age and BMI were tested to determine whether they had 
a linear or non-linear relationship with cancer incidence. As categorical variables, there 
were no assumptions about the shape of the relationship between the variable and the 
outcome. The null hypothesis that the relationship was linear, was tested using the 
Likelihood Ratio Test (LRT) by comparing the log likelihood from the model using the 
continuous variable with the log likelihood with the model using the variable split into 
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categories (e.g. BMI: underweight; normal; overweight; obese).296  For BMI the LRT 
was significant meaning there was evidence against the null hypothesis and BMI was 
better modelled as a non-linear categorical variable which was subsequently used in 
the adjusted analyses. This was not the case for age. 
4.7.5.1.2 Excluding highly correlated variables  
If two highly correlated variables are included in an adjusted model they are likely to 
produce an underestimation of their association with the outcome, and are said to be 
collinear.296 If included together neither may appear to be associated with the outcome 
even if one or both are strongly associated with it.296 For instance it was inappropriate 
to adjust for both BMI and weight, or BMI and waist size, or weight and waist size since 
the Pearson’s correlation between these (0.67 or higher) showed they were highly 
correlated. However since most of the variables were categorical it was difficult to 
determine whether the categorical variables were too highly related. Nevertheless, 
large increases in the standard error estimate in the risk analyses for two or more 
variables may indicate a problem.296 
4.7.5.2 Assessment of potential confounders by Directed Acyclic Graphs 
Directed Acyclic Graphs (DAGs) can provide a visual and logically rigorous way of 
summarising causal links between exposures and disease outcome, and can be used 
to check whether sufficient confounders have been selected for adjustment. Figure 13 
and Figure 14 show causal pathways representing the first step in using the theory of 
DAGs to identify potential confounders relating to dietary and supplement vitamin C 
intake in unselected populations. The majority of these have been identified a priori 
from previous studies. All variables shown in Figure 13 and Figure 14, apart from 
‘health consciousness’, were derived in the UKWCS datasets. 
The arrows in the DAGs show the direction of influence from one variable to another, 
with the main causal pathway from exposure of interest to outcome highlighted in red. 
As explained by Greenland,302,303 confounding is present if an association remains 
between the exposure of interest and outcome after removing all exposure effects from 
the exposure of interest. Therefore exposure effects of vitamin C should be removed 
on the diagram; on Figure 13 this includes removing the arrow from dietary vitamin C 
exposure to ‘supplement use’ in addition to removing the red arrow to breast cancer 
incidence. It can be argued that if low dietary vitamin C intake significantly promoted 
supplement use then the latter would mediate the effect of dietary vitamin C on breast 
cancer incidence; adjusting for it could create bias rather than reduce it. On the 
contrary, the odds of supplement use were found to increase significantly with 
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increasing dietary vitamin C intake; being health conscious was likely to have 
increased both.  
Using these diagrams confounders can be detected by finding common influences on 
exposure and outcome. Identifying a minimum set of confounders for adjustment was 
done by tracing open backdoor paths from the outcome (breast cancer incidence) to 
the exposure (vitamin C intake); to aid their detection the first arrows in these backdoor 
paths were coloured blue in Figure 13. Paths containing colliders are not used for 
selecting confounding variables; these are closed backdoor paths where the path 
enters and exits a variable as follows: 
 
 
An example of a collider is illustrated below; here pill use cannot have an effect on the 
other two variables which are conditions that existed before pill use occurred.  
 
 
 
 
 
The Figure 13 and Figure 14 show that all open backdoor pathways pass through the 
variable ‘Health consciousness’; this variable, therefore, is the main common link 
between exposure and outcome. Given this and the fact it is not a collider, according to 
the DAG theory it would be sufficient in adjusted analyses to control for this one 
variable only.303 Unfortunately, this latent variable was not readily available in the 
datasets, though it could have been created using factor analysis. Nevertheless, for 
each open backdoor path which passes through this variable there are other more 
readily derived variables that can be used for adjustment instead; additionally there is 
no direct path from this to the outcome. 
 
As explained by Greenland,303 at least one variable on each open backdoor path from 
the outcome breast cancer incidence to the exposure, should be controlled for in 
adjusted analyses. In these diagrams every variable linked directly by a blue line to the 
outcome can be traced back to vitamin C on open backdoor paths, therefore each of 
these variables could be used in adjustments, assuming there is evidence of their 
effects on breast cancer. For example, ‘cumulative breastfeeding’ is linked directly to 
the outcome, and can be traced back through ‘education’, ‘health consciousness’ and 
‘fruit and vegetable intake’ to ‘dietary vitamin C intake’. It is questionable, though, 
HRT or 
pill use 
Education 
Family 
history 
of cancer 
collider 
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whether smoking status has a direct effect on breast cancer and whether it should be 
included as a confounder. However, a meta-analyses has reported smoking increases 
breast cancer risk in women with NAT2 slow acetylator genotypes, which occurs in 
about 50% of Causaians.304  
Greenland posits that adjusting for more than the minimally sufficient set of 
confounders may cause confounding.303 Thus in most cases it will be unnecessary to 
adjust for more than one variable on each open backdoor path. For instance it appears 
that education should not be included as a confounder in addition to ‘parity’ and 
‘cumulative breast feeding’. Furthermore, one can question whether ‘BMI’ ‘weight’, 
waist size’ and ‘total energy intake’ should all be included as confounders since one 
open backdoor back passes through them all. A discussion about this is included in 
section 4.7.5.1.2. 
Socio-economic status (SES) has been linked to health behaviours in the UK,305 and 
women of higher SES are generally more health conscious. Conversely women of 
higher SES are likely to have fewer children which would increase their risk of breast 
cancer. However, it can be argued that SES should not be also included as a 
confounder since other variables on open backdoor pathways containing SES could 
control for its indirect effects. There may be possible biological mechanisms, however, 
by which low SES may have an effect on breast cancer risk, for instance via stress 
responses caused by unfairness and inequality. Although these have not been 
specifically researched in relation to breast cancer, low control in the workplace was 
not associated with increased breast cancer risk in the Nurses Health Study.306,307 
Nevertheless to avoid residual confounding SES has been included as a confounder in 
the UKWCS adjusted analyses when education has not been included.  
     
 90 
 
 
    
Health 
consciousness 
Fruit & 
veg intake 
Exposure 1: 
Adult dietary 
vitamin C 
intake 
 
Meat, 
intake 
Smoking 
status 
Regular 
vigorous 
exercise 
Total 
energy 
intake 
Weight 
BMI 
Family 
history 
of cancer 
HRT 
or pill 
use 
Menopausal 
status  
Age 
Education 
 SES 
Cumulative 
breast 
feeding 
Outcome: 
Breast cancer 
incidence 
 
 
Alcohol 
intake 
Waist 
Supplement 
use 
parity 
Figure 13 A Directed Acyclic Graph (DAG) of factors associated with dietary vitamin C intake and breast cancer 
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Figure 14 A Directed Acyclic Graph (DAG) of factors associated with supplement vitamin C intake and breast cancer 
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Additional variables which were considered for adjustment that were not included in 
Figure 13 and Figure 14 DAGs were height, age at menarche and history of 
hysterectomies and oophorectomies. It has been established that height is associated 
with breast cancer.7 Additionally, fat free mass has been independently associated with 
breast cancer incidence.308 Eating patterns in childhood and adolescence influence age 
of menarche, height and fat free mass, therefore these variables may confound the 
main causal pathway between adult dietary intake and breast cancer via a variable 
relating to the maintenance of eating habits established in childhood (see Figure 15). 
Since height and age of menarche reflect childhood nutrition as well as the action of 
growth factors, they are often used as proxies for the early nutritional environment. 
Additionally, since height and FFM are correlated, height may be used as a proxy for 
fat free mass (FFM) which is not readily available. Note that the UK Dietary Cohort 
Consortium made the decision to use height and weight as a covariates rather than 
BMI which was used in other analyses in this thesis. 
4.7.5.2.1 Other unmeasured variables relating to health consciousness. 
There are various unmeasured factors which influence health consciousness or health 
behaviours. These include attitudes, norms, intentions and perceived behavioural 
control as presented in Fishbein and Ajzen’s (1975) Theory of Planned Behaviour.36 
This model, together with three additional predictors of intentions (self-identity, health 
value and perceived susceptibility) and beliefs, underlying attitudes, intentions and 
perceived control has been used to predict supplement use in 303 UKWCS 
participants.37 Results showed that intentions were the major predictor of dietary 
supplement use, and in turn these were influenced by behavioural beliefs: an 
individual’s value of health and their perception that supplements might reduce 
susceptibility to illness.37 Additionally, participants also believed media influenced their 
behaviour.  
 
Personality is also likely to influence health consciousness, health behaviours and 
health outcomes. Indeed out of the Big Five personality dimensions (Neuroticism, 
Extraversion, Openness to Experience, Conscientiousness and Agreeableness)309 
Neuroticism and Conscientiousness, and its facets, have been shown to influence 
health behaviours and health outcomes.310-312 These have not been measured for the 
UKWCS datasets used in this thesis, however a questionnaire has been designed to 
measure them in a sub-sample of UKWCS women. 
 
Since many health behaviours have been adjusted for in the UKWCS it would be 
unnecessary to also control for these other factors that influence health behaviour 
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unless they have a direct influence on risk themselves. It is possible that the level of 
neuroticism could have a direct biological effect on the development of cancer. 
4.7.5.3 Energy intake 
Energy intake had been calculated from FFQ listings at baseline and from diary intake 
in the phase 2 nested case-control dataset, though this was not available for the full 
phase 2 dataset. There are various methods for controlling for energy intake, as 
discussed by Willet (1998).301 A decision was made to produce two sets of adjusted 
risk analysis results relating to dietary vitamin C intake: using absolute vitamin C intake 
adjusted by energy intake; and the other using nutrient density intake (vitamin C intake/ 
metric mega joule energy intake), which was then adjusted further by energy intake in 
the risk analyses. 
Nutrients such as dietary vitamin C intake tended to be weakly correlated with total 
energy intake even though they do not contribute energy;301 this is because total food 
intake correlates with both. If it is hypothesised that vitamin C intake relative to body 
size has a biological influence on breast cancer risk, rather than absolute vitamin C 
intake, then given that energy intake tends to reflect body size, an adjustment for total 
energy intake would be appropriate. This assumes that a specific amount of vitamin C 
would have less effect on a larger, high energy consuming person than a smaller 
person.301 These assumptions, however, cannot be applied to smaller people who are 
very physically active and are high energy consumers; for such women an analysis of 
absolute amounts of vitamin C may be more appropriate. Alternatively, adjusting for 
BMI or weight and physical activity in addition to energy intake may be suitable. 
Furthermore, if total energy intake is associated with breast cancer then an association 
between dietary vitamin C and breast cancer may be due to the former association, 
therefore adjustment for energy intake would be warranted. 
An alternative approach to control for energy intake is through nutrient densities,301 
which are calculated by dividing total vitamin C dietary intake by total energy intake. 
Although its use tends to reduce between-person variations it may result in a nutrient 
density variable that is inversely related to breast cancer, if energy intake is related to 
breast cancer. Willet states that this inverse relationship with disease outcome is more 
likely when the nutrient is weakly correlated with total energy intake; furthermore he 
found a weak correlation between energy intake and vitamin C (Pearson’s r=0.28).301 
Therefore, creating a vitamin C nutrient density variable would not necessarily control 
for energy intake. Willet suggests this can be overcome by adjusting nutrient density 
analyses by total energy intake.  
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To avoid over-adjustment, the intake of fat, meat and other specific energy containing 
foods were not adjusted for. However alcohol, which contains energy and for which 
there is convincing evidence of a positive association with breast cancer risk,7 was 
adjusted for in addition to total energy intake in the analyses in this thesis. Some 
analyses were adjusted by a dichotomous variable which split the dataset into alcoholic 
drinkers and those drinking less than once a week or not at all; this may avoid over-
adjustment of the energy contained in alcohol.  
4.7.6 Sensitivity analyses  
A variety of sensitivity analyses were carried out on the datasets e.g. excluding outliers 
or excluding women with a family history of breast cancer; details of the methods for 
these are given below in sections 4.7.6.1 and 4.7.6.3. Since sensitivity analyses were 
not decided a priori, they were not consistently used across the different datasets; 
therefore further sensitivity analyses on some of the results could be carried out later. 
For instance in addition to those excluded in other chapters, women with a family 
history of cancer at baseline could be excluded in sensitivity analyses for chapter 7 on 
general supplement use and breast cancer risk. Plans to exclude self-reported cancer 
in sensitivity analyses were not carried out. Risk results reported in chapter 8 on 
vitamin C supplementation did exclude self-reported prevalent cancers, however since 
self-reported cancers could be inaccurate, or could have been non-malignant, it may 
have been better to have included these women in the main analysis and excluded 
them in sensitivity analyses.  
4.7.6.1 Excluding outliers e.g. for high dietary vitamin C intake 
Various methods for dealing with outliers have been suggested and researched.313 314 
Many are only applicable to test univariate data or assume data is normally distributed 
or are designed to check for one outlier only. Grubbs method uses mean and standard 
deviations to calculate outliers,315 however since these can be influenced by outliers 
themselves this univariate method may not be reliable. A simple alternative method 
which does not use the mean and does not assume a normal distribution is the use of 
box-plots.313 This defines the lower and upper thresholds for outliers as 1.5 times the 
inter-quartile range (the upper quartile i.e. 75% percentile less the lower quartile i.e. 
25% percentile). Figure 18 in section 5.3 shows that many dietary vitamin C data points 
in the UKWCS baseline dataset lie beyond the lines of the upper threshold. This 
method has been used in sensitivity analyses in this thesis to exclude outliers. 
However, some outliers calculated using the inter-quartile range method may occur 
due to natural variation rather than error.313 There is evidence that multivariate methods 
which used Mahalanobis distance calculations produced better agreement with 
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opinions of experts in the subject matter examined. 313 Unlike box-plots these methods 
do not sort all the data into ascending order but calculate the distance from each point 
to the geometric centre of all the scattered points; the processing time, however, is long 
for large datasets. Sensitivity analyses for dietary vitamin C intake were undertaken 
omitting outliers calculated using this type of multivariate method developed by Hadi 
and applied in Stata v10.316,317  
4.7.6.2 Adjustment for vitamin E 
The amount of vitamin E consumed from supplements recorded in the UKWCS phase 
2 diaries was adjusted for in a sensitivity analysis of breast cancer risk and vitamin C 
intake from supplements in chapter 8. Vitamin E from supplements was cleaned and 
the mean daily intake was calculated in a similar manner to that described for vitamin C 
supplement data in section 4.5.3.3. Diary recordings of multivitamins which contained 
both vitamin C and E had already been cleaned earlier. The intake of vitamin A or other 
antioxidants in other supplements was not cleaned so could not be adjusted for.  
Intake of vitamin E, along with vitamin A, which may affect cancer risk via their 
antioxidant or other properties, had been controlled for in the Danish nested case-
control study which assessed the relationship between vitamin C intake and breast 
cancer risk.245 No other previous studies had adjusted for these. By supplying electrons 
vitamin C reduces and regenerates the fat soluble vitamin E radical back to its active 
antioxidant form. Indeed, in vitro experiments have shown that vitamin E can act as a 
pro-oxidant in the absence of co-antioxidants such as vitamin C.49 However, this may 
mean vitamin E may be on the causal pathway between vitamin C intake and breast 
cancer risk, and perhaps adjusting for vitamin E could create bias.  
 
4.7.6.3 Excluding or adjusting for women with a family history of cancer 
Since women with a family history of breast cancer may have a higher risk of breast 
cancer and may also be more likely to take supplements, these women could be 
excluded or adjusted in sensitivity analyses to provide better risk estimates for women 
without a family history. Since many women with a family history are not genetically at 
raised risk of breast cancer an attempt was made using the detailed family history data 
at phase 2 to identify women who may be classed at raised or higher risk (see section 
4.7.6.3.2). The data at baseline, however, was not detailed enough to estimate those at 
raised or high risk of breast cancer. 
A review of 14 studies that evaluated both positive and negative self-reported family 
history cancers by comparing them with cancer registry records found that patient-
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reported family cancer histories for first-degree relatives are accurate and valuable for 
breast and colon cancer risk assessments.318 Negative family history reports for 
ovarian cancer was not so good, although the prevalence of this is low within 
families.318 
4.7.6.3.1 UKWCS Baseline 
At baseline a family history of breast cancer was defined as having a first degree 
relative; mother, father, brothers or sisters who had breast cancer. No information was 
given about aunts or uncles. Participants were asked to provide more details, but this 
was often incomplete. Since some participants had stated that a first degree relative 
had cancer but did not specify what type of cancer, additional adjustments/exclusions 
were made in sensitivity analyses for women who had a first degree relative with any 
type of cancer.  
 
Figure 16 Questions asked at baseline relating to family history of cancer 
 
4.7.6.3.2 UKWCS Phase 2 
At phase 2 a family history of breast cancer was defined as having a blood relative 
diagnosed with breast cancer as reported by participants at phase 2 in the 
questionnaire; they were questioned about cancers in mothers, fathers, sisters, 
brothers, aunts, uncles. Unlike at baseline, participants were specifically asked which 
family members had breast cancer and their age at diagnosis (see Figure 17 compared 
to Figure 16); therefore the breast cancer family history information provided by 
participants at phase 2 was likely to be more accurate. 
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Figure 17 Questions asked at phase 2 relating to family history of cancer 
 
Based on information from the NICE report on Familiar breast cancer issued October 
2006,319 it was possible to estimate a small percentage of the phase 2 UKWCS women 
who may have been at raised risk (2.1%) or high risk (0.8%) of developing breast 
cancer (see 0). Unfortunately the NICE guidelines could not be followed in some areas; 
therefore the categories are only estimates. In this report women with a 10-year risk of 
3–8% between the ages of 40–49 or a lifetime risk of 17% or greater but less than 30% 
were classed as having raised risk of developing breast cancer. Women with a 10-year 
risk of greater than 8% between the ages of 40–49 or a lifetime risk of 30% or greater 
were classed as at high risk; it included those with a 20% or greater chance of a faulty 
BRCA1, BRCA2 or TP53 gene in the family.  
4.7.7 Samples sizes 
Sample sizes were calculated a priori. There were sufficient numbers of women in the 
whole of the UKWCS phase 2 cohort exposed to high doses of vitamin C 
supplementation greater or equal to 500mg/day when sub-analysed into pre/post-
menopausal status in phase 2 of the UKWCS to detect relative risks of 1.3 or above in 
breast cancer risk analyses (e.g. with 404 pre-menopausal women detectable HR = 
0.797 or 1.278).  
Assumptions: 
Average follow-up time = 7.5 years 
Median time on the control treatment = 7 years 
Power of study = 90%, Level of significance = 5% 
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However, in case-control analyses of total vitamin C intake from phase 2 UKWCS 
diaries with only 200 breast cancer cases it would only be possible to detect odds 
ratios for breast cancer of 0.486 or 1.804 in women exposed to vitamin C above 
60mg/day supplements relative to unexposed subjects (see assumptions below). 
Furthermore there would be only 45% power to detect odds ratios of 1.4 for breast 
cancer in those taking vitamin C above 60mg/day relative to those not taking these.  
Moreover, the power would reduce further if the breast cancer cases were split into 
pre-menopausal and post-menopausal, or other sub-analyses were performed, or the 
exposure level was increased. To detect odds ratios of 1.4 with 90% power, 657 case 
patients with five matched controls per case would be required, meaning the UK 
Dietary Cohort Consortium studies had to be consolidated in order to sufficiently power 
the case-control analyses for total vitamin C intake. 
Assumptions: 
Number of matched breast cancer cases = 200 
Ratio of matched controls per case = 5 
Probability of vitamin C exposure above 60mg/day from supplements among controls = 
0.20 
Correlation coefficient for exposure between matched cases and controls = 0.1  
Power of study = 90%, Level of significance = 5%  
 
 
The next chapter evaluates the recording of dietary and supplement vitamin C intake in 
the UKWCS, then the following chapter determines whether women in the UKWCS 
with a history of breast cancer are more likely to take vitamin C supplements. The 
subsequent four chapters assess the relationships between breast cancer risk in UK 
women and general supplement use, vitamin C supplement use, dietary vitamin C 
intake and finally total vitamin C intake. 
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CHAPTER 5 
5 Evaluation of diet and supplement vitamin C 
intake recordings in the UKWCS 
5.1 Summary 
Objective: Since measurement error of diet can attenuate or exaggerate associations 
between dietary intake and disease incidence and reduce the power to find these, it is 
important to evaluate how well dietary tools record dietary exposure. The objective of 
this chapter was to evaluate vitamin C intake derived from diet and supplement 
recordings in the UKWCS using a variety of assessment methods. 
Methods:   
Firstly, the frequency of taking supplements containing vitamin C recorded by diary was 
compared to the frequency of vitamin C supplement use recorded in the phase 2 
questionnaire by 11,184 UKWCS participants. This was evaluated using kappa 
statistics and tabulations.  
Secondly, fruit and vegetable servings derived from FFQ recordings were compared 
with summary cross-check questions recorded concurrently by 33,521 UKWCS 
baseline participants. Agreement between fruit and vegetable intake and vitamin C 
intake derived from the FFQ were also assessed. Spearman’s correlations, tabulations, 
Bland-Altman plots and kappa statistics were used in the evaluations.  
Thirdly, vitamin C intake derived from recordings from diaries and FFQs were 
compared to plasma ascorbic acid and plasma total vitamin C concentrations for 273 
women who provided a blood sample at phase 2. This was evaluated using 
Spearman’s correlations and regression analysis.  
Results:  
Daily vitamin C supplement use reported on the questionnaire captured most of the 
women recording high dose vitamin C (>500mg) by diary in the UKWCS, the majority of 
which was likely to be single ingredient supplements. The inclusion of daily reporting of 
multivitamin/mineral use, as well as vitamin C use, on the questionnaire, produced 
substantial agreement with diary recordings of supplements containing any vitamin C 
dose taken on three or four of the four diary days.  
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Although there were fair to moderate associations between the two methods of 
recording fruit and vegetable servings using Spearman’s correlations and kappa 
agreement methods, high discrepancies were seen using Bland-Altman’s plots. The 
associations and agreement between cross-check fruit and vegetable servings and 
FFQ derived dietary vitamin C was also fair to moderate, nevertheless the agreement 
between grams of fruit and vegetable recorded by FFQ and derived dietary vitamin C 
was good. Women who were vegetarians, or not supplement users or on a low fat or 
slimming diet or eating small portions were significantly more likely to have high 
discrepancies in vegetable reporting between the two methods. Non-graduates and 
women from lower SES groups were more likely to report high discrepancies for either 
fruit or vegetables. Correcting FFQ derived vitamin C using the cross-check question 
data appeared inappropriate. 
In the final evaluation, FFQ derived dietary vitamin C correlations with plasma ascorbic 
acid, and also with dietary vitamin C calculated from diary recordings, were weak to 
moderate but in line with previous studies. Although the derived values of vitamin C 
consumed may be inaccurate, the relative ranking of individuals for the full UKWCS 
cohort based on a similar FFQ may be acceptable for assessing associations between 
vitamin C dietary intake and breast cancer risk. 
Conclusion: The comparisons between FFQs, diary and plasma concentrations were in 
line with those from other studies and were considered suitable for further analysis. 
These results highlighted some weaknesses in methods used in the UKWCS and other 
studies for recording food and supplements containing vitamin C, which should be 
taken into account when interpreting results of associations between vitamin C intake 
and breast cancer risks in the UKWCS. 
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5.2 Comparison of diary and questionnaire methods 
to assess vitamin C supplement use at phase 2 
5.2.1 Introduction 
One aim of this thesis was to explore the associations between vitamin C contained in 
supplements and breast cancer risk, results of which are provided in chapter 8. To 
explore dose-response relationships, however, it is important to include vitamin C from 
all supplements taken, not only from single ingredient vitamin C supplements. As seen 
in section 4.5.3.2 of the methods chapter, a large proportion of supplements containing 
vitamin C up to the EU recommended daily allowance (EU RDA 60mg/day 53) are 
branded as multivitamins in the UK. Supplements which include more than the EU RDA 
but less than 500mg/day are often named as multivitamins or antioxidants, whereas 
vitamin C supplements containing high doses of 500mg or more are usually single 
ingredient. Some of the previous studies which have examined associations between 
vitamin C supplementation and breast cancer appear not to have used an ingredient 
database to take account of the amount of vitamin C in all supplements, although 
doses for multivitamins appear to have been allocated in some studies.242 267 270  
Other than checks described in section 4.5.3.3 which were made whilst cleaning the 
supplement database, unfortunately it was not possible to assess whether the dose of 
vitamin C had been correctly assigned to supplements recorded in the UKWCS phase 
2 diaries. In this section, however, an attempt was made to verify the frequency of 
intake recorded in the diaries with that recorded in questionnaires, and to determine 
whether the agreement depended on the type of supplement recorded in the diaries 
and their recorded or derived vitamin C amount. Daily intake of vitamin C was 
assessed since this may have a greater influence on cancer risk than less regular 
intake because, as mentioned in chapter 2, excess vitamin C is excreted. It was 
expected that many women would have indicated use of vitamin C supplements on the 
phase 2 health and lifestyle questionnaires only if they had taken single supplement 
vitamin C, or if vitamin C was specified in the name. On the other hand it was expected 
that women would not indicate they took vitamin C supplements on the questionnaire if 
they took multivitamins or antioxidants, and other supplements which contained vitamin 
C but did not mention it in the name.  
This analysis compares daily vitamin C use recorded by the phase 2 health and 
lifestyle questionnaire with supplements containing vitamin C which were recorded in 
the 4-day diary at phase 2 in the UKWCS.  
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5.2.2 Methods 
5.2.2.1 Subjects 
At phase 2 of the UKWCS, 12,453 women completed a health and lifestyle 
questionnaire and a 4-day food diary, both of which included sections on supplement 
use. Women who were to be excluded from the related time-to-event analyses in 
chapter 8 because of their cancer status were also excluded in this evaluation, leaving 
11,184 women for the analysis. 
5.2.2.2 Dietary assessment methods 
For each of the four diary days, the women were required to record supplement brand, 
name, amount taken and dosage of any supplement taken (as shown in section 
4.5.3.1). This information was electronically captured and matched against a database 
of supplement descriptions and ingredient composition obtained from product labels 
provided by participants, suppliers’ websites or directly from manufacturers. The 
cleaning of the supplement usage database is detailed in section 4.5.3.3. 
Additionally, the frequency of use of 17 types of dietary supplements had been 
captured from the phase 2 health and lifestyle questionnaire (as shown in section 
4.5.2). In addition to vitamin C, the types listed included antioxidant supplements, 
multivitamins, and multivitamin plus mineral supplements. Frequencies were 
categorised as: more than daily; daily; weekly; monthly; less than monthly.  
5.2.2.3 Statistical analyses 
Descriptive statistics of the 11,184 women at phase 2 are included in chapter 8 which 
examines associations between vitamin C supplement use and breast cancer risk. 
The agreement between the two methods of capturing frequency of vitamin C use, i.e. 
diaries and phase 2 questionnaire, was compared using kappa statistics.320 
Agreements were interpreted as suggested by Landis and Koch detailed in section 
5.3.2.3.321 The definition of frequent use of supplements containing vitamin C was 
relaxed to three or more of the four diary days, to allow for women who may have 
accidentally missed completing this section on one of the diary days. Tabulations 
between the two methods were also produced, including tabulations with vitamin C 
dose split between1-60mg/d; >60<500mg/d; ≥500mg/d. These are categories used in 
chapter 8 on vitamin C supplement use and breast cancer risk. 
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5.2.3 Results 
5.2.3.1 Comparisons between vitamin C intake recorded by diary and 
supplements recorded by the phase 2 questionnaire 
When vitamin C supplement use recorded on three or four of the four diary days were 
split into categories by dose at zero, 60 mg and 500 mg cut-off points, about a third of 
users were in each intake category. As observed in Table 9, of women who recorded 
on the phase 2 questionnaires they took daily vitamin C supplements, 18% recorded no 
use of supplements containing vitamin C in the diaries on 3 or more diary days, about a 
third took supplements containing less than 500mg/d vitamin C on 3 or more diary 
days, and half recorded in the phase 2 diaries they took supplements containing 
500mg/d vitamin C or more on 3-4 of the diary days.  
Table 9 Women who recorded daily use of vitamin C on the phase 2 questionnaire split 
by diary vitamin C intake category 
Vitamin C supplement use 
recorded by diary split into 
categories by dose (taken on 
3 or 4 of the four diary days) 
Daily use of vitamin C on phase 2 questionnaires 
split by diary intake category 
Yes No Total 
No vitamin C     351 (18%)  7042 (76%) 7393 (66%) 
1-60mg/d          200 (10%) 1293 (14%) 1493 (13%) 
>60<500mg/d    418 (22%) 817 (9%) 1235 (11%) 
≥500mg/d        947 (50%) 116 (1%) 1063 (10%) 
Total 1916 (100%) 9268 (100%) 11184 (100%) 
 
However, from the perspective of diary recordings, 2210 (56%) of the 3791 diary 
vitamin C supplement users documented use of supplements containing less than 
500mg/d vitamin C in the diary but did not record vitamin C use in the questionnaire. As 
seen in Table 10 women (89%) who took 500mg/d vitamin C on three or four diary 
days also recorded on the phase 2 questionnaire that they took daily vitamin C 
supplements. As found from the inspection of the ingredient database in section 
4.5.3.2., the majority of these supplements were likely to be single supplement vitamin 
C. About a third of women in the medium and high vitamin C intake categories reported 
on the questionnaire they took antioxidants. Forty percent of women in the highest 
vitamin C category also recorded the frequent use of multivitamins on the 
questionnaire, compared to 72% of women in the less than or equal to 60mg/d vitamin 
C category.  
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Table 10 Percentage of women in each vitamin C intake category who recorded daily 
intake of vitamin C, antioxidants or multivitamins on the phase 2 questionnaire 
 
 
Vitamin C supplement use recorded  
by diary split into categories by dose 
(taken on 3 or 4 of the four diary days) 
Percentage of women in each vitamin C 
intake category who recorded daily intake 
on phase 2 questionnaire of: 
Vitamin C 
N=1916 
Antioxidant 
N=1099 
Multivitamin 
N=2714 
No vitamin C     N= 7393 (66%)            5% 3% 8% 
1-60mg/d          N= 1493 (13%) 13% 10% 72% 
>60<500mg/d   N= 1235 (11%) 34% 34% 53% 
≥500mg/d         N= 1063 (9.5%) 89% 28% 40% 
 
Using kappa statistics, the measure of agreement between the two methods of 
capturing frequency of vitamin C supplement usage at phase 2 varies between fair to 
substantial depending upon what questionnaire data is included in the calculation 
(Table 11). 
 
Table 11 Kappa agreements between frequency of vitamin C intake captured via diary 
and that captured via the phase 2 questionnaire  
Questionnaire: Supplement 
taken daily 
Supplement containing 
vitamin C from 4 days of 
diary keeping  
Kappa  
(95%CI) 
Agreement 
321 
Vitamin C a 4 out of 4 days (daily) 0.39 (0.37-0.41) Fair 
Vitamin C at least 3 out of 4 days 0.41 (0.39-0.43) Moderate 
Vitamin C or multivitamin d at least 3 out of 4 days 0.70 (0.69-0.71) Substantial 
Vitamin C or multivitamin or 
antioxidant e 
at least 3 out of 4 days 0.71 (0.70-0.72) Substantial 
Vitamin C or antioxidant b >60mg, 3 out of 4 days 0.61 (0.60-0.62) Substantial 
Vitamin C ≥500mg, 3 out of 4 days 0.59 (0.58-0.59) Moderate 
Multivitamin/ mineral c 1-60mg, 3 out of 4 days 0.41 (0.40-0.42) Moderate 
a
ticked takes vitamin C daily, or more than daily on the phase 2 questionnaire 
b
ticked takes vitamin C or antioxidant daily, or more than daily on the questionnaire 
c
ticked takes multivitamin or multivitamin and mineral daily, or more than daily on the questionnaire 
d
ticked takes vitamin C, multivitamin or multivitamin and mineral daily, or more than daily on the 
questionnaire 
e 
ticked takes vitamin C, multivitamin or multivitamin and mineral daily, or more than daily, 
 
Only fair agreement (kappa=0.39; 95%CI: 0.37, 0.41) occurs when comparing those 
women who have ticked daily vitamin C supplement usage on the questionnaire with 
those shown to have taken four days of supplements containing vitamin C during diary 
completion (Table 11). As observed in Table 12 77.7% of recordings are in the 
expected quadrant. According to the kappa statistics, the agreement increases if the 
comparison is relaxed to usage on three or four of the four diary days. The agreement 
becomes substantial if daily multivitamin use indicated on the questionnaire is also 
included in the comparison (kappa=0.70; 95%CI: 0.69, 0.71). This kappa statistic alters 
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only slightly if daily antioxidant supplement use on the questionnaire is then also 
included in the comparison ((kappa=0.71; 95%CI: 0.70, 0.72); as seen in Table 13 
86.6% are in the expected quadrant). Excluding women who were ill or on a weight 
reducing diet during diary recording, and who may have taken vitamin C or antioxidants 
or multivitamins during this time, perhaps on a temporary basis, does not alter the 
kappa statistic (kappa=0.71; 95%CI: 0.70, 0.72).  
 
Table 12 Cross-tabulation of daily vitamin C supplement use recorded by questionnaire 
with daily intake of supplement containing vitamin C recorded by diaries  
Questionnaire: 
Daily vitamin C 
use 
Diary: daily use of supplements containing vitamin C  
(4 out of 4 diary days) 
No Yes Total 
No 7332 (65.5%) 1936 (17.3%) 9268 (82.8%) 
Yes 556 (5.0%) 1360 (12.2%) 1916 (17.2%) 
Total  7888 (70.5%) 3296 (29.5%) 11184 (100%) 
Kappa  = 0.39 (0.37-0.41) 
 
 
Table 13 Cross-tabulation of daily vitamin C or antioxidant or multivitamin supplement 
use recorded by questionnaire with intake of supplement containing vitamin C on 3 or 4 
diary days   
Questionnaire: 
Daily vitamin C or 
antioxidant or 
multivitamin use 
Diary: use of supplements containing vitamin C  
on 3 or 4 diary days 
 
No Yes Total 
No 6497 (58.1%) 604 (5.4%) 7101 (63.5%) 
Yes 896 (8.0%) 3187 (28.5%) 4083 (36.5%) 
Total  7393 (66.1%) 3791 (33.9%) 11184 (100%) 
Kappa  = 0.71 (0.70-0.72) 
 
Table 14 Cross-tabulation of daily vitamin C or antioxidant supplement use recorded by 
questionnaire and taking supplements containing vitamin C above 60mg for 3 or 4 diary 
days 
Questionnaire: 
Daily vitamin C or 
antioxidant use 
Diary: use of supplements containing vitamin C above 60mg 
 on 3 or 4  diary days 
No Yes Total 
No 8054 (72.0%) 647 (5.8%) 8701 (77.8%) 
Yes 832 (7.5%) 1651 (14.7%) 2483 (22.2%) 
Total  8886 (79.5%) 2298 (20.5%) 11184 (100%) 
Kappa = 0.61 (0.60-0.62) 
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Substantial agreement also occurs in comparisons between supplements containing 
over 60 mg/d of vitamin C recorded by diary on three or four days and daily vitamin C 
supplement or antioxidant usage indicated on the questionnaire ((kappa=0.61; 95% CI: 
0.60, 0.62); 86.7% are in the expected quadrant in Table 14). Similar results are 
produced in comparisons between supplements containing 500mg or more of vitamin C 
recorded by diary on three or four days and daily vitamin C supplement usage 
indicated on the questionnaire (kappa=0.59; 95% CI: 0.60, 0.62). Similar results are 
also produced after excluding women who completed the diary between the winter 
months, November to end of February, who may only take antioxidants or the higher 
doses of vitamin C throughout the winter or when they develop winter colds 
(Kappa=0.58; 95% CI: 0.56, 0.58)).  
However, there was only moderate agreement when recording of supplements 
containing low amounts of vitamin C (60mg/d or less) on three or four diary days were 
compared with daily multivitamin recordings on the questionnaire (kappa=0.41, 95%CI: 
0.40, 0.42). 
5.2.4 Discussion 
Only moderate agreement occurred when comparing those women who ticked daily 
vitamin C supplement usage on the questionnaire with those shown to have taken 
supplements containing vitamin C on three or four days of the 4-d diary. This was 
unsurprising given the difference seen in the various tabulations. For instance, over a 
third of women consuming supplements containing vitamin C as per diary recordings 
were consuming ones less than or equal to 60mg, and the majority of women in this 
category recorded daily multivitamin use rather than vitamin C or antioxidant use on the 
questionnaire. The results clearly show that responses to a simple question about 
vitamin C supplement use on a questionnaire will not capture the recording of a large 
proportion of supplements containing vitamin C. Therefore, it was not possible to verify 
the frequency of diary recorded supplements containing vitamin C using only the 
vitamin C question on the questionnaire. Only after taking account of the reporting of 
daily use of multivitamin/minerals as well as vitamin C on the questionnaire, was 
substantial agreement reached between diary and questionnaire reports.  
However, the results indicate that previous studies which have examined associations 
between vitamin C supplementation and breast cancer risk and allocated doses for 
single supplement vitamin C, multivitamins and antioxidants may have picked up the 
majority of supplements used containing vitamin C.242 267 270 Nevertheless, the dose 
estimates that were allocated may have been somewhat inaccurate if no ingredient 
database was used. Furthermore, as seen from the inspection of the UKWCS 
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ingredient database in section 4.5.3.2, the majority of supplements in the medium 
vitamin C dose range are types other than those branded as vitamin C, multivitamins 
and antioxidants; these, however, may be less commonly consumed.  
Although women recording  supplements containing high doses of vitamin C (500mg/d 
or more) in the diaries usually reported vitamin C supplement on the phase 2 
questionnaire, only half the women who reported the latter appeared to take high 
doses. Therefore, confirmative answers to vitamin C use on the questionnaire were not 
representative of high dose use in the diary, indicating that questionnaires should not 
be used for this purpose. 
Although the majority of women (72%) using supplements containing doses of 60 
mg/day or below (the EU recommended allowance) appear to report multivitamin use 
on the questionnaire, the overall kappa agreement between this diary category with 
recordings of daily use of multivitamins or multivitamins with minerals on the 
questionnaire was fairly poor. There are likely to be two reasons for this: the average 
multivitamin in the UK supplement data base contains over 70mg therefore some 
multivitamins will contain more than 60mg; and many women in the higher dose 
categories may also be taking low dose multivitamins so may have ticked the vitamin C 
and a multivitamin box on the questionnaire. 
The questionnaire relates to a longer time period than the 4-d diary; this is likely to 
have lowered the agreement between the two tools. It is not clear from the section in 
the questionnaire whether the period of assessment for each supplement type listed 
relates to current use or use in the last year. The 4-d diary recordings are more likely to 
represent short-term episodic intake, particularly because high dose vitamin C is 
promoted for reducing seasonal common colds. Despite this, the agreements between 
the methods did not change when women who completed the diaries in the winter 
months were excluded. Neither did the agreement between methods change when 
women were excluded who were ill or on a weight reducing diet, and who may have 
been concerned that they lacked nutrients during this time and taken supplements 
temporarily. Furthermore, vitamin C supplementation was found to have the highest 
long-term use stability of any nutrient in a US study which compared supplement data 
collected by two questionnaires that were on average 2.4 years apart (kappa=0.64; 955 
CI: 0.60, 0.67).322 A similar agreement was found comparing 24-hr recall methods with 
the second questionnaire data, but comparisons with diary data were not 
undertaken.322  
A previous study compared information transcribed from supplement packaging (the 
gold standard) with data from self-administered questionnaire, producing kappa 
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statistics for supplement type as 0.67 (0.53, 0.89) for vitamin C, and 0.68 (0.52, 0.84) 
for once a day multivitamins.323 The questionnaires in this study requested  more detail 
than those of the UKWCS, and the UKWCS diary recordings may not be as accurate 
as the gold standard, nevertheless some of the current results were in line with these 
results. The Spearman’s correlation coefficients for dose of vitamin C in all 
supplements was 0.76 for this study.323  
In the UKWCS the diary and questionnaire were completed within a short time period 
of each other; although this increases the likelihood that supplements were recorded 
on either tool, it may have also created recall bias and produced overstated 
comparisons.324 Nevertheless, anomalies remain in the UKWCS data that may be due 
to recording or input error, which cannot be explained by changes in supplement use 
owing to seasonal differences, illnesses or weight-reducing diets. Despite the time that 
had been spent allocating supplement types from the ingredient database to 
supplements recorded in the diaries, and cleaning these, the methods used in recent 
research on the EPIC-Norfolk cohort to allocate vitamin C dose could potentially 
produce a more accurate vitamin C intake consumed from supplements.38  
Despite diary assessment taking place over a narrow four day period, overall these 
results indicate that, after checking and cleaning supplements containing vitamin C, the 
validity of daily vitamin C supplement use is good when compared with the 
questionnaire assessment of vitamin C and multivitamin supplement use. This and the 
results of the final spot check indicate the data is acceptable for use in further 
analyses.  
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5.3 Comparisons relating to dietary vitamin C intake 
and servings of fruit and vegetable consumed at 
baseline  
5.3.1 Introduction 
Since measurement error of dietary exposure could distort the associations between 
vitamin C intake and breast cancer incidence in the UKWCS, it is important to evaluate 
the recording of food containing vitamin C in the UKWCS. At baseline self-reported 
FFQs were used to record diet since the cost and ease of administering them to over 
35,000 women were lower than other methods. Additionally, the FFQs estimate intake 
over 12 months, being superior in this respect compared to diaries or biomarkers. This 
section focuses on the evaluation of UKWCS baseline FFQ recordings of fruit and 
vegetables, the main source of vitamin C. 
Over-estimation of fruit and vegetables by FFQs is a known problem which has been 
previously assessed using data from 6,572 women at baseline in the UKWCS.288 If 
estimated intake was systematically inflated for most women in the cohort then this 
may not impact on cancer risk ratios. However, the earlier analysis found that 
vegetarians and those on slimming diets were slightly more likely to have a large 
discrepancy between FFQ fruit and vegetable recordings and total portions of fruit and 
vegetables consumed given in two cross-check questions.288 Women with higher 
education levels were less likely to over-estimate. The authors suggest that average 
portions of vegetables consumed in mixed dishes may have been over-estimated and 
socially desirable answers may have been given. Possible errors in FFQ derived fruit 
and vegetable or vitamin C intakes can be adjusted by applying a correcting factor for 
each subject using cross-check summary questions which ask for total fruit and 
vegetable portions consumed per day or per week.288 325-327 
Expanding on the initial analysis of 6,572 women,288 this baseline analysis of the full 
UKWCS cohort will compare fruit and vegetable intake derived from FFQ recordings 
with concurrent recordings by cross-check questions. Agreement between fruit and 
vegetable intake and vitamin C intake derived from the FFQ will also be assessed. The 
suitability of using the cross-check questions to correct for possible over-estimation of 
vitamin C derived from fruit and vegetables reported in the UKWCS FFQs will be 
discussed. 
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5.3.2 Methods 
5.3.2.1 Subjects 
General information about the recruitment of the 35,372 women who completed the 
baseline questionnaire is provided in section 4.1.1.1 of this thesis. Women who were to 
be excluded from the subsequent time-to-event analyses in chapter 9 were also 
excluded in this evaluation. This left 33,521 middle-aged women from the UKWCS who 
completed the baseline FFQ for this evaluation analysis. 
5.3.2.2 Dietary assessment methods 
At baseline the mean daily dietary vitamin C intake had been calculated from the list of 
simple and mixed food items on the FFQ. This FFQ was developed from one used in 
EPIC UK studies,289 290 by adding extra vegetable composition dishes to accommodate 
the higher proportion of vegetarians in the UKWCS to produce a 217 item FFQ.279 
Thirty one vegetables (excluding potatoes), 19 fresh fruit and five dried fruit items were 
listed in the FFQ. Nine of the fresh fruit were seasonal; no canned or frozen fruit were 
specifically listed. As seen in section 4.5.1, for each item participants chose from 10 
pre-coded frequency of consumption categories ranging from never to 6 or more times 
per day, on average over the past year. The cross-check questions were on a separate 
section of the baseline questionnaire: 
Q7 How many servings of vegetable or vegetable containing dishes (excluding 
potatoes) do you usually eat each week? 
Q11 How many servings of fruit or fruit containing dishes do you usually eat each 
week? 
5.3.2.3 Statistical analyses 
Descriptive statistics of the 33,521 women at baseline are included in chapter 9 on 
associations between dietary vitamin C intake and breast cancer risk. 
After exclusions, histograms and box plots were produced of dietary vitamin C and total 
fruit and vegetable intake (see Figure 18). All graphs were skewed to the right and also 
showed twelve women with much higher intakes. No obvious errors were found 
between answers provided on the questionnaire and data electronically captured for 
these women. However, comparisons between the completion of the FFQ lists of fruit 
and vegetables and the number of servings given in the cross-check questions 
indicated that some women with very high intakes may have completed some sections 
incorrectly. For all but one participant, it was not obvious which parts were completed 
incorrectly, therefore no corrections or further exclusions were made at this stage.  
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The distributions of the variables were skewed, and so the median intakes and inter-
quartile ranges (IQR) were calculated as well as the means for fruit and vegetables and 
for derived vitamin C intake split by fruit, vegetables, juice and potatoes. The Wilcoxon 
sign-rank test, for paired non-parametric data, was used to compare servings of fruit or 
vegetables measured by FFQ and by cross-check question for each woman. The 
correlations between total fruit and vegetable servings and also intake as grams and 
derived vitamin C were calculated using Spearman’s correlation coefficients for non-
parametric data (using pair-wise deletion of observations with missing values). This 
method is less influenced by outliers than Pearson’s product moment correlations. The 
Spearman’s method ranks data for each variable and calculates the Pearson’s 
correlation between the ranks which is the number of standard deviations that one 
variable changes for a standard deviation change in the other. Unfortunately, 
correlations between two variables can be strong even if one is consistently much 
higher than the other variable, making the technique misleading.328 Correlations 
measure the strength of the association between two variables but, unlike the Bland-
Altman technique, cannot assess the extent of the agreement between them. The 
Bland-Altman technique can only be used to compare two methods with the same 
underlying units of measurement such as fruit and vegetable servings; the ratio of 
servings derived from FFQs to servings reported by the cross-check question was 
plotted against the mean of the two measures using log scales.328 329 More specifically, 
this was achieved by plotting the exponential of the difference in the two log-
transformed measures against the exponential of the mean of the log-transformed 
variables on log scaled graphs. The ratio was used instead of the difference between 
the two measures normally used in Bland-Altman plots, since the differences increased 
substantially as the servings increased. The ratios between the two variables should be 
relatively small for the agreement between the two measurements to be considered 
good. The 731 women who did not complete either cross-check question were 
excluded from the plot. 
In a similar manner to previous research on the smaller sample of UKWCS, 288 the 
characteristics of women with FFQ derived servings that were more than five times 
larger than the cross-check answers were tabled. 
For comparisons of variables with different underlying units, the variables were 
categorised into 5 groups of ascending intake and the agreement between the 
categorisation of participants using the two methods was compared using kappa 
statistics;320 a technique normally used to measure agreement between two raters or 
measure reproducibility between two time points. Unweighted and weighted kappa 
statistics, К and Кw, were produced. 
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For instance, the kappa statistic compared the observed portion of agreement between 
fruit intake in grams and fruit servings with the portion of agreements that would be 
expected by chance. Given that 5 categories were used, the chance of 
misclassification was quite high which tended to decrease the value of kappa. Rather 
than assigning no agreement, classification occurring in adjacent categories was 
counted as partial agreement and was weighted accordingly. The following linear 
weighting was used: 
Кwi =1 – ( i /(n -1)) 
where i is the number of categories of difference between the two methods for each 
participant, and n is the number of categories.  This gave weightings of: 1; 0.75; 0.5; 
0.25, and 0 depending on whether the classifications differed by none, 1, 2, 3, or 4 
categories respectively. 
Agreements were interpreted as suggested by Landis and Koch (1977):321  
К =0 none, no better than chance 
К <0.2 slight agreement 
К ≥0.21 ≤0.40 fair agreement 
К ≥0.41 ≤0.60 moderate agreement 
К ≥0.61 ≤0.80 substantial/good agreement 
К >0.8-1.00 very good agreement 
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Figure 18 Box whisper plots and histograms showing distributions of FFQ derived 
dietary vitamin C (mg/d), total fruit and vegetable intake (g/d), and total servings per 
day of fruit and vegetables  
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Figure 19 Histograms showing distributions of total fruit and vegetables servings per 
week recorded by cross-check question, and separate distributions for fruit and for 
vegetables  
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5.3.3 Results 
The median intake in grams (IQR) per day derived from the FFQ was 264g (164-399) 
for fruit, 281g (195-393) for vegetables, and 565g (210-400) for total fruit and vegetable 
including juices. The median total vitamin C derived from the FFQs was 156mg (114-
210) for all women and 160mg (117-218) for vegetarians, a difference of only 3%. 
Mean totals were 171.2mg (sd 86.3) and 178.0mg (sd 93.9), respectively. Vegetarians 
were defined from the FFQ as eating meat or fish less than once per week. Dietary 
vitamin C intake calculated from juice, fruit, vegetables and potatoes are shown in 
Table 15 for all women and for vegetarians, who comprised of 19% of this dataset. The 
main source of vitamin C was from fruit and vegetables, making up 75% for all women 
and only slightly more for vegetarians at 76% (as calculated from means). Juice made 
up 19% of the total dietary vitamin C intake derived from the FFQ. 
Table 15 The main dietary sources of vitamin C at baseline in the UKWCS for all 
women and for vegetarians separately 
 All women FFQ defined vegetarians 
Vitamin C  
from   
Median 
(IQR) mg/d 
Mean 
(sd) mg/d 
% of  
total
a
 
Median 
(IQR) mg/d 
Mean 
(sd) mg/d 
% of  
total
a
 
Juice 24.1 (5.1-56.5) 32.4( 38.5) 19% 22.1 (5.1-56.6) 33.0 (41.5) 19% 
Fruit 48.9 (28.3-77.2) 61.6 (56.7) 36% 51.3 (29.7-81.3) 65.5 (64.0) 37% 
Vegetable 57.7 (36.9-85.9) 66.3 (43.3) 39% 60.8 (39.7-88.8) 69.5 (44.6) 39% 
Potatoes 14.0 (9.2–19.2) 15.1 (9.4) 9% 12.4 (7.51-18.3) 13.8 (10.1) 8% 
a
Percentage of totals are based on means (these add up to slightly more than 100% due to some errors in 
splitting vitamin C between sources) 
 
The median (IQR) daily servings of fruit and vegetables reported on the cross-check 
questions were 1.4 (1-2) and 1.4 (1-2), whereas the median servings derived from the 
FFQ were much higher: 4.3 (2.7-6.5) and 4.7 (3.2-6.6). The medians from the cross-
check questions are significantly different from the FFQ servings (P<0.001). For total 
fruit and vegetables from the cross-check questions and from the FFQ the mean 
servings were 2.8 (sd 1.8) and 10.6 (sd 6.1) respectively. These averages excluded 
women with missing data. Of the 33,521 women, 731 (2%) had missing data for both 
cross-check questions, 4122 (12%) had missing responses for fruit only and 1397 (4%) 
for vegetables. 
5.3.3.1 Comparisons between methods of recording fruit and vegetables 
There were some anomalies relating to juice in the comparisons for fruit. Some 
participants may have included fruit juice in their responses to cross-check questions, 
others may not. Up to one portion of fruit juice per day was allowed in the calculation of 
number of fruit servings derived from the FFQ, which had been previously 
calculated.330Juice was not included in ‘fruit in grams’ and in ‘vitamin C from fruit’, both 
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derived from the FFQ. Comparisons relating to vegetables did not include potatoes, 
which made up 8-9% of total vitamin C intake. Participants were asked not to include 
potatoes in the vegetable cross-check question. 
The log-transformed Bland-Altman plots in Figure 20 show that for 95% of women the 
fruit and vegetable servings per day derived from the FFQ exceeds the cross-check 
question recordings by between 1.2 and 11.9 times. The mean ratios and 95% 
confidence limits were similar for vegetarians (Figure 20) and non-vegetarians (not 
shown) and for fruit and vegetables separately (Figure 21). 
 
Figure 20 Bland-Altman plots of ratios between FFQ and cross-check question 
recording total fruit and vegetable servings for all women and for vegetarians only  
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Figure 21 Separate fruit and vegetable Bland-Altman plots of ratios between servings 
measured by FFQ and by cross-check question 
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Despite the large reported discrepancies found above there was moderate correlation 
with Spearman’s ranked correlations coefficients between the methods for recording 
servings for fruit (rs=0.54) and for vegetables (rs=0.40). There was also moderate 
correlation between the cross-check answers and the FFQ derived fruit or vegetable in 
grams or as vitamin C as seen in Table 16 and Table 17. The correlation was strong 
between servings (or grams) of fruit or vegetables derived from the FFQ and the 
vitamin C from fruit calculated from the FFQ, and similarly for vegetables (rs=0.91 and 
0.86). 
 
Table 16 Spearman’s correlations between fruit as servings and as grams, and 
between derived vitamin C intake 
Comparison variables for fruit Spearman’sa  Correlationb  
X-check fruit servingc  FFQ fruit servingsd 0.54 (p<0.001) Moderate 
X-check fruit serving  FFQ fruit (g)
e
 0.61 (p<0.001) Moderate 
X-check fruit serving  FFQ vit C from fruitf 0.54 (p<0.001) Moderate 
FFQ fruit servings FFQ vit C from fruit 0.91 (p<0.001) Strong 
FFQ fruit (g) FFQ vit C from fruit 0.89 (p<0.001) Strong 
a
Spearmans’s ranked correlation coefficients for non-parametric data 
b
Given strength of correlation is based on classification of Peason’s correlation coefficients 
c
Fruit servings consumed, obtained from cross-check questions 
d
Fruit servings consumed, derived from the FFQ 
e
Grams of fruit consumed, derived from the FFQ 
f
Dietary vitamin C intake from fruit, derived from the FFQ 
 
 
Table 17 Spearman’s correlations between vegetables as servings and as grams, and 
between derived vitamin C intake 
Comparison variables for vegetables Spearman’s  Correlation  
X-check veg serving  FFQ veg servings 0.40 (p<0.001) Moderate 
X-check veg serving  FFQ veg (g) 0.40 (p<0.001) Moderate 
X-check veg serving  FFQ vit C from veg 0.37 (p<0.001) fair 
FFQ veg servings FFQ vit C from veg 0.86 (p<0.001) Strong 
FFQ veg (g) FFQ vit C from veg 0.90 (p<0.001) Strong 
See notes to Table 16 
 
Alternatively, using the Kappa method to measure the extent of the agreement, the fruit 
serving cross-check responses were split into five roughly equal groups and cross-
tabulated against fruit servings derived from the FFQ split similarly (Table 18). Only 
35% of participants were classified in the same fifths producing a kappa statistic of 
0.19, of slight agreement (Table 19). However, 74% were classified in the same or 
adjacent fifths producing a weighted Kappa of 0.36 of fair agreement. (The kappa 
weighted method is explained in section 5.3.2). At the extremes, 9% were classified in 
groups greater than two groups difference. As seen in Table 19 the weighted Kappa 
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was similar for comparisons between fruit serving cross-check responses and vitamin 
C from fruit derived from the FFQ (Кw=0.37). As expected the latter’s agreement with 
fruit as grams derived from the FFQ was substantial (Кw=0.71). 
 
Table 18 Tabulation of fruit servings from cross-check answers and those derived from 
the FFQ excluding women with missing data  
Cross-check 
fruit group  
FFQ derived fruit servings per week 
1 (0-16) 2 (17-25) 3 (26-34) 4 (35-49) 5 (50 +) Total (%) 
(servings/week) 20% 20% 18% 21% 21% 100% 
1 (0-5)   3,165      1,257       695        445 286 5,848 (20) 
2 (6-7) 1,458      1,742       1,312         1,156 849 6,517 (22) 
3 (8-11) 668  1,350       1,265       1,211         851 5,345 (18) 
4 (12-14) 345 1,047      1,309       1,603       1,626 5,930 (20) 
5 (15 & above) 145 530  882 1,674       2,526 5,757 (20) 
Total 5,781       5,926       5,463       6089       6,138       29,397 (100) 
 
 
Table 19 Kappa agreements between groupings of fruit consumed as servings, intake 
in grams and derived vitamin C intake  
Comparison variables Kappa (SE) Agreement321 
X-check fruit servings  FFQ fruit servings 0.19 (0.0029) 
0.36 (0.0040)w 
Slight 
Fair 
X-check fruit servings  FFQ fruit (g) 0.23 (0.0029) 
0.42 (0.0040)w 
Fair 
Moderate 
X-check fruit servings  FFQ vit C from fruit 0.19 (0.0029) 
0.37 (0.0040)w 
Slight 
Fair 
FFQ vit C from fruit FFQ fruit (g) 0.48 (0.0029) 
0.71 (0.0040)w 
Moderate 
Substantial 
W
Weighted to taken into account observations allocated to adjacent groups (see section 5.3.2) 
SE= standard error 
Women with missing fruit cross-check serving data were excluded from all the above kappa calculations  
 
 
It proved difficult to split the vegetable serving cross-check responses into five roughly 
equal groups due to their uneven distribution. When these were cross-tabulated 
against vegetables servings derived from the FFQ split similarly (Table 20) only 29% of 
participants were classified in the same fifths producing a Kappa statistic of 0.11, of 
slight agreement (Table 21). However, 72% were classified in the same or adjacent 
fifths producing a weighted Kappa of 0.25 of fair agreement. At the extremes 9% were 
classified in groups greater than two groups difference. The weighted Kappa was 
similar for comparisons between vegetable serving cross-check responses and vitamin 
C from vegetables derived from the FFQ (Кw=0.24). The latter’s agreement with 
vegetables as grams derived from the FFQ was substantial (Кw=0.72). 
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Table 20 Tabulation of vegetable servings from cross-check answers and those 
derived from the FFQ excluding women with missing data 
Cross-check 
vegetable group  
FFQ derived vegetable servings per week 
1 (0-18) 2 (19-28) 3 (29-38) 4 (39-54)  5 (55+) Total (%) 
(servings/week) 17% 23% 22% 23% 15% 100% 
1 (0-6) 2,340 1,553 1,001 621 252 5,767 (18) 
2 (7) 1,530 2,000 1,642 1,473 791 7,436 (23) 
3 (8-11) 982 1,830 1,703 1,529 790 6,834 (21) 
4 (12-14) 574 1,411 1,771 2,154 1,628 7,538 (24) 
5 (15 & above) 171 635 1,061 1,486 1,194 4,547 (14) 
Total 5,597 7,429 7,178 7,263 4,655 32,122 (100) 
 
Table 21 Kappa agreements between grouping of vegetable consumed as servings, 
intake in grams and derived vitamin C intake  
Comparison variables Kappa (SE) Agreement321 
X-check veg servings  FFQ veg  servings 0.11 (0.0028) 
0.25 (0.0038)w 
Slight 
Fair 
X-check veg servings  FFQ veg (g)
e
 0.11 (0.0028) 
0.25 (0.0038)w 
Slight 
Fair 
X-check veg servings  FFQ vit C from vegf 0.11 (0.0028) 
0.24 (0.0038)w 
Slight 
Fair 
FFQ vit C from veg FFQ veg (g) 0.49 (0.0028) 
0.72 (0.0038)w 
Moderate 
Substantial 
W
Weighted to taken into account observations allocated to adjacent groups (see section 5.3.2) 
SE= standard error 
Women with missing vegetable cross-check serving data were excluded from all the above kappa 
calculations  
 
The Kappas produced for comparisons of total fruit and vegetables were similar (not 
shown).  
5.3.3.2 Women with high discrepancies 
Fruit servings derived from the FFQ were more than double the responses for cross-
check questions for 78% of women who completed the cross-check questions, similarly 
for 82% of women relating to vegetable servings. FFQ derived servings were more 
than five times larger than the cross-check answers for about a quarter of the women 
(23% of the all women reporting fruit and 24% reporting vegetables, and 21% and 28% 
respectively for FFQ defined vegetarians). The characteristics of women with these 
large discrepancies are shown in Table 22. On average, high discrepancy fruit and 
vegetable reporters had higher median FFQ servings per day compared to other 
women but lower median servings per day reported on the cross-check questions 
compared to others (Table 22). These women, including the FFQ defined vegetarians 
amongst them, had a median of one serving per day for fruit and for vegetables as per 
the cross-check question. FFQ derived servings were seven times that of the cross-
check answers for over half of the high discrepancy reporters, and for about 10% of 
total women. 
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Table 22 Characteristics of women with large discrepancies between methods of 
measuring fruit and vegetable portions 
 High discrepancy Other women 
 Fruit 
reporting 
Veg 
reporting 
Fruit 
reporting 
Veg 
reporting 
FFQ servings, median (IQR)   6.4 (4.3-9.8) 6.7 (5.2-8.8) 4.0 (2.6-5.8) 4.1 (2.9-5.7) 
X-check servings per day, 
median (IQR)   
1.0 (0.6-1.4) 1.0 (0.7-1.3) 1.4 (1-2) 1.4 (1-2) 
Age years, mean (sd) 52.4 (9.3) 51.6 (9.2) 51.6 (9.2) 52.0 (9.3) 
BMI kgm-2, mean (sd) 24.5 (4.3) 24.4 (4.3) 24.4 (4.3) 24.4 (4.3) 
     
Typical food portionsa-small 1033 (27%) 1089 (26%) 2783 (73%) 3105 (74%) 
                                medium 5122 (23%) 5814 (24%) 17109(77%) 18492(76%) 
                                     large 659 (22%) 778 (24%) 2397 (78%) 2523 (76%) 
Vegetarian -    Yes 1188 (21%) 1679 (28%) 4342 (79%) 4294 (72%) 
                        No 5695 (24%) 6075 (23%) 18174(76%) 20076(77%) 
Low fat diet -   Yes 1829 (24%) 2324 (28%) 5932 (76%) 6113 (72%) 
                        No/missing 5054 (23%) 5430 (23%) 16584(77%) 18257(77%) 
Slimming diet -Yes 505 (21%) 724 (27%) 1924 (79%) 1930 (73%) 
                        No/missing 6378 (24%) 7030 (24%) 20592(76%) 22440(76%) 
Socio-economic status -1 2437 (21%) 2794 (22%) 9011 (79%) 9660 (78%) 
                                       2 2951 (24%) 3294 (25%) 9374 (76%) 10124(75%) 
                                       3 1354 (26%) 1508 (26%) 3798 (74%) 4207 (74%) 
Educated to degree - Yes 1481 (19%) 1736 (21%) 6150 (81%) 6476 (79%) 
                                    No 5402 (25%) 6018 (25%) 16366(75%) 17894(75%) 
Supplement user      - Yes 2572 (23%) 2798 (23%) 8540 (77%) 9371 (77%) 
                                    No 4223 (23%) 4855 (25%) 13788(77%) 14781(75%) 
a
Self-categorised portions 
 
High discrepancies in vegetable reporting were more likely for women who were 
vegetarian, or on a low fat or slimming diet (p<0.001), or eating small portions (p=0.01) 
or not supplement users (p<0.001), despite there being no differences in BMI on 
average between them and other women. There was no such clear pattern between 
diet and high discrepancy fruit reporting, though eating small portions (p<0.001) and 
not being on a slimming diet (p=0.001) was significantly associated with discrepancies. 
Non-graduates and women from lower SES were more likely to report high 
discrepancies for either fruit or vegetables (p<0.001). 
5.3.4 Discussion 
The majority of the dietary vitamin C estimated from FFQ recordings at baseline in the 
UKWCS came from fruit and vegetables (75%) and the remaining was from juice and 
potatoes. This compares with an estimate of 62% vitamin C from fruit and vegetables 
using 24-hour recall methods for 264 women from the UKWCS.331 In the current 
analysis, Spearman’s correlations and weighted kappa statistics confirmed that FFQ 
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derived grams of fruit and vegetables had strong agreement with total derived dietary 
vitamin C. However the corresponding non-weighted kappa statistics showed only 
moderate agreement; this may reflect the fact that some women may consume some 
types of fruit and vegetables that are more vitamin C rich than others. Furthermore, the 
accuracy of vitamin C derived from diet records is limited by the accuracy of food tables 
that are used to convert recordings into amounts of vitamin C consumed, in addition to 
limitations relating to the allocation of portion weight and recording of frequency of 
consumption. The derivation methods used for the UKWCS have been explained in 
section 4.5.1 and elsewhere.288 A review found that the inclusion of portion-size 
questions produced lower correlation coefficients specifically for vitamin C, than if 
standard portions were used.332 Although the UKWCS FFQ included a question about 
portion sizes, it was not used to derive nutrient values; a standard portion size was 
used. 
The vitamin C intake estimates for vegetarians in this UKWCS baseline dataset were 
only 3% more than for non-vegetarians. Women in this cohort were generally more 
health conscious than the general population and may be likely to consume high 
intakes of fruit and vegetables, whether or not they are vegetarians. Additionally, they 
may have given socially desirable answers they believed were related to the aims of 
the research.333  
Spearman’s correlation method using relative rankings showed moderate agreement 
between the cross-check answers and other variables; however other methods such as 
the Bland-Altman and the Kappa statistics showed weaker agreement. In line with the 
initial analysis of 6,572 women at baseline in the UKWCS,288 the current results 
confirmed there were considerable inconsistencies between the two variables 
representing fruit and vegetable servings. The initial analysis showed 15% of 
participants had differences of more than five times between fruit serving derived from 
the FFQ and those reported on the cross-check questions. With regard to vegetables, 
26% of women reported a difference of more than five times. 288 These current results 
showed a similar percentage for vegetables (25%) and a much higher percentage for 
fruit (23%). 
Reasons why most FFQ derived servings were much higher than cross-check 
responses could be because participants may have misunderstood how to complete 
the FFQ; they may have ticked too many items listed on the FFQ or over-stated their 
frequency of consumption. For instance, from checks of questionnaires of women with 
very high fruit and vegetable intake it was found that one woman had ticked every fruit 
and vegetable listed on the FFQ as being consumed once or 2-3 times per day, yet for 
the cross-check response she stated vegetable servings consumed were only 14 per 
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week, adding 2 per day as clarification. Research has shown that in comparisons of 
FFQs using 20, 33 or 40 fruit and vegetable items, those with more items lead to higher 
reporting of fruit and vegetables, ranging from a mean intake of 23.8 to 38.8 portions 
per week.334 By comparison the UKWCS FFQ had 55 fruit and vegetable items in total 
and a mean total of 10.6 portions per day equating to 74 portions per week, which 
indicates an over-estimation of intake. Some discrepancies may have occurred due to 
counting vegetables twice; once in mixed dishes and once in the separate listings.335 
On the other hand, many women may have misread the cross-check questions as 
servings per day instead of per week. Indeed servings per day calculated from cross-
check answers were over seven times lower than FFQ servings for more than 10% of 
the women. The fact that high discrepancy fruit and vegetable reporters had both a 
higher median FFQ serving per day compared to other women but lower median 
servings per day reported on the cross-check questions compared to others, supports 
all explanations given above. Nevertheless the histograms in Figure 19 clearly show 
that a large proportion of women reported intake in multiples of seven, indicating that 
they correctly reported intake per week rather than per day. However, since the cross-
check answers for many of these women, including the vegetarians amongst them, 
were on average much lower than the national average intake of fruit and vegetables at 
the time, 336 this indicates that many of them may have misinterpreted the cross-check 
question as servings per day rather than servings per week. On the other hand, the 
median FFQ intake of high discrepancy reporters was well above the national average 
calculated from a sample of 6000 households in 1998 (4.25 portions based on a total 
average of 340g of fruit and vegetable intake per day which included fruit juice and 
excluded potatoes).336 However, this difference could be due to the women in the 
UKWCS being highly health conscious rather than it being an over-estimation. 
Possible errors in fruit and vegetables and vitamin C intake derived from FFQs can be 
attenuated by applying a correcting factor for each subject using answers to summary 
cross-check questions as demonstrated in previous studies.288 325-327 For the 6,572 
women in the initial UKWCS analysis, each person’s intake was adjusted by dividing 
the response to the cross-check question on the UKWCS questionnaire by the sum of 
frequencies from the FFQ, for each food group, as shown below: 
Number of servings/week from cross-check question 
Number of servings/week from individual food items on the FFQ 
 
After applying the weightings the mean vitamin C intake reduced by 44% from 151 to 
85 mg/d.288 One study found that the correction of FFQ derived vitamin C improved its 
Pearson’s correlation coefficients with 4-d diet records.326 Another study found that 
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rankings remained relatively unchanged after corrections which reduced vitamin C 
intake by 20%.325  
The above weightings could be used to adjust FFQ derived vitamin C used in the 
analyses of associations between breast cancer risk and vitamin C intake in the 
UKWCS. However, it was decided not to apply this weighting, since it was unclear 
whether the cross-check answers reflected true intake or at least true ranking of fruit 
and vegetable servings any better than the FFQ in the UKWCS. Similar concerns were 
expressed by Amanatidis et al. (2001) who also warned against comparing corrected or 
uncorrected FFQ figures with national target intakes.325  
A review of studies found that FFQ recordings of vegetable intake had weak 
correlations (r=0.39) with other assessment methods, whereas fruit produced 
somewhat higher correlations (r=0.49).337 Since then the Norfolk-EPIC study reported 
their FFQ recorded fruit and vegetable intake was about double that recorded by 7-day 
diaries.338 Given that the UKWCS FFQ is based on the Norfolk-EPIC FFQ but has more 
fruit and vegetable items, its average intake may be more than double that recorded by 
diaries. Comparisons with biomarkers, or weighed food records, are considered 
appropriate methods of evaluating dietary assessment methods, but neither was 
employed at baseline in the UKWCS, and therefore could not be used to evaluate fruit 
and vegetable intake or vitamin C intake derived from the UKWCS FFQ. However, in 
the next section vitamin C derived from a similar FFQ is compared with biomarkers and 
food diary records at phase two on a small sample of women who provided blood 
samples. 
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5.4 Comparison of vitamin C intake recorded by FFQ 
and by diary with biomarkers in a small sample of 
the UKWCS at phase 2 
5.4.1 Introduction 
Biomarkers are used to assess the nutrient status of individuals, and have also been 
used to investigate associations between nutrient status and disease risk. In relation to 
plasma vitamin C and breast cancer risk, no evidence of an association was fund in a 
nested case-control study,268 and conflicting evidence has been produced in 
retrospective case-control studies.339-341   
Biomarkers have also been used as objective measures to assess the validity of 
dietary measurement tools, although their usefulness in this respect is questionable  for 
some nutrients; since the absorption and storage of vitamin C is limited, particularly 
above 400mg/d, 65 vitamin C plasma levels are unlikely to reflect dietary vitamin C 
intake well. Previously 4-d diary and 24hr records of estimated vitamin C intake have 
been compared with biomarkers in a small sample of women from the UKWCS.331 
Results of the regression analysis showed that plasma ascorbic acid was a good 
indicator of previous vitamin C intake from all foods sources but not a good proxy for 
specific food groups such as fruit and vegetables recorded by these dietary methods. 
Conversely, an EPIC-Norfolk study found plasma vitamin C correlated weakly but 
significantly with fruit and vegetables recorded by FFQ.342 In a systematic review of 
dietary assessment methods, vitamin C intake estimated from FFQs correlated weakly 
with biomarkers, the mean correlation coefficient being only 0.28.343 However, in an 
earlier review, Cade et al. (2004) found correlations with biomarkers in 15 studies were 
somewhat higher at r=0.46.337 The large difference between reviews may be due to the 
small number of studies involved, the assay methods used to measure biomarkers, or 
the quality weighting that studies were assigned in the later review. 
Diaries have been the reference method most often used to validate FFQs; these have 
shown moderate correlations for vitamin C of r=0.50 in two reviews,337 343 and slightly 
higher in a third review (r=0.59).332 
This analysis will compare three methods of measuring vitamin C intake in a small sub-
sample of women from the UWKCS, measured in close proximity and derived from: the 
217 item FFQ; the 4-d diary; and blood samples. The resulting correlation coefficients 
and regression analysis will be compared with previous studies. 
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5.4.2 Methods 
5.4.2.1 Subjects 
Phase 2 UKWCS participants who lived within a 30 mile radius, or one hour drive of 
Leeds, were contacted between 3 and 5 years after baseline and a nurse arranged to 
take blood samples from 273 of these women.280 The women also completed a 4-d 
diary and a FFQ which were returned to the nurse when the blood samples were 
collected. Dietary vitamin C intake was derived from the 4-d diaries and also from the 
FFQ, and vitamin C supplement dose was also recorded in the FFQs.   
5.4.2.2 Dietary assessment methods 
Blood samples were collected into lithium heparin (8ml) after an overnight fast. They 
were kept cool and within 2 hours of collection were separated and prepared for 
storage at -70oC.280 Plasma ascorbic acid and total vitamin C (ascorbic acid and 
dehydroascorbic acid) was analysed by high-performance liquid chromatography,344 in 
the Division of Pathological Sciences, Department of Clinical Medicine at the University 
of Leeds. The food listings FFQs used for this dataset were almost identical to the FFQ 
used at baseline. The diaries used were the ones used in the full phase 2 dataset. 
5.4.2.3  Statistical analyses 
Characteristics of women grouped into fifths according to self-recorded vitamin C 
intake were produced. The strength of the associations between plasma ascorbic acid 
or total vitamin C (which includes dehydroascorbic acid as well as ascorbic acid) and 
vitamin C intake derived from FFQs and diary records at phase 2 was calculated using 
Spearman’s pairwise correlation coefficients, since the data was not normally 
distributed. The analysis was repeated for non-vitamin C supplement users; i.e. those 
women who did not record either frequency or dose of vitamin C supplements taken. 
Spearman’s correlation between vitamin C intake derived from phase 2 FFQs and diary 
records was also calculated. Spearman’s method was used as opposed to Pearson’s 
method for parametric data because the vitamin C intake derived from phase 2 FFQs 
and diary records in this dataset was not normally distributed. In the pairwise 
correlation coefficient calculations, pairs are excluded if one of the two variables is 
missing. Due to vitamin C’s role in the regeneration of vitamin E and in the absorption 
of iron and in the Fenton reaction,76 correlations between plasma ascorbic acid or total 
vitamin C and plasma iron and plasma vitamin E concentration were also assessed. 
Regression analysis was used to quantify the percentage increase in plasma ascorbic 
acid and plasma total vitamin C when vitamin C consumed from all foods were 
doubled, as derived from diary or from FFQ recordings. For regression estimates to be 
 128 
 
 
valid, it is assumed the residuals (.i.e. the difference between actual values and the 
estimated line of best fit) are normally distributed and have uniform variance. These 
assumptions were examined using histograms of residues, and q-q plots of residues 
against the predictor variable. Since these did not follow normal distribution patterns, it 
was decided to log-transform the vitamin C variables for the regression analysis. The 
analysis of all women was adjusted for vitamin C supplement use and energy intake, 
and the sub-analysis by vitamin C supplement taking was adjusted for energy intake.  
Although recommended,337 Bland-Altman plots were not used to assess correlations 
between plasma concentrations and FFQs and diaries because of the different units 
used between assessment methods (Nevertheless, standardized units, such as 
standard deviations, could have been compared).  
5.4.3 Results 
The mean vitamin C derived from diary recordings was 128 mg compared to 191 mg 
from FFQs. When women were split into fifths according to dietary vitamin C intake 
recorded by diary and by FFQ, their mean plasma ascorbic acid and plasma total 
vitamin C recordings increased with increasing fifths (Table 23 & Table 24). On 
average women were older and more likely to self-report being a vegetarian in each 
fifth of increasing vitamin C intake. There were no clear patterns for BMI or vitamin C 
supplement use.  
As observed in Table 25, the estimates of dietary vitamin C intake from diaries and 
from FFQs correlated weakly with plasma ascorbic acid and plasma total vitamin C with 
diaries showing stronger correlations (r=0.35 and 0.34 vs. 0.26). When vitamin 
supplement dose recorded in the FFQ was added to the dietary FFQ value then 
correlations with plasma total vitamin C were 0.36 and 0.35. Correlations of plasma 
concentrations were even weaker with fruit and vegetable portions recorded by 
questionnaire, being higher for fruit than vegetables (0.20 and 0.21 vs. 0.08 and 0.13). 
Correlations between plasma ascorbic acid or total vitamin C and plasma iron and 
plasma vitamin E were also poor (0.09-0.18). In general the correlations were higher 
when 115 women (42%) were excluded who recorded vitamin C supplement use in 
either the frequency or dose section of the FFQ (Table 26). Dietary vitamin C recorded 
by diary for all women had a substantial correlation with that recorded by FFQ (r=0.49, 
Table 25). For 21 women (12%) taking supplement doses of 500mg or more vitamin C, 
substantial correlations were also found between supplement vitamin C intake and 
plasma ascorbic acid or plasma total vitamin C, being 0.60 and 0.48 respectively. 
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Table 23 Characteristics of women by dietary vitamin C intake recorded by FFQ 
 Dietary vitamin C intake recorded by FFQ split by fifths  
 lowest 2nd fifth 3rd fifth 4th fifth highest Total 
Dietary vitamin C, mean mg (sd) 85.6 (20.7) 135.2 (11.2) 175.2 (10.8) 214.7 (14.2) 340.8 (104) 190.8 (99.5) 
Plasma ascorbic acid, µg ml-1(sd) 10.5 (5.4) 11.5 (3.5) 12.6(3.8) 11.8 (3.3) 14.0 (4.5) 12.1 (4.3) 
Plasma vitamin C, µg ml-1 (sd) 12.1 (5.0) 13.4 (3.2) 14.1 (4.1) 13.7 (3.1) 15.6 (4.6) 13.8 (4.2) 
       
Age, mean (sd) 49.8 (8.5) 48.8 (8.0) 49.9 (9.2) 50.3 (8.4) 53.8 (9.2) 50.5  (8.8) 
BMI, mean (sd) 25.7 (5.6) 23.2 (3.1) 24.2 (4.0) 24.5 (3.9) 24.9 (4.3) 24.5 (4.3) 
Vit C supplement use, n (%) 22(42)    22(42)       20 (37)       28 (53)       22 (41)      114 (43) 
Vegetarian self-reported, n (%)  17 (34)      18 (35)       17 (33)       20 (38)       22 (42)       94 (37) 
       
 
 
Table 24 Characteristics of women by dietary vitamin C intake recorded by diary 
 Dietary vitamin C intake recorded by Diary split by fifths  
 lowest 2nd fifth 3rd fifth 4th fifth highest Total 
Dietary vitamin C, mean mg (sd) 42.5 (13.6) 75.6 (9.2) 106.2 (10.2) 146.1 (13.4) 266.8 (122) 127.9 (95.7) 
Plasma ascorbic acid µg ml-1 (sd) 10.3 (5.5) 11.4 (3.9) 11.7 (2.8) 13.0 (3.8) 13.9 (4.2) 12.1 (4.3) 
Plasma vitamin C µg ml-1 (sd) 11.8 (5.0) 13.3 (3.4) 13.2 (2.9) 15.1 (3.4) 15.6 (4.1) 13.8 (4.1) 
       
Age, mean (sd) 48.7 (8.0) 49.2 (8.5) 50.4 (8.4) 51.0 (8.2) 53.6 (10.0) 50.6  (8.7) 
BMI, mean (sd) 25.1 (4.5) 24.2 (4.4) 24.8 (4.8) 24.2 (4.6) 24.3 (3.4) 24.5 (4.4) 
Vit C supplement use, n (%) 27 (52)       19 (37)       20 (38)       23 (44)       25 (47)       114 (44) 
Vegetarian self-reported, n (%) 13 (26)       18 (38)      15 (29)      23 (44)      23 (44)      92 (37) 
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Table 25 Spearman’s correlation coefficients between different measures of vitamin C for all UKWCS women who 
provided blood samples  
 Plasma Diary FFQ Questionnaire 
 Ascorbic 
acid 
Total 
 vit C 
Dietary 
vit C 
Dietary 
vit C 
Total 
vit C 
Fruit 
portions 
Veg 
portions 
Total 
portions 
Plasma ascorbic acid 1        
Plasma total vitamin  C 0.76 1       
Diary dietary vitamin C 0.35 0.34 1      
FFQ dietary vitamin C 0.26 0.26 0.49 1     
FFQ total vitamin C 0.36 0.35 0.33 0.79 1    
Questionnaire fruit portions 0.20 0.21 0.39 0.43 0.31 1   
Questionnaire veg portions 0.08   0.13 0.23 0.27 0.24 0.47 1  
Total fruit & veg portions 0.17   0.19 0.34 0.43 0.36 0.86 0.82 1 
Plasma iron 0.15 0.18 0.09 0.05 0.11 -0.01 0.02 0.05 
Plasma vitamin E 0.16 0.09 -0.01 0.14 0.25 -0.06 0.05 0.06 
Numbers in bold are statistically significant p<0.05 
(N varies from 259 to 272) 
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Table 26 Spearman’s correlation coefficients between different measures of vitamin C for non-vitamin C 
supplement usersa in the sub-sample of UKWCS women who provided blood  
 Plasma Diary FFQ Questionnaire 
 Ascorbic 
acid 
Total 
 vit C 
Dietary 
vit C 
Dietary 
vit C 
Fruit 
portions 
Veg 
portions 
Total 
portions 
Plasma ascorbic acid 1       
Plasma total vitamin C 0.73 1      
Diary dietary vitamin C 0.46 0.49 1     
FFQ dietary vitamin C 0.36 0.35 0.51 1    
Questionnaire fruit portions 0.33 0.31 0.41 0.46 1   
Questionnaire veg portions 0.15   0.16 0.27 0.31 0.55 1  
Total fruit & veg portions 0.25  0.22 0.32 0.46 0.88 0.86 1 
Plasma iron 0.13 0.24 0.04 0.06 -0.03 0.00 0.05 
Plasma vitamin E 0.10 0.01 -0.05 0.18 0.09 -0.03 0.10 
Numbers in bold are significant
 
a
Not indicated as vitamin C supplement users on the questionnaire 
(N varies from 148 to 157)
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The regression analyses showed that plasma ascorbic acid concentrations increased 
significantly by 19% when total vitamin C from all food sources recorded by diary was 
doubled (Table 27). When vitamin C supplement users were excluded this rose to 23%, 
but for the sub-analysis for non-vitamin C users the increase was only 15%. Similar 
results were found for recordings by FFQ. Increases in total plasma vitamin C 
concentrations were not as large; an increase of 14% occurred when total vitamin C 
from all food sources recorded by diary were doubled. When vitamin C supplement 
users were excluded this rose to 19%. Again, similar results were found for recordings 
by FFQ. The R2 values ranged from 0.07 for vitamin C supplement users to 0.26 for 
women who did not take vitamin C supplements, indicating that plasma concentrations 
were not explained well by FFQ and diary recordings, particularly for supplement users.  
 
Table 27 Percentage increase in plasma concentrations of ascorbic acid and total 
vitamin associated with a doubling of vitamin C from all foods recorded by diary and by 
FFQ 
 Plasma 
ascorbic acid 
% increase (95%CI) 
Plasma 
vitamin C 
% increase (95%CI) 
Total women (N=262)a   
Diary dietary vitamin C intake 18.9 (13.1, 25.0)  13.6 (9.3, 18.0) 
FFQ dietary vitamin C intake 19.9 (12.0, 28.3) 14.4 (8.6, 20.4) 
Excluding vitamin C supplement users (N=148)b 
Diary dietary vitamin C intake 23.0 (15.3, 31.3) 18.5 (12.8 24.4) 
FFQ dietary vitamin C intake 26.9 (16.4, 38.4) 18.9 (11.2, 27.3) 
Vitamin C supplement users (N=114) b   
Diary dietary vitamin C intake 14.5 (5.7, 24.0) 8.8 (2.3, 15.6) 
FFQ dietary vitamin C intake 12.5 (1.1, 25.2) 9.1 (0.8, 18.2) 
a
Adjusted for energy intake and supplement taking 
b
Adjusted for energy intake 
 
 
5.4.4  Discussion 
The FFQ vitamin C correlations with plasma ascorbic acid and also with diary derived 
dietary vitamin C for the UKWCS were weak (ranging from 0.26 to 0.51) but in line with 
the mean coefficients between these measurement methods calculated in two 
reviews.337 343 However, the UKWCS results are different from many of the energy 
adjusted correlations between plasma ascorbic acid and vitamin C intake for women 
derived from EPIC FFQs from a variety of European countries; these correlations 
ranged from 0.04 in Greece, to 0.29 in Italy, to 0.65 in Spain.345 As observed in a 
previous EPIC-Norfolk study,346 UKWCS diary derived vitamin C intakes correlated 
better with plasma ascorbic acid than FFQ data when they were recorded in close 
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temporal proximity. Both plasma concentrations and diaries reflect relatively short-term 
intake compared to FFQs which usually assess the previous 12 months’ intake. 
However, in the previous study, correlations with biomarker levels re-measured several 
years later were found to be similar for diaries and FFQs. 346 347 In the current study, 
although significant, correlations between plasma ascorbic acid and total fruit and 
vegetables portions were even weaker than those with FFQ derived vitamin C intake; 
reflecting the fact that fruit and vegetables, excluding juice and potatoes, make up only 
about two thirds of total vitamin C consumptions, as observed in section 5.3.3. 
Similarly, the weak correlations between ascorbic acid and plasma iron and plasma 
vitamin E were expected to be greater due to ascorbic acids’ role in the regeneration of 
vitamin E, in the absorption of iron and in the Fenton reaction.76  
The most recent review found no difference in correlations for vitamin C between FFQs 
and diaries which recorded seven or more days’ intake and those recording less than 
seven days.343 However another review observed lower correlations for diaries 
recording less than seven days and these were more in line with the 4-d UKWCS diary 
correlations than the longer diaries (0.55 vs. 0.63).332 Additionally, the most recent 
review found no large differences in correlations between studies that included vitamin 
supplements and those that did not;343 however, this result has been questioned due to 
inconsistencies found in classifying studies as those including supplements.348 Contrary 
to this, correlations for the UKWCS were substantially stronger when women taking 
supplements were excluded. Indeed dietary only intake is likely to correlate more 
strongly with plasma levels when the latter does not contain vitamin C from 
supplements. Surprisingly though, correlations in the UKWCS were the strongest 
between supplement vitamin C intake and plasma ascorbic acid for women taking high 
doses (>=500mg/d); such doses are unlikely to be absorbed or stored by the body and 
plasma levels are likely to fall within hours due to excretion. This may be a spurious 
result due to low numbers analysed. In contrast, the previous UKWCS analysis 
reported that plasma levels of ascorbic acid reached a plateau with dietary intakes 
around 60mg/d,331 which is much lower than the average dietary vitamin C intake of the 
UKWCS, and lower than the 400mg/d plateau reported by Levine et al. (2001).65 
In one review correlation coefficients between FFQs and references measures were 
higher in general if participants were allowed to describe their own portion sizes 
(r=0.54).337 However another review found that portion-size questions produced lower 
correlation coefficients specifically for vitamin C (0.60 vs. 0.68).332 Although a general 
question about portion sizes (small, medium or large) was asked in the UKWCS, it was 
not used to calculate the weight of fruit and vegetables consumed and derived vitamin 
C intake. The review also observed lower vitamin C correlations for FFQs developed 
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from the EPIC FFQ (as was the case for the UKWCS FFQ) than ones developed from 
the Willet or Block FFQs (0.53 vs. 0.67 and 0.63).326 332 345 349 The EPIC based FFQ on 
average contained substantially more food items than the other two FFQs (154 vs. 113 
and 100), but in general FFQs containing 200 items (as was the case for the UKWCS 
FFQ) correlated slightly better for vitamin C with non-biomarker reference measures 
than those containing 150 or 100 (r=0.64 vs. 0.60 vs. 0.56).332  
The results of the regression analysis, which measures the extent of agreement 
between methods, were inline with those from the earlier study of the UKWCS after 
excluding women who were vitamin C supplement users.331 For vitamin C supplement 
users in the current study, the increase in plasma ascorbic acid from a doubling of 
dietary intake recorded by diary or FFQ was about half that of the non-users, since 
their plasma levels were likely to be generally higher due to intake from supplements. 
As mentioned in section 2.2.2, there are a number of physiological processes that 
determine plasma ascorbic acid concentrations meaning they do not simply reflect 
intake. Plasma ascorbic levels reflect the effects of digestion, absorption, uptake, 
utilisation, metabolism, excretion, homeostatic mechanisms, intake of other nutrients as 
well as the influence of health-related behaviours and the presence of chronic illness. 
Therefore, plasma records naturally will not correlate well with FFQ, diary or 24-hr 
recordings of intake. Since the human body has limited capacity to absorb and store 
water-soluble vitamin C,65 excess is excreted within hours of consumption. Given this, 
plasma vitamin C biomarkers are likely to reflect short-term intake. In general, FFQs, 
including the UKWCS FFQ, estimate the previous 12 months’ intake; therefore they are 
unlikely to correlate well with short-term measures of vitamin C intake. Furthermore, 
repeatability, an aspect of validity, is poor for biomarkers of vitamin C as reported in an 
earlier UKWCS assessment where second samples were taken after 18 months.331 
Derived values of vitamin C consumed may be inaccurate, however the relative ranking 
of individuals, important in the risk analyses and observed from the correlations, were 
acceptable compared to previous studies, although weak. None of the measurement 
methods of recording vitamin C intake in the UKWCS are ideal and all have strengths 
and weaknesses; biomarker and diary recordings tend to reflect short-term intake and 
although FFQs cover longer-term intake and are easier to administer at lower costs, 
they are limited by their retrospective nature and by problems reporting portion sizes 
and fruit and vegetable consumption. Nevertheless, the general difficulties in accurately 
measuring vitamin C consumed and correctly ranking the cohort individuals by intake, 
needs to be taken into account when interpreting the risk analysis results in the 
following chapters. Measurement error of intake can lead to substantial reduction of 
calculated disease-exposure relative risks.350  
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5.5 Conclusion from evaluations 
The comparisons between FFQs, diary and plasma concentrations in all three sections 
in this chapter showed some weaknesses in methods used in the UKWCS for 
recording food and supplements containing vitamin C. However, on the whole the 
results were in line with those from other studies and were considered suitable for 
further analyses. Nevertheless, the weaknesses found should be taken into account 
when interpreting results of associations between vitamin C intake and breast cancer 
risks in the UKWCS. 
In the following chapters, breast cancer risk will be assessed in relation to  
 Any supplement use (chapter 7) 
 Vitamin C contained in supplements at phase 2 of the UKWCS (chapter 8) 
 Dietary vitamin C intake from FFQs (split by supplement users and non-users) 
at baseline in the UKWCS (chapter 9) 
 Total vitamin C  intake (from diet and supplements) from dairy records in the UK 
Dietary Cohort Consortium (chapter 10) 
First, in the next chapter, the characteristics of women which predict vitamin C 
supplement use at phase 2 in the UKWCS will be determine and also whether women 
who have a history of breast cancer are more likely to use high dose vitamin C 
supplements.   
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CHAPTER 6 
6 Is vitamin C supplement use associated with a 
personal or family history of cancer and what 
characteristics predict vitamin C supplement 
use in UK women? A phase 2 analysis of the 
UKWCS 
6.1 Summary 
Objectives: To determine whether frequent vitamin C supplement use is associated 
with a personal or family history of cancer and to determine what characteristics predict 
vitamin C supplement use in UK women.1 
Methods: This cross-sectional analysis of 12,453 women aged between 37-79 years 
from phase 2 of the UKWCS examines the odds of taking supplements containing 
vitamin C as recorded in 4-day food diaries, based on lifestyle characteristics and 
cancer history self-reported by questionnaire. 
Results: Women frequently taking supplements containing vitamin C, compared to 
those who did not, had healthier behaviours, including higher consumption of fruit and 
vegetables. Frequent high dose vitamin C takers (>=1000mg) had a higher 
socioeconomic status, visited alternative practitioners more often than family or private 
doctors, and were more likely to be ex-smokers, and to drink little or no alcohol than 
women who did not take high doses. Women who self-reported having had cancer 
(OR=1.33; 95% CI: 1.00, 1.76) or specifically breast cancer (OR=1.70; 95% CI: 1.14, 
2.55), or reported a family history of cancer (OR=1.16 (95% CI: 0.95, 1.41)) or breast 
cancer (OR=1.26; 95% CI: 1.01, 1.58) had increased odds of being frequent high dose 
users after adjusting for socio-demographic and health behaviours.  
Conclusion: High dose vitamin C use by UK women was associated with healthier 
behaviours and a history of breast cancer. 
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6.2 Introduction 
Despite lack of evidence of benefits,7 351 vitamin supplement use reported by UK 
women increased from 17% in 1986/1987 to 41% reported in 2008/9.24 25  A recent UK 
survey showed users are most likely to be women above 55 years and of higher 
socioeconomic status.26 An analysis of the UK Women’s Cohort Study (UKWCS) found 
that users were significantly more likely to lead healthier lifestyles: to be more 
physically active; have a lower alcohol intake; a lower body mass index (BMI) and eat 
diets which met recommended dietary intakes.27 Therefore they were less likely to need 
supplements than non-users.27 Further support for this ‘inverse supplement hypothesis’ 
has been found in the UK,25 28 29 and elsewhere.30-35  
Moreover, those classifying themselves as high strength supplement users in the 2008 
UK Random Location Omnibus Survey were particularly health conscious.26 They were 
more likely to consider the health implications of what they ate, to actively look for 
information about how to stay healthy and to believe that they needed vitamin and 
mineral supplements to feel and stay healthy.26 Thirty eight percent of the 801 people 
surveyed reported taking high strength supplements,26 and only 6% of these were likely 
to report they were in excellent health compared to 25% of non-users.26  
Vitamin C is one of the most commonly used supplements in the UK,26 352 and is often 
taken at high doses, however little is known about the characteristics of women who 
frequently take them. Although many users may take vitamin C supplements to boost 
their immune systems, suggestions that vitamin C is able to reduce the incidence of 
colds, have been unsubstantiated in randomised controlled trials.45 It is unknown 
whether users take vitamin C supplements for other health reasons, such as reducing 
cancer risk or cancer reoccurrence. Despite some clear evidence of an association 
between plasma vitamin C levels and reduced mortality from all causes in men and 
women, and also reduced cancer mortality in men,67 there is limited evidence to 
suggest that supplementation with vitamin C is associated with reduced risk of mortality 
or cancer.7 351 The Vitamins and Lifestyle (VITAL) study in the US found no overall 
association between vitamin C supplement-taking (>=150mg) and prevalent cancer in a 
cross-sectional analysis,353 despite general supplement use being widespread in 
cancer survivors in the US, particularly in breast cancer survivors.354 However, a US 
study of women physicians showed those with pre-existing breast cancer were more 
likely to take vitamin C supplements than women who were free from breast cancer.31 
An EPIC study reported that UK health-conscious women were more likely to be 
supplement users if they had prevalent cancer than if they were cancer free.352  
However, no study has examined the relationship between vitamin C supplement use in 
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UK women and a personal or family history of cancer. The main aim of this analysis 
was to determine whether women in the UKWCS who reported having had cancer, or 
reported a relative who had cancer, were more likely to use vitamin C supplements 
than those who did not report these histories. Breast cancer was the principle focus of 
the analyses. A further aim, which has not been examined in UK women, was to 
determine which characteristics and health behaviours predicted vitamin C supplement 
use, particularly at high doses of 1000mg/d or more.  
6.3 Methods
 
UKWCS baseline data was gathered between1995-1998 from 35,367 women who 
completed a 217-item Food Frequency Questionnaire (FFQ).279 Further details are 
found in section 4.1.1.1. At baseline 62% of participants took some type of dietary 
supplement.  
All the initial participants were re-contacted at phase 2 between 1999 and 2004, on 
average 4 years after recruitment; 12,453 (35%) completed a follow-up health and 
lifestyle questionnaire and a 4-day food diary. For each day, the diaries requested 
supplement brand, name, amount taken and dosage of any supplement taken. This 
information was matched against a database of supplement descriptions and ingredient 
composition as explained in section 4.5.3.1 of the methods chapter. The average daily 
vitamin C intake contained in all supplement types was calculated for the total number 
of diary days vitamin C was taken. 
Univariate logistic regression was applied to the phase 2 data to determine which 
participant characteristics predicted frequent supplement use in two different 
classifications of users: those taking any dose of vitamin C (yes/no); and those taking 
high doses of vitamin C (>=1000mg, yes/no). These were compared to women not 
frequently taking ‘any’ or ‘high’ doses respectively. Intakes above 1000mg/d have been 
linked to adverse effects, particularly gastrointestinal disturbance.52 355 This level is 
more than 15 times the recommended daily allowance (EU RDA = 60mg/day53) 
normally found in multivitamins. Frequent use of supplements containing vitamin C in 
this study was defined as taking on at least three out of the four diary days. As 
described in section 5.2, this agreed well with daily use of vitamin C and multivitamin 
supplements reported on the phase 2 questionnaire, which was completed concurrently 
with the diary. Socio-demographic and health related lifestyle variables that were 
significantly associated with either any dose or high intake were all included in a logistic 
regression model for mutual adjustment. Variables that remain significant should be 
predicative of vitamin C use over and above the effects of the other variables in these 
multivariable models.  
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Social class and marital status variables were derived from answers to the 
questionnaire used at baseline since this information was not provided at phase 2.  All 
other variables were taken from responses to the phase 2 questionnaire: BMI (kg/m2); 
smoking status; level of physical activity; parity; drinking alcohol less than once a week, 
red meat servings; total fruit and vegetable servings; frequency of visits to doctors and 
alternative practitioners. Vigorous activity was defined as activity causing shortness of 
breath, rapid heart rate and sweating. Attendance at routine health checks was not 
significantly associated with vitamin C supplement use, and therefore was excluded 
from the models. 
These variables, excluding visits to doctors and alternative practitioners, were used in 
logistic regression analyses to adjust the odds of women with a family or personal 
history of cancers taking any or high doses (>=1000mg) of vitamin C. Additional 
analyses were performed at doses above or equal to 250mg; 500mg; and 2000mg. 
Given that vitamin C supplements are more likely to be taken in winter because well-
publicised research had linked it to reduced duration of the seasonal common cold,45 
sensitivity analyses were performed to assess the robustness of results to weighting 
the analyses by the inverse of the probability of being sampled in each season. 
All information relating to family or personal history of cancers was reported by the 
participant at phase 2. They were asked whether or not family members (blood 
relatives only) ever had the following cancers: breast, skin, lung, colon and rectum, 
ovary, stomach, cervix, ovary, pancreas, or prostate. The cancer history of first and 
second degree relatives was used to identify women potentially at raised or high risk of 
hereditary breast cancer (further information on determining this is given in section 
4.7.6.3.2 of the methods chapter). It was unknown whether affected relatives were on 
the same side of the family, therefore this could only approximate to the guidelines 
provided by the UK’s National Institute for Health and Clinical Excellence (NICE).319 
Participants were also asked to report their own history of disease, including whether 
they had previously been told they had a diagnosis of one of the cancers listed above.  
6.4 Results 
Thirty-four percent (4242) of women frequently took supplements containing any dose 
of vitamin C, on at least three of the four diary days, and 5% (579) frequently took high 
doses of 1000mg or more. Twenty-seven percent (1165) of those frequently taking any 
dose and 52% (299) taking high doses of vitamin C took four or more types of 
supplements. Furthermore, 82% of users taking any dose and 86% of the high dose 
users took some type of supplement at baseline, on average four years earlier. 
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After mutual adjustment, significant lifestyle predictors of frequently taking supplements 
containing either high dose or any dose of vitamin C were eating more than five 
servings of fruit and vegetables per day; eating less servings of red meat; and visiting 
an alternative practitioner more often than women not frequently taking these 
supplements (Table 28). Odds of visiting an alternative practitioner four or more times 
in the last 12 months were substantially greater for high dose takers compared to any 
dose takers (OR=2.84; 95% CI: 2.20, 3.66 vs. OR=1.75; 95% CI: 1.51, 2.03).  
Additionally, the odds of taking supplements containing any dose of vitamin C were 
significantly higher in women who exercised vigorously more than three times a week 
(OR=1.52; 95% CI: 1.23, 1.8); or were aged 45 years or more; of intermediate social 
class; divorced; childless; frequent visitors to their GP; or leaner. Significant predictors 
of frequent high dose taking were being an ex-smoker when compared with never 
smokers (OR=1.25; 95% CI: 1.02, 1.53), drinking alcohol less than once a week 
(OR=1.37; 95% CI: 1.12, 1.67) and being of high socio-economic status compared to 
low status (OR=1.45; 95% CI: 1.06, 2.00). 
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Table 28 Characteristics associated with taking supplements containing any dose of 
vitamin C and taking supplements containing high doses of vitamin C (1000mg or 
above)   
 Any dose  >=1000mg p 
Characteristics   OR (95% CI)a P value OR (95% CI)a value 
Age (years)b     
<45   1  0.07 1 0.3 
45-54   1.20 (1.03, 1.41)  1.11 (0.81, 1.54)  
55-64     1.26 (1.07, 1.48)  0.85 (0.60, 1.20)  
65 and above   1.23 (1.03, 1.47)  0.91 (0.62, 1.34)  
Social classc     
High   1  0.1 1 0.04 
Intermediate  1.10 (1.01, 1.21)  0.96 (0.78, 1.17)  
Low  1.07 (0.94, 1.22)  0.69 (0.50, 0.94)  
Marital statusc     
Married/living together   1  0.4 1 0.9 
Divorced/separated  1.31 (1.14, 1.51)  1.25 (0.94, 1.66)  
Widowed     0.95 (0.78, 1.16)  1.14 (0.72, 1.80)  
Single     0.86 (0.72, 1.03)  0.88 (0.61, 1.28)  
Had children     
Yes   1  0.001 1  0.09 
No      1.24 (1.11, 1.39)  1.23 (0.97, 1.56)  
Body mass index   
(BMI kg/m2)b 
    
Underweight  (<18)  1.03 (0.72, 1.46)  1.07 (0.53, 2.15)  
Normal  (18-24.99) 1  0.08 1 0.6 
Overweight  (25-30) 0.90 (0.82, 0.99)  0.87 (0.69, 1.09)  
Obese  (>30)  0.93 (0.80, 1.07)  1.11 (0.81, 1.54)  
Smoking statusc     
Never smoked  1  0.4 1 0.02 
Ex-smoker  1.07 (0.98, 1.17)  1.25 (1.02, 1.53)  
Current smoker 0.91 (0.75, 1.00)  1.19 (0.79, 1.81)  
Drinks alcohol more than once 
a week 
    
Yes 1 0.1 1 0.001 
No 1.07 (0.98, 1.17)  1.37 (1.12, 1.67)  
Physical activityc     
No weekly activity  1  <0.001 1 0.008 
Light moderate   1.16 (0.95, 1.41)  0.94 (0.60, 1.48)  
Vigorous 1-2/week   1.18 (0.96, 1.46)  0.98 (0.61, 1.57)  
Vigorous >=3/week 1.52 (1.23, 1.89)  1.36 (0.85, 2.19)  
Servings of red meat eaten 
per weekc 
    
None    1  <0.001 1 <0.001 
1-3  0.79 (0.72, 0.87)  0.68 (0.55, 0.85)  
4 or more  0.61 (0.54, 0.68)  0.48 (0.35, 0.65)  
Servings of fruit and veg eaten 
per dayc 
    
<=2  1  <0.001 1 0.01 
3-5  1.21 (1.08, 1.37)  1.11 (0.84, 1.48)  
More than 5  1.45 (1.26, 1.67)  1.40 (1.02, 1.92)  
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Table continued: Characteristics associated with taking supplements containing any 
dose of vitamin C and taking supplements containing high doses of vitamin C (1000mg 
or above)   
 Any dose  >=1000mg p 
Characteristics   OR (95% CI)a P value OR (95% CI)a value 
     
Number of visit to doctors in 
last 12mthsc 
    
None 1  <0.001 1 0.9 
1-4 1.27 (1.12, 1.42)  0.98 (0.76, 1.25)  
>4  1.45 (1.26, 1.67)  0.98 (0.72, 1.33)  
Number of visit to alternative 
practitioner in last 12mthsc 
    
None 1  <0.001 1 <0.001 
1-4 1.41 (1.23, 1.61)  1.77 (1.35, 2.31)  
>4 1.75 (1.51, 2.03) 
 
 2.84 (2.20, 3.66)  
Number of participants in the 
models  
10161 
 
 10161  
aMutually adjusted for the other variables listed above, OR =Odds ratio 
bp for trend over the continuous variable 
cp for trend over categories 
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Table 29 shows that, after adjustment, frequent high dose use of vitamin C remained 
significantly associated with a personal history of any cancer (OR=1.33; 95% CI: 1.00, 
1.76) and any hormone related cancer (OR=1.68; 95% CI: 1.16, 2.43); specifically 
breast cancer (OR= 1.70; 95% CI: 1.14, 2.55). Additionally, frequent high dose use was 
significantly greater for women with a family history of breast cancer (OR=1.26; 95% 
CI: 1.01, 1.58) and appeared more likely, though non-significant, in women with a 
family history of any cancer (OR=1.16; 95% CI: 0.95, 1.41), any hormone related 
cancer (OR=1.19; 95% CI: 0.98, 1.46), and pancreatic cancer (OR=1.44; 95% CI: 0.94, 
2.21). Taking any dose of vitamin C was significantly associated with a family history of 
cancer of the uterus (OR=1.38; 95% CI: 1.10, 1.74). These results were very similar 
when the analysis was weighted to take into account differential sampling in each 
season. For instance, the seasonally weighted odds of being a high dose user with a 
personal history of breast cancer was OR = 1.61 (95% CI: 1.07, 2.41), or with a family 
history of breast cancer was OR = 1.29 (95% CI: 1.03, 1.62) or with a family history of 
pancreatic cancer was OR = 1.53 (95% CI: 0.99, 2.36). However, the result for a 
personal history of total cancers was not significant (OR = 1.30; 95% CI: 0.97, 1.73) 
after seasonally weighting. 
 
It may be observed in Table 30 that the odds of taking vitamin C increased with 
increasing doses above 500mg for women who had any family member with a history 
of breast cancer or who had a personal history of breast cancer. For the latter, ORs 
were 1.09 (95% CI: 0.78, 1.52) at >=500mg, 1.70 (95% CI: 1.14, 2.55) at >=1000mg 
and 2.36 (95% CI: 1.00, 5.56) at intakes of 2000mg or above. A similar pattern occurs 
for those with a personal history of cancer of the uterus or cervix, and was also seen in 
the total analyses of any cancer or any hormone related cancer. The small numbers of 
women in some of the categories, however, may have produced spurious results. 
Although the odds of having a mother or sister with breast cancer or potentially being at 
raised risk of this cancer increased at higher intakes, these were not statistically 
significant. 
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Table 29 Odds ratios of taking supplements containing vitamin C: any dose; or 1000mg or more for 
UKWCS women who self-reported a personal or a family history of cancer  
  Any Dose: N=4242 (34%) >=1000mg: N =579 (5%) 
  Unadjusted Adjusteda Unadjusted Adjusteda 
Type of cancer Nb OR(95% CI) OR(95% CI) OR(95% CI) OR(95% CI) 
Personal history of       
      
Any cancer 1268 1.14 (1.01, 1.29) 1.12 (0.97, 1.28) 1.31 (1.02, 1.68) 1.33  (1.00,1.76) 
      
Any hormone 642   1.11 (0.94, 1.31) 1.08 (0.89, 1.31) 1.50 (1.09, 2.08) 1.68 (1.16, 2.43) 
      
Breast 523 1.13 (0.94,1.36) 1.10 (0.89, 1.35) 1.53 (1.08, 2.18) 1.70 (1.14, 2.55) 
Uterus 75 0.85 (0.52, 1.39) 0.77 (0.44, 1.34) 1.78 (0.77, 4.12) 1.97 (0.77, 5.02) 
Ovarian 60 1.29 (0.77, 2.17)    1.28 (0.71, 2.33) 1.35 (0.60, 3.07) 0.84 (0.20, 3.51) 
      
Any non-hormone 
cancer 
584 1.16 (0.98, 1.40) 1.11 (0.91, 1.34) 1.16 (0.80, 1.70) 1.05 (0.68, 1.60) 
Skin 324 1.14 (0.91, 1.43) 1.04 (0.81, 1.34) 0.85 (0.48, 1.49) 0.71 (0.36, 1.39) 
Cervix 190 1.26 (0.94, 1.69) 1.20 (0.86, 1.66) 2.03 (1.22, 3.36) 1.70 (0.94, 3.05) 
Colon Rectum 63 1.19 (0.71, 1.98) 1.30 (0.73, 2.30) 1.07 (0.34, 3.44) 0.98 (0.24, 4.10) 
      
 
Family history of 
     
      
 Any cancer   7,259 1.08 (1.00, 1.16) 1.04 (0.96, 1.13) 1.15 (0.97, 1.36) 1.16 (0.95, 1.41) 
      
Any hormone cancer 3,629 1.09 (1.01, 1.18) 1.09 (0.99, 1.19) 1.16 (0.97, 1.38) 1.19 (0.98, 1.46) 
      
Breast 2,370 1.06 (0.97, 1.17) 1.04 (0.94, 1.16) 1.23 (1.00, 1.51) 1.26 (1.01, 1.58) 
Prostate 958 1.09 (0.95, 1.25) 1.13 (0.97, 1.32) 1.04 (0.76, 1.41) 1.09 (0.77, 1.51) 
Ovarian 423 1.10 (0.90, 1.35) 1.12 (0.90, 1.41) 1.07 (0.69, 1.70) 1.09 (0.66, 1.79) 
Uterus 380 1.41 (1.14, 1.73) 1.38 (1.10, 1.74) 1.08 (0.68, 1.73) 1.11 (0.66, 1.87) 
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Table continued: Odds ratios of taking supplements containing vitamin C: any dose; or 1000mg or more or 
for UKWCS women who self-reported a personal or a family history of cancer 
  Any Dose: N=4242 (34%) >=1000mg: N =579 (5%) 
  Unadjusted Adjusteda Unadjusted Adjusteda 
Type of cancer Nb OR(95% CI) OR(95% CI) OR(95% CI) OR(95% CI) 
      
Family history of      
      
Any non-hormone 5,227 1.07 (0.99, 1.16) 1.03 (0.95,1.12) 1.03 (0.87, 1.22) 1.04 (0.86, 1.25) 
      
Lung 2,066 1.06 (0.96, 1.17) 1.00 (0.89, 1.11) 1.07 (0.86, 1.33) 1.00 (0.78, 1.29) 
Colon/Rectum 1,608 0.96 (0.86, 1.08) 0.98 (0.86, 1.11) 0.97 (0.76, 1.25) 1.08 (0.82, 1.43) 
Stomach 1,300 1.02 (0.90, 1.15) 1.01 (0.88, 1.16) 0.91 (0.69, 1.21) 0.97 (0.71, 1.33) 
Skin 957 1.01 (0.88, 1.16) 0.97 (0.83, 1.13) 0.88 (0.64, 1.23) 0.86 (0.60, 1.24) 
Pancreas 455 1.13 (0.93, 1.37) 1.11 (0.90, 1.38) 1.41 (0.96, 2.08) 1.44 (0.94, 2.21) 
Cervix 311 1.03 (0.81, 1.31) 1.04 (0.79, 1.36) 0.68 (0.36, 1.28) 0.74 (0.38, 1.46) 
aAdjusted for BMI, age, social class, marital status, children, smoking status, level of physical activity, low 
alcohol consumption, red meat servings, total fruit and vegetable servings. 
bTotal numbers with history of cancer  
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Table 30 Odds ratios of taking supplements containing vitamin C for a range of doses for UKWCS women 
who self-reported a personal history of cancer or a family history of breast cancer  
 Frequent use of supplements containing vitamin C doses greater or equal to 
  250mg  500mg  1000mg  2000mg 
  OR(95% CI)
a
  OR(95% CI)
a
  OR(95% CI)
a
  OR(95% CI)
a
 
 N
b
 N=1,448 (12%) N
b
 N=1,195(10%) N
b
 N=579 (5%) N
b
 N==92(1%) 
Personal history          
Any cancer 159 1.06 (0.87, 1.30) 131 1.03 (0.83, 1.29) 74 1.33  (1.00,1.76) 19 2.86 (1.64, 4.98) 
         
Any hormone cancer 81 1.04 (0.79, 1.39) 69 1.08 (0.80, 1.46) 43 1.68 (1.16, 2.43) 12 3.50 (1.75, 7.01) 
         
Breast cancer 68 1.10 (0.81, 1.49) 56 1.09 (0.78, 1.52) 36 1.70 (1.14, 2.55) 8 2.36 (1.00, 5.56) 
Uterus 8 0.99 (0.45, 2.22) 8 1.25 (0.56, 2.78) 6 1.97 (0.77, 5.02) 3 8.64 (2.52, 29.6) 
Ovarian 7 0.50 (0.15, 1.62) 7 0.64 (0.20, 2.06) 3 0.84 (0.20, 3.51) 1 2.75 (0.37, 20.8) 
         
Any non-hormone cancer  69 0.98 (0.73, 1.30) 56 0.97 (0.71, 1.33) 31 1.05 (0.68, 1.60) 8 2.52 (1.19, 5.32) 
         
Skin 34 0.79 (0.53, 1.20) 26 0.74 (0.47, 1.19) 13 0.71 (0.36, 1.39) 2 1.08 (0.26, 4.49) 
Cervix 32 1.43 (0.93, 2.21) 29 1.60 (1.03, 2.52) 17 1.70 (0.94, 3.05) 4 3.14 (1.10, 8.94) 
Colon Rectum 5 0.69 (0.24, 1.94) 3 0.41 (0.10, 1.72) 3 0.98 (0.24, 4.10) 2 7.20 (1.62, 32.1) 
         
Family history of breast cancer         
Any family member 299 1.15 (0.99, 1.34) 244 1.10 (0.93, 1.30) 129 1.26 (1.01, 1.58) 27 1.69 (1.01, 2.83) 
         
Mother or sister 163 1.13 (0.93, 1.37) 129 1.04 (0.84, 1.29) 67 1.16 (0.87, 1.55) 15 1.55 (0.81, 2.96) 
Respondent at raised risk 32 1.11 (0.73, 1.68) 25 1.04 (0.66, 1.65) 15 1.31 (0.73, 2.32) 4 2.03 (0.62, 6.56) 
Respondent at high risk
c
 9 0.67 (0.30, 1.47) 8 0.71 (0.31, 1.65) 4 0.69 (0.22, 2.23)   
         
a
Adjusted for BMI, age, social class, marital status, children, smoking status, level of physical activity, low alcohol 
consumption, red meat servings, total fruit and vegetable servings. Comparison group = all respondents not taking 
stated dose. 
b
Total numbers with a history of cancer listed taking doses specified. 
c
Insufficient numbers at higher doses. 
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6.5 Discussion 
The frequent use of supplements containing any dose or high doses of vitamin C in the 
UKWCS was associated with healthier lifestyle behaviours, and therefore supports the 
inverse supplement hypothesis, as seen in analyses of any supplement-taking in the 
UK or elsewhere.25 28-35  Women taking either high (>=1000mg per day) or any dose of 
vitamin C were more likely to consume over five servings of  fruit and vegetables, the 
main dietary source of vitamin C.67 This is consistent with evidence from studies of any 
supplement-taking,27 28 33  and US studies of vitamin C supplement-taking,30 33 and 
suggests that many high dose vitamin C takers are less likely to need them. 
Furthermore, in-line with US findings, UKWCS vitamin C takers were likely to eat less 
meat.31 They also exercised vigorously more often, supporting previous research 
linking activity to supplement use.27-29 32-35 Distinguishing characteristics of high dose 
vitamin C takers in the UKWCS were being an ex-smoker, drinking alcohol less than 
once a week and being of high socio-economic status. These characteristics were not 
significant predictors of using supplements containing any dose of vitamin C in the 
UKWCS, however they have been positively associated with taking any type of 
supplement in other studies.26 29 Additionally, the current results indicated high dose 
vitamin C users relied more on alternative practitioners rather than family or private 
doctors. Healthy behaviours associated with vitamin C supplement use are likely to 
reduce health risks, therefore these behaviours identified should be considered for 
adjustment in longitudinal studies of risks.33 
Despite controversy surrounding evidence of benefits of high dose vitamin C 
supplementation for prolonged cancer survival,87-89 our results showed prior to seasonal 
weighting women with any type of cancer were more likely to be high dose vitamin C 
supplement-takers than women with no history of cancer. Since antioxidants can 
potentially reduce the effectiveness of anti-cancer drugs,77 356 patients should be 
encouraged to discuss their supplement use with their doctors in order to avoid 
contraindications. For some cancer patients supplement use may be a coping 
behaviour and a way of taking control.37 357  Similar health related behaviours may also 
occur in women with concerns about risk of developing cancer: for instance women 
who attended mammography have also been positively associated with supplement 
use in the US.33 Likewise, women attending UK breast screening clinics had similar 
characteristics to supplement users in the UKWCS and wanted diet and exercise 
advice to be provided at these clinics.16 Doses below 1000mg/d and any dose of 
vitamin C, however, were not significantly associated with total cancer in the UKWCS; 
this has been also observed in some US studies.353 358 
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To the best of our knowledge this is the first UK study to analyse associations between 
vitamin C supplement use and specific prevalent cancers, and therefore the first to 
report significant associations of frequent high dose vitamin C taking (=>1000mg/day) 
in UK women with a personal or family history of breast cancer. This supports findings 
that US women physicians with breast cancer were more likely to take vitamin C.31 
Furthermore, our results show the odds of having a history of cancer increased at 
higher doses (>=2000mg). However, whilst US research found that women at high risk 
of breast cancer and with inconclusive genetic test results were significantly more likely 
to take any supplements, the increased odds of taking high doses of vitamin C in the 
UKWCS for women with increased risk of hereditary breast cancer or those having 
mothers or sisters with breast cancer were not significant.359  Our results may be due to 
low numbers and lack of power. In general, a history of non-hormone related cancer 
did not appear to be associated with vitamin C supplement-taking in the UKWCS, 
nevertheless associations with a personal history of cervical cancer remained 
significant at some doses after adjustments, including adjustment of socio-economic 
status which is known to be linked with this cancer.360 
In relation to prevention of cancer and other chronic diseases, the 5 A Day fruit and 
vegetable initiative based on the World Health Organisation (WHO) recommendations 
could have influenced antioxidant supplement sales at the time of the phase 2 UKWCS 
follow-up.9 Proactive marketing by supplement companies would have also increased 
sales. The 1997 WCRF report, nevertheless, stated that supplements were probably 
unnecessary and unhelpful for reducing cancer risk.8 Whilst the recent 2007 WCRF 
report found no probable or convincing evidence that vitamin C supplementation affects 
cancer risk there was evidence of an increased or decreased risk with some other 
supplement types (Appendix B), though this was usually from studies of high-risk 
groups.7 In summary the 2007 report states that it is unwise to recommend widespread 
supplement use for cancer prevention since effects cannot be confidently predicted in 
the general population.7 Indeed high doses of some supplements, including vitamin C 
may promote cancer,77  although doses above 400mg of this water soluble vitamin are 
likely to be excreted in healthy women.65 Its antioxidant properties may reduce DNA 
damage by reactive oxygen species during the initial stage of cancer particularly in 
individuals with high levels of ROS.77 This antioxidant property, however, may 
decrease beneficial apoptosis, the ROS induced programmed death of damaged 
cells,81 and thereby lead to the progression of cancer particularly in individuals with low 
levels of ROS.77 Vitamin C may also act as a pro-oxidant creating highly reactive and 
damaging hydroxyl radicals via the Fenton reaction in the presence of iron.76 However 
this hypothesis is controversial since free iron is normally unavailable in vivo.76 Apart 
from a family history of breast cancer and a moderate but non-significant association 
 149 
 
 
with a family history of pancreatic cancer our results indicate that UK women were 
probably not taking high dose vitamin C supplements as a preventive measure due to a 
family history of cancer in general. Since cancer of the pancreas has a poor prognosis, 
some women with this family history may have been more motivated to take high doses 
of vitamin C supplements.  
It is unknown why vitamin C supplements were taken by women in the UKWCS. Given 
that only a relative small proportion of the UK population are advised by the medical 
profession to take supplements for health reasons,26 some health conscious UK 
women may be self-treating with vitamin C. Alternatively, women with or without cancer 
may take supplements under the belief supplements can make them feel better 
generally or increase immune function.361 Additionally, due to the cross-sectional 
nature of the study the direction of cause and effect cannot be determined; it is 
unknown whether vitamin C has been taken to prevent or manage cancer symptoms or 
whether vitamin C has caused cancer. 
 
Lack of information to determine whether cancer developed before or after frequent 
vitamin C supplement use started is a limitation of this study. Although cancer registry 
data was available for the cohort we suggest it is women’s self-reported perceived 
health, whether accurate or not, that influences their supplement-taking behaviour. 
Self-reporting of supplement descriptions, for only four days by diary were limitations of 
the study. Whilst 4-day diaries are capable of capturing daily, and near daily intake, in 
reality some three to four day diary recordings may represent spasmodic rather than 
frequent intake. Nevertheless, our results in section 5.2 of the evaluation chapter show 
that substantial agreement was found between these frequent diary recordings and 
daily use recorded concurrently by questionnaire. Although the number of years of 
supplementation was not collected in either the diary or questionnaire, and no further 
follow-up was conducted, the majority of vitamin C users (82%) were taking a 
supplement of some type on average four years earlier at baseline. An additional 
problem was the wide variety of formulations of supplements used which made coding 
difficult. Whilst high dose vitamin C supplements were unlikely to contain other 
micronutrients,35 our results show that consistent with other research,26 women taking 
high doses were highly likely to take other supplements. Therefore vitamin C use may 
be a marker for the intake of other supplements. 
Our study capitalises on the large sample size of the UKWCS, substantial numbers of 
women frequently taking vitamin C (34%) and as well as the wide variety of 
characteristics and cancers recorded. However, the small numbers of women in some 
of the categories, particularly those shown in Table 30 and especially those taking 
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2000mg/day or more, may have produced spurious results. Another limitation of our 
study is that UKWCS participants were more health conscious than the general 
population and therefore not representative of the whole UK population. Differences in 
characteristics between frequent takers and non-frequent takers in the UKWCS may 
not be as pronounced as that found in the general population.  
Our research may help to identify high-dose users, such as ex-smokers, low alcohol 
drinkers and women with a history of breast cancer who could be made aware of 
inconsistencies in evidence relating to suggested benefits, and of warnings relating to 
high strength supplements.362 Furthermore, patients should be encouraged to discuss 
their supplement use with their doctors to avoid contraindications.81 356 Finally, 
additional research is needed to establish the effects of both supplement and dietary 
vitamin C intake on cancer initiation and development. Breast cancer risks for UK 
women in relation to vitamin C intake are reported in chapter 8, 9 and 10. First, breast 
cancer risk in relation to general supplement use is explored in the next chapter. 
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CHAPTER 7 
7 Is general supplement use associated with 
breast cancer risk in the UKWCS?  
7.1 Summary 
Objectives: To determine whether general supplement use is associated with breast 
cancer risk at baseline in the UK Women’s Cohort Study (UKWCS) and whether use 
modifies risks in different groups of women. In addition breast cancer risks for women 
who were users at both baseline and phase 2 will be determined. 
Methods: Hazard ratios were calculated for 33,138 middle-aged women in the UKWCS 
in relation to any supplement use recorded by questionnaire at baseline. The median 
follow-up period was 11.2 years with 982 registered breast cancer incidences. Risks for 
12,917 of these women, who also completed the phase 2 questionnaires on average 
4.4 years later, were analysed in relation to consistent supplement use. Median follow-
up for these women was 11.6 years from baseline during which 414 breast cancers 
occurred. Adjustments were made for potential confounders measured at baseline. 
Interactions between baseline supplement use and other characteristics of the women 
were tested.  
Results: There was no evidence of associations with breast cancer risk for baseline 
supplement users (HR=1.00; 95% CI: 0.87, 1.16) compared to non-users, or for women 
who were still taking supplements at phase 2 (HR=0.96; 95% CI: 0.74, 1.26) compared 
to never-users. There were also no significant risks for pre- (HR=1.14; 95% CI: 0.91, 
1.43) or post-menopausal women (HR=0.89; 95% CI: 0.73, 1.08) for baseline users or 
similarly for consistent users. Significant interactions were found between baseline 
supplement use and menopausal status (p=0.04), socio-economic status (p=0.01) and 
vigorous exercise (p=0.05). Increasing healthier behaviours were apparent from never 
users, to inconsistent users, to consistent users. 
Conclusion: There were no overall associations in this UK cohort between breast 
cancer risk and general supplement use, including women who were users on average 
4.4 years later. However, the results indicate supplement users may have different 
risks from non-users depending on their menopausal status, their socio-economic 
status or level of physical activity.  
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7.2 Introduction 
Due to the unregulated increased use of supplements by UK women, which has risen 
from 17% in 1986/1987 to 41% reported in 2008/9,24 25 it is important to establish 
whether or not general supplement use is associated with detrimental effects, such as 
an increased risk of breast cancer. Indeed the 2007 WCRF review clearly states that 
supplements are not recommended for cancer prevention, furthermore it reports no 
convincing evidence that supplements protect against breast cancer.7 Most studies 
evaluating the relationship between supplement use and breast cancer risk have 
focused on individual supplement types or ingredients. Only a few studies mentioned in 
the 2007 WCRF review examined general supplement use in relation to breast cancer 
and these were case-control studies which may be prone to selection bias and recall 
bias.257-259 No associations were found in the Danish and US studies reported in the 
2007 review,257 259 whereas a significant protective effect of supplements on breast 
cancer was found in a Taiwanese study (OR=0.40, 95% CI: 0.3, 0.7). Furthermore, 
there is a lack of evidence on whether general supplement use modifies factors linked 
to breast cancer risk; supplement use could be beneficial for some groups of women 
but detrimental for others.  
 
Additionally, no study has assessed whether consistent use of supplements in general 
is associated with breast cancer risk. Only one study has analysed the consistency of 
general supplement use in relation to cancer, though this was for total cancer mortality 
and no significant associations were found for women who were consistent users at 
three survey points over 11 years.363 Nevertheless, in this German cohort, consistent 
users had a healthier diet compared to inconsistent users as well as non-users.364 As 
reported in the previous chapter, 6, supplement users are more likely to lead healthier 
lifestyles, for instance they are more likely to be physically active, have a lower BMI 
and eat diets which meet recommended dietary intakes. However, there is no research 
on whether consistent users are more health conscious than inconsistent users in the 
UK. 
The current study prospectively examines the relationship between breast cancer 
incidence and use of any type and amount of supplements at baseline in the UKWCS, 
and also compares the risk for women who are still using any supplements at phase 2 
with those who are inconsistent users and those who are never-users. It also describes 
characteristics of consistent and inconsistent users. Furthermore, it capitalises on the 
large sample size of the UKWCS at baseline by testing for interactions between 
supplement use at baseline and women’s characteristics and their associations with 
breast cancer risk.  
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7.3 Method 
7.3.1 Study population 
General information about the recruitment of the UKWCS baseline population used in 
this analysis is provided in section 4.1.1.1 of the methods chapter. Of the 35,372 
women in the UKWCS who completed the baseline questionnaire, 34,958 (99%) 
provided information about whether or not they took supplements. Women with any 
prevalent malignant cancers recorded in the cancer registries before baseline 
questionnaire date and women diagnosed with breast cancer within 6 months after the 
questionnaire date were excluded. To be consistent with other baseline analyses that 
will be presented in this thesis, women with extremely low or high total energy intake 
(more than 6000kcal and less than 500kcal) were also excluded. This left 33,138 
women for the time-to-event analysis. Over the median follow-up period of 11.2 years 
there were 982 incident breast cancers which were registered by the censor date 
01/01/08. 
Risks for 12,917 of these women who also completed supplement questions on the 
UKWCS phase 2 questionnaires on average 4.4 years after baseline, were analysed in 
relation to consistent supplement use. Consistent users are defined in this analysis as 
women who were taking any type of supplement at both baseline and phase 2. The 
same types of exclusions were made as above. Over a median follow-up of 11.6 years 
from baseline there were 414 incident breast cancers registered to censor date 
01/07/08.  
7.3.2 Exposure measurement  
General supplement use at baseline was determined by questionnaire using yes/no 
answers to: 
 Q29 Do you take any vitamins, minerals, fish oils or other food supplements? 
 
Supplement use at phase 2 was determined by questionnaire using yes/no answers to: 
 Q15 Do you presently use any dietary supplements? 
Supplements had previously been defined on the phase 2 questionnaire as vitamins, 
minerals, fibre, fish oils or other food supplements.  
 
Additionally, if participants did not answer yes to the above questions but provided 
details of any type of supplements taken, regardless of amount taken, then these 
women were designated as being general supplement users. As a result an extra 3083 
women were coded as general supplement users at baseline, and also an extra 846 
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women at phase 2 were coded as users who detailed they took supplements weekly or 
more frequently on the phase 2 questionnaire (see sections 4.5.1 and 4.5.2). These 
numbers are before exclusions mentioned in 7.3.1. 
7.3.3 Statistical analyses 
Characteristics of users and non-users at baseline were described using means and 
percentages; significant differences between means were established using t-tests and 
significant differences between categories were established using chi squared tests. 
Women who had also completed the phase 2 questionnaire were split into three 
categories: Never users at baseline and phase 2; inconsistent users (use at only one 
collection point); Consistent users (use at both baseline and phase 2). Characteristics 
of these women were described using means and percentages. Significant trends for 
means across groups from never users to inconsistent users to consistent users were 
calculated using linear regression followed by tests for linear hypotheses. 
 
Cox proportional hazard ratios were used to estimate breast cancer risk relating to 
supplement use of women in the UKWCS. The proportional hazard assumption was 
checked using graphs of log-log curves. Covariates used for adjustment were based on 
those previously identified as risk factors for breast cancer which had also previously 
been associated with supplement use, as illustrated in the DAG in Figure 14 in section 
4.7.5.2. These were age; BMI (underweight, normal, overweight, obese); parity (none, 
1-2, 3 or more); estimated cumulative breast feeding (wks); age at menarche; minutes 
sweating exercise per week; contraceptive pill use (never, past, current); HRT use 
(never, past, current); alcohol intake (g/day); smoking status (never, past, current); food 
group (meat, oily fish, fish, vegetarians); total energy intake; and also where 
appropriate supplement use (yes, no); menopausal status (postmenopausal; 
premenopausal) and socio-economic status (high: professional and managerial; 
intermediate; low: routine and manual). Menopausal status was determined at baseline 
based on the answers to this questionnaire (see section 4.7.4 including Figure 12 ). 
Covariates were derived from the health and lifestyle part of the baseline questionnaire 
apart from total energy intake, total alcohol intake and food groups which in turn had 
been derived from the FFQ part of the baseline questionnaire. 
To investigate whether supplement use at baseline modified the effects of women’s 
characteristics on breast cancer risks, adjusted likelihood ratio tests for overall 
interactions were performed between supplement use status and each of the following 
characteristics: menopausal status; HRT use; socio-economic status (SES); 
educational level; BMI; level of exercise; and allocated food group. These are factors 
that have been associated with breast cancer risk, many of which are discussed in the 
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literature review chapter, 3, and/or in section 4.7.5.2 of the methods chapter. The 
hazard ratios shown in Table 35 include interaction terms for joint effects of supplement 
use status and each characteristic, which were adjusted for the same covariates in the 
other time-to-event analyses. Linear combinations of coefficients were used to 
calculate the hazard ratios for the users after running the main Cox proportional hazard 
command (using the Stata lincom command).365  
7.4 Results 
Of the 33,138 total women, 62% percent were supplement users at baseline and 54% 
of the 12,917 women followed-up at phase 2 had taken supplements at both recording 
points, and were classed as consistent users. Twenty-four percent of women at phase 
2 were inconsistent users (had taken supplements at either recording point but not at 
both) and 21% were never users. Of the 8,896 (69%) women who were currently taking 
supplements at phase 2 as many as 6,992 (79%) were classed as consistent users.  
There were significant differences between general supplement users and non-users at 
baseline for the majority of characteristics listed in Table 31 except for age at 
menarche, smoking status, socio-economic status and family history of breast cancer. 
In particular users were more likely to have a higher fruit and vegetable intake (mean 
652 vs. 591 g/d), a lower meat intake (mean 59.8 vs. 72.9 g/d), more likely to exercise 
vigorously (15.9 mins/d vs. 14.1 mins/d), but less likely to engage in breast feeding 
(22.6 vs. 25.1 cumulative weeks) than non-users. Users were slightly less likely to have 
a degree than non-users. There were similar differences in the prospective comparison 
in Table 33 which showed increasingly healthier behaviours from never users at 
baseline and phase 2, inconsistent users, to consistent users at phase 2 (e.g. fruit and 
vegetable intake respectively was 603 vs. 627 vs. 676 g/d). 
There was no difference in breast cancer incidence between supplement users and 
non-users for total women either in the unadjusted or adjusted analyses (HR=1.00; 
95% CI: 0.87, 1.16) For post-menopausal women hazard ratios for users were lower 
and for pre-menopausal hazard ratios were raised, compared to non-users (HR=0.89; 
95% CI: 0.73, 1.08 and HR=1.14; 95% CI: 0.91, 1.43 respectively), but they were not 
significant (Table 32). For women who reported taking any supplement at both baseline 
and phase 2 similar patterns of non-significant risks were found; these also were not 
significant (Table 34). 
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Table 31 Characteristics of supplement users and non-users at baseline in the 
UKWCS 
 Non-users 
N=12678  
(38%) 
Users 
N=20460  
(62%) 
 
p 
Age  (years) mean (sd)  51.5 (9) 52.3 (9) <0.001 
BMI (kg/m2) mean (sd) 24.8 (4) 24.2 (4) <0.001 
Age at menarche (years) 12.8 (2) 12.8 (2)   0.8 
Parity mean (sd) 1.9 (1) 1.8 (1) <0.001 
Cumulative breast feeding (weeks) mean 
(sd)  
25.1 (31) 22.6 (34) <0.001 
Vigorous exercise (mins/d) mean (sd) 14.1 (28) 15.9 (30) <0.001 
Total energy intake (cal/d) mean (sd) 2323 (710) 2360 (717) <0.001 
Alcohol intake (g/day) mean (sd) 9.0 (11) 8.5 (10) <0.001 
Total meat intake (g/day) mean (sd) 72.9 (63) 59.8 (60) <0.001 
Total fruit & veg (g/day) mean (sd) 591 (329) 652 (354) <0.001 
    
Never smoked (%) 58.2 57.5   0.2 
Never used HRT (%) 70.0 66.5 <0.001 
Never used pill (%) 31.1 32.6   0.008 
Socio-economic status (%)   
Higher 39.2 39.0    0.8 
Middle 42.3 42.7     
Lower 18.5 18.3  
Education level, (%)    
Degree 26.9 25.7    0.05 
Family history of breast cancer (%) 7.5 7.7    0.4 
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Table 32 Breast cancer risks according to any supplement use at baseline in the 
UKWCS 
Any supplements use 
at baseline 
Cases/ Unadjusted Adjusteda 
Non-cases HR (95% CI) HR (95% CI) 
Total women      
Non-users 364/12314 1  1  
Users 618/19842 1.04 (0.92, 1.18) 1.00 (0.87, 1.16) 
      
Post-menopausal      
Non-users 218/6061 1  1  
Users 353/10514 0.91 (0.76, 1.08) 0.89 (0.73, 1.08) 
      
Pre-menopausal      
Non-users 146/6253 1  1  
Users 265/9328 1.21 (0.99, 1.48) 1.14 (0.91, 1.43) 
      
a
Adjusted for baseline covariates: age, BMI (grouped), socio-economic status, parity, estimated 
cumulative breast feeding, age at menarche, hrs exercise sweating per week, contraceptive pill use, 
HRT use, alcohol intake, smoking status, food group, total calories 
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Table 33 Baseline characteristics of women in the UKWCS according to supplement 
use at baseline and phase 2: never users; inconsistent users; and consistent users 
 Never
a
 
users 
Inconsistent
b
 
users 
Consistent
c
 
users 
N=6992  
(54%) 
ptrend 
 N=2756  
(21%) 
N=3169  
(24%) 
Age  (years) mean (sd)  52.1 (9) 51.2 (9) 52.6 (9) <0.001 
BMI (kg/m
2
) mean (sd) 24.4 (4) 24.4 (5) 23.9 (4) <0.001 
Age at menarche (years) mean (sd) 12.8 (2) 12.8 (2) 12.8 (2)   0.2 
Parity mean (sd) 1.4 (1) 1.4 (1) 1.3 (1)   0.002 
Cumulative breast feeding (weeks) 
mean (sd) 
28.5 (39) 26.1 (37) 24.4 (35) <0.001 
Vigorous exercise (mins/d) mean (sd) 13.4 (26) 13.9 (23) 16.6 (31) <0.001 
Total energy intake (cal/d) mean (sd) 2341 (674) 2366 (709) 2364 (694) <0.001 
Alcohol intake (g/day) mean (sd) 8.9 (13) 8.6 (10) 8.0 (10) <0.001 
Total meat intake (g/day) mean (sd) 67.0 (62) 60.5 (59) 53.0 (56) <0.001 
Total fruit & veg (g/day) mean (sd) 603 (312) 627 (337) 676 (347) <0.001 
     
Never smoked (%) 63.4 61.0 61.3  0.2 
Never used HRT (%) 72.0 69.6 65.3  0.007 
Never used pill (%) 34.2 28.4 33.0  0.03 
Socio-economic status (%)     0.8 
Higher 41.9 41.0 41.0  
Middle 41.7 41.7 42.7  
Lower 16.4 16.7 16.3  
Education level, (%)     
Degree 31.0 30.0 27.2  0.001 
Family history of breast cancer (%) 8.0 7.7 8.2  0.7 
     
a
Never users: women who reported no supplement use at baseline and at phase 2  
b
Inconsistent users: women who reported supplement use on only one questionnaire, either baseline and 
at phase 2  
c
Consistent users: women who reported supplement use at both baseline and at phase 2  
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Table 34 Breast cancer risks according to any supplement use for never users, 
inconsistent users and consistent users according to use at baseline and phase 2 of 
the UKWCS 
Any supplements use at 
baseline or phase 2 
Cases/ Unadjusted Adjusteda 
Non-cases HR (95% CI) HR (95% CI) 
Total women      
Never users at BL & P2 85/2671 1  1  
Inconsistent users 99/3070 1.00 (0.75, 1.34) 0.92 (0.67, 1.26) 
Consistent users 230/6762 1.05 (0.82, 1.35) 0.96 (0.74, 1.26) 
      
Post-menopausal      
Never users at BL & P2 54/1389 1  1  
Inconsistent users 54/1438 0.95 (0.65, 1.39) 0.87 (0.57, 1.33) 
Consistent users 130/3667 0.89 (0.65, 1.23) 0.80 (0.56, 1.15) 
      
Pre-menopausal      
Never users at BL & P2 31/1282 1  1  
Inconsistent users 45/1632 1.13 (0.71, 1.79) 1.01 (0.63, 1.63) 
Consistent users 100/3095 1.32 (0.88, 1.98) 1.16 (0.77, 1.76) 
      
a
Adjusted for baseline covariates: age, BMI (grouped), socio-economic status, parity, estimated 
cumulative breast feeding, age at menarche, hrs exercise sweating per week, contraceptive pill use, 
HRT use, alcohol intake, smoking status, food group, total calories 
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In the test for interactions, supplement use was found to modify the effect of socio-
economic status (SES), vigorous exercise, as well as menopausal status on breast 
cancer incidence after adjustment for potential confounders and inclusion of interaction 
terms for joint effects of supplement use status and each characteristic. Table 35 
shows that pre-menopausal users tend to have a slightly higher breast cancer risk than 
non-users whereas post-menopausal users have a slightly lower risk than non-users, 
though individual risk estimates are not significant. Table 35 also shows that 
supplement use has little effect on breast cancer risk for women of high SES, but risks 
are different for middle and low SES groups depending on whether or not they used 
supplements. Non-users in the lowest SES group had a higher breast cancer risk 
(HR=1.52; 95% CI: 1.11, 2.07) than users in the lowest SES group (HR=0.97; 95% CI: 
0.72, 1.31), when compared to women of high SES who did not take supplements. 
However, supplement users in the middle SES group had higher risks (HR=1.23; 95% 
CI: 0.98, 1.54) than non-users in the middle SES group, though these estimates were 
not statically significant. The unadjusted increased risk for middle SES group 
supplement users compared to other SES groups of supplement users is illustrated in 
the Kaplan Meier curve in Figure 22. Additionally, women who exercise vigorously had 
a higher risk of breast cancer if they took supplements than if they were not users 
(HR=1.16; 95% CI: 0.94 1.42). However women who did not exercise vigorously were 
at greater risk (HR=1.27; 95% CI: 0.99 1.62) if they were non-users than if they took 
supplement (HR=1.10; 95% CI: 0.87 1.39).  However individual risk estimates did not 
reach statistical significance. Effects of HRT use, BMI, educational level and food 
group were not significantly modified by supplement use.  
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Table 35 Assessment of modifying effects of supplement use at baseline on breast 
cancer risk using interaction terms for joint effects of supplement use and other 
characteristics  
 Cases/ Non-cases HR (95% CI)
a 
p
b
 
 Non-users Users Non-users Users  
      
Menopausal status      
Post 174/4713 271/8213 1 0.88 (0.73, 1.07)  
Pre 124/5293 219/7803 0.98 (0.72, 1.33) 1.17 (0.89, 1.55) 0.04 
      
HRT use      
Never 182/6987 302/10661 1 1.07 (0.89, 1.29)  
Prior 27/775 56/1603 1.23 (0.82, 1.85) 1.23 (0.90, 1.67)  
Current 89/2244 132/3751 1.43 (1.14, 1.97) 1.32 (1.03, 1.68) 0.5 
Socio-economic status     
High  109/4018 189/6351 1 1.09 (0.86, 1.38)  
Medium 123/4250 230/6826 1.08 (0.84, 1.40) 1.23 (0.98, 1.54)  
Low 66/1738 71/2838 1.52 (1.11, 2.07) 0.97 (0.72, 1.31) 0.01 
      
Education level      
None 50/1330 75/2260 1 0.87 (0.61, 1.25)  
O’level 90/2894 145/4741 0.93 (0.65, 1.32) 0.91 (0.64, 1.24)  
A’level 69/2340 120/3731 0.88 (0.60, 1.29) 0.95 (0.67, 1.33)  
Degree 72/2710 110/4082 0.83 (0.56, 1.22) 0.83 (0.57, 1.19) 0.8 
      
BMI      
Low 2/97 5/232 0.99 (0.19, 5.14) 0.80 (0.33, 1.95)  
Normal  166/6071 311/10610 1 1.04 (0.86, 1.26)  
Overweight 92/2699 133/3810 0.94 (0.68, 1.31) 1.19 (0.94, 1.50)  
Obese 38/1139 41/1363 0.85 (0.53, 1.38) 1.08 (0.76, 1.52) 0.9 
      
Exercise vigorously     
Yes 138/5515 293/9812 1 1.16 (0.94 1.42)  
No 158/4455 193/6136  1.27 (0.99 1.62) 1.10 (0.87, 1.39) 0.05 
      
Food Group      
Meat 231/7444 345/10667 1 1.00 (0.85, 1.19)  
Oily fish 4/163 12/488 0.80 (0.39, 2.15) 0.79 (0.44, 1.42)  
Fish 17/743 49/1670 0.75 (0.46, 1.22) 0.93 (0.68, 1.27)  
Vegetarian 46/1656 84/3190 0.94 (0.68, 1.30) 0.88 (0.68, 1.13) 0.9 
 
a
Adjusted for age, BMI (grouped), socio-economic status, parity, estimated cumulative breast feeding, age 
at menarche, hrs exercise sweating per week, contraceptive pill use, HRT use, low alcohol, smoking 
status, food group, total calories. 
b
Test for interaction 
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 Figure 22 Breast cancer time-to-event curve for supplement users split by socio-
economic status 
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7.5 Discussion  
In line with previous research, descriptive results from these UKWCS baseline and 
phase 2 analyses support the inverse supplement hypothesis that supplement users 
lead a healthier lifestyle than non-users, as found in the UK25 28 29 and elsewhere.30-35 In 
particular, supplement users had on average a higher intake of fruit and vegetables, a 
lower intake of meat and spent more time exercising vigorously. Whilst UKWCS 
supplement users were generally more health conscious, they had spent less time on 
average breast feeding than non-users or never-users. Additionally, UKWCS users 
were less likely to be educated to degree level. However a previous analysis of an 
initial 13,822 respondents from the baseline UKWCS found no significant association 
for education, though this was after mutual adjustment for other variables,27 and other 
studies have reported higher qualifications for supplement users. 32,353 
Furthermore, the descriptive results showed that consistent users (users at both 
baseline and phase 2) have healthier behaviours than inconsistent users, as well as 
never users. Only one other cohort has analysed the characteristics of consistent 
supplement users compared to non-users and inconsistent users;364 women in this 
EPIC-Heidelberg cohort who were consistent users had the highest intake of dairy 
products, fish, fruit and vegetables and wine but the lowest intake of meat compared to 
inconsistent users as well as non-users. In this German cohort only inconsistent use 
was associated with self-reported cancers. In the UKWCS inconsistent or consistent 
users were not more likely to have a family history of breast cancer. Further analysis of 
the UKWCS using a multivariate logistic regression model mutually adjusting for 
variables is required to assess significant predictors of consistent supplement use in 
the UKWCS cohort, which remain significant over and above associations with other 
factors. In comparison to the German study which reported a low percentage of 
consistent women users (23%), a large percentage (54%) of women at phase 2 of the 
UKWCS were consistent users from baseline. Reasons for the differences may be as 
follows: baseline supplement use in the German study was much lower than in the 
UKWCS (39% vs. 62%); supplement recordings occurred over three follow-up time 
points in the German study compared to two in the UKWCS; and the German cohort 
may not have been as health conscious as the women in UKWCS which included a 
high percentage of vegetarians. 
In the current analysis there was no evidence of significant associations between 
breast cancer risk and supplement use at baseline for total women and by menopausal 
status. This supports the results of both the Danish and US study reported257 259 in the 
2007 WCRF review which found no convincing evidence for beneficial effects of 
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supplements on breast cancer risk.7 However the current results are in contrast to the 
Taiwanese study where general supplement use was associated with a reduced risk.258 
Taiwanese women may generally have lower intake levels of nutrients than western 
women and therefore may require supplementation to reduce their risk. In contrast, 
there was a weak increased risk for pre-menopausal supplement use at baseline in the 
UKWCS which was close to significance, but only in the unadjusted analysis. Given 
that users generally have a healthier lifestyle than non-users, lower breast cancer risks 
for users before adjustment for lifestyle factors had been expected. 
Additionally, there was no evidence of significant associations between breast cancer 
risk and consistent supplement use between baseline and phase 2 for total women and 
by menopausal status. This is the first study to assess breast cancer risk and long-term 
supplement use. Only one previous study has analysed the consistency of general 
supplement use in relation to cancer, though this was for total cancer mortality.363 This 
EPIC-Heidelberg analysis reported a weak increased cancer mortality risk for 
consistent users which was non-significant, but reported evidence of a significant 
moderate increased risk in new users which became non-significant after excluding 
women diagnosed between the baseline and follow-up surveys.363 This supports 
research mentioned in the previous chapter 6 which reported cancer patients tend to 
take supplements after cancer diagnosis. A limitation in both studies is that it is 
unknown whether participants were taking the same types of supplements at the 
follow-up as at baseline: for how long, how frequently, how many and at what doses 
they were taking them is also unknown. Some breast cancer cases (129 of the total 
414) occurred between baseline and phase 2 in the UKWCS, consequently the shorter 
duration of supplement use for these women was likely to have had less influence on 
cancer development than incidences occurring after phase 2. Additionally, it is 
unknown how many years supplements were used before baseline.  
Additionally, the current analysis found that supplement use modified the effects of 
menopausal status, socio-economic status and vigorous exercise on breast cancer risk 
in UK health conscious women. For supplement users, differences in breast cancer 
risks between menopausal statuses could arise because pre-menopausal women may 
tend to take different supplements from post-menopausal women and these may have 
different effects on breast cancer risk. For instance, a small 2008 UK national survey 
reported cod liver oil was used by half of those aged 55 plus (who were likely to be 
post-menopausal) compared with a quarter (26%) of those aged 16-54, whereas 
multivitamins and vitamin C were more likely to be used by 16-54 year old supplement 
users than those aged 65 plus.26 Another explanation for higher risk in pre-menopausal 
women is that there may be a large proportion of pre-menopausal women at high risk 
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of genetically inherited breast cancer in this cohort, who in the hope of reducing their 
cancer risk may have been more likely to take supplements. Sensitivity analyses could 
be undertaken excluding women who had a family history of breast cancer, though 
these women were not associated with supplement use and the recording of this at 
baseline appeared incomplete, as mentioned in section 4.7.6.3.1. One reason why 
non-supplement users of lower SES were found to have significantly higher risks of 
breast cancer than low SES supplement users or non-supplement of other SES is 
perhaps they were more likely to be poorly nourished. In relation to exercise, one study 
reported vitamin C supplementation was detrimental to the beneficial effects of physical 
exercise on insulin resistance366 which in turn may affect breast cancer risk, as 
mentioned in section 3.5.6 of chapter 3. Further sub-group analysis was not 
undertaken since it has been acknowledged that this should be discouraged because it 
may lead to spurious findings from multiple testing, especially when no overall 
significance was found prior to sub-grouping.367 Conversely Hemila and Kaprio (2008) 
argue that given the investment of time and resources into the establishment of large 
databases it is morally right to sub-analyse data, especially when biological and social 
affects are complex and not well established.368  
Although general supplement use in poorly nourished populations may be required for 
the body to function adequately against the development of cancer, any effects of 
general supplement use per se on breast cancer risk in well-nourished populations may 
be more difficult to explain biologically. The women in the UKWCS appear to be well-
nourished, and high intakes of different nutrients from supplements are likely to have 
different effects on cancer risk, some may produce opposing effects. What is more, as 
seen in the previous chapter, 6, a large proportion of women take many different types 
of supplements. Alternatively differences in risk could arise due to lifestyles or 
characteristic differences between users and non-users that have not been adequately 
adjusted for. Another limitation is that UKWCS participants were more health conscious 
than the general population and therefore not representative of the UK population as a 
whole. Results were not weighted to account for the large proportion of vegetarians in 
the UKWCS; nevertheless the aim was to examine the effects on health conscious 
women who may be prepared to alter their behaviour in light of new evidence. 
To conclude, there was no evidence of significant associations between general 
supplement use and breast cancer risk in this UK cohort which comprised of mainly 
health conscious women. However, the results suggest that UK women who take 
supplements may have different breast cancer risks from non-users depending on their 
menopausal status, their socio-economic status or level of physical activity.  
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CHAPTER 8 
8 Do women who take supplements containing 
vitamin C in the UK have an increased risk of 
breast cancer? Phase 2 analyses of the UKWCS. 
8.1 Summary 
Objective: To determine whether breast cancer incidence in the UKWCS is associated 
with the use of supplements containing vitamin C. 
Method: 11,184 middle-aged women from phase 2 of the UK Women’s Cohort Study 
(UKWCS) were followed up for a median of 7.4 years. Associations between 239 
registered incident breast cancers and vitamin C contained in supplements recorded by 
4-day diaries were analysed by Cox’s regression models using four intake categories: 
no frequent use of supplements containing vitamin C; frequent intake up to and 
including EU recommended allowances (1-60mg/d); between 60mg and 500mg/d; and 
high intake (≥500mg/d). Additionally, the relationship between breast cancer risk and 
phase 2 questionnaire reports of daily multivitamin use, a common source of low dose 
vitamin C, was examined for 12,642 women, including 269 cases. Adjustments were 
made for relevant covariates.  
Results: Compared to women who did not use supplements containing vitamin C, there 
was no evidence of significant associations between breast cancer incidence and 
frequent vitamin C supplementation in any intake category, or in post-menopausal sub-
analyses. Additionally, no dose-response associations were found (HR=0.98 per 
60mg/d; 95% CI: 0.94, 1.02; Ptrend=0.3). However pre-menopausal women in the lowest 
intake category (1-60mg/d) had statistically significantly increased risks (HR=2.56; 95% 
CI: 1.41, 4.66; p=0.002) compared to non-users of vitamin C. There was also a 
moderate increased risk for pre-menopausal daily multivitamin users, however, this 
was not significant (HR=1.51; 95% CI: 0.90, 2.54). 
Conclusion: There was little evidence that supplementation with vitamin C per se was 
associated with breast cancer incidence in UK women, even at high doses. The 
increased breast cancer risk for pre-menopausal women consuming supplements 
containing vitamin C less than or equal to EU recommendations may be due to the 
effects of other ingredients in the supplements, though the multivitamin use results did 
not entirely support this. Alternatively the positive associations may be spurious.  
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8.2 Introduction 
As mentioned in chapter 2, vitamin C is one of the most commonly used dietary 
supplements in the UK.26 352 In a small 2008 nationally representative UK survey 24% 
of people reported its use and it was one of the top three reported supplements used 
along with multivitamins (36%) and cod liver oil (35%).26 In the UKWCS 17.5% of 
women recorded they took vitamin C on the phase 2 questionnaire; other popular 
supplements were multivitamins, fish oils and evening primrose oil. In total, phase 2 
questionnaire recordings showed that 35.5% of UKWCS women used vitamin C, 
multivitamins, or antioxidants; all likely to contain vitamin C (Figure 2, chapter 2). This 
was comparable to diary recordings at phase 2 which, as seen in chapter 6, showed 
that 34% of women frequently took supplements containing any dose of vitamin C. 
Additionally, diary recordings showed that 10% frequently took high doses of 500mg or 
more and 5% frequently took doses of 1000mg or above (chapter 6).1  
In addition to associations with healthier lifestyle behaviours, the frequent use of 
supplements containing vitamin C by UKWCS participants was also associated with a 
family history of breast cancer, as reported in chapter 6.1 It is unknown, however, 
whether these women took vitamin C supplements for cancer prevention, or took them 
to increase immune function or for general health and well-being, the latter being a 
popular reason for taking supplements in general in the 2008 UK survey.26 The 2007 
WCRF/AICR  report states that it is unwise to recommend widespread supplement use 
for cancer prevention since effects cannot be confidently predicted in the general 
population.7 Indeed there are mechanisms whereby vitamin C could potentially 
increase or decrease cancer, as discussed in chapter 2.77 81 Whilst supplement use by 
UK women continues to increase,24 25 evidence is lacking regarding the benefits of 
vitamin C, in relation to mortality,351 cancer and breast cancer specifically.7 351   
As seen in section 3.7.4 of the literature review chapter, results from prospective 
studies examining associations between vitamin C from supplements and breast 
cancer risk have been inconsistent. Only six cohort studies have assessed the 
relationship between breast cancer incidence and vitamin C supplement intake by 
dose, without the inclusion of dietary intake.242 245 247 267 270 273 These are summarised 
together in Table 36, along with one RCT.14 Each study has assessed different 
categories of intake, but no pattern of risk emerges. 
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Table 36 Studies analysing breast cancer risk by vitamin C supplement dose 
Author, 
year 
Study Design Supplement 
information requested 
Follow up and 
cancer incidence 
Menopause 
status 
Vitamin C supplement associations, 
compared to non-users: OR, RR, HR 
Rohan 
et al. 
1993
267
 
Canadian 
Breast 
screening 
Study 
Prospective 
Nested case-
control  
Age 50-59  
Specific vitamins 
Multivitamins 
1982-1987 
519 cases 
1184 controls 
Total of pre 
& post 
<250mg/d:    1.04 (0.78-1.39) 
>250mg/d:    1.46 (1.05-2.01) 
Kushi  
et al. 
1996
242
 
Iowa 
Women’s 
Health 
Study, 
 US 
Prospective 
Cohort 
N=34,387  
Age 55-69 
A,C,E,  
Multivitamin 
brand name  
frequency 
Av 7yrs: 
1986-1992 
879 cases 
 
Post <200mg/d:    0.91 (0.77-1.08) 
200-500:       0.94 (0.73-1.21) 
500-1000:     0.86 (0.65-1.14) 
>1000:          0.77 (0.50-1.17) 
ptrend = 0.20 
Zhang 
et al. 
1999
247
 
Nurses 
Health 
Study 
US 
Prospective 
Cohort 
N=77,925 
Age 33-60 
Brand, doses, duration 
of specific vitamins & 
multivitamins 
Ingredients obtained 
14yrs: 
1980-1994 
2523 cases 
Pre-meno ~27% 
Total of pre 
& post 
<400mg/d:    0.96 (0.73-1.25) 
400-700:      1.08 (0.93-1.27) 
750-1250:    1.02 (0.85-1.23) 
>1300:         1.04 (0.77-1.42) 
Nissen 
et al. 
2003
245
 
Danish Diet 
& Cancer 
Cohort 
Prospective  
Nested case-
control 
Age 50-64 
Brand, doses, 
frequency in last year 
Ingredients obtained  
Mean 4.7yrs: 
1993-1997 
228 cases  
246 controls 
Post Per additional 100mg/d 
                     1.06 (1.01-1.13) 
 
Cui  
et al. 
2008
270
 
Women’s 
Health 
Initiative  
US 
Prospective 
Cohort 
N=84,805 
Age 50-79 
Multiple and single 
vitamins 
A,C, E estimated 
Av 7.6yrs 
2879 cases 
Post >0<61mg/d:  1.03 (0.91-1.16) 
61<347:        0.99 (0.88-1.11) 
347-711:       1.04 (0.92-1.16) 
>711:            1.16 (1.04-1.30) 
ptrend = 0.029 
Roswall 
et al 
2010
273
 
Diet, 
Cancer & 
Health 
Cohort 
Denmark 
Prospective 
Cohort 
N=26,224 
1993-1997 
Age 50-64 
Vitamin C content by 
brand obtained 
Median 10.6yrs 
1072 cases 
Post >0≤40mg/d:  0.95 (0.74-1.21) 
>40 ≤64:       1.03 (0.80-1.33) 
>64           :    0.96 (0.77-1.21) 
ptrend = 0.41 
Lin  
et al. 
2009
14
 
Women’s 
Antioxidant 
Cardio-
vascular 
Study, US 
RCT 
Factorial 
design 
N=7,627 
Age >=40 
500mg/d vitamin C 
600 IU/d vitamin E 
50/2d beta carotene 
Av 9 yrs 
135 cases 
Post Compared to placebo group 
500mg/d:      1.11 (0.87–1.41) 
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Table 37 Methods and factors controlled for in studies of breast cancer risk and vitamin C supplement use 
Author, 
year 
Exclusions Hormonal factors 
controlled for 
Dietary factors 
controlled for 
Other factors controlled for  
Rohan 
et al. 
1993
267
 
History of breast cancer 
Had mammograms 
Age at menarche 
Age at first live birth 
Surgical menopause 
Energy intake Age 
Years of education 
Family history of breast cancer 
History of benign breast disease 
 
Kushi 
et al. 
1996
242
 
Post menopausal 
Full or partial breast removal 
Cancer (other than skin) 
Missing >30 items on FFQ. 
Extreme total energy intake 
Age at menarche 
Age at first live birth 
Parity 
Age at menopause 
Alcohol intake 
(Energy intake in 
sensitivity analysis) 
 
Age 
Educational attainment 
BMI @ BL & 18yrs 
Waist/hip ratio 
Breast cancer family history in first degree relatives 
History of benign breast disease 
 
Zhang 
et al. 
1999
247
 
Previous cancer diagnosis 
Implausible total energy intake 
<500>3500kcal/d 
Missing >10 FFQ blank 
Age at menarche 
Age at first live birth 
Parity 
Age at menopause 
HRT use 
Menopausal status 
Alcohol intake 
Energy intake 
Length of follow up 
Age 
Height 
BMI & BMI @18 yr 
Weight change from 18 
Breast cancer in mother or sister 
 
Nissen 
et al. 
2003
245
 
Previous cancer diagnosis 
Pre-menopausal 
Missing items on FFQ 
Missing items on lifestyle questionnaire 
regarded as potential confounders 
Age at first birth 
Parity 
HRT duration 
 
Intake of vitamin A & E 
Alcohol intake 
(Energy intake in 
sensitivity analysis) 
School education 
History of benign breast disease 
BMI 
(Matched on age at baseline) 
Cui  
et al. 
2008
270
 
History of breast cancer 
Implausible total energy intake 
<600>5000kcal/d 
 
Age at menarche 
Age at first live birth 
Parity 
Age at menopause 
Contraceptive use 
HRT use 
Hysterectomy 
Bilateral oophorectomy 
Energy intake 
Alcohol intake 
Dietary folate intake 
Dietary vitamin C 
Age 
Ethnicity 
Educational level 
Smoking 
Family history of breast cancer 
History of benign breast disease 
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Table continued - Methods and factors controlled for in studies of breast cancer risk and vitamin C supplement use 
Roswall 
et al 
2010
273
 
Cancer diagnosis 
No lifetime menstruation 
Missing covariates and micronutrient 
intake 
HRT 
Parity 
Age at first birth 
Alcohol intake 
Total intake of vitamin 
E and β-carotene 
Dietary or supplement 
vitamin C intake 
mutually adjusted 
Age (used as the underlying time scale for hazard 
ratio rather than adjusted for it as a covariate) 
BMI 
Education 
Lin  
et al. 
2009
14
 
Self-reported cancer diagnosis (other 
than skin) 
Unwilling to avoid vitamin A,C or E use 
Randomised Randomised Randomised 
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Half of the cohorts in Table 36 show no evidence of associations compared to women 
with no intake. In the Nurses’ Health Study, Zhang et al. (1999) reported no evidence of 
associations for intake categories of <400mg/d, 400-700mg/d, 750-1250, and 
>=1300mg/d supplement vitamin C for pre-menopausal, post-menopausal or total 
women.247 Kushi et al. (1996) also found no significant associations with risk for intake 
categories of <200mg/d, 200-500mg/d, 500-1000 or >1000 or per 100mg/d increase 
intake for post-menopausal women in the Iowa Women’s Health Study.242 The recent 
analyses of the full Danish cohort by Roswall et al. (2010) using much lower categories 
of intake (<40, 40-64, >64mg/d) also reported no associations.273 Similarly, in 
comparisons between total vitamin C users and non-vitamin C users, no associations 
with breast cancer risk were found in the Netherland Cohort Study or in the Nurses 
Health Study.246 247 Duration of use was also not associated with risk.247 Only one RCT 
has used vitamin C supplements to assess breast cancer risk, where in a factorial 
design 500mg/d was taken singly or with vitamin E or beta carotene by North American 
women at high risk for cardiovascular events. There was no evidence of a statistically 
significant effect on breast cancer risk for vitamin C (OR=1.11; 95% CI: 0.87, 1.41).14 
Conversely, in the Danish nested case-control study of post-menopausal women, 
Nissen et al. (2003) provided weak evidence of an increased risk per 100mg/d increase 
intake (OR=1.06; 95% CI: 1.01, 1.13), and results were similar after excluding users 
who consumed above 300mg/d.245 In another nested case-control study Rohan et al. 
(1993) reported evidence of a larger increase in breast cancer risk in the Canadian 
Breast Screening Study for women consuming more than 250mg/d (OR=1.45; 95% CI: 
1.05, 2.01) compared to women with no vitamin C intake from supplements.267 Results 
split by post-menopausal or other women were not statistically significantly different.267 
In addition, a modest increase in breast cancer incidence was reported by Cui et al. 
(2008) for post-menopausal women in the Women’s Health Initiative Observational 
Study for intakes of 711mg/d and over (HR=1.16 95% CI: 1.0, 1.30).270  
The current analysis is the first UK study to examine the relationship between breast 
cancer risk and vitamin C intake from supplements. The study is important since a 
variety of supplements containing vitamin C are commonly consumed in the UK, as 
single or multi-ingredient types, and the consequences of taking them are unclear at 
population level. In contrast to previous studies, the aim for the current study was to 
determine whether the frequent use of supplements containing vitamin C recorded by 
diary, and categorised in relation to the EU recommended daily allowance (60mg/d) 
and high dose intake, was associated with breast cancer risk in UK women. Evidence 
of a dose-response relationship was also assessed. The initial study hypothesis, based 
on antioxidant and pro-oxidant mechanisms discussed in chapter 2, was that women 
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taking supplements containing low to medium amounts of vitamin C (up to 60mg/d or 
between 60-500mg/d) may be at lower risk than non-users and also high users (over 
500mg/d); i.e. there may be a U-shaped relationship with breast cancer incidence. 
Additionally, the relationship between breast cancer risk and questionnaire reports of 
daily multivitamin use, a common source of low dose vitamin C, was examined. 
8.3 Methods 
8.3.1 Subjects 
UKWCS baseline data was gathered between 1995-1998 from 35,367 women.279 
Further details are found in section 4.1.1.1. At baseline 62% of participants took some 
type of dietary supplement.  
All the initial participants were re-contacted at phase 2 between 1999 and 2004, on 
average 4 years after recruitment; 12,453 (35%) completed a follow-up health and 
lifestyle questionnaire and a 4-day food diary. Of the 12,453 women who had 
completed both the phase 2 diary and questionnaire, 1011 women were excluded who 
had any registered malignant cancer prevalent at diary date (except for skin cancer). 
An extra 252 women who self-reported cancer and a further six were excluded 
because they developed breast cancer within six months of the diary date. This left 
11,184 women for the vitamin C analyses, including 239 cases.  
8.3.2 Determining supplement use 
8.3.2.1 Vitamin C use from diary recordings 
The diaries requested supplement brand, name, amount taken and dosage of any 
supplement taken for each of the four diary days as shown in section 4.5.3.1 of the 
methods chapter. As explained in section 4.5.3.2, the supplement data provided by the 
women were matched against a database of supplement descriptions and ingredient 
composition. The mean daily vitamin C intake contained in all supplement types was 
calculated across the total number of diary days vitamin C was taken; this meant the 
women were more likely to be categorised by doses actually taken than if intake had 
been averaged across the four diary days. (A focus towards doses actually taken was 
decided because averaging across the four diary days could not provide a meaningful 
mean vitamin C amount absorbed by the body since vitamin C is not stored in the body 
in large amounts. Excretion from the body in urine starts at intakes of about 100mg/day 
and tissue saturation is reached between 200-400 mg/day.65 Doses above 400mg are 
likely to be excreted in healthy women.65) Frequent use of supplements containing 
vitamin C in this study was defined as taking these on at least three out of the four 
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diary days. Because excess vitamin C is excreted, the nutrient is most likely to have an 
effect on the body if taken daily, or almost daily. Women taking supplements containing 
vitamin C on only one or two diary days were categorised in the reference category as 
non-frequent users. 
 
The study population was split into four intake categories: women not frequently taking 
supplements containing vitamin C; those frequently taking up to and including 60mg/d; 
frequently taking between 60mg and less than 500mg/d; frequently taking 500mg/d or 
more vitamin C. Substantial agreement with frequencies given in the phase 2 
questionnaire, completed concurrently with the diary, was observed and reported in 
section 5.2 of chapter 5. Category cut-off points in the current analysis were chosen 
with the aim of determining whether intakes in relation to the EU recommended daily 
allowance (60mg/d) were beneficial or detrimental in relation to breast cancer risk. As 
described in section 4.5.3.2 of the methods chapter, multivitamins consumed in the UK 
often contain the EU recommended daily allowance (EU RDA 60mg/d),53 and 
‘antioxidant’ supplements usually include more than the EU RDA but less than 
500mg/d. The highest intake category of 500mg/d or more was chosen because 
supplements containing 500mg/d and above are usually classed as high dose and 
these usually do not contain other micronutrients. Women’s characteristics by these 
categories of consumption were described using means and percentages by intake 
category. Significant differences in characteristics between vitamin C intake categories 
were established using chi squared tests for trend over categorical characteristics or 
tests for linear trend over the continuous variables. 
 
The breast cancer risk of users taking high doses of 1000mg/d was assessed 
separately. It was observed in chapter 6 that phase 2 women who had a family history 
of breast cancer were significantly more likely to frequently take supplements 
containing 1000mg/d or more of vitamin C. In line with this analysis and in contrast to 
the main analysis, these high dose users were compared to women who did not take 
1000mg/d or more vitamin C, instead of being compared to women who did not take 
any vitamin C from supplements. These 502 users, however, comprised only 4.5% of 
the study population, providing considerably less numbers to power this secondary 
analysis compared to the main analysis where there were 9.5% of women in the 
highest intake category (≥500mg/d). This high dose of 1000mg/day has been 
recommended as the safe upper limit; intakes at this level and above have been linked 
to adverse effects, particularly gastrointestinal disturbance.52 This level is more than 15 
times the recommended daily allowance (EU RDA = 60mg/day53) normally found in 
multivitamins.  
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Note that dietary vitamin C could not be included in any analyses since this had not 
been captured electronically from the food diary details; however total fruit and 
vegetable intake, the main source of vitamin C, had been electronically captured from 
diary data, and thus was available for adjustment.  
8.3.2.2 Multivitamin use from questionnaire recordings 
Since multivitamins are a common source of low-dose vitamin C (as seen in section 
4.5.3.2) additional analyses were produced to explore whether multivitamin use as 
recorded on the phase 2 questionnaire was associated with breast cancer risk. The 
frequency use of multivitamins with minerals, and multivitamins without minerals had 
been recorded as: more than daily; daily; weekly; monthly; less than monthly (as seen 
in section 4.5.2 in the methods chapter). The study population was split into: women 
currently taking multivitamins or multivitamins with minerals either daily or more than 
daily; and those women not taking these supplements daily. In relation to frequent use, 
the reporting of daily multivitamin use on the questionnaires may be more 
representative than 4-d diary recordings. Of the 14172 women who had completed the 
phase 2 questionnaire, 78 were excluded because of a missing questionnaire date, 
1154 women were excluded who had any registered malignant cancer prevalent at 
diary date (except for skin cancer). An extra 292 women who self-reported cancer and 
a further 6 were excluded because they developed breast cancer within six months of 
the diary date. This left 12,642 women for the analysis including 269 cases. 
8.3.3 Statistical analyses 
Cox proportional hazard modelling was used to estimate breast cancer risks relating to 
vitamin C intake from supplements. Hazard ratios were adjusted for age, BMI 
(underweight; normal; overweight; obese), parity, estimated cumulative breast feeding 
(wks), age at menarche, estimated units of alcohol per week (based on a glass of wine 
= 2.5 unit; half pint of beer = 1 unit; glass of sherry =1 unit; spirit measure= 1.5 units), 
physical activity (none; light/moderate physical activity most weeks; vigorous activity for 
at least 20 minutes once or twice a week; vigorous activity at least 20 minutes three or 
more times a week), smoking status (never; past; current), highest education level 
(none; CSE/O’ level; A’ level/City & Guilds; HNC; Degree; other), current HRT use, 
ever used a contraceptive pill, menopausal status at phase 2 (post-menopausal; pre-
menopausal) and family history of breast cancer. Vigorous activity was defined as 
activity causing shortness of breath, rapid heart rate and sweating. Unlike the majority 
of prior studies, further adjustment was made for total fruit and vegetable intake 
(gms/d) and intake of vitamin E from supplements (mg/d), both recorded by diary, as 
explained in the discussion. All variables were taken from responses to the phase 2 
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questionnaire except for education level which was derived from answers to the 
questionnaire used at baseline since this information was not provided at phase 2. 
Reasons for selecting confounders are discussed in section 4.7.5 of this thesis. 
Menopausal status at phase 2 was determined as explained in chapter 4. Red meat 
was adjusted for in an additional sensitivity analysis since intake was found to be 
significantly and inversely associated with vitamin C supplementation in chapter 6,1 and 
was positively associated with breast cancer incidence in this dataset in unadjusted 
analysis. A further sensitivity analysis was performed to adjust for fish oil 
supplementation which had been inversely associated with breast cancer risk in a US 
cohort,369 though not significantly associated in this cohort. 
The length of follow-up was calculated for each individual in the study as the number of 
days since completion of the phase 2 diaries for the vitamin C analyses (or 
questionnaire date for the multivitamin analyses) until the date of breast cancer 
diagnosis or to 1st July 2008, whichever is the sooner. The median follow-up period 
was  7.4 years. The assumption of proportional hazards over follow-up time was met; 
the log-log curves for intake categories were more or less parallel for pre-menopausal, 
post-menopausal and total women. An increment of 60mg/day was used to test for 
linear trends over continuous intake.  
 
Likelihood ratio tests were used to determine whether breast cancer risk differed by 
menopausal status and sub-group time-to-event analyses were produced by 
menopausal status. Likelihood ratio tests were also performed for socio-economic 
status (high: professional and managerial; intermediate; low: routine and manual) and 
exercise behaviour since these variables were found to have significant effect 
modifications on breast cancer risk with supplement use/none use in chapter 7 of this 
thesis.  
8.3.4 Excluding family history of breast cancer 
Exclusions were made in two separate sensitivity analyses for women with a family 
history of breast cancer, and for women estimated to be at raised genetic risk of breast 
cancer. A family history of breast cancer was defined as having a blood relative 
diagnosed with breast cancer as reported by participants at phase 2 in the 
questionnaire; they were questioned about cancers in mothers, fathers, sisters, 
brothers, aunts, and uncles. This information was also used to identify a small 
percentage (2%) of phase 2 UKWCS women who may have been at raised risk of 
developing breast cancer based on guidelines from the NICE report on familiar breast 
cancer.319  As explained in detail in section 4.7.6.3.2  and 0 of this thesis, being at 
raised risk depended on the age of diagnosis of their relatives and whether they were 
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1st or 2nd degree relatives. Unfortunately these NICE guidelines319 could not be followed 
in some areas for this analysis; the UKWCS had no information on daughters or sons 
with breast cancer. NICE guidelines also stated that women with a first degree relative 
diagnosed with bilateral breast cancer before the age of 50 would also be at raised risk; 
however cases of bilateral breast cancer in the UKWCS could not be identified. 
 
8.4 Results 
In this dataset 34% of women frequently took supplements containing vitamin C, on at 
least three of the four diary days; 13% (1493) took doses less than or equal to 60mg/d; 
11% (1235) took between 60mg and 500mg/d; 9.5% (1063) took  500mg/d or more 
(Table 38) and 4.5% (503) frequently took high doses of 1000mg or more.  
There was a tendency for women who took supplements containing higher doses of 
vitamin C (≥500mg/d) to have a lower BMI, or to consume more fruit and vegetables or 
less red meat (Table 38). They also were more likely to take many types of other 
supplements, visit alternative practitioners, have a family history of cancer, or have 
fewer children. Women in the low or mid-range categories (1-60mg/d and 
>60<500mg/d) were less likely to be educated to A’ level compared to women taking 
higher doses or not taking any. Although 49% of women not taking any supplements 
containing vitamin C at phase 2 did take some other types of supplements at baseline, 
the percentage taking other supplements at baseline was much higher in the other 
vitamin C intake categories (78-86%). 
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Table 38 Characteristics of women at phase 2 in the UKWCS by vitamin C supplement intake group  
 Vitamin C supplement intake on 3-4 diary days   
 None  1-60mg/d >60<500mg/d ≥500mg/d Total P value
a
 
 N=7393 N=1493 N=1235 N=1063 N=11184  
Age (years), mean (sd) 56.5 (9.1) 55.9 (8.7) 57.5 (8.8) 56.0 (8.7) 56.5 (9.0) 0.9 
BMI (kg/m
2
), mean (sd) 24.9 (4.5)  24.4 (4.2) 24.6 (4.2) 24.2 (4.1) 24.7 (4.4) <0.001 
Waist, mean (sd) 81.7 (11.4) 80.7 (10.8) 81.0 (11.0) 79.9 (10.7) 81.3 (11.3) <0.001 
Age at menarche, mean (sd) 12.8 (1.6) 12.8 (1.6) 12.7 (1.6) 12.8 (1.5) 12.8 (1.6) 0.2 
Age at first birth, mean (sd) 26.1 (4.6)  25.7 (4.4) 25.6 (4.7) 26.0 (4.9) 26.0 (4.6) 0.006 
Number of children, mean (sd) 1.9 (1.3) 1.8 (1.3) 1.8 (1.3) 1.7 (1.3) 1.8 (1.3) <0.001 
Est. cumulative breastfeeding weeks (sd)    27 (37) 26 (36) 23 (33) 24 (36) 26 (37) <0.001 
Portions red meat /week median (IQR) 2 (0-4) 1 (0-3) 1 (0-3) 0 (0-2) 1 (0-3) <0.001 
Portions white meat /week median (IQR) 2 (0-3) 1 (0-3) 1 (0-3) 1 (0-3) 2 (0-3) <0.001 
Portions fish meat /week median (IQR) 1 (1-2) 1 (0-2) 1 (0-2) 1 (0-2) 2 (0-3) 0.02 
Portions fruit /week median (IQR) 12 (7-18) 14 (8-20) 14 (7-20) 14 (8-20) 14 (7-20) <0.001 
Portions vegetables /week median (IQR) 12 (7-15) 12 (7-17) 13 (7-18) 14 (8-18) 12 (7-16) <0.001 
Diary fruit intake (grams) mean (sd) 858 (628) 943 (658) 947 (647) 1026 (702) 895 (644) <0.001 
Diary veg. intake (grams) mean (sd) 827 (452) 865 (462) 922 (506) 960 (536) 855 (536) <0.001 
Vitamin E sup. intake (mg), mean (sd)   8 (39)   25 (69) 49 (82) 75 (130) 21 (67) <0.001 
Number of supplement types taken 1.2 (1.6) 2.7 (1.7) 3.7 (2.1) 4.5 (2.4) 2.0 (2.1) <0.001 
Professional or managerial n(%) 2981 (41) 592 (40) 510 (42) 455 (43) 4538 (41) 0.03 
Educated to ‘A’-level or above n(%) 4307 (60) 807 (55) 691 (57) 641 (61) 6446 (59) 0.7 
No children n(%) 1492 (20) 307 (21) 290 (23) 300 (28) 2389 (21) <0.001 
Ever used contraceptive pill n(%) 4860 (68) 1030 (70) 832 (69) 752 (72) 7474 (68)   0.002 
Current HRT use n(%) 1481(20) 343 (23) 300 (24) 254 (24) 2378 (21)  <0.001 
Post-menopausal at phase 2 4952 (67) 973 (65) 894 (72) 705 (66) 7524 (67)  0.2 
Ex-smoker n(%) 2151 (29) 438 (30) 398 (32) 377 (36) 3364 (30) <0.001 
Drinks alcohol less than once a week 2450 (33) 512 (34) 423 (34) 371 (35) 3756 (34) 0.2 
Vigorous activity >=3/week n(%) 1241 (18) 294 (21) 275 (24) 236 (24) 2046 (19) <0.001 
Bowel movements more than once/day 1226 (17) 279 (19) 258 (22) 237 (23) 2000 (18) <0.001 
Takes any supplements at baseline n(%) 3312 (49) 1054 (78) 924 (82) 842 (86) 6132 (60) <0.001 
Takes more than 4-10 supplement types 560 (8) 324 (22) 479 (39) 476 (45) 1839 (16) <0.001 
Visits alternative practitioner >=5 /year  463 (6) 119 (8) 132 (11) 159 (15) 873 (8) <0.001 
Family history of breast cancer n(%) 1362 (18) 261 (17) 242 (20) 211 (20) 2076 (19) 0.2 
Family history of any cancer n(%)
b
 4232 (57) 851 (57) 764 (62) 638 (60) 6485 (55) 0.006 
a
p= test for trend over continuous variable, sd =standard deviation
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8.4.1 Breast cancer risk and use of supplements containing  
vitamin C 
Compared to women who did not take supplements containing vitamin C there was no 
evidence of an association between breast cancer risk and regular intake of 
supplements containing vitamin C for total women for any of the intake categories in 
the unadjusted and adjusted analyses (Table 39). Neither was there evidence of a 
dose-response association across these supplement users (HR=0.98 per 60mg/d; 95% 
CI: 0.94, 1.02; ptrend=0.3) or when non-users of these supplements were included. 
Excluding women with a family history of breast cancer or women at raised risk of 
breast cancer made little difference to the results (Table 40 and Table 41). In the tests 
for effect modification, menopausal status was found to significantly modify the effect of 
vitamin C supplement intake groups on breast cancer incidence (adjusted p=0.02). 
Socio-economic status was also found to modify the associations of risk with vitamin C 
intake (adjusted p=0.03) but exercise behaviour did not (adjusted p=0.7). Unfortunately 
the number of cases was considered too low to power sub-analyses by socio-economic 
status.  
 
In the subgroup analysis by post-menopausal status no significant associations were 
found relating to dose-response relationships (HR=1.00 per 60mg/d; 95% CI: 0.96, 
1.05; ptrend=1.0) or intake category.  
Dose-response relations for pre-menopausal women were also non-significant. 
However pre-menopausal women who frequently took supplements containing less 
than or equal to 60mg/d of vitamin C were over twice as likely to develop breast cancer 
(HR=2.37; 95% CI: 1.32, 4.27; p=0.004) compared to women not taking any 
supplements containing vitamin C, in the multivariate model after adjustment of the 
majority of potentially confounding factors. The odds increased further after adjustment 
by fruit and vegetable intake and vitamin E supplement intake recorded by diary 
(HR=2.56; 95% CI: 1.41, 4.66; p=0.002). Additional adjustments for red meat intake 
strengthened the risks slightly e.g. for all pre-menopausal women in the low dose group 
(HR=2.78; 95% CI: 1.52, 5.09; p=0.001), and adjusting for daily fish oil 
supplementation made little difference to hazard ratios (both not tabled). As observed 
in Table 40 and Table 41, a significant positive association for pre-menopausal women 
who frequently took supplements containing less than or equal to 60mg/d of vitamin C 
was also found in sensitivity analyses excluding women with a family history of breast 
cancer (HR=3.02; 95% CI: 1.53, 5.96; p=0.002) and when only women at raised risk of 
breast cancer (HR=2.78; 95% CI: 1.52, 5.09; p=0.001) were excluded.  
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Table 39 Breast cancer risks of women supplementing with vitamin C recorded by 
diaries at phase 2 in the UKWCS 
Supplement vitamin 
C intake
a
 
Cases/  Unadjusted Multivariate
b
 Fully adjusted
c
 
Non- 
cases 
 
HR (95% CI) HR (95% CI) HR (95% CI) 
Total women     
No vitamin C 156/7237 1 1 1 
1-60mg/d 35/1458 1.10 (0.76, 1.58) 1.16 (0.77, 1.75) 1.15 (0.76,1.74) 
>60<500mg/d 29/1206 1.10( 0.74, 1.64) 1.17 (0.75, 1.82) 1.15 (0.73,1.80) 
≥500mg/d 19/1044 0.83 (0.51, 1.33) 0.77 (0.43, 1.37) 0.75 (0.41,1.35) 
     
Per 60mg/d (users) 83/3708 1.00 (0.97, 1.02) 0.98 (0.94, 1.02) 0.98 (0.94, 1.02) 
ptrend  0.8 0.3 0.3 
Per 60mg/d (all) 239/10945 1.00 (0.99, 1.04) 0.99 (0.96, 1.02) 0.99 (0.95, 1.02) 
ptrend  0.5 0.4 0.4 
     
Post-menopausal     
No vitamin C 112/4840 1 1 1 
1-60mg/d 15/958 0.67 (0.39, 1.14) 0.67 (0.36, 1.26) 0.65 (0.34, 1.23) 
>60<500mg/d 25/869 1.22 (0.79, 1.89) 1.25 (0.77, 2.05) 1.21 (0.74, 2.00) 
≥500mg/d 14/691 0.86 (0.49, 1.50) 0.77 (0.38, 1.53) 0.70 (0.34, 1.43) 
     
Per 60mg/d (users) 54/2518 1.02 (0.99, 1.05) 1.00 (0.96, 1.05) 1.00 (0.96, 1.05) 
ptrend  0.2 0.8 1.0 
Per 60mg/d (all) 166/7358 1.02 (0.99, 1.04) 1.00 (0.96, 1.03) 1.00 (0.96, 1.03) 
ptrend  0.2 0.9 0.8 
     
Pre-menopausal     
No vitamin C 44/2397 1 1 1 
1-60mg/d 20/500 2.14 (1.26, 3.63) 2.37 (1.32, 4.27) 2.56 (1.41, 4.66) 
>60<500mg/d 4/337 0.64 (0.23, 1.79) 0.83 (0.29, 2.34) 1.01 (0.34, 2.99) 
≥500mg/d 5/353 0.76 (0.30, 1.91) 0.77 (0.27, 2.20) 0.91 (0.31, 2.65) 
     
Per 60mg/d (users) 29/1190 0.93 (0.86, 1.01) 0.91 (0.81, 1.01) 0.92 (0.82, 1.02) 
ptrend  0.08 0.07 0.1 
Per 60mg/d (all) 73/3587 0.98 (0.93, 1.03) 0.96 (0.89, 1.03) 0.97 (0.90, 1.04) 
ptrend  0.4 0.2 0.3 
     
 
  
 180 
 
 
Table 40 Breast cancer risks of women supplementing with vitamin C recorded by 
diaries in the UKWCS, excluding women with a family history of breast cancer 
 Cases/  Unadjusted  Fully adjusted
a
 
Supplement vitamin C intake 
 
Non- 
cases HR 
 
(95% CI) HR (95% CI) 
Total women      
No vitamin C taken 3-4 days 115/5916 1  1  
1-60mg/d 30/1202 1.26 (0.85, 1.89) 1.22 (0.77, 1.94) 
>60<500mg/d 24/969 1.26 (0.81, 1.96) 1.20 (0.72, 2.00) 
≥500mg/d 15/837 0.90 (0.53, 1.55) 0.75 (0.38, 1.48) 
      
Per 60mg/d (users) 69/3008 0.98 (0.94, 1.02) 0.98 (0.94, 1.03) 
ptrend   0.4  0.4 
Per 60mg/d (all) 184/8924 1.01 (0.98, 1.03) 0.99 (0.96, 1.03) 
ptrend   0.6  0.6 
      
Post-menopausal      
No vitamin C taken 3-4 days 85/3925 1  1  
1-60mg/d 13/787 0.75 (0.42, 1.35) 0.67 (0.33, 1.36) 
>60<500mg/d 20/694 1.32 (0.81, 2.14) 1.20 (0.68, 2.14) 
≥500mg/d 11/553 0.90 (0.48, 1.69) 0.68 (0.30, 1.54) 
      
Per 60mg/d (users) 44/2034 1.01 (0.97, 1.04) 1.01 (0.96, 1.06) 
ptrend   0.7  0.7 
Per 60mg/d (all) 129/5959 1.02 (0.99, 1.05) 1.00 (0.96, 1.04) 
ptrend   0.2  0.9 
      
Pre-menopausal      
No vitamin C taken 3-4 days 30/1991 1  1  
1-60mg/d 17/415 2.67 (1.47, 4.84) 3.02 (1.53, 5.96) 
>60<500mg/d 4/275 0.95 (0.34, 2.70) 1.32 (0.43, 3.99) 
≥500mg/d 4/284 0.91 (0.32, 2.59) 1.01 (0.29, 3.47) 
      
Per 60mg/d (users) 25/974 0.91 (0.82, 1.01) 0.87 (0.75, 1.01) 
ptrend   0.07  0.07 
Per 60mg/d (all) 55/2965 0.97 (0.90, 1.03) 0.96 (0.88, 1.05) 
ptrend   0.3  0.4 
      
a
Adjusted for age, BMI (grouped), age at menarche, parity, estimated alcohol units consumed per 
week, activity intensity and frequency, smoking status (never, ex, current), education level, current 
HRT use, ever used a contraceptive pill, estimated cumulative breast feeding, total fruit and 
vegetable intake recorded by diary (gms/d) and vitamin E supplements use (mg/d) recorded by 
diary 
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Table 41 Breast cancer risks of women supplementing with vitamin C recorded by 
diaries in the UKWCS, excluding women at raised risk of breast cancer 
 Cases/  Unadjusted  Fully adjusted
a
 
Supplement vitamin C intake 
 
Non-cases 
HR 
 
(95% CI) HR (95% CI) 
Total women      
No vitamin C taken 3-4 days 147/7103 1  1  
1-60mg/d 35/1425 1.17 (0.81, 1.69) 1.24 (0.81, 1.88) 
>60<500mg/d 28/1177 1.14 (0.76, 1.70) 1.19 (0.75, 1.90) 
≥500mg/d 18/1023 0.83 (0.51, 1.36) 0.81 (0.45, 1.47) 
      
Per 60mg/d (users) 81/3625 0.98 (0.95, 1.01) 0.98 (0.94, 1.02) 
ptrend   0.3  0.3 
Per 60mg/d (all) 228/10728 1.00 (0.98, 1.02) 0.98 (0.96, 1.02) 
ptrend   0.9  0.5 
      
Post-menopausal      
No vitamin C taken 3-4 days 106/4739 1  1  
1-60mg/d 15/938 0.70 (0.41, 1.21) 0.70 (0.37, 1.33) 
>60<500mg/d 24/851 1.24 (0.80, 1.93) 1.26 (0.76, 2.11) 
≥500mg/d 13/680 0.84 (0.47, 1.49) 0.77 (0.37, 1.57) 
      
Per 60mg/d (users) 52/2469 1.00 (0.96, 1.04) 1.00 (0.96, 1.05) 
ptrend   1.0  0.9 
Per 60mg/d (all) 158/7208 1.01 (0.98, 1.04) 1.00 (0.96, 1.04) 
ptrend   0.5  0.9 
      
Pre-menopausal      
No vitamin C taken 3-4 days 41/2364 1  1  
1-60mg/d 20/487 2.32 (1.36, 3.96) 2.78 (1.52, 5.09) 
>60<500mg/d 4/326 0.70 (0.25, 1.96) 1.08 (0.36, 3.19) 
≥500mg/d 5/343 0.82 (0.33, 2.08) 1.00 (0.34, 2.92) 
      
Per 60mg/d (users) 29/1156 0.93 (0.86, 1.01) 0.92 (0.82, 1.02) 
ptrend   0.08  0.1 
Per 60mg/d (all) 70/3520 0.98 (0.93, 1.03) 0.97 (0.91, 1.04) 
ptrend   0.5  0.4 
      
a
Adjusted for age, BMI (grouped), age at menarche, parity, estimated alcohol units consumed per 
week, activity intensity and frequency, smoking status (never, ex, current), education level, current 
HRT use, ever used a contraceptive pill, estimated cumulative breast feeding, family history of breast 
cancer, total fruit and vegetable intake recorded by diary (gms/d), and vitamin E supplements use 
(mg/d) recorded by diary 
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No associations were found between breast cancer risk and frequent use of 
supplements containing 1000mg or more vitamin C compared with women not taking 
these amounts. Adjusted hazard ratios for pre-menopausal women were HR=0.37 
(95% CI: 0.05, 2.70) and for post-menopausal women were HR=1.08 (95% CI: 0.47, 
2.52); none were close to significance (Table 42). The number of cases in these 
analyses was extremely low. 
 
 
Table 42 Breast cancer risks of women supplementing with 1000mg/d or more vitamin 
C (N=502) compared to women not taking these doses at phase 2 in the UKWCS 
Supplement  
vitamin C intake 
Cases  
/Non- 
cases 
Unadjusted Multivariate
a
 Fully adjusted
b
 
 
HR (95% CI) HR (95% CI) HR (95% CI) 
Total women     
<1000mg/d
c
  1 1 1 
1000mg or more (y/n) 10/492 0.92 (0.49, 1.73) 0.88 (0.41, 1.87) 0.85 (0.39, 1.84) 
     
Post-menopausal      
<1000mg/d
c
  1 1 1 
1000mg or more (y/n) 8/310 1.14 (0.56, 2.32) 1.17 (0.51, 2.66) 1.08 (0.47, 2.52) 
     
Pre-menopausal     
<1000mg/d
c
  1 1 1 
1000mg or more (y/n) 2/182 0.52 (0.13, 2.14) 0.32 (0.04, 2.34) 0.37 (0.05, 2.70) 
     
 
 
 
There were no substantial differences in any of the above results if self-reported 
prevalent cancers were not excluded.  
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8.4.2 Breast cancer risk and multivitamin use 
From the questionnaire data on supplement use it was observed that compared to 
women who did not take multivitamin supplements every day there was no evidence of 
significant associations between breast cancer risk and daily use of multivitamin 
supplements for total women in the unadjusted and adjusted analyses (Table 43) or for 
post-menopausal women. However both the unadjusted and adjusted results for pre-
menopausal women showed a moderate positive association and the unadjusted result 
was close to significance (HR=1.55; 95% CI: 0.98, 2.45 and HR=1.51; 95% CI: 0.90, 
2.54 respectively). Results did not change substantially when women with a raised risk 
of breast cancer were excluded (Table 45). When women with a family history of breast 
cancer were excluded the risk for pre-menopausal multivitamin users was 
strengthened, the unadjusted results reached significance and the adjusted result was 
close to significance (unadjusted HR=1.81; 95% CI: 1.08, 3.05 and adjusted HR=1.79; 
95% CI: 0.99, 3.22, Table 44).   
 
Results did not alter substantially when women who recorded daily vitamin C 
supplement use on the phase 2 questionnaires were excluded (results not shown). 
 
Table 43  Breast cancer risks of women using multivitamins recorded by questionnaire 
at phase 2 in the UKWCS 
Daily multivitamin intake Cases/  Unadjusted Adjusted
a
 
 Non-cases HR (95% CI) HR (95% CI) 
Total women      
Not taking daily multivitamins 198/9362 1  1  
Taking daily multivitamins 71/3011 1.09 (0.81, 1.43) 1.12 (0.81, 1.54) 
      
Post-menopausal      
Not taking daily multivitamins 149/6396 1  1  
Taking daily multivitamins 42/1901 0.93 (0.66, 1.31) 0.95 (0.63, 1.42) 
      
Pre-menopausal      
Not taking daily multivitamins 49/2966 1  1  
Taking daily multivitamins 29/1110 1.55 (0.98, 2.45) 1.51 (0.90, 2.54) 
      
a
Adjusted for age, BMI (grouped), age at menarche, parity, estimated alcohol units consumed per 
week, activity intensity and frequency, smoking status (never, ex, current), education level, current 
HRT use, ever used a contraceptive pill, estimated cumulative breast feeding, family history of 
breast cancer and total fruit and vegetable intake recorded by diary (gms/d). 
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Table 44 Breast cancer risks of women using multivitamins recorded by questionnaire 
at phase 2 in the UKWCS, excluding women with a family history of breast cancer 
Daily multivitamin intake Cases/  Unadjusted  Adjusted
a
 
 Non-cases HR (95% CI) HR (95% CI) 
Total women      
Not taking daily multivitamins 151/7668 1  1  
Taking daily multivitamins 59/2447 1.20 (0.89, 1.62) 1.25 (0.88, 1.78) 
      
Post-menopausal      
Not taking daily multivitamins 116/5204 1  1  
Taking daily multivitamins 35/1537 1.00 (0.69, 1.46) 1.05 (0.67, 1.65) 
      
Pre-menopausal      
Not taking daily multivitamins 35/2464 1  1  
Taking daily multivitamins 24/910 1.81 (1.08, 3.05) 1.79 (0.99, 3.22) 
      
a
Adjusted for age, BMI (grouped), age at menarche, parity, estimated alcohol units consumed per 
week, activity intensity and frequency, smoking status (never, ex, current), education level, current 
HRT use, ever used a contraceptive pill, estimated cumulative breast feeding and total fruit and 
vegetable intake recorded by diary (gms/d). 
 
 
Table 45 Breast cancer risks of women using multivitamins recorded by questionnaire 
at phase 2 in the UKWCS, excluding women at raised risk of breast cancer 
Daily multivitamin intake Cases/  Unadjusted  Adjusted
a
 
 Non-cases HR (95% CI) HR (95% CI) 
Total women      
Not taking daily multivitamins 190/9193 1  1  
Taking daily multivitamins 68/2938 1.09 (0.83, 1.44) 1.16 (0.84, 1.61) 
      
Post-menopausal      
Not taking daily multivitamins 143/6271 1  1  
Taking daily multivitamins 40/1860 0.92 (0.65, 1.31) 0.97 (0.64, 1.48) 
      
Pre-menopausal      
Not taking daily multivitamins 47/2922 1  1  
Taking daily multivitamins 28/1078 1.58 (0.99, 2.52) 1.60 (0.94, 2.70) 
      
a
Adjusted for age, BMI (grouped), age at menarche, parity, estimated alcohol units consumed per 
week, activity intensity and frequency, smoking status (never, ex, current), education level, current 
HRT use, ever used a contraceptive pill, estimated cumulative breast feeding and total fruit and 
vegetable intake recorded by diary (gms/d) and family history of breast cancer. 
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8.5 Discussion 
This analysis of phase 2 of the UKWCS found little evidence of associations between 
breast cancer incidence and vitamin C supplementation per se, when compared to 
women not consuming supplements containing vitamin C, as recorded by food diaries. 
Specifically, there was no evidence of a dose-response relationship for total, pre- or 
post-menopausal women. Additionally there was no evidence of a U-shaped 
relationship that was initially hypothesised to occur between vitamin C intake and 
breast cancer risk. Conversely, the Danish nested-case control study found evidence of 
a slight dose-response relationship: a significant increase in risk per additional 
100mg/d of vitamin C intake from supplements for postmenopausal women (HR=1.06; 
95% CI: 1.01, 1.13) (Table 36).245  
No significant associations were found for total women or for post-menopausal women 
in any of the intake categories. This is consistent with US results from the Nurses 
Health Study, the Iowa Women’s Health Study and the RCT of the Women’s 
Antioxidant Cardiovascular Study,14 242 247 and also the most recent findings from a 
Danish cohort.273 However, it is in contrast with another US study, the Women’s Health 
Initiative, and also with the Canadian and a nested case-control analysis of the Danish 
study which did find increased risks for post-menopausal women taking vitamin C 
supplements.245 267 270 The latter two studies used case-control methodology which 
unlike full cohort studies could have been affected by biased selection of controls.245 267 
The Women’s Health Initiative had the highest average age of all the cohorts (64 
years), involving women as old as 79,270 and their positive associations (shown in 
Table 36) could indicate that high doses of vitamin C may promote the progression of 
cancer in the later stages of the disease. Differences in results cannot be explained by 
the number of cases involved to power the analyses since the two largest studies, the 
Nurses Health Study and Women’s Health Initiative, produced conflicting results.247 270 
The length of follow-up for all but one of the studies, including ours, was on average 
between four and nine years; the average follow-up for the Nurses Health Study which 
found no association was considerably longer: 14 years.247 Longer follow-up studies 
may be less likely to find associations if supplement usage did not remain relatively 
constant. Another explanation for the null results of studies for total and post-
menopausal women, is that vitamin C may not affect hormonal mechanisms of cancer 
initiation or development; as discussed in Chapter 3, levels of endogenous sex 
hormones are one of the main risk factors for post-menopausal breast cancer.147  
In the current study, however, for pre-menopausal women an increased risk of breast 
cancer was associated with the lowest category of intake: below or equal to 60mg/d. 
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Similar to most studies, the classification of pre-menopausal women was at recording 
date rather than diagnosis or censor date, meaning that pre-menopausal women taking 
supplements in this category appear to have an increased risk of later developing 
breast cancer; whether this was when they were pre- or post-menopausal. Although 
vitamin C intake has been associated with increased breast density, an increased risk 
factor for breast cancer, this result for low dose vitamin C is difficult to explain 
biologically. The result may be due to other characteristics of these pre-menopausal 
women in the UKWCS. Indeed, in a previous UKWCS analysis of pre-menopausal 
women another result was difficult to account for; vegetarians were found to have a 
significantly higher breast cancer risk than low meat consumers.82 The authors 
suggested a family history of breast cancer may have increased a tendency for 
vegetarianism as well as an increased risk of breast cancer. 82  However, the significant 
association in the current analysis is unlikely to be attributed to women genetically at 
high risk since the results were adjusted for women with a family history of breast 
cancer. Furthermore, excluding these women in sensitivity analyses increased the risk 
further. The level of significance was high therefore this result may not have occurred 
by chance despite the multiple testing through sub-analyses, although the number of 
cases was low and could have produced spurious results. Previously, the Canadian 
study reported a significant moderate increase in risk evident for intakes above 
250mg/d compared to women with no intake for a subgroup combining pre- and peri-
menopausal women.267 No previous study has analysed pre-menopausal women 
consuming intakes as low as 60mg/d vitamin C. In the UKWCS analysis there was no 
evidence of significant associations for pre-menopausal women supplementing with 
vitamin C above the EU recommended daily intake of 60mg/d. However, since there 
were less than 10 cases in these higher intake groups, the analysis is likely to have 
been underpowered to find an effect for pre-menopausal women. In chapter 7 of this 
thesis a non-significant increased risk of breast cancer was found for pre-menopausal 
women who took any type of supplement at baseline, compared to those who did not; 
the use of supplements containing low levels of vitamin C may have contributed to this 
result. The reason the results did not reach significance, may have been due to dilution 
by use of other supplement types which did not have the same effect.  
Although the use of supplements containing 1000mg/d of vitamin C was associated 
with a family history of breast cancer in the UKWCS in chapter 6 of this thesis,1 there 
was no evidence in the current analysis that women taking these high doses had a 
significantly different risk of breast cancer compared to women not taking them, even 
when adjusting for family history of breast cancer. Due to the very small number of 
women who developed breast cancer and who had taken doses more than or equal to 
1000mg/d, the analysis is likely to have been underpowered to find an effect. Only one 
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previous study assessed intakes specifically above 1000mg/d, the Iowa Women’s 
Health Study,247 which showed a non-significant inverse association for post-
menopausal women with wide confidence intervals (HR=0.77; 95% CI: 0.50, 1.17).  
Women with prevalent self-reported cancers were excluded in the UKWCS analyses, 
which meant that some women who had non-malignant cancers may have been 
inadvertently excluded from the analyses. However sensitivity analyses which included 
prevalent self-reported cancers did not produce substantially different results. From the 
reports of previous studies it was not clear whether their exclusions for prevalent 
cancers were self-reported or not.  
It is unlikely that differences in results between this and previous studies were due to 
variations in adjustments for potential confounding factors; the current analyses 
controlled for the majority of those used in previous studies (as shown in Table 37). 
However, unlike previous studies, no adjustment was made for energy intake in the 
UKWCS since this data was not electronically captured for all women. Nevertheless 
two studies reported that adjustments for energy intake in sensitivity analyses did not 
alter their results.242 245 Contrary to previous studies no adjustment was made for age at 
first live birth in the UKWCS analyses due to large numbers of missing data; instead 
cumulative time of breast feeding and parity was used which have been found to be a 
good predictor of breast cancer risk.167 Of prior studies that reported an increase in risk 
for post-menopausal women, the Women’s Health Initiative adjusted for dietary vitamin 
C intake,270 and the Danish study adjusted for vitamin A and E supplement intake;245 
this was in contrast to the other studies detailed in Table 37. Although dietary vitamin C 
and supplement vitamin A was not available in the UKWCS, further adjustments were 
made for vitamin E supplement intake and for dietary fruit and vegetable intake, which 
has been found to correlate well with plasma vitamin C;67 these, however, did not 
substantially alter the results. Adjustment were made for these variables since vitamin 
C supplement use has been significantly associated with fruit and vegetable 
consumption1 and due to vitamin C’s role in the regeneration of vitamin E76 the latter 
could potentially modulate vitamin C’s activity relating to cancer development. The 
majority of supplements containing vitamin C at medium to low doses such as those 
classed as multivitamins and antioxidants also contain vitamin E. However, as 
discussed in 4.7.6.2, vitamin E may be a mediator between vitamin C and breast 
cancer incident so adjusting for it could create bias, therefore this was only undertaken 
in the sensitivity analyses. 
Fish oil supplements, which are taken by 26.5 % of UKWCS women (figure 2, chapter 
2), have been inversely associated with breast cancer risk;369 and in a recent UK 
survey half of women over 55 years of age reported taking cod-liver oil compared to a 
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quarter of younger women.26 However, additional adjustment for daily use of fish oil 
supplements did not change the results for the breast cancer and vitamin C analysis in 
the UKWCS. Furthermore, although there was evidence of a reduced breast cancer 
risk from daily use of fish oil supplements in the UKWCS, it was not significant. 
Previous studies in Table 36 did not adjust for fish oil supplements. 
Since the body has limited capacity to absorb and store this water soluble vitamin; 65 
daily vitamin C supplement use is plausibly more likely to have an effect on the body 
than infrequent intake. Therefore only women recording at least 3 out of 4 days intake 
of supplements containing vitamin C were classed as frequent users in this analysis. 
Regardless of this, the diary recordings may represent short-term episodic intake, 
particularly because vitamin C is promoted for reducing seasonal common colds and 
no seasonal adjustments to the results have been made. Nevertheless, the majority of 
vitamin C users (82%) in the UKWCS reported taking a supplement on average four 
years earlier, however the type taken is unknown and respective seasons were not 
assessed.1 Therefore due to its short-term nature, diary data may not be more superior 
than questionnaire data for elucidating the relationship between breast cancer risk and 
long-term use of supplements, unless repeated measures are taken.370 Unfortunately 
baseline details of supplements used had not been electronically captured. 
Vitamin C contained in a wide variety of supplement types recorded by diary was 
determined using a database of brand specific vitamin C content and extensive 
cleaning was done (as described in the methods chapter). Therefore intake assessed 
in relation to breast cancer risk in the UKWCS may be more accurate than other 
approaches used in some of the previous studies. Only the Nurses Health Study, which 
found no associations, and the two Danish studies, which found conflicting 
associations, appeared to have used a database of supplement ingredients.245 247 273 In 
contrast some of the other studies appear have estimated or not accounted for the 
vitamin C content of many supplements used, and this may have reduced their ability 
to find a dose-response affect if one existed. Nevertheless, comparisons between 
UKWCS diary data and questionnaire data in section 5.2 of chapter 5 indicated that 
taking account of multivitamins and antioxidants, as well single supplement vitamin C, 
may pick up a large proportion of supplements containing vitamin C. 
As seen in section 5.2.3 of chapter 5, the vitamin C responses on the phase 2 
questionnaire had reasonable agreement with the recordings of supplements 
containing 500mg/d or more vitamin C from diaries. Therefore, it is possible that high 
dose users may be defined more accurately by combining recordings from both the 
phase 2 questionnaire and diaries. However, since some reporting was not consistent, 
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this would result in fewer high dose users in the analysis and therefore would lower the 
power to detect significant associations.  
Previous chapters have provided evidence that women in the low intake category (less 
than or equal to 60mg/d of vitamin C) were likely to be taking multivitamins which 
contained a wide range of other micronutrients (as reported in section 4.5.3.2 and 
section 5.2.3.1, though the Kappa agreement was only weak to moderate К=0.41(0.40-
42)). Conversely, women in the reference group did not take supplements containing 
any vitamin C and therefore were unlikely to be frequently taking multivitamins, most of 
which contain vitamin C. Furthermore, it was also observed from the questionnaire 
responses that 22% of women in the low intake category took four to ten types of 
supplements (though women in the highest vitamin C intake category were twice as 
likely to do this). Therefore, one or more, or an interaction of these micronutrients in 
multivitamins or from the variety of supplements taken, may have had an effect on 
breast cancer risk for premenopausal women rather than the low dose of vitamin C per 
se. For instance iron and vitamin C together may exert a pro-oxidant effect via the 
Fenton reaction,76 or ingredients other than vitamin C may have an effect. A clearer 
way to assess the effects of vitamin C intake per se without confounding by other 
supplement ingredients would be by analysing the dietary vitamin C intake of non-
supplement users (as reported in chapter 9) or by implementing an RCT using a 
vitamin C supplement verse a placebo where the consumption of other supplements 
would be randomised between intervention groups.  
A higher proportion of pre-menopausal compared to post-menopausal women took 
multivitamin supplements in the UKWCS (as seen in Table 43). Similarly, the 2008 UK 
survey found multivitamins were more likely to be used by 16-54 year old supplement 
users than those aged 65 plus.26 The UKWCS adjusted analysis of multivitamin use 
recorded by questionnaire at phase 2 showed a moderate non-significant increased 
risk of breast cancer for pre-menopausal women. This strengthened and became close 
to significance when women with a family history of breast cancer were excluded. One 
explanation for the association with multivitamins being non-significant and weaker 
than the low dose vitamin C results may be because the former analysis did not 
exclude higher doses of vitamin C, whereas the latter did. This may indicate that taking 
multivitamins without also taking medium to high doses of vitamin C may increase 
breast cancer risk. A possible biological explanation is, perhaps, at low concentrations 
in the presence of certain nutrients vitamin C is a pro-oxidant but at high concentrations 
it is an antioxidant. However, the multivitamin use results did not alter substantially 
when women who recorded daily vitamin C supplement use on the phase 2 
questionnaires were excluded, who were likely to be consuming high doses. Further 
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analyses could be undertaken to explore the risks for women specifically reporting 
multivitamin use in the diaries.  
Results of a recent Swedish study show that multivitamin use was significantly 
associated with a 22% increased risk of breast cancer for all women using them for 
over 3 years.261 The authors suggest that folic acid in the multivitamins may have 
promoted cancer, since there is no mandatory folic acid fortification of food in Sweden. 
Conversely, the US does fortify food with folic acid and several US studies, including 
the Nurses Health Study, have not found an increased risk of breast cancer with 
multivitamin use.247 371 A recent meta-analysis found no evidence of a significant 
association between multivitamin use and breast cancer risk.260 Since fortification is not 
mandatory in the UK, folic acid in multivitamins could explain the increased risk for 
UKWCS pre-menopausal women who took supplements containing low vitamin C 
doses, though the multivitamin results do not strongly support this. Despite many 
multivitamins containing folic acid, very few women reported on the UKWCS 
questionnaire that they took folic acid supplements; therefore the questionnaire data 
would be underpowered to find an association with breast cancer incidence. However, 
an analysis of associations between breast cancer risk and folic acid use by dose 
ascertained from the phase 2 diary supplement database may be able to illuminate this 
hypothesis further.  
To conclude, this UK study found little evidence that supplementation with vitamin C 
per se was beneficial or detrimental in relation to breast cancer incidence in UK 
women, even at high doses. However the results indicate that frequent use of 
supplements containing less than or equal to 60mg/d vitamin C, or the frequent use of 
multivitamins, may increase breast cancer risk in pre-menopausal women. Although 
these results may be spurious, it would be prudent to conduct further research on 
supplement use in the UK, particularly relating to multivitamins, to identify whether 
some micronutrients or combination of micronutrients might produce an increase in 
breast cancer risk in pre-menopausal users. 
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CHAPTER 9 
9 Is breast cancer incidence associated with 
dietary vitamin C or fruit and vegetable intake? 
Does supplement use modify these 
relationships? A baseline analysis of the UKWCS 
9.1 Summary 
Objectives: To determine whether dietary vitamin C or fruit and vegetable intake at 
baseline in the UKWCS is associated with breast cancer risk. Since the use of 
supplements may have obscured associations in previous studies, sub-analyses by 
general supplement use were also undertaken.  
Method: This time-to-event analysis of 33,520 middle-aged women at baseline in the 
UK Women’s Cohort Study (UKWCS) calculated Hazard Ratios (HRs) over a median 
follow-up period of 11.2 years for 989 registered incident breast cancers in relation to 
fruit and vegetable and dietary vitamin C intake recorded by Food Frequency 
Questionnaire (FFQ) and cross-check questions. Sub-analyses by supplement use and 
menopausal status were produced. Additionally, non-linear relationships between 
intakes of 60mg-350mg/d vitamin C were modelled using restricted cubic splines. 
Results: All hazard ratios were non-significant relating to intake and breast cancer risk. 
Furthermore, in tests for interactions, relationships were not significantly different 
between women who took any type of supplement and non-users for total fruit and 
vegetable servings (p =0.6) and for dietary vitamin C intake (p=0.2). Additionally, no 
significant interactions were found relating to menopausal status or family history of 
breast cancer. Although breast cancer risks appeared to increase with increasing 
dietary vitamin C intake for non-supplement users, and specifically post-menopausal 
women (HR per 60mg/d vitamin C HR=1.05; 95% CI: 0.94, 1.19), risks were non-
significant. In the tabled analysis by fifths of intake, a U-shaped relationship was 
apparent for these women when vitamin C was expressed as nutrient density, but this 
was less clear on the graphed models.  
Conclusion: There was no evidence of significant associations between breast cancer 
incidence and intake of fruit and vegetables or dietary vitamin C derived from FFQ in 
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the UKWCS. There was also no statistically significant evidence that supplement use 
modified the relationship between breast cancer risk and intake. 
9.2 Introduction 
Fruit and vegetables are the main dietary sources of vitamin C,67 whose antioxidant 
properties are believed to protect against DNA damage and cancer development by 
decreasing reactive oxygen species (ROS) that may cause DNA damage.74 
Additionally, many other bioactive compounds such as phytochemicals in fruit and 
vegetables are thought to protect against cancer.7 Although it is widely believed that 
high intakes of fruit and vegetables reduce cancer risk, there is no conclusive evidence 
for this or for breast cancer specifically.7 11 12 The 2007 WCRF report stated there was 
probable rather than convincing evidence that they decreased the risk of many cancers 
such as mouth, oesophagus, stomach and colorectal cancer, but not breast cancer.7 
Furthermore, a recent EPIC analysis found only a very small inverse association 
between intake of total fruits and vegetables and total cancer risk.212 Initial findings 
from retrospective case-control studies reported a reduction in breast cancer risk with 
increasing intake by as much as 25%.8 213 However, results of a subsequent pooled 
analysis of cohort studies showed that fruit and vegetable consumption during 
adulthood was not significantly associated with breast cancer risk.12 
 
Similarly, as stated in section 3.6.4.1 of the literature review, the meta-analyses in the 
WCRF 2007 report of 14 case-control studies of dietary vitamin C intake provides 
evidence of a statistically significant protective association for breast cancer (RR=0.88, 
95% CI: 0.84-0.92, per 100mg/day); analyses comparing high versus low intake 
categories, plus pre-menopausal and post-menopausal analyses support this.7 
However, overall cohort results were inconclusive.239 240 242 243 245-247 264-267 In the 2007 
WCRF report no significant associations were produced for dietary vitamin C in the 
post-menopausal women meta-analyses of three cohort studies (HR=1.15 per 
100mg/d, 95% CI: 0.92-1.43), 7 245 246 265 or in the high versus low intake analysis of two 
additional studies.242 247 Differences in findings between study types may be due to 
selection or recall bias in the retrospective case-control studies. Most recently no 
significant evidence was found between dietary intake of vitamin C and breast cancer 
risk for either pre- or post-menopausal women in the EPIC study, involving 7,502 
breast cancer cases,244 or for post-menopausal women in a Danish cohort analysed by 
Roswall et al. (2010).273 A recent analysis of the Women’s Health Initiative 
Observational Study found that dietary vitamin C was not associated with breast cancer 
risk, although weak positive associations were found for breast cancer for total vitamin 
C and supplemental vitamin C intake in the highest versus lowest intake analyses.270 
 193 
 
 
In contrast to the overall WCRF meta-analysis results, Nissen et al. (2003) in an earlier 
nested case-control analysis of the Danish ‘Diet, Cancer and Health’ cohort (418 case 
and 394 controls) did find a significant doubling in risk per 100mg/d increase in intake 
for post-menopausal women (RR= 2.06, 95% CI: 1.45-2.91).245 Unlike other studies 
mentioned, this dietary analysis was restricted to women who consumed vitamin C 
through both diet and supplements; women who did not consume vitamin C 
supplements were excluded.245 This nested case-control study followed Danish, 
postmenopausal women for 4.7 years; a shorter period than the other studies. Unlike 
the other studies in the WCRF meta-analysis, adjustment was made for intake of the 
other antioxidant vitamins A and E.  
 
As seen in previous chapters supplement users in general have healthier behaviours 
than non-users,27 therefore excluding all types of supplement users from analyses will 
reduce potential confounding and provide a clearer picture of associations between 
dietary vitamin C intake and risk. There is a lack of evidence relating to non-
supplement users, other than non-significant findings reported above for the recent 
EPIC study, which did exclude all supplement users in their dietary vitamin C 
analysis.244 When vitamin C supplement users were excluded in the Danish nested 
case-control study reported by Nissen et al. (2003), this reduced the association 
substantially from a doubling in risk to RR=1.54 (95% CI: 0.80-2.96 per 100mg/day), 
which also became non-significant.245 No analysis, however, was produced excluding 
all supplement users. The more recent analysis of the Danish study by Roswall et al. 
(2010) also did not exclude supplement users.273 An analysis of the Iowa Women’s 
Health Study excluded women who took antioxidant supplements A,C and E and this 
increased the point estimate in the high verse low calculation from an non-significant 
decrease (HR=0.88 95% CI: 0.70-1.11) to a non-significant increase in risk (HR=1.06 
95% CI: 0.77-1.47).  
 
Furthermore, it is possible that the effect of dietary intake on cancer risk may be 
different for women genetically predisposed to developing breast cancer. In a test for 
interaction Zhang et al. (1999)247 found that family history of breast cancer significantly 
modified the relationship between dietary vitamin C and breast cancer risk (p<0.05). 
Moreover pre-menopausal women with a family history of breast cancer whose dietary 
vitamin C intake was in the highest fifth were found to have a significantly reduced risk 
of breast cancer compared to those in the lowest fifth; RR=0.37 (95% CI: 0.17, 0.80). 
However, no association was apparent when vitamin C from supplements was 
included; RR=0.97 (95% CI: 0.52, 1.79).   
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The current analyses examined the relationship between breast cancer incidence and 
fruit and vegetable intake, and dietary vitamin C intake at baseline in the UKWCS, 
which incorporates a wide range of intakes. Based on the hypothesis that a U-shaped 
relationship may exist, non-linear relationships between intake and breast cancer risk 
were explored, in addition to linear. Although the amount of vitamin C in supplements 
taken by users was unknown at baseline, women who reported supplement use of any 
type were excluded in sub-analyses to provide a clearer picture of the relationship 
between dietary vitamin C and breast cancer risk. The effects of family history and 
menopausal status were also examined.  
9.3 Method 
9.3.1 Study population 
General information about the recruitment of the 35,372 women who completed the 
baseline questionnaire is provided in section 4.1.1.1 of this thesis. All analyses 
excluded 1735 women with any prevalent malignant cancers recorded in the cancer 
registry before the baseline questionnaire date and excluded a further 33 women who 
were diagnosed with breast cancer within 6 months after the questionnaire date. The 
analyses also excluded an additional 83 women with extremely low or high total energy 
intake (more than 6000kcal and less than 500kcal). During the median follow up period 
of 11.2 years, 989 women developed incident breast cancers; these were registered 
with cancer registries by the censor date 01/01/08. 
Of the 33,520 women included in the analyses of dietary vitamin C and fruit and 
vegetable intake, 33,137 (99%) provided information on whether or not they took 
dietary supplements. Sixty-two percent (20,460 women) in the cohort took 
supplements. Ninety-four percent (31,559 women) also provided information on 
whether or not they had a family history of cancer, 8% (2,406) of whom had a family 
history of breast cancer and 39% (12,350) had a family history of any type of cancer.  
9.3.2 Exposure measurement  
9.3.2.1 Fruit and vegetable intake 
Fruit and vegetable intake had been measured in grams and also by two methods of 
calculating total servings: from answers to the 217 item FFQ; also from answers to 
cross-check questions 7 and 11 of the baseline questionnaire. Fruit and vegetable 
intake in grams was derived from total servings from the FFQ. 
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The cross-check questions were:  
Q7 How many servings of vegetables or vegetable containing dishes (excluding 
potatoes) do you usually eat each week?  
Q11 How many servings of fruit or fruit containing dishes do you usually eat each 
week? 
Five roughly equal groups were created from the cross-check question data for 
servings per day. Total servings derived from the answers to the FFQ, and also total 
grams of fruit and vegetable consumed per day derived from the FFQ, were divided 
into fifths. The range of fruit and vegetable servings in each group and the mean 
servings for each group are shown in Table 48. As reported in section 5.3 of the 
evaluation chapter, the agreement between the two methods of calculating servings 
was not good, and reporting misjudgements by participants are likely to have occurred 
with both methods. However, because there were substantial correlations between 
vitamin C derived from FFQ and fruit and vegetable servings or grams calculated from 
FFQ, analyses using FFQ derived fruit and vegetable servings and grams were not 
undertaken apart from for comparisons in the initial analysis in Table 48. 
9.3.2.2 Vitamin C intake  
Dietary vitamin C consumed per day was derived from FFQs. As explained in section 
4.5.1 in the methods chapter, the FFQ data had been entered into the DANTE program 
which used micronutrient content of foods as listed in The Royal Society of Chemistry 
Food tables, version 5 and supplements to estimate vitamin C consumed.287  
Vitamin C nutrient density per mega joule was calculated for each participant as 
vitamin C/ MJ. The reason for undertaking additional analyses with nutrient densities is 
discussed in section 4.7.5.3 of the methods chapter. 
Five equal groups were created from the dietary vitamin C as absolute values and also 
from vitamin C expressed as nutrient densities. The mean intake for each fifth of 
dietary vitamin C intake is shown in Table 48. 
9.3.2.3 Supplement use 
Supplement users at baseline had been determined from yes/no answers to the 
question: 
 Q29 Do you take any vitamins, minerals, fish oils or other food supplements? 
Women who did not answer this question but recorded information about the type of 
supplements taken on the questionnaire were also classed as supplement users.  
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9.3.3 Statistical analyses 
Women’s characteristics by category of consumption were described using means and 
percentages, and displayed in separate tables for absolute vitamin C intake and for fruit 
and vegetables intake recorded by the cross-check questions. Significant differences in 
characteristics in relation to intake were established from p-values using regression 
tests for trend for continuous variables and chi squared tests for trend for categorical 
variables. 
 
Cox proportional hazard ratios were used to model the associations between breast 
cancer incidence and fifths of vitamin C and also fifths of fruit and vegetable intake. To 
test for linear trends, continuous intake variables were used per increment of one 
serving for fruit and vegetable intake and approximately one standard deviation of 
mean vitamin C intake (e.g. 60mg/d for absolute vitamin C intake and 8mg/MJ/day for 
vitamin C intake density). Tables of hazard ratios were adjusted for age, BMI (under; 
normal; overweight), parity, estimated cumulative breast feeding (weeks), age at 
menarche, hours exercise sweating per week, contraceptive pill use (never, past, 
current), HRT use (ever, past, current), low alcohol use, socio-economic class 
(professional and managerial; intermediate; routine and manual), smoking status 
(never, past current), total energy intake, and also supplement use (yes, no), and 
menopausal status (postmenopausal; premenopausal) where appropriate. Reasons for 
selecting confounders are discussed in section 4.7.5 of this thesis. In sensitivity 
analyses further adjustment was made for family history of cancer in first degree 
relatives (any, breast). As detailed in section 4.7.6.3 women were asked whether their 
mother, father, brothers or sisters ever suffered from cancer, and were asked to 
provide details. Family history may be a confounder since women in the UKWCS who 
were aware that they may be at increased risk of breast cancer may have consumed 
more fruit and vegetables and supplements in an effort to reduce the risk. 
 
Both unadjusted and adjusted likelihood ratio test for overall interactions were used to 
test whether breast cancer risk differed between supplement groups, menopausal 
status or family history of breast cancer. Sub-group time-to-event analyses were 
produced by supplement use and for menopausal status. 
 
Non-linear relationships between intake and breast cancer risk were modelled using 
restricted cubic splines consisting of four cubic polynomial segments (α + β1x + β2x
2 + 
β3x
3) separated by five knots. This produced a smooth curve for each model: the 
models show straight lines before the first and after the last knot and are continuous at 
knot boundaries.365 Harrell (2001) recommended using five knots which are placed at 
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the following percentiles of the exposure variable: 5, 27.5, 50, 72.5, 95.372 These 
models were adjusted using the means of the continuous covariates: age, BMI, total 
calories parity, estimated cumulative breast feeding (weeks), age at menarche, hours 
exercise sweating per week. This produced estimated breast cancer risks over a range 
of vitamin C intakes for a woman with these average UKWCS characteristics. No 
adjustments were made for categorical variables, since each of the categories would 
need to be adjusted for in separate analyses, thereby reducing the power of the 
analyses. In the model of total women (minus exclusions and outliers) knots occurred 
at 76.7, 120.3, 155.2, 197.7 and 288.5mg/d vitamin C. Separate knots and covariate 
means were calculated for menopausal and supplement status sub-groups. 
Women with a family history of breast cancer were excluded from the restricted cubic 
spline models. The upper threshold for excluding outliers, i.e. 350mg/d of vitamin C, 
was determined as 1.5 times the inter-quartile range and comprised 3.6% of the total 
women. 
 
25% percentile = 113.6mg/d vitamin C 
75% percentile = 209.7mg/d   
Inter-quartile range = 96.1mg/d 
1.5 * range  = 144.2mg/d 
Upper threshold = 209.7 + 144.2 = 353.9mg/d  
 
Women with intakes below the RDA of 60mg/d were also excluded since they formed 
less than 3% of the total and appeared to disproportionately influence the extremities of 
the graphs. Seventy-one other data points were excluded using Mahalanobis distance 
calculations between vitamin C intake and the total fruit and vegetable intake from the 
cross-check question. This multivariate method of determining outliers was developed 
by Hadi and applied in Stata v10316,317 (see section 4.7.6.1 of the methods chapter). 
The predicted hazard ratios shown for the graphs are relative to women taking 60mg/d 
vitamin C. 
 
9.4 Results 
The mean (sd) values for the lowest intake groups were 0.9 (0.4) and 4.4 (1.2) servings 
of fruit and vegetables per day recorded by cross-check question and by FFQ 
respectively, and 19mg per day of dietary vitamin C. Mean values for the highest intake 
groups were 5.1 (1.3) and 19.7 (6.6) servings per day for the cross-check question and 
FFQ respectively and 301mg (86) per day dietary vitamin C.  
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From the tests for trends across intakes, as observed in Table 46 and Table 47, there 
were significant relationships between the majority of the characteristics listed and 
increasing intakes of fruit and vegetables (as per the cross-check question) and also 
increasing intakes of dietary vitamin C. For instance, with increasing intake, there were 
obvious trends in relation to longer breast feeding, exercising vigorously for longer, 
higher energy intake, and also higher dietary vitamin A and E intake. Similarly, there 
were obvious trends towards having no children, taking supplements, and being a 
current smoker in the higher intake groups. Paradoxically, although lower meat 
consumption occurred with increased fruit and vegetables intake in Table 46, whereas, 
an increase in meat consumption occurred with increased vitamin C consumption in 
Table 47. Although there were no significant trends for total alcohol (ethanol) intake, 
significant trends were seen in relation to drinking less than once a week; women who 
had low fruit and vegetable or vitamin C intake were also more likely to have a very low 
alcohol intake.  
In the breast cancer time-to-event analyses in Table 48 there was no significant 
evidence of differences between the lowest intake group and other intake groups for 
any of the methods of recording intake before or after adjustment of potentially 
confounding covariates, or after further adjustment for family history of cancer. 
Furthermore, no linear trends in risks were apparent in this table, which was prior to 
testing for modification effects of supplements. Instead, the highest but weak and non-
significant risks for breast cancer were found in the middle intake group of fruit and 
vegetables and also for absolute vitamin C values (HR=1.16; 95% CI: 0.93, 1.46; mean 
intake 156mg/d vitamin C). The lowest risks were found for the highest fruit and 
vegetable intake groups derived from the FFQ analysed by servings (HR=0.85; 95% 
CI: 0.66, 1.09) and by grams consumed (HR=0.89; 95% CI: 0.69, 1.15), though these 
were also non-significant. The restricted cubic spline model (Figure 23) also shows no 
clear association between breast cancer risk and dietary vitamin C, with little evidence 
of any significant non-linear relationships, as seen from the wide confidence intervals in 
the bottom graph. 
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Table 46 Characteristics of women at baseline in the UKWCS by category of fruit and vegetable servings consumed (as per Q7 & Q11) 
  Total fruit and vegetable consumption (as per Q7 & Q11) grouped 
 1 2 3 4 5 Total P value
a
 
Mean (sd) servings/day (sd) 0.9 (0.4) 1.9 (0.2) 2.5 (0.2) 3.3 (0.3) 5.1 (1.3) 2.8 (1.6)  
 N=6638 
(20%) 
N=6235 
(19%) 
N=6298 
(19%) 
N=6675 
(20%) 
N=7674 
(23%) 
N=33520 
(100%) 
 
Age (years), mean (sd) 52.3 (9.5) 52.3  (9.9) 51.0 (9.1) 52.1 (9.3) 52.3 (9.0) 52.0 (9.3)    0.4 
BMI (kg/m
2
), mean(sd) 24.8 (4.7) 24.5 (4.3) 24.5 (4.2) 24.3 (4.2) 24.2 (4.4) 24.5 (4.4) <0.001 
Weight change since aged 20, mean(sd) 9.0 (10.4) 8.6 (9.8) 8.2 (9.7) 7.5 (9.7) 6.9 (10.2) 8.0 (10.0) <0.001 
Height (cm), mean (sd) 163.1 (7.1) 163.7 (6.9) 163.7 (6.7) 164.0 (6.7) 164.0 (6.7) 163.7 (6.9) <0.001 
Age at menarche, mean (sd) 12.93 (1.7) 12.86 (1.6) 12.81 (1.6) 12.76 (1.6) 12.72 (1.6) 12.8(1.6) <0.001 
Age at first birth, mean (sd) 25.2 (4.7) 25.9 (4.8) 25.9 (4.8) 26.1 (4.7) 26.0 (4.6) 25.8 (4.7) <0.001 
Parity, mean (sd) 1.9 (1.3) 1.9 (1.3) 1.9 (1.3) 1.9 (1.3) 1.9 (1.3) 1.9 (1.3)    0.006 
Est. total breast feeding (wks), mean(sd) 19.0 (1.9) 21.2 (32.8) 24.3 (35.3) 25.1 (35.3) 27.6(38.4) 23.6 (35.0) <0.001 
Physical activity (min), mean (sd) 13 (28) 14 (28) 15 (29) 16 (30) 18 (30) 15 (29) <0.001 
Total meat (grams), mean (sd) 72 (63) 69 (63) 68 (62) 63 (61) 55 (59) 64 (62) <0.001 
Total fruit (grams), mean (sd) 224 (215) 261 (19) 273 (186) 340 (210) 444 (263) 314 (232) <0.001 
Total vegetables (grams), mean (sd) 250 (174) 285 (165) 297 (155) 333 (169) 396 (199) 315 (181) <0.001 
Total ethanol intake (grams), mean (sd) 8.2 (11.5) 8.4 (10.4) 9.6 (11.1) 8.8 (10.1) 9.5 (9.8) 8.7 (10.6)    0.1 
Total energy intake (Kcal), mean (sd)  2212 (740 ) 2295 (726) 2338 (685) 2391 (697) 2473 (703) 2346 (716) <0.001 
Dietary vitamin A intake (µg), mean (sd) 1111 (622) 1187 (575) 1209 (532) 1288 (598) 1368 (613) 1238 (598) <0.001 
Dietary vitamin E intake (mg), mean (sd) 8.6 (4.1) 9.2 (4.1) 9.6 (4.1) 10.1 (4.2) 10.8 (4.4) 9.7 (4.3) <0.001 
Dietary vitamin C intake (mg), mean (sd) 139 (85) 155 (78) 160 (72) 181 (78) 213 (93) 171 (86) <0.001 
Vitamin C from fruit (mg), mean (sd) 43 (51) 51 (46) 54 (48) 66 (52) 88 (68) 62 (57) <0.001 
Vitamin C from veg (mg), mean (sd) 53 (42) 60 (40) 62 (37) 70 (40) 83 (49) 66 (43) <0.001 
Professional or managerial (%) 31 35 41 42 44 39 <0.001 
Educated to ‘A’-level or above (%) 38 46 55 58 60 52 <0.001 
No children (%) 20 20 20 20 22 20 <0.001 
Ever used contraceptive pill (%) 66 68 72 68 67 68   0.5 
Ever used HRT (%) 29 28 27 27 28 28   0.07 
Current smoker (%) 18 13 11 9 6 11 <0.001 
Drinks alcohol less than once a week(%) 37 35 30 32 33 33 <0.001 
Takes any supplements (%) 58 59 60 63 68 62 <0.001 
Family history of breast cancer (%) 6.8 7.2 8.1 8.1 7.9 7.6    0.003 
Family history of any cancer (%)
b
 38.4 39.7 38.7 38.9 40.0 39.2    0.2 
a
p= test for trend, 
 b
family history
 
in first degree relatives 
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Table 47 Characteristics of women at baseline in the UKWCS by category of dietary vitamin C consumption
 
 Total dietary vitamin C consumption from FFQ by fifths  
  Lowest 2nd Fifth 3rd Fifth 4th Fifth Highest Total P value
a
 
Mean vitamin C mg/d (sd) 79 (18) 122 (10) 156 (10) 197 (15) 301 (87) 171 (86)  
 N=6704 N=6704 N=6704 N=6704 N=6704 N=33520  
Age (years), mean (sd) 51.2 (9.3) 51.6 (9.3) 52.1 (9.3) 52.6 (9.2) 52.7 (9.2) 52.0 (9.3) <0.001 
BMI (kg/m
2
), mean (sd) 24.6 (4.6) 24.4 (4.3) 24.4 (4.2) 24.4 (4.2) 24.4 (4.5) 24.5 (4.4)    0.2 
Weight change since aged 20 mean,(sd) 8.4 (10.5) 8.0 (9.9) 7.8 (9.6) 7.9 (9.7) 7.8 (10.4) 8.0 (10.0)    0.05 
Height (cm), mean (sd) 163.3 (6.9) 163.7 (6.9) 163.9 (7.1) 164.0 (6.8) 163.9 (6.6) 163.7 (6.9) <0.001 
Age at menarche, mean (sd) 12.85 (1.6) 12.86 (1.6) 12.79 (1.6) 12.79 (1.6) 12.78 (1.6) 12.8(1.6)    0.02 
Age at first birth, mean (sd) 25.6 (4.8) 26.0 (4.8) 26.0 (4.8) 25.9 (4.6) 25.7 (4.6) 25.8 (4.7)    0.1 
Parity, mean (sd) 1.7 (1.3) 1.8 (1.3) 1.9 (1.3) 1.9 (1.3) 2.0 (1.3) 1.9 (1.3) <0.001 
Est. total breast feeding (wks), mean(sd) 18.6 (31.4) 22.6 (33.8) 24.6 (35.3) 25.4 (36.3) 26.7 (37.7) 23.6 (35.0) <0.001 
Physical activity (min), mean (sd) 12 (26) 13 (28) 14 (27) 16 (28) 20 (35) 15 (29) <0.001 
Total meat (grams), mean (sd) 61 (54) 64 (58) 65 (61) 67 (64) 66 (71) 64 (62) <0.001 
Total fruit (grams), mean (sd) 145 (93) 224 (116) 288 (138) 358 (161) 553 (329) 313 (231) <0.001 
Total vegetables (grams), mean (sd) 168 (71) 241 (84) 298 (103) 361 (124) 509 (244) 315 (181) <0.001 
Total ethanol intake (grams), mean (sd) 8.4 (11.3) 8.9 (10.9) 8.9 (10.7) 8.7 (9.8) 8.5 (10.1) 8.7 (10.6)    0.2 
Total energy intake (Kcal), mean (sd)  1904 (570) 2157 (580) 2322 (596) 2501 (655) 2849 (796) 2346 (716) <0.001 
Dietary vitamin A intake (µg), mean (sd) 895 (440) 1089 (464) 1222 (509) 1361 (556) 1620 (712) 1237 (598) <0.001 
Dietary vitamin E intake (mg), mean (sd) 7.1 (3.3) 8.6 (3.6) 9.6 (3.7) 10.5 (3.8) 12.7 (4.8) 9.7 (4.3) <0.001 
Vitamin C from fruit (mg), mean (sd) 24 (16) 40 (21) 53 (26) 70 (34) 120 (90) 62 (57) <0.001 
Vitamin C from veg (mg), mean (sd) 31 (14) 48 (19) 62 (23) 78 (29) 112 (60) 66 (43) <0.001 
Professional or managerial (%) 36 39 40 41 39 39 <0.001 
Educated to ‘A’-level or above (%) 47 53 54 54 53 52 <0.001 
No children (%) 24 21 19 19 18 20 <0.001 
Ever used contraceptive pill (%) 69 70 68 67 66 68 <0.001 
Ever used HRT (%) 26 26 28 29 30 28 <0.001 
Current smoker (%) 16 12 10 8 9 11 <0.001 
Drinks alcohol less than once a week(%) 38 33 31 30 34 33 <0.001 
Takes any supplements (%) 57 58 62 64 68 62 <0.001 
Family history of breast cancer (%)
b
 7.3 7.7 7.7 7.8 7.6 7.6    0.5 
Family history of any cancer (%)
b
 39.0 38.7 38.3 39.9 39.8 39.2    0.2 
a
p= test for trend.  
b
In first degree relatives 
sd =standard deviation 
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Table 48 Breast cancer risks by fruit and vegetable intake and dietary vitamin C intake at baseline in the UKWCS 
 
 
Mean (SD) Cases/ 
non-cases
a
 
Unadjusted HR 
(95% CI) 
Adjusted HR 
(95% CI)
b
 
Adjusted for 
family history 
(95% CI)
c
 
Fruit & vegetable servings/d, from Q7 & Q11  
1 (0-1.4)  0.9 (0.4) 188/6450 1 1 1 
2 (1.6-2) 1.9 (0.2) 176/6059 0.98 (0.80, 1.21) 1.09 (0.86, 1.38) 1.08 (0.85, 1.37) 
3 (2.1-2.9) 2.5 (0.2) 191/6107 1.06 (0.87, 1.30) 1.12 (0.89, 1.42) 1.13 (0.88, 1.41) 
4 (3-3.9) 3.3 (0.3) 200/6475 1.04 (0.85, 1.27) 1.05 (0.83, 1.33) 1.04 (0.82, 1.33) 
5 (4 & above) 5.1 (1.3) 234/7440 1.05 (0.87, 1.28) 1.04 (0.83, 1.31) 1.04 (0.82, 1.31) 
 Per serving/d   1.01 (0.97, 1.05) 1.00 (0.95, 1.04) 1.00 (0.95, 1.05) 
ptrend   0.6 0.9 1.0 
      
Fruit & vegetable servings/d, FFQ derived  
1 (0-6.1) 4.4 (1.2) 188/6515 1 1 1 
2 (6.1-8.4) 7.2 (0.7) 202/6499 1.06 (0.87, 1.30) 0.99 (0.79, 1.24) 0.99 (0.79, 1.25) 
3 (8.4-10.7) 9.5 (0.7) 217/6489 1.13 (0.93, 1.38) 1.04 (0.83, 1.30) 0.99 (0.79, 1.25) 
4 (10.7-14.2) 12.3 (0.9) 208/6498 1.08 (0.88, 1.31) 0.94 (0.75, 1.19) 0.93 (0.74, 1.18) 
5 (14.2 & above) 19.7 (6.6) 174/6530 0.89 (0.72, 1.09) 0.85 (0.66, 1.09) 0.84 (0.65, 1.08) 
Per serving/d   0.97 (0.91, 1.03) 0.97 (0.90, 1.05) 0.96 (0.88, 1.05) 
ptrend   0.3 0.5 0.4 
      
Fruit & veg g/d, FFQ derived
 
 
  1 lowest fifth 266g/d (72) 180/6524 1 1 1 
  2   433g/d (39) 198/6506 1.09 (0.89, 1.33) 0.99 (0.79, 1.24) 0.97 (0.77, 1.23) 
  3   566g/d (40) 220/6484 1.21 (0.99, 1.47) 1.16 (0.93, 1.45) 1.12 (0.89, 1.40) 
  4   730g/d (58) 212/6492 1.15 (0.95, 1.41) 1.01 (0.80, 1.28) 0.99 (0.78, 1.26) 
  5  highest fifth 1149g/d (360) 179/6525 0.96 (0.78, 1.18) 0.89 (0.69, 1.15) 0.87 (0.67, 1.13) 
Per 80g/d   0.99 (0.97, 1.00) 0.99 (0.88, 1.01) 0.99 (0.97, 1.01) 
ptrend   0.2 0.2 0.2 
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Table continued: Breast cancer risks by fruit and vegetable intake and dietary vitamin C intake at baseline 
in the UKWCS 
 Mean (SD) Cases/ 
non-cases
a
 
Unadjusted HR 
(95% CI) 
Adjusted HR 
(95% CI)
b
 
Adjusted for 
family history 
(95% CI)
c
 
Dietary vitamin C mg/d, FFQ derived  
  1 lowest fifth   79mg/d (18) 182/6522 1 1 1 
  2   122mg/d (10) 176/6528 0.96 (0.78, 1.18) 0.96 (0.76,1.21) 0.94 (0.74, 1.20) 
  3   156mg/d (10) 218/6486 1.19 (0.98, 1.45) 1.16 (0.93, 1.46) 1.15 (0.91, 1.45) 
  4   197mg/d (15) 219/6485 1.20 (0.98, 1.45) 1.12 (0.88, 1.41) 1.08 (0.85, 1.37) 
  5  highest fifth 301mg/d (87) 194/6512 1.05 (0.86, 1.28) 1.05 (0.81, 1.35) 1.03 (0.79, 1.33) 
Per 60mg/d   1.00 (0.96, 1.05) 1.00 (0.94, 1.06) 0.94 (0.93, 1.05) 
ptrend   1.0 0.9 0.7 
      
Dietary vitamin C density, FFQ derived  
  1  lowest fifth   9.1/d (1.9) 178/6526 1 1 1 
  2   13.3/d (0.9) 190/6514 1.06 (0.86, 1.30) 1.04 (0.83, 1.31) 1.07 (0.84, 1.35) 
  3   16.6/d (1.0) 204/6500 1.14 (0.93, 1.39) 1.07 (0.85, 1.34) 1.09 (0.87, 1.38) 
  4   20.4/d (1.4) 206/6498 1.14 (0.93, 1.39) 1.08 (0.86, 1.35) 1.06  (0.84,1.33) 
  5  highest fifth 29.7/d (7.2) 211/6493 1.16 (0.95, 1.42) 1.09 (0.87, 1.37) 1.07 (0.85, 1.35) 
Per 8mg/MJ/d   1.02 (0.96, 1.09) 1.00 (0.93, 1.08) 0.99 (0.92, 1.07) 
ptrend   0.5 0.9 0.9 
      
a
Numbers of cases for the unadjusted analyses 
b
Adjusted for age, BMI, socio-economic status, parity, estimated cumulative breast feeding, age at menarche, hours exercise 
sweating per week, contraceptive pill use, HRT use, low alcohol use, smoking status, supplement use, total calories (other than 
nutrient density). 
c
Adjusted for the above, plus family history of cancer in first degree relatives (any cancer, breast cancer). 
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There were no significant modifying effects of menopausal status, supplement use, or 
family history of breast cancer on the relationship between dietary intake and breast 
cancer risk (Table 49). Although the interactions were non-significant in the test 
between supplement use and fruit and vegetable intake or dietary vitamin C intake 
(p=0.6, 0.2, 0.3), breast cancer time-to-event analyses were stratified by supplement 
use status (Table 51). Similarly, stratified analyses were tabled by menopausal status 
(Table 50) and by supplement use for post-menopausal (Table 52) and pre-
menopausal women (Table 53).  
Although different patterns of risk were seen in sub-analyses, there was little evidence 
of non-linear relationships, and indeed no evidence of any significant associations 
between breast cancer incidence and dietary intake after stratifying by supplement use 
or by menopausal status. Additionally, there were no differences in patterns of hazard 
ratios in sensitivity analyses after adjusting for family history of breast cancer and any 
cancer (not shown). Patterns of risk appeared different for pre- and post-menopausal 
women as seen in Table 50, but these differences were not statistically significant. In 
the restricted cubic-spline models (Figure 24), compared to risks at 60mg/d vitamin C, 
deviations of risk from unity for intakes between 60mg/d to 350mg/d were weak and 
also non-significant; confidence intervals, which were not shown, were wide. If 
anything, the spline model for pre-menopausal women indicated risks increased 
slightly, but non-significantly, with increasing vitamin C intake, though the results in 
Table 50 did not reflect this. 
For non-supplement users, there appeared to be non-significant trends towards higher 
risks with increased dietary vitamin C intake, with moderate but non-significant 
increases in risk in the high verse low risk comparison (HR=1.38; 95% CI: 0.92, 2.06; 
Table 51), and similarly for post-menopausal non-supplement users (HR=1.52; 95% CI: 
0.89, 2.58; Table 52). Likewise, in the predicted spline model (Figure 25) breast cancer 
risk tended to increase in non-supplement users with increasing dietary vitamin C 
intake, with the predicted risk at 350mg/d roughly 2.3 compared to 60mg/d intake, but 
confidence intervals were wide. Similarly, a predicted hazard ratios of 3 for 
postmenopausal non-supplement users was seen at this intake in spline models (not 
shown). The results, however, were not statistically significant since the upper 
confidence limits were very wide.  
The hazard ratios for the nutrient density analyses for non-supplement users in Table 
51 and Table 52, however, did indicate a U-shaped relationship, with women in the 2nd 
group having the lowest, though non-significant risks (HR=0.68; 95% CI: 0.40, 1.14; 
Table 52 of post-menopausal women). However, the restricted cubic spline model 
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showed that the relationship was reasonably flat (Figure 27), and non-significant 
(confidence intervals not shown).  
 
For supplement users the relationships were largely flat (as observed in Table 51 to 
Table 52). This was also apparent in the spline model for total supplement users 
(Figure 26), and also separately for post-menopausal and pre-menopausal women (not 
shown). Any deviations occurring in the middle intake groups in the tables and graphs 
were weak and also non-significant as confidence intervals were wide. The shape of 
the graphs did not change when women with the top and bottom 5% or 10% of intakes 
were excluded (not shown).  
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Table 49 Assessment of modification by menopausal status, supplement use and 
family history of breast cancer on fruit and vegetable and dietary vitamin C intake and 
associations with breast cancer risk in the UKWCS 
Tests for modification by P values 
Unadjusted 
P values 
Adjusted 
1) Menopausal status   
Fruit & veg servings, Q7 & Q11 * Menopausal status 0.6 0.8 
Dietary vitamin C mg/d * Menopausal status 0.7 0.6 
Dietary vitamin C (density) * Menopausal status 
 
0.8 0.8 
2) Supplement use status   
Fruit & veg servings, Q7 & Q11 * supplement use 0.7 0.6 
Dietary vitamin C mg/d * supplement use 0.1 0.2 
Dietary vitamin C (density) * supplement use 0.3 0.3 
Supplement use status: pre-menopausal women   
Fruit & veg servings, Q7 & Q11 * supplement use 0.6 0.6 
Dietary vitamin C mg/d * supplement use 0.7 0.9 
Dietary vitamin C (density) * supplement use 0.8 0.8 
Supplement use status: post-menopausal women   
Fruit & veg servings, Q7 & Q11 * supplement use 0.4 0.9 
Dietary vitamin C mg/d * supplement use 0.1 0.2 
Dietary vitamin C (density) * supplement use 
 
0.5 0.3 
3) Family history of breast cancer status   
Fruit & veg servings, Q7 & Q11 * family history 0.9 0.9 
Dietary vitamin C mg/d * family history 0.9 1.0 
Dietary vitamin C (density) * family history 0.9 1.0 
Family history of breast cancer: pre-menopausal women   
Fruit & veg servings, Q7 & Q11 * family history 0.8 0.5 
Dietary vitamin C mg/d  * family history 0.6 0.6 
Dietary vitamin C (density) * family history 0.9 0.5 
Family history of breast cancer: post-menopausal women   
Fruit & veg servings, Q7 & Q11 * family history 0.9 0.7 
Dietary vitamin C mg/d * family history 1.0 0.9 
Dietary vitamin C (density) * family history 0.7 0.5 
 
a
Adjusted for age, BMI, socio-economic status, parity, estimated cumulative breast feeding, age 
at menarche, hrs exercise sweating per week, contraceptive pill use, HRT use, low alcohol use, 
smoking status, supplement use, total calories (other than nutrient density). 
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Table 50 Breast cancer risks by fruit and vegetable intake and dietary vitamin C intake 
at baseline in the UKWCS by menopausal status 
Total women split by Pre-menopausal Post-menopausal 
 cases/ 
non- 
casesa 
 
HR (95% CI)b 
cases/ 
non- 
casesa 
 
HR (95% CI)b 
Fruit & vegetable servings/day, Q7 & Q11 
1 lowest 57/2376 1 77/2368 1 
2  70/2362 1.19 (0.84, 1.69) 79/2380  1.00 (0.73, 1.37) 
3  76/2753 1.12 (0.79, 1.58) 83/2274  1.10 (0.80, 1.50) 
4  71/2667 1.04 (0.74, 1.49) 89/2652 1.03 (0.76, 1.41) 
5 highest 69/2937 0.92 (0.64, 1.32) 117/3252 1.10 (0.82, 1.48) 
     
Per serving/d  0.95 (0.89, 1.03)    1.02 (0.96, 1.08) 
ptrend  0.2  0.5 
     
Dietary vitamin C mg/d, FFQ derived 
  1 lowest fifth   70/2832 1 74/2279 1 
  2   74/2797 1.04 (0.75, 1.45) 70/2484 0.88 (0.63, 1.22) 
  3   78/2625 1.13 (0.81, 1.58) 97/2591 1.17 (0.85, 1.59) 
  4   62/2459 0.96 (0.67, 1.38) 109/2797 1.21 (0.89, 1.65) 
  5  highest fifth 59/2382 0.94 (0.64, 1.38) 95/2775 1.10 (0.79, 1.54) 
     
Per 60mg/d   0.96 (0.87, 1.05)  1.01 (0.94, 1.09) 
ptrend  0.4  0.7 
     
Dietary vitamin C density, FFQ derived 
  1  lowest fifth   71/2968 1 72/2242 1 
  2   76/2755 1.10 (0.79, 1.52) 81/2516  0.98 (0.71, 1.35) 
  3   72/2626 1.07 (0.77, 1.49) 89/2601 1.04 (0.76, 1.42) 
  4   69/2496 1.07 (0.76, 1.49) 95/2708 1.05 (0.77, 1.44) 
  5  highest fifth 55/2250 0.95 (0.66, 1.35) 108/2859 1.15 (0.85, 1.55) 
     
Per 8mg/MJ/d  0.93 (0.83, 1.05)  1.04 (0.95, 1.15) 
ptrend  0.3  0.4 
     
a
Numbers of cases for the adjusted analyses 
b
Adjusted for age, BMI, socio-economic status, parity, estimated cumulative breast feeding, age at 
menarche, hours exercise sweating per week, contraceptive pill use, HRT use, low alcohol use, smoking 
status, supplement use, total calories (other than nutrient density). 
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Table 51 Breast cancer risks by fruit and vegetable intake and dietary vitamin C intake 
at baseline in the UKWCS by supplement use 
Total women split by Non-users Supplement users 
 
 
cases/ 
non- 
casesa 
 
HR (95% CI)b 
cases/ 
non- 
casesa 
 
HR (95% CI)b 
Fruit & vegetable servings/day, Q7 & Q11 
1 lowest 55/2026 1 79/2718 1 
2  65/1956 1.20 (0.84,1.72) 84/2786 1.01 (0.74, 1.37) 
3  56/2029 1.04 (0.71,1.51) 103/2998 1.16 (0.86, 1.55) 
4  64/1977 1.20 (0.83, 1.72) 96/3342 0.96 (0.71, 1.30) 
5 highest 58/2018 1.04 (0.71, 1.52) 128/4171 1.03 (0.79, 1.37) 
     
Per serving/d  0.97 (0.90, 1.05)  1.01 (0.95, 1.06) 
ptrend  0.5  0.8 
     
Dietary vitamin C mg/d, FFQ derived 
  1 lowest fifth   58/2234 1 86/2877 1 
  2   63/2208 1.09 (0.76, 1.57) 81/3073 0.87 (0.64, 1.18) 
  3   56/2001 1.07 (0.74, 1.57) 119/3215 1.20 (0.90, 1.59) 
  4   61/1883 1.22 (0.84, 1.79) 110/3373 1.04 (0.77, 1.40) 
  5  highest fifth 60/1680 1.38 (0.92, 2.06) 94/3477 0.88 (0.64, 1.22) 
     
Per 60mg/d  1.05 (0.96, 1.16)  0.96 (0.89, 1.04) 
ptrend  0.3  0.3 
     
Dietary vitamin C density, FFQ derived 
  1  lowest fifth   64/2266 1 79/2944 1 
  2   52/2164 0.80 (0.55,1.16) 105/3107 1.21 (0.91 1.63) 
  3   60/2009 0.98 (0.69, 1.40) 101/3218 1.13 (0.84, 1.51) 
  4   62/1848 1.11 (0.78, 1.58) 102/3356 1.07 (0.80, 1.44) 
  5  highest fifth 60/1719 1.12 (0.79, 1.60) 103/3390 1.07 (0.80, 1.44) 
     
 Per 8mg/MJ/d  1.07 (0.95, 1.20)  0.96 (0.88, 1.06) 
ptrend  0.3  0.4 
     
a
Numbers of cases for the adjusted analyses 
b
Adjusted for age, BMI, socio-economic status, parity, estimated cumulative breast feeding, age 
at menarche, hours exercise sweating per week, contraceptive pill use, HRT use, low alcohol 
use, smoking status, total calories (other than nutrient density). 
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Table 52 Breast cancer risks by fruit and vegetable intake and dietary vitamin C intake 
at baseline in the UKWCS by supplement use in post-menopausal women 
Post-menopausal Non-users Supplement users 
 
 
cases/ 
non- 
casesa 
 
HR (95% CI)b 
cases/ 
non- 
casesa 
 
HR (95% CI)b 
Fruit & vegetable servings/day, Q7 & Q11 
1 lowest 34/927 1 43/1441 1 
2  33/934 0.98 (0.61,1.59) 46/1446 1.01 (0.66, 1.53) 
3  31/869 1.00 (0.61, 1.63) 52/1405 1.16 (0.77, 1.74) 
4  37/956 1.13 (0.70,1.82) 52/1696 0.97 (0.65, 1.46) 
5 highest 39/1027 1.09 (0.68, 1.76) 78/2225 1.11 (0.76, 1.62) 
     
Per servings/d  0.99 (0.89, 1.10)  1.03 (0.96, 1.11) 
ptrend  0.9  0.4 
     
Dietary vitamin C mg/d, FFQ derived 
  1 lowest fifth   29/951 1 45/1328 1 
  2   34/976 1.13 (0.68, 1.87) 36/1508 0.70 (0.45, 1.09) 
  3   32/932 1.11 (0.66, 1.87) 65/1659 1.14 (0.77, 1.69) 
  4   39/964 1.35 (0.81, 2.23) 70/1833 1.09 (0.74, 1.62) 
  5  highest fifth 40/890 1.52 (0.89, 2.58) 55/1885 0.87 (0.56, 1.35) 
     
Per 60mg/d   1.05 (0.94, 1.19)  0.99 (0.90, 1.09) 
ptrend  0.3  0.8 
     
Dietary vitamin C density, FFQ derived 
  1  lowest fifth   33/913 1 39/1329 1 
  2   25/972 0.68 (0.40, 1.14) 56/1544 1.21 (0.80, 1.82) 
  3   37/958 1.02 (0.64 1.64) 52/1643 1.04 (0.68, 1.57) 
  4   39/911 1.14 (0.71, 1.82) 56/1797 1.01 (0.67,1.53) 
  5  highest fifth 40/959 1.12 (0.70, 1.78) 68/1900 1.16 (0.78, 1.72) 
     
Per 8mg/MJ/d  1.08 (0.93, 1.26)  1.02 (0.90, 1.15) 
ptrend  0.3  0.8 
     
a
Numbers of cases for the adjusted analyses 
b
Adjusted for age, BMI, socio-economic status, parity, estimated cumulative breast feeding, age 
at menarche, hours exercise sweating per week, contraceptive pill use, HRT use, low alcohol 
use, smoking status, total calories (other than nutrient density). 
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Table 53 Breast cancer risks by fruit and vegetable intake and dietary vitamin C intake 
at baseline in the UKWCS by supplement use in pre-menopausal women 
Pre-menopausal Non-users Supplement users 
 
 
cases/ 
non- 
casesa 
 
HR (95% CI)b 
cases/ 
non- 
casesa 
 
HR (95% CI)b 
Fruit & vegetable servings/day, Q7 & Q11 
1 lowest 21/1099 1 36/1277 1 
2  32/1022 1.50 (0.86, 2.60) 38/1340 1.00 (0.63, 1.58) 
3  25/1160 1.05 (0.59, 1.89) 51/1593 1.11 (0.73, 1.72) 
4  27/1021 1.27 (0.71, 2.27) 44/1646 0.91 (0.59, 1.44) 
5 highest 19/991 0.89 (0.49, 1.69) 50/1946 0.90 (0.58, 1.40) 
     
Per servings/d  0.93 (0.82, 1.06)  0.96 (0.88, 1.05) 
ptrend  0.3  0.4 
     
Dietary vitamin C mg/d, FFQ derived 
  1 lowest fifth   29/1283 1 41/1549 1 
  2   29/1232 1.05 (0.62, 1.77) 45/1565 1.04 (0.68,1.60) 
  3   24/1069 1.02 (0.59, 1.78) 54/1556 1.22 (0.80, 1.86) 
  4   22/919 1.05 (0.59, 1.89) 40/1540 0.91 (0.58, 1.45) 
  5  highest fifth 20/790 1.13 (0.60, 2.13) 39/1592 0.86 (0.53, 1.41) 
     
Per 60mg/d  1.03 (0.88, 1.20)  0.92 (0.82, 1.04) 
ptrend  0.7  0.2 
     
Dietary vitamin C density, FFQ derived 
  1  lowest fifth   31/1353 1 40/1615 1 
  2   27/1192 0.94 (0.56, 1.59) 49/1563 1.20 (0.79, 1.83) 
  3   23/1051 0.89 (0.52, 1.54) 49/1575 1.19 (0.78, 1.82) 
  4   23/937 1.00 (0.58, 1.72) 46/1559 1.12 (0.73, 1.72) 
  5  highest fifth 20/760 1.07 (0.60, 1.89) 35/1490   0.91 (0.58, 1.45) 
     
Per 8mg/MJ/d  1.02 (0.85, 1.25)  0.89 (0.76, 1.03) 
ptrend  0.8  0.1 
     
a
Numbers of cases for the adjusted analyses 
b
Adjusted for age, BMI, socio-economic status, parity, estimated cumulative breast feeding, age 
at menarche, hours exercise sweating per week, contraceptive pill use, HRT use, low alcohol 
use, smoking status, total calories (other than nutrient density). 
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Figure 23 Adjusted restricted cubic spline models of breast cancer risks by dietary 
vitamin C intake before sub-grouping (confidence intervals shown in bottom graph) 
 
(confidence intervals shown in bottom graph) 
 
Adjusted covariates set to mean: age = 51.8, total calories = 2341, BMI = 24.4, cumulative 
breast feeding wks = 24.7, age at menarche = 12.8, vigorous exercise hr/wk = 0.25, parity = 
1.86 
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Figure 24 Adjusted restricted cubic spline models of breast cancer risks by vitamin C 
intake for pre-menopausal and post-menopausal women (without confidence intervals) 
 
Adjusted covariates set to mean: age = 44.6, total calories = 2360, BMI = 23.9, cumulative 
breast feeding wks = 29.2, age at menarche = 12.8, vigorous exercise hr/wk =0.27, parity = 1.67 
  
Adjusted covariates set to mean: age = 58.8, total calories = 2323, BMI = 25.0, cumulative 
breast feeding wks = 20.2, age at menarche = 12.9, vigorous exercise hr/wk = 0.24, parity = 
2.05 
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Figure 25 Adjusted restricted cubic spline models of breast cancer risks by vitamin C 
intake for non-supplement users (confidence intervals shown in bottom graph)
 
 
(Confidence intervals shown in bottom graph) 
 
Adjusted covariates set to mean: age = 51.2, total calories = 2333, BMI = 24.8, cumulative 
breast feeding wks = 26.6, age at menarche = 12.8, vigorous exercising hr/wk = 0.24, parity = 
1.93 
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Figure 26 Adjusted restricted cubic spline models of breast cancer risks by vitamin C 
intake for supplement users (confidence intervals shown in bottom graph) 
 
 
(Confidence intervals shown in bottom graph) 
 
Adjusted covariates set to mean: age = 52.2, total calories = 2346, BMI = 24.2, cumulative 
breast feeding wks = 23.5, age at menarche = 12.8, vigorous exercising hr/wk = 0.26, parity 
1.82 
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Figure 27 Adjusted restricted cubic spline models of breast cancer risks by nutrient 
density for non-supplement users and supplement users (without confidence intervals) 
 
Adjusted covariates set to mean: age = 51.2, total calories = 2327, BMI = 24.8, cumulative 
breast feeding wks = 26.4, age at menarche = 12.8, vigorous exercise hr/wk = 0.24, parity = 
1.92 
 
 
 
Adjusted covariates set to mean: age = 51.2, total calories = 2363, BMI = 24.2, cumulative 
breast feeding wks = 23.5, age at menarche = 12.8, vigorous exercise hr/wk = 0.26, parity = 
1.82 
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9.5 Discussion 
The results of this UKWCS baseline analysis showed that neither total fruit and 
vegetable intake nor dietary vitamin C intake were significantly associated with breast 
cancer incidence. This is inline with previous research.7 11 12 244 270 273 The 2007 WCRF 
research review and the 2008 WCRF continuous update reported no associations 
between breast cancer risk and fruit and vegetable or vitamin C intake.7 169  
Although the amount of vitamin C in supplements taken by users was unknown at 
baseline in the UKWCS, meaning relationships with total vitamin C intake could not be 
assessed, the sub-analysis of women who did not take any supplements provided a 
clearer picture of the relationship between dietary vitamin C intake and breast cancer 
risk. A very weak positive dose-response relationship was noticeable for UKWCS non-
supplement users in the vitamin C intake models, but this was not statistically 
significant. Nissen et al. (2003) reported significant evidence of a doubling in breast 
cancer risk with dietary vitamin C intake per 100mg/d increases in post-menopausal 
women in a small Danish nested case-control study, however vitamin C supplement 
users were included in this analysis.245 When vitamin C supplement users were 
excluded in this Danish study, the risk was reduced to a moderate association and this 
also became non-significant.245 Unlike our analysis other supplement users were not 
excluded. The recent large European wide EPIC analysis did exclude all supplement 
users and found no evidence of associations between dietary vitamin C intake and 
breast cancer risk for all pre- or post-menopausal women.244 A significant trend of 
reduced risk with increasing vitamin C intake, however, was apparent for post-
menopausal women using exogenous hormones.244 These relationships should be 
examined in other cohorts; however, there may be insufficient power to undertake HRT 
sub-analyses in the UKWCS. 
For supplement users in the UKWCS, the non-significant decreased risks evident at 
higher vitamin C intakes could be attributable to other micronutrients in the 
supplements which have protective effects; and, as seen in chapter 8, these women 
were likely to have used a variety of supplements. Alternatively, the results could be 
explained by residual confounding; reduced risk in supplement users may be due to 
other health related behaviours associated with supplement use despite attempts to 
adjust for them. However, since the results were non-significant they were likely to 
have occurred by chance. Apart from the Nissen et al. study (2003),245 the current 
results support the non-significant results for dietary vitamin C analyses reported in the 
2007 WCRF review,7 and results of more recent analyses which did not exclude 
supplement users270 273 (as seen in Table 2 and Table 3 in section 3.7.2). Only the Iowa 
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Women’s Heath Study has reported dietary vitamin C analyses by supplement users 
only, i.e. excluding all non-users, which reported no evidence of associations.242  
There is no simple biological explanation for these non-significant patterns observed in 
these UKWCS analyses. As explained in chapter 2, it is thought that via its antioxidant 
properties, vitamin C reduces the risk of cancer initiation by reducing DNA damage 
from ROS, particularly in individuals with high levels of ROS.77 A biological explanation 
for increased risk with increased intake, which was the most pronounced for UKWCS 
post-menopausal women non-supplement users, is that antioxidant properties of 
vitamin C may decrease beneficial apoptosis, the ROS induced programmed death of 
damaged cells.81 Such a reduction in programmed cell death could lead to the 
progression of cancer particularly in individuals with age-related damage.77 
Additionally, natural increases in iron stores during menopause may cause vitamin C to 
act as a pro-oxidant creating highly reactive and damaging hydroxyl radicals via the 
Fenton reaction.76 A U-shaped relationship, which could be hypothesised from the 
above, was observed for vitamin C dietary intake expressed as nutrient density for non-
supplement users. However, since high intakes of this water-soluble vitamin are 
excreted,65 risks were expected to flatten out at high intakes, rather than increase or 
decrease, as seen in some of the graphed models. No previous study of vitamin C and 
breast cancer risk reported results analysed by nutrient density. 
Given the antioxidant hypothesis, at very low vitamin C intakes, decreased risks with 
increasing intake up to 60mg/d would be expected. However, from FFQ recordings, 
only 3% of women in this predominately health conscious cohort were calculated to 
have vitamin C dietary intakes below the EU recommended daily allowance of 60mg/d. 
Indeed, the mean intake was 79mg/d (sd 18) in the reference category, the lowest fifth 
of intake. Furthermore, the graphed models excluded these women since they may 
have disproportionately influenced the extremities of the graphs. Thus, the analyses 
apparently could not assess the relationship between vitamin C deficiency and breast 
cancer risk. Nevertheless, as discussed in chapter 5, the evaluation chapter, the use of 
FFQs tends to overestimate intake, therefore this cohort may contain a larger 
percentage of women with intakes below the EU RDA than calculated. 
Contrary to previous research,247 the effect of dietary vitamin C on breast cancer risk 
was not modified by family history of breast cancer in first degree relatives, even after 
stratifying the interaction test by menopausal status. Therefore the current results do 
not support the hypothesis that mechanisms of breast carcinogenesis in relation to 
dietary intake may vary according to genetic predispositions or intergeneration 
transmission of other factors that may affect risk. Sensitivity analysis using breast 
cancer family history data from France, Spain, Cambridge and Norway centres in the 
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EPIC study also found no substantial differences.244 The current results, however, may 
have been under powered to find an effect. It was expected that the UKWCS would 
have more women with a genetic predisposition than the national average since they 
were recruited via the WCRF. Previous analysis of pre-menopausal women at baseline 
found that vegetarian women had a higher risk than low meat consumers, which the 
authors suggested may relate to a family history of breast cancer.82 Although, initial 
adjustments for family histories of cancers did not alter results in the current analyses, 
further sensitivity analyses could be undertaken to exclude women with a family history 
of breast cancer. However, misclassification of breast cancer family history may have 
occurred at baseline when participants did not specify the type of cancer their relatives 
developed. 
A limitation of the study is that patterns of risk varied depending upon the tools and 
methods used to assess intake. Vitamin C intake was calculated from the list of fruit 
and vegetables ticked on the FFQ using food table nutrient compositions. As seen in 
section 5.3 of the thesis the agreement between servings of fruit and vegetables 
measured by the cross-check questions, Q7 & Q11, and that measured by the FFQ, 
was not good. The mean servings per day from the FFQ were considerably higher than 
those calculated from the cross-check questions. Indeed 11% of women (731) in group 
1 of the fruit and vegetable cross-check question had not answered either the fruit or 
vegetable serving question; some participants may have missed these cross-check 
questions. Others may have misread the servings per week as servings per day and 
therefore under-reported their intake. Additionally, there may be a tendency for 
participants to underestimate in their answers to cross-check questions. Conversely, 
FFQs tended to encourage over-reporting of fruit and vegetables consumed, therefore 
the derived vitamin C amount is also likely to be overestimated especially in the high 
intake group. As explained in section 5.3 overestimation of fruit and vegetables by 
FFQs is a known problem which has been assessed in the UKWCS.288 The authors 
suggest errors can be attenuated by applying a weighting factor for each subject. 
However, it was decided not to apply this weighting for this analysis, since it was 
unclear whether the cross-check answers reflected true intake or at least true ranking 
of fruit and vegetable servings any better than the FFQ in the UKWCS. 
Using vitamin C density, i.e. dividing vitamin C intake by total energy intake, may have 
reduced the effect of over-reporting on the FFQ. Furthermore, Willet (1998) explains 
that using nutrient densities has a tendency to produce inverse association with 
disease if total energy intake is associated with the disease, even when the nutrient is 
not independently associated with the disease.301 Willet suggests adjusting for total 
energy in nutrient density analyses to reduce this potential problem which could be 
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done in sensitivity analyses; this additional energy adjustment has been used in the 
next chapter on total vitamin C intake.301  
A strength of the restricted cubic splines, over the tables, was that the splines 
estimated breast cancer risks at all levels of intake within a wide intake range (60-
350mg/d, in comparison to 60mg/d intake), allowing any potential non-linear 
relationships to become apparent. Conversely, risk estimates shown in the tables were 
based on average intakes for each of the five intake groups so any non-
linear relationships from these would have been less clear. Also the small numbers of 
women with extreme intakes, who could have influenced the extremities of the graphs, 
were excluded. Taking account of potential confounders in the cubic splines, 
however, was much more limited compared to the adjustments made in the tables. The 
graphs showed estimated risks for only the average woman in the cohort or in the sub-
groups with respect to the confounding continuous variables; the mean values for these 
continuous variables, such as age and BMI, were noted below the graphs. Graphs for 
each category of the confounding categorical variables were not produced since sub-
grouping the women further would have substantially reduced the power of the 
cubic spline analyses. Nevertheless, the conclusions from the results of the tables and 
from the graphs were the same; that there was no evidence of any significant linear or 
non-linear associations between breast cancer risk and vitamin C intake.  
To explore whether breast cancer risk is influenced by nutrients in fruit and vegetables 
which are highly correlated with vitamin C rather than vitamin C per se, risks could be 
sub-analysed by vitamin C in fruit and by vitamin C in vegetables, though there may be 
insufficient power for further sub-analyses in the UKWCS. If different statistically 
significant patterns are found between fruit and vegetables with equivalent vitamin C 
content this would indicate that other bioactive compounds in fruit and vegetables may 
have more influence on breast cancer than vitamin C. 
In summary the results observed from this baseline analysis of the UKWCS indicated 
that fruit and vegetable intake and dietary vitamin C intake are not associated with 
breast cancer risk. 
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CHAPTER 10 
10  Is total vitamin C intake associated with breast 
cancer incidence? An analysis of diary data 
from the UK Dietary Cohort Consortium nested 
case-control study 
10.1 Summary 
Objectives: To determine whether total vitamin C intake is associated with breast 
cancer risk as few studies have included intake from both supplements and diet in their 
analyses. Furthermore, Food Frequency Questionnaires used in prospective studies 
can over-report fruit and vegetable intake, the main source of vitamin C. This is the first 
study to investigate breast cancer risk and vitamin C intake using food diaries.2 
Methods: Estimated dietary vitamin C intake was derived from four to seven day food 
diaries pooled from five prospective studies in the UK Dietary Cohort Consortium. This 
nested case-control study of 851 incident breast cancer cases and 2727 matched 
controls examined breast cancer risk in relation to dietary vitamin C intake using 
conditional logistic regression adjusting for relevant covariates. Additionally, total 
vitamin C intake from supplements and diet was analysed in three cohorts.   
Results: No evidence of associations were observed between breast cancer risk and 
vitamin C intake analysed for dietary vitamin C intake (OR = 1.00 per 60mg/d, 95%CI: 
0.91 to 1.09, Ptrend = 1.0) or total vitamin C intake (OR = 1.01 per 60mg/d, 95%CI: 1.00 
to 1.03, Ptrend = 0.1). Additionally, there was no significant association for post-
menopausal women (OR = 1.02 per 60mg/d, 95%CI: 1.00 to 1.05, Ptrend = 0.06). In the 
supplement only analysis, there was evidence of significant associations between 
vitamin C intake and incidence of breast cancer for pre-menopausal women (OR=2.51; 
95%CI: 1.22 to 5.15; p=0.01) and total women (OR=1.39; 95%CI: 1.05 to 1.82; 
p=0.02). 
Conclusions: This pooled analysis of individual UK women found no evidence of 
significant associations between breast cancer incidence and dietary or total vitamin C 
intake derived uniquely from detailed diary recordings. However, there was some 
evidence that supplements containing low doses of vitamin C were associated with an 
increased risk of breast cancer.  
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10.2 Introduction 
In the previous two chapters the relationship between breast cancer risk and vitamin C 
intake has been examined for supplement intake only, recorded by diary at phase 2 
(Chapter 8) and for dietary intake only, recorded by FFQ at baseline (Chapter 9). 
These analyses have produced little evidence that vitamin C intake per se, or fruit and 
vegetable intake were associated with breast cancer incidence in UK women. Total 
vitamin C intake, however, could not be assessed for the full UKWCS baseline or 
phase 2 datasets since both dietary and supplement vitamin C intake were not 
electronically captured at both collection points for the full cohort.  
In summary, initial findings from retrospective case-control studies have shown that 
fruit and vegetable intake, the main source of vitamin C, and also vitamin C intake were 
inversely associated with breast cancer risk. 7 8 213 However, no conclusive evidence of 
a protective effect from fruit and vegetables has been produced prospectively from 
cohort studies.7 10-13 Similarly, the meta-analyses of prospective cohorts using FFQs in 
the 2007 WCRF report showed no significant associations with dietary or supplement 
vitamin C intake, nor in subgroup analyses by menopausal status.7 Only four 
prospective studies in this report included vitamin C from supplements as well as 
diet,239 242 245 247 one of which showed an increased risk with increased total vitamin C 
intake.245 Only two studies since the WCRF report was published have assessed total 
vitamin C intake and breast cancer risk,270 273 one of which found a weak positive 
association. 270  
FFQs tend to encourage the over-reporting of fruit and vegetable consumption,288 335 347 
leading to the over-estimation of vitamin C intake,347 Alternatively, diaries may more 
accurately record numbers of fruit and vegetable portions consumed individually or in 
mixed dishes,347 over a period of days, though they are limited by their short-term 
nature. 
The current analysis is one of a small number of prospective studies assessing the 
relationship of breast cancer risk with total vitamin C intake, which includes intake from 
supplements as well as from diet. Pooling of the phase 2 UKWCS nested case-control 
data with those from four other UK cohorts was necessary to power the analysis. This 
pooled analysis of the UK Dietary Cohort Consortium is the first study to investigate the 
relationship between breast cancer risk and vitamin C intake using food diaries, an 
alternative tool to FFQs used in previous analyses. (Note that this uses an additional  
583 controls and 144 matched cases than the UK Dietary Cohort Consortium analysis 
accepted for publication.2 These were omitted from the dataset analysed for publication 
due to potential selection bias, as discussed later.) 
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10.3 Methods 
10.3.1 Subjects 
Individual participant data were pooled from five established cohort studies within the 
UK Dietary Cohort Consortium: EPIC-Norfolk;283 the UK Women’s Cohort Study 
(UKWCS);279 EPIC-Oxford;281 Whitehall II;284 and the MRC National Survey of Health 
and Development (NSHD).285 Additional information on these cohorts is provided in 
section 4.1.2 of the methods chapter. Methods used were similar to those previously 
described for colorectal case-control analyses nested within this UK consortium.293  
10.3.2 Case ascertainment and matching 
Incident cases of breast cancer were identified from data provided by UK cancer 
registries based on the International Classification of Diseases (ICD) version 9 (174) or 
10 (C50). Diagnoses within six months of food diary completion were excluded to 
ensure that latent disease without formal diagnosis was not present; otherwise disease 
suspected by participants could have influenced their dietary habits. Across the cohorts 
851 incident cases and 2727 controls were used in the dietary vitamin C analysis. Only 
three cohorts (EPIC-Oxford, EPIC-Cambridge and UKWCS) were used in the total 
vitamin C analysis which involved 745 incident cases and 2308 controls (85% of the 
consortium participants); the remaining two cohorts did not have adequate supplement 
use data to determine the vitamin C content of supplements consumed at diary date. 
Within each cohort, each case was matched to randomly selected controls based on 
age at recruitment (± 3 years) and date of diary completion (± 3 months or as close as 
possible). The number of controls matched to cases was four for EPIC-Norfolk, 
Whitehall and NSHD, and up to five for UKWCS. In EPIC-Oxford one control was 
matched to each case, to within six months of case diary completion. Controls had no 
registry-reported cancer diagnosis at recruitment (except non-melanoma skin cancer) 
and were free from breast cancer at the end of the follow-up period. The mean length 
of follow-up for cases in the cohorts ranged from 2.4 years to 10.8 years as detailed in 
Table 54; these were not adjusted for in the analyses.  
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Table 54 Characteristics of the five cohorts from the UK Dietary Cohort Consortium included in the analyses of vitamin C and breast 
cancer risk  
Cohort Participants Diary 
days 
Years when 
food diary 
completed 
Last follow 
up date 
Mean time 
to 
diagnosis 
of cases 
Cases Controls Mean(sd) 
dietary 
 vit C 
intake 
Mean(sd)  
total 
vit C 
intake 
EPIC-Norfolk General population in 
Norfolk 
7 days 1993-1998 31.12.2006 6.0 yrs 365 1329 91 (50) 118 (167) 
EPIC-Oxford General population and 
vegetarians in the UK 
7 days 1993-1998 31.12.2004 3.5 yrs 194 194 111 (61) 233 (436) 
UK Women’s 
Cohort Study 
(UKWCS) 
Middle aged women in 
the UK 
4 days 1999-2003 31.12.2006 2.4 yrs 186 785 117 (61) 239 (361) 
Whitehall II Civil servants in the UK 7 days 1991-1993 30.09.2005 7.8 yrs 70 275 101 (51) _
a
 
National 
Survey of 
Health and 
Development 
(NSHD) 
Nationally reprehensive 
cohort of women who 
were born in one week 
in March 1946 in 
England, Wales and 
Scotland. 
5 days 1989 31.12.2006 10.8 yrs 36 144 66 (37) _
a
 
aWhitehall and NSHD did not have detailed diary data of vitamin C intake from supplements 
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10.3.3 Dietary methods 
All cohorts collected dietary information using semi-weighed food diaries or included 
photographs to aid the estimation of portion size. The number of days’ intake recorded 
for each cohort is shown in Table 54; this varied from four to seven day of recording.  
Food diary details were input by trained food diary analysts; the majority (88%) were 
entered into Data into Nutrients for Epidemiological Research (DINER) developed at 
Cambridge. The details were checked and nutrient data was derived using a linked 
system (DINERMO).373 Diaries from 42 cases and 201 controls from the UKWCS were 
entered using an in-house Microsoft Access-based dietary analysis program (DANTE), 
which had previously been validated against DINER on a subsample of 100 randomly 
selected diaries, with acceptable agreement.293 Diaries from the NSHD were entered 
into DIDO295 which, after validation, proved to use portion sizes and recipes that were 
more concurrent with the time of NSHD diary completion. Owing to time and cost it was 
not possible for all diet diaries to be coded using a single data entry program. All 
estimated dietary vitamin C intake was based on standard tables of food composition 
and daily averages were calculated.287 The underlying food tables used were the same 
for all coding systems. Furthermore, since cases were matched to controls within the 
same cohort, the different coding systems were not expected to have had any adverse 
effect on results. 
In three cohorts (EPIC-Norfolk, EPIC-Oxford and UKWCS), in separate sections of the 
diaries, participants were asked to record supplement brand, name and amount per 
day for any supplement taken. Databases had been created to match this information 
against manufacturers’ information for EPIC-Norfolk;38 and UKWCS1. The UKWCS 
ingredient supplement database is described in section 4.5.3.2; this database was also 
used to allocate vitamin C amounts to supplements taken by EPIC-Oxford women. The 
two ingredient databases used included supplement descriptions and ingredient 
composition from product labels directly obtained from manufacturers or the 
participants' descriptions and/or labels. Where participants were unclear in their 
description, a weighted average of vitamin C from similar supplements was calculated 
from the database and applied.38 For instance, separate generic averages were 
calculated for multivitamins, antioxidant ACE supplements and high dose vitamin C 
supplements. For each participant the average daily vitamin C amount consumed from 
all supplement types was calculated. No supplement data was analysed for Whitehall II 
and NSHD. For the Whitehall II study supplement data had been collected via a 
questionnaire but was not detailed enough to determine the vitamin C content of all 
supplements consumed. Since the NSHD cohort had collected supplement data at later 
follow-up phase, this was not included. 
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10.3.4 Statistical analyses 
10.3.4.1 Dietary and total vitamin C analyses 
Separate quintile cut points were determined for dietary intake (mg per day), dietary 
vitamin C intake density (mg per megajoule per day) and total vitamin C intake 
including supplements (mg per day). Dietary vitamin C intake density was analysed as 
an alternative method of controlling for potential confounding by total energy intake. 
Conditional logistic regression was used to model the associations between fifths of 
vitamin C intake and breast cancer incidence. To test for linear trends continuous 
intake variables per increment of approximately one standard deviation of mean intake 
(being 60mg/day for dietary intake and 8mg/MJ/day for intake density) were used. No 
supplement intakes were implausible.  
Owing to the process of matching cases and controls the conditional logistic regression 
model automatically adjusted for date of diary completion, age (in years) and cohort. 
The multivariate model adjusted for exact age, parity (0, 1, 2, 3, 4+, missing), hormone 
replacement therapy use (current, non-current, missing), alcohol intake, total energy 
intake, weight (<60kg, 60-, 66-, >72kg, missing), height (<158cm, 158-, 163-, >168cm, 
missing), physical activity (low, low-medium, medium-high, high, missing), and 
menopausal status (pre, peri or post-menopausal, missing). The level of missing data 
ranged from 0% for alcohol and total energy intake, to 0.3% for parity to 4.2% for 
physical activity. Alcohol and total energy intake were ascertained from the diaries. All 
other covariates were collected by standard questionnaires, either self-administered or 
by trained researchers at or close to the time of diary completion. Sensitivity analysis 
was performed to adjust for variables which have weaker associations with breast 
cancer risk (smoking status and level of education), and also to adjust for important risk 
variables which had moderate levels of missing data (age at menarche (13%) and 
cumulative duration of breastfeeding (weeks) (15%)). This restricted the sensitivity 
analysis to 2811 participants. Additional sensitivity analyses also controlled for dietary 
vitamin E and iron which affect vitamin C bioavailability. No allowance was made for 
the different number of days reporting for the diaries in the different cohorts. However, 
the assumption of no heterogeneity across the different cohorts was formally tested by 
including an exposure by centre interaction term in the models. Analyses were carried 
out using Stata version 10 and results were based on a significance level of p<0.05. 
Note that peri-menopausal women were included in the analyses of total women but 
excluded from menopausal sub-analyses. 
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10.3.4.2 Supplement only vitamin C analyses 
To test the results reported in chapter 8, which found pre-menopausal women from 
phase 2 of UKWCS who took supplements containing low dose vitamin C (1-60mg/d) 
had a significantly increased risk of breast cancer, compared to women who did not 
use supplement containing any vitamin C, a similar analysis was undertaken with the 
pooled nested case-control data from the three cohorts: EPIC-Norfolk, EPIC-Oxford 
and UKWCS. These were adjusted for covariates described above. 
 
10.4 Results 
10.4.1 Dietary vitamin C intake 
On average the total women (2851) in the five cohorts were 56 years old and 
consumed 366g/d fruit and vegetables; 65% were post-menopausal, 60% had never 
smoked, 23% were educated to degree, HNC or HND level, and only 20% took HRT at 
the date of diary completion. 
As observed in Table 55, total cases (851) had similar characteristics to the 2727 
controls and their mean (sd) dietary vitamin C intakes were 99mg/d (55) and 101mg/d 
(50) respectively.  Women with a higher dietary vitamin C intake tended to have a 
higher energy intake, consume more alcohol, dietary vitamin E  and iron as well as 
more fruit and vegetables. Additionally, they were more active, had attained higher 
levels of education, or were more likely to be of higher socio-economic status or to 
have never smoked (Table 55). 
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Table 55 Characteristics of women by fifth of dietary vitamin C intake derived from food diaries in the UK Dietary Cohort Consortium  
  Breast cancer Dietary vitamin C intake (diary fifths)  
Covariates (at diary date)   Cases Controls 1 2 3 4 5 p
a
 
Cases/controls  851 2727 171/544 161/555 167/548 179/537 173/543  
Dietary vitamin C intake (mg/day) mean (SD) 99 (55) 101 (50) 38.6 (10.1) 65.0 (6.7) 88.8 (7.4) 119.1 (10.3) 186.4(47.6)  
Fruit Intake (g/d) mean (SD) 196 (140) 199 (143) 90 (78) 142 (89) 193 (103) 235 (121) 325 (167) <0.001 
Vegetable intake (g/d) mean (SD) 167 (88) 175 (95) 107 (52) 146 (65) 168 (69) 196 (92) 228 (108) <0.001 
Age at diary completion (yr) mean (SD) 56.5 (9.4) 56.0 (9.7) 55.4 (9.7) 55.9 (9.6) 56.9 (9.1) 57.1 (9.1) 56.6 (9.2) 0.03 
Height (cm) mean (SD) 162 (7) 163 (7) 161.0 (6.4) 162.0 (6.5) 162.1 (6.8) 162.8 (6.4) 163.6 (6.4) <0.001 
Weight (kg) mean (SD) 67.2 (12.2) 68.1 (12.2) 67.7 (11.5) 67.9 (13.1) 67.6 (13.1) 67.0 (11.5) 66.8 (11.4) 0.02 
Energy intake (diary, MJ/day) mean (SD) 7.5 (1.7) 7.6 (1.7) 6.8 (1.7) 7.3 (1.6) 7.5 (1.7) 7.7 (1.7) 8.1 (1.7) <0.001 
Alcohol intake (diary, g/day) mean (SD) 9.5 (13.8) 10.6 (13.9) 8.4 (13) 9.8 (14) 9.9 (13) 9.9 (13) 10.7 (15) 0.009 
Total fat (g/d) mean (SD) 67.5 (22.6) 69.3 (22.0) 64.5 (21.9) 68.3 (21.5) 67.3 (22.5) 69.3 (22.9) 69.7 (23.1) <0.001 
Dietary vitamin E (mg/d) mean (SD) 9.5 (4.0) 10.0 (4.1) 8.2 (3.9) 9.2 (3.6) 9.5 (3.7) 10.2 (4.6) 11.0 (4.3) <0.001 
Dietary Iron (mg/d) mean (SD) 11.5 (3.5) 11.9 (3.5) 9.8 (3.1) 11.1 (3.0) 11.8 (3.5) 12.2 (3.4) 13.3 (3.6) <0.001 
Parity (number of children) mean (SD) 2.0 (4.9) 2.3 (6.0) 2.5 (6.8) 2.6 (8.2) 1.9 (1.3) 2.0 (3.9) 2.1 (6.4) 0.1 
Exercise ( medium - high) n (%) 297 (37) 1021 (39) 206 (30) 246 (36) 261 (38) 297 (43) 308 (45) <0.001 
HRT use (current user) n (%) 157 (19) 524 (20) 125 (18) 142 (20) 139 (20) 154 (22) 121 (17) 0.9 
Menopausal status (post-menopausal) n (%) 519 (63) 1801 (67) 439 (63) 460 (66) 465 (66) 488 (69) 468 (66) 0.3 
Never smoked n (%) 499 (59) 1613 (60) 341 (49) 405 (57) 445 (63) 433 (61) 488 (69) <0.001 
Education level (degree) n (%) 202 (26) 568 (22) 75 (11) 116 (17 ) 142 (21) 203 (30) 234 (35) <0.001 
Social class (professional or intermediate) n (%) 331 (51) 1272 (51) 257 (40) 304 (48) 321 (51) 356 (57) 365 (61) <0.001 
a
p is ptrend over continuous exposure for continuous variables, and trend over ordered exposure groups for χ2 tests for categorical variables 
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The odds ratios for breast cancer according to dietary intake of vitamin C in the five 
cohorts are shown in Table 56 for the unadjusted and multivariate model. There was no 
evidence of any significant association between dietary vitamin C intake and incidence 
of breast cancer for total women in the five cohorts. In the adjusted analysis for total 
women the odds ratio of breast cancer per 60mg/day increments was 1.00 (95%CI: 
0.91 to 1.09, Ptrend = 1.0) Similarly, there was no evidence of any linear trends or 
significant associations between dietary vitamin C intake groups and incidence of 
breast cancer in the sub-analysis by post-menopausal status (OR=1.00 per 60mg/day, 
95%CI: 0.89 to 1.13, Ptrend = 1.0) or by pre-menopausal status (OR=0.98 per 60mg/day, 
95%CI: 0.77 to 1.24, Ptrend = 0.8). The results remained non-significant in sensitivity 
analyses after further adjustment for smoking status, age at menarche, cumulative 
duration of breastfeeding (weeks), and level of education. Odds ratios did not alter 
substantially. There was no evidence of any linear trends or significant associations 
between the incidence of breast cancer and dietary vitamin C expressed as intake 
density (Table 57).  
In tests for heterogeneity there was evidence of differences between the five study 
centres when a study centre by dietary vitamin C intake group interaction term was 
included (p=0.03 total women; p=0.07 post-menopausal; pre-menopausal p=0.3), but 
no evidence when testing only the three largest study centres (p=0.5 total women; 
p=0.3 post-menopausal). When only UKWCS, EPIC-Norfolk and EPIC-Oxford, the 
three largest cohorts, were pooled (data not shown) there was no substantial difference 
in odds ratios for dietary vitamin C compared to the results for all five cohorts 
presented in Table 56. As observed in Table 54, the mean (sd) dietary intakes for 
NSHD (66mg/d (37)) was lower than EPIC-Norfolk, Whitehall II, EPIC-Oxford, and 
UKWCS (91mg/d (50), 101mg/d (51), 111mg/d (61) and 117mg/d (61) respectively). 
The lower intake for the younger, nationally representative NSHD women (mean age 
43 vs. 50s in other cohorts) reflected previous findings from households with similar 
aged adults.374  
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Table 56 Breast cancer risks by dietary vitamin C intake recorded by diaries in the UK 
Dietary Cohort Consortium  
Dietary vitamin C intake Cases/ Unadjusted
a
 Adjusted
b
 Sensitivity
c
 
Fifths: mean mg/day (SD) Controls OR (95% CI) OR (95% CI) OR (95% CI) 
Total women     
1 (lowest):    38.6 (10.1) 171/544 1.10 (0.85, 1.42) 1.14 (0.88, 1.47) 1.09 (0.80,1.50) 
2                   65.0 (6.7) 161/555 1  1  1 
3                   88.8 (7.4) 167/548 1.02 (0.80, 1.32)  1.02 (0.79,1.31) 1.01 (0.75, 1.37) 
4                 119.1 (10.3) 179/537 1.12 (0.87, 1.44) 1.07 (0.82, 1.38) 1.18 (0.86, 1.60) 
5 (highest): 186.4 (47.6) 173/543 1.04 (0.81, 1.35) 0.99 (0.76, 1.29) 1.10 (0.80, 1.52) 
P  trend per 60mg/d  0.5 1.0 0.5 
Estimate per 60mg/d  1.02 (0.93, 1.12) 1.00 (0.91, 1.09) 1.04 (0.93, 1.16) 
     
Post-menopausal     
1 (lowest)      38.5 (9.9) 100/339 1.08 (0.77, 1.52) 1.16 (0.82, 1.64) 1.17 (0.79, 1.73) 
2                    65.3 (6.6) 99/361 1 1 1 
3                    88.8 (7.3) 106/359 1.12 (0.81, 1.55) 1.16 (0.83, 1.62) 1.29 (0.88, 1.88) 
4                 119.1 (10.2) 112/376 1.12 (0.81, 1.56) 1.10 (0.78, 1.53) 1.26 (0.86, 1.84) 
5 (highest)  186.3 (47.5) 102/366 0.99 (0.71, 1.38) 0.96 (0.67, 1.36) 1.03 (0.69, 1.53) 
P trend per 60mg/d  0.4 1.0 0.7 
Estimate per 60mg/d  1.03 (0.91, 1.15)  1.00 (0.89,1.13) 1.03 (0.90, 1.18) 
     
Pre-menopausal     
1 (lowest)     38.5 (10.6) 41/136 1.32 (0.76, 2.27) 1.39 (0.76, 2.53) 1.39 (0.57, 3.37) 
2                    64.6 (6.9) 36/127 1 1 1 
3                    89.1 (7.9) 30/120 0.98 (0.54, 1.78) 1.01 (0.54, 1.90) 0.83 (0.32, 2.15)  
4                 119.3 (10.6) 37/101 1.25 (0.71, 2.20) 1.11 (0.59, 2.07) 1.46 (0.58, 3.69) 
5 (highest)  182.1 (41.4) 37/110 1.29 (0.71, 2.28) 1.17 (0.63, 2.19) 1.24 (0.49, 3.15) 
P  trend per 60mg/d  0.8 0.8 0.6 
Estimate per 60mg/d  1.03 (0.83, 1.28) 0.98 (0.77, 1.24) 1.09 (0.77, 1.54) 
     
a
Conditional logistic regression on cases and controls matched by centre, age, date of diary 
completion and length of follow-up 
b
As for the unadjusted model with additional adjustment for exact age, height (<158cm, 158-, 
163-, 168+), weight (<60kg, 60-, 66-, 72+), physical activity, parity (0,1,2,3,4+), current HRT 
use, menopausal status, diary-derived alcohol consumption and total energy intake. Missing 
data added as a category. 
c
Sensitivity analysis, as for the adjusted model with additional adjustment for age at menarche, 
cumulative breast feeding, educational level and smoking status 
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Table 57 Breast cancer risks by dietary vitamin C density intake recorded by diaries in 
the UK Dietary Cohort Consortium  
vitamin C nutrient density Cases/ Unadjusted
a
 Adjusted
b
 Sensitivity
c
 
Fifths:mean mg/MJ/d (SD) Controls OR (95% CI) OR (95% CI) OR (95% CI) 
Total women     
1 (lowest):      5.4  (1.3) 175/540 1.04 (0.81, 1.32) 1.03 (0.80, 1.33) 1.15 (0.85,1.57) 
2                     8.8 (0.9) 170/546 1 1 1 
3                    12.0 (1.0) 166/549 0.94 (0.73, 1.20) 0.93 (0.72, 1.19) 1.05 (0.78, 1.42) 
4                    16.2 (1.4) 177/539 1.03 (0.80, 1.32) 1.02 (0.79, 1.32) 1.13 (0.84, 1.53) 
5 (highest):    25.6 (7.0) 163/553 0.89 (0.69, 1.15) 0.90 (0.69, 1.17) 1.08 (0.78, 1.48) 
P trend per 8 mg/MJ/d  0.7 0.8 0.6 
Estimate per 8 units  0.98 (0.90, 1.07) 0.99 (0.90, 1.08) 1.03 (0.92,1.14) 
     
Post-menopausal     
1 (lowest):      5.5  (1.3) 99/315 1.04 (0.74, 1.46) 1.03 (0.73, 1.46) 1.15 (0.77, 1.70) 
2                     8.9 (0.9) 95/344 1 1 1 
3                    12.0 (1.0) 104/371 0.94 (0.67, 1.31) 0.93 (0.66, 1.32) 1.02 (0.69, 1.50) 
4                    16.2 (1.4) 120/385 1.05 (0.75, 1.46) 1.07 (0.77, 1.51) 1.13 (0.78, 1.65) 
5 (highest):    25.8 (7.1) 101/386 0.87 (0.62, 1.23) 0.90 (0.63, 1.29) 1.01 (0.67, 1.51) 
P trend per 8 mg/MJ/d  0.8 0.9 0.7 
Estimate/ 8 units  0.98 (0.88, 1.10) 1.00 (0.89,1.12) 1.03 (0.90, 1.17) 
     
Pre-menopausal     
1 (lowest):      5.4  (1.4) 46/149 1.30 (0.76, 2.24) 1.32 (0.74, 2.34) 1.33 (0.57, 3.10) 
2                     8.8 (0.9) 42/136 1 1 1 
3                    12.0 (1.0) 31/107 1.02 (0.57, 1.84) 0.95 (0.52, 1.75) 0.89 (0.37, 2.18) 
4                    16.2 (1.4) 35/98 1.14 (0.63, 2.03) 1.04 (0.56, 1.93) 1.46 (0.64, 3.30) 
5 (highest):    24.8 (6.0) 27/104 0.95 (0.52, 1.74) 0.90 (0.47, 1.74) 1.13 (0.45, 2.80) 
P trend per 8 mg/MJ/d  0.7 0.7 0.6 
Estimate/ 8 units  0.96 (0.78, 1.19) 0.94 (0.75, 1.20) 1.11 (0.79, 1.56) 
     
a
Conditional logistic regression on cases and controls matched by centre, age, date of diary 
completion and length of follow-up. 
b
As for the unadjusted model with additional adjustment for exact age, height (<158cm, 158-, 
163-, 168+), weight (<60kg, 60-, 66-, 72+), physical activity, parity (0,1,2,3,4+), current HRT 
use, menopausal status, alcohol consumption and total energy intake. Missing data added as a 
category. 
c
Sensitivity analysis, as for the adjusted model with additional adjustment for age at menarche, 
cumulative breast feeding, educational level and smoking status 
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10.4.2 Total vitamin C intake 
In the analyses of total vitamin C, cases had a somewhat higher total vitamin C intake 
than controls 191mg/d (sd 400) vs. 165mg/d (sd 246). As observed in Table 54 the 
mean vitamin C supplement intake per day for EPIC-Norfolk was significantly less than 
those for UKWCS or EPIC-Oxford (means mg/d (sd) were 28 (160), 122 (529) and 123 
(695) respectively); likewise for total intake (means mg/d (sd) were 119 (168), 239 
(361) and 234 (436) respectively). Based on diary completion date, mean total intake in 
autumn and winter compared to spring and summer were not significantly different 
(173.3 (sd 327) vs. 169.9 (sd 254) mg/d); comprising respectively of 47.1% and 52.9% 
of these women. The relationships between total vitamin C intake split by fifths and 
lifestyle characteristics are shown in Table 58 and were similar to those for dietary only 
intake (Table 55). The highest intake group had the highest vitamin C intake from both 
diet and supplements (mean (sd) 159 (76) mg/d) and 326 (561) mg/d respectively); 
72% took supplements containing vitamin C and 84% of these women took them every 
day. 
In pooling the three cohorts which recorded vitamin C intake from supplements there 
was also no evidence of any significant associations between total vitamin C intake and 
incidence of breast cancer in the adjusted analysis for the continuous estimate for all 
women (OR = 1.01 per 60mg/d, 95%CI: 1.00 to 1.03, Ptrend = 0.1), or for post-
menopausal women (OR = 1.02 per 60mg/d, 95%CI: 1.00 to 1.05, Ptrend = 0.06) or for 
post-menopausal women (OR = 1.01 per 60mg/d, 95%CI: 0.94 to 1.09, Ptrend = 0.8) or 
by fifths of total vitamin C intake (Table 59). The results remained non-significant in 
sensitivity analyses after further adjustment for smoking status, age at menarche, 
cumulative duration of breastfeeding, and level of education. There was no evidence of 
significant differences between the three study centres when formally tested using a 
study centre by fifths of total vitamin C intake interaction term, for total, post- or pre- 
menopausal women (p=0.7, p=0.9 and 0.5 respectively).  
For both dietary and total intake no substantial differences in the estimates were found 
in sensitivity analyses controlling for dietary vitamin E and iron.  
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Table 58 Characteristics by case/control status & total vitamin C intake of women in EPIC-Oxford, EPIC-Norfolk and UKWCS nested case-control cohorts 
    Total vitamin C intake (diary fifths)  
Covariates (at diary date)   Cases Controls 1 2 3 4 5 p
a
 
Cases/controls  745 2308 132/478 145/466 163/447 153/458 152/459  
Total vitamin C intake (mg/day) mean (SD) 190.8 (399.6) 165.3 (245.8) 42.4 (11.8) 74.7 (8.4) 105.2 (9.9) 149.3 (17.5) 485.6 (541.8)  
Dietary vitamin C intake (mg/day) mean (SD) 104.4 (59.7) 100.5 (55.5) 42.0 (11.9) 73.1 (10.5) 99.3 (18.5) 134.0 (31.6) 158.9 (75.5) <0.001 
Supplement vitamin C intake (mg/day) mean (SD) 86.4 (391.7) 64.8 (236.2) 0.4 (3.3) 1.6 (7.3) 6.0 (16.1) 15.3 (29.9) 326 (561) <0.001 
Days/week vitamin C supplement taken mean (SD 1.4 (2.5) 1.1 (2.6) 0.1 (0.8) 0.3 (1.2) 0.7 (2.0) 1.3 (2.4 ) 3.6 (2.7) <0.001 
Age at diary completion (yr) mean (SD) 57.1 (9.6) 58.0 (9.1) 57.9 (9.2) 58.5 (9.5) 58.4 (9.1) 57.1 (8.8) 57.3 (9.5) 0.004 
Height (cm) mean (SD) 163.3 (6.5) 162.0 (6.5) 161.1 (6.1) 161.9 (6.6) 162.3 (6.8) 162.9 (6.4) 163.4 (6.5) <0.001 
Weight (kg) mean (SD) 68.4 (12.1) 67.4 (12.1) 68.5 (11.5) 68.8 (13.3) 67.6 (12.8) 67.8 (11.8) 65.6 (10.8) 0.2 
Energy intake (diary, MJ/day) mean (SD) 7.6 (1.7) 7.4 (1.7) 6.8 (1.6) 7.3 (1.7) 7.6 (1.7 ) 7.8 (1.6) 7.9 (1.7) <0.001 
Alcohol intake (diary, g/day) mean (SD) 10.5 (13.3) 9.2 (13.4) 8.0 (12.9) 9.0 (12.5) 9.7 (12.3) 10.1 (13.3) 10.7 (14.8) 0.1 
Total fat (g/d) mean (SD) 68.4 (21.9) 66.5 (22.1) 63.4 (19.9) 66.6 (22.2) 68.0 (22.4) 67.8 (20.9) 69.1 (23.7) 0.006 
Non starch Polysaccharide (g/d) mean (SD) 15.6 (5.7) 15.2 (5.6) 11.6 (4.2) 14.2 (4.7) 15.6 (5.1) 16.8 (5.3) 18.0 (6.2) <0.001 
Parity (number of children) mean (SD) 1.8 (1.2) 2.0 (1.3) 2.1 (1.2) 2.0 (1.2) 2.0 (1.2) 2.0 (1.3) 1.8 (1.3) <0.001 
Taking supplements with vitamin C n (%) 193 (26) 541 (23) 9 (1) 33 (5) 93 (15) 159 (26) 440 (72) <0.001 
Takes any supplement n (%) 387 (52) 1175 (51) 179(29) 239 (39) 290 (48) 345 (56) 509 (83) <0.001 
Exercise ( moderate - high) n (%) 254 (37) 866 (39) 176 (30) 219 (37) 240 (41) 232 (40) 253 (44) <0.001 
HRT use (current user) n (%) 144 (20) 471 (21) 113 (19) 126 (21) 124 (21) 120 (20) 132 (22) 0.4 
Menopausal status (post-menopausal) n (%) 489 (67) 1682 (74) 447 (74) 456 (76) 444 (74) 415 (69) 409 (68) 0.001 
Never smoked n (%) 440 (60) 1398 (61) 313 (52) 361 (60) 376 (62) 381 (63) 407 (67) <0.001 
Education level (degree) n (%) 191 (27) 506 (23) 61 (10) 103 (17) 145 (25) 181 (31) 207 (36) <0.001 
Social class (professional or intermediate) n (%) 271 (50) 1033 (50) 198 (37) 256 (47) 269 (52) 274 (54) 307 (62) <0.001 
a
p is ptrend over continuous exposure for continuous variables, and trend over ordered exposure groups for χ2 tests for categorical variables 
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Table 59 Breast cancer risks by total vitamin C intake recorded by diaries in EPIC-
Oxford, EPIC-Norfolk and UKWCS cohorts of the UK Dietary Cohort Consortium 
Total vitamin C intake 
Cases/ Unadjusted
a
 Adjusted
b
 Sensitivity
c
 
Fifths: mean mg/day (SD) 
Controls OR (95% CI) OR (95% CI) OR (95% CI) 
Total women     
1 (lowest):   42.4 (11.8) 132/478 0.86 (0.66, 1.14) 0.88 (0.66, 1.16) 0.96 (0.71, 1.32) 
2                  74.7 (8.4) 145/466 1 1 1 
3                 105.2 (9.9) 163/447 1.15 (0.88, 1.50) 1.13 (0.86, 1.49) 1.14 (0.85, 1.54) 
4                 149.3 (17.5) 153/458 1.00 (0.76, 1.31) 0.96 (0.72, 1.26) 1.07 (0.78, 1.46) 
5 (highest): 485.6 (542) 152/459 1.01 (0.76, 1.35) 0.99 (0.74, 1.32) 0.98 (0.70, 1.35) 
P for trend per 60mg/d  0.2 0.1 0.3 
Estimate per 60mg/d  1.01 (0.99, 1.03) 1.01 (1.00, 1.03) 1.01 (0.99, 1.03) 
     
Post-menopausal     
1 (lowest)     42.7 (11.7) 95/352 1.01 (0.72, 1.41) 1.07 (0.75, 1.51) 1.18 (0.81, 1.72) 
2                    74.3 (8.4) 99/357 1 1 1 
3                  105.4 (9.9) 112/332 1.23 (0.88, 1.71) 1.29 (0.92, 1.82) 1.39 (0.96, 2.01) 
4                 149.1 (17.8) 91/324 1.00 (0.70, 1.41) 0.97 (0.67, 1.39) 1.09 (0.73, 1.61) 
5 (highest)  463.3 (492) 92/317 1.12 (0.78, 1.59) 1.11 (0.77, 1.59) 1.16 (0.77, 1.74) 
P for trend per 60mg/d  0.09 0.06 0.2 
Estimate per 60mg/d  1.02 (1.00, 1.04) 1.02 (1.00,1.05) 1.02 (0.99, 1.05) 
     
Pre-menopausal     
1 (lowest)     41.1 (12.5) 17/74 1.04 (0.45, 2.37) 0.79 (0.31, 2.02) 1.02 (0.33, 3.14) 
2                    75.3 (8.1) 22/64 1 1 1 
3                   104.0 (9.3) 24/72 1.28 (0.56, 2.92) 1.27 (0.51, 3.11) 1.34 (0.44, 4.08) 
4                 149.8 (17.4) 32/78 1.26 (0.59, 2.66) 1.13 (0.49, 2.58) 1.61 (0.56, 4.66) 
5 (highest)  457.5 (349) 26/85 1.46 (0.65, 3.29) 1.33 (0.55, 3.23) 1.06 (0.35, 3.20) 
P for trend per 60mg/d  0.7 0.8 0.9 
Estimate per 60mg/d  1.01 (0.95, 1.09) 1.01 (0.94, 1.09) 0.99 (0.91, 1.09) 
     
a
Conditional logistic regression on cases and controls matched by centre, age, date of diary 
completion and length of follow-up 
b
As for the unadjusted model with additional adjustment for height (<158cm, 158-, 163-, 168+), 
weight (<60kg, 60-, 66-, 72+), physical activity, parity (0,1,2,3,4+), current HRT use, 
menopausal status, diary-derived alcohol consumption and total energy intake 
c
Senstivity analysis as for the adjusted model with additional adjustment for age at menarche, 
cumulative breast feeding, educational level and smoking status 
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10.4.3 Supplement-only vitamin C intake 
In the supplement-only analysis there was evidence of significant associations between 
vitamin C intake and incidence of breast cancer for total women and pre-menopausal 
women who took supplements containing low doses of vitamin C (1-60mg/d). As seen 
in Table 60, the odds ratio was higher for pre-menopausal women (OR=2.51; 95%CI: 
1.22 to 5.15; p=0.01) than for total women (OR=1.39; 95%CI: 1.05 to 1.82; p=0.02). A 
moderate increased risk was also seen for post-menopausal women in this intake 
range but this was not significant (OR=1.24; 95%CI: 0.84 to 1.80). No significant 
associations were found in the other intake ranges (>60<500mg/d and ≥500mg/d).  
Similar results were produced in sensitivity analyses after further adjustment for 
smoking status, age at menarche, cumulative duration of breastfeeding (weeks), and 
level of education. Odds ratios increased for pre-menopausal women taking 
supplements containing low doses of vitamin C (OR=3.34; 95%CI: 1.37, 8.17; 
p=0.008).  
As observed in Table 61, the majority (66%) of the pre-menopausal women in this 
supplement intake category were from the UKWCS. Results of separate analyses for 
the UKWCS nest case-control for pre-menopausal women using supplements 
containing low dose of vitamin C were much higher than the analysis which combined 
the other two cohorts and the latter was not significant ((OR=4.54; 95%CI: 5.3, 13.6; 
p=0.007) vs. (OR=1.62; 95%CI: 0.54, 4.91; p=0.4) not tabled). 
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Table 60 Breast cancer risks according to vitamin C content of supplements recorded 
by diaries in EPIC-Oxford, EPIC-Norfolk UK and UKWCS cohorts of the UK Dietary 
Cohort Consortium  
Supplement vit C  Cases/ Unadjusted
a
 Adjusted
b
 Sensitivity
c
 
Intake mean mg/day  Controls OR (95% CI) OR (95% CI) OR (95% CI) 
Total women     
No vitamin C  552/1767 1 1 1 
1-60mg/d 93/221 1.35 (1.03, 1.78) 1.39 (1.05, 1.83) 1.39 (1.03, 1.90) 
>60<500mg/d 59/199 0.89 (0.64, 1.24) 0.89 (0.64, 1.24) 0.83 (0.56, 1.22) 
≥500mg/d 41/121 0.99 (0.66, 1.48) 0.98 (0.65, 1.48) 0.90 (0.56, 1.44) 
     
Post menopausal     
No vitamin C  383/1312 1 1 1 
1-60mg/d 48/153 1.16 (0.80, 1.67) 1.24 (0.84, 1.80) 1.34 (0.89, 2.02) 
>60<500mg/d 35/139 0.91 (0.60, 1.38) 0.90 (0.58, 1.37) 0.89 (0.55, 1.45) 
≥500mg/d 23/78 1.04 (0.60, 1.80) 1.01 (0.58, 1.78) 0.89 (0.47, 1.68) 
     
Pre- menopausal     
No vitamin C  81/270 1 1 1 
1-60mg/d 22/39 2.34 (1.21, 4.51) 2.51 (1.22, 5.15) 3.34 (1.37, 8.17) 
>60<500mg/d 8/39 0.92 (0.36, 2.35) 0.88 (0.30, 2.58) 0.90 (0.25, 3.27) 
≥500mg/d 10/25 1.34 (0.51, 3.54) 1.28 (0.45, 3.67) 0.92 (0.27, 3.18) 
     
a
Conditional logistic regression on cases and controls matched by cohort, age and date of diary 
completion 
b
As for the unadjusted model with additional adjustment for exact age, height (<158cm, 158-, 
163-, 168+), weight (<60kg, 60-, 66-, 72+), physical activity, parity (0,1,2,3,4+), current HRT 
use, menopausal status, diary-derived alcohol consumption total energy intake, and dietary 
vitamin C. Missing data added as a category. 
c
Senstivity analysis as for the adjusted model with additional adjustment for age at menarche 
cumulative breast feeding, educational level and smoking status. 
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Table 61 The percentage of women in each supplement category from the three 
cohorts of the UK Dietary Cohort Consortium in the vitamin C supplement analyses 
Numbers (%) Epic-Norfolk UKWCS Epic-Oxford Total 
Total     
No vitamin C  1433 (62%) 618 (26%) 268(12%) 2319 (100%) 
1-60mg/d 141 (45%) 133 (42%) 40 (13%) 314 (100%) 
>60<500mg/d 92 (36%) 120 (46%) 46 (18%) 258 (100%) 
≥500mg/d 28 (17%) 100 (62%) 34 (21%) 162 (100%) 
Total 1694 (55%) 971 (32%) 388 (13%) 3053 (100%) 
     
Post-
menopausal 
    
No vitamin C  1183 (70%) 389 (23%) 123 (7%) 1695 (100%) 
1-60mg/d 114 (57%) 76 (38%) 11 (5%) 201 (100%) 
>60<500mg/d 73 (42%) 84 (48%) 17 (10%) 174 (100%) 
≥500mg/d 24 (24%) 66 (65%) 11 (11%) 101 (100%) 
Total  1394 (64%) 615 (28%) 162 (8%) 2171 (100%) 
     
Pre-menopausal     
No vitamin C  171 (49%) 155 (44%) 25 (7%) 351 (100%) 
1-60mg/d 19 (31%) 40 (66%) 2 (3%) 61 (100%) 
>60<500mg/d 13 (28%) 27 (57%) 7 (15%) 47 (100%) 
≥500mg/d 4 (11%) 25 (72%) 6 (17%) 35 (100%) 
Total  207 (42%) 247 (50%) 40 (8%) 494 (100%) 
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10.5 Discussion 
This pooled analysis of individual participant data from five UK cohorts found no 
evidence of an association between incidence of breast cancer and dietary vitamin C 
intake recorded by food diaries. Neither was there any evidence of an association with 
total vitamin C intake when vitamin C from supplements was included for three of the 
cohorts. The non-significant results relating to dietary vitamin C intake support null 
results found in chapter 9 which used data from the whole of the UKWCS baseline. 
The current results for post-menopausal women also support the results of the 2007 
WCRF meta-analyses of three cohort studies (RR=1.15 per 100mg/d, 95% CI: 0.92-
1.43),7 245 246 265 also the high versus low intake results of two US studies,242 247 and the 
recent European Prospective Investigation into Cancer (EPIC) analysis involving the 
pooling of data from 10 European countries (highest vs. lowest quintile HR = 0.98, 95% 
CI: 0.87–1.11);244 all of which used FFQs. The current results for dietary vitamin C are 
in conflict with significant evidence of a 12-14% reduced risk found in the meta-analysis 
of retrospective case-control studies which,7 unlike our study, are prone to recall bias.  
In contrast to the results from the current analysis and other studies,239 242 247 273 the 
large Women’s Health Initiative study270 found significant but weak evidence of 
increased breast cancer risk for total intake. The advanced age of the participants in 
this cohort (average 64 years) might suggest that high vitamin C intake may promote 
the progression of cancer in older people or at later stages of the disease. Similarly 
positive associations with post-menopausal breast cancer for both dietary and total 
vitamin C intake (OR= 2.06 per 100mg/d, 95% CI: 1.45-2.91; and OR=1.08 per 
100mg/d, 95% CI: 1.02-0.1.15 respectively) were found in a small Danish nested case-
control study,245 but not in the recent full analysis of this Danish cohort;273 selection 
bias of controls or restricting to women who consumed vitamins from both dietary and 
supplement sources may have possibly influenced the earlier results. Total intake 
could not be assessed for the full UKWCS baseline or phase 2 datasets, since both 
dietary and supplement vitamin C intake was not captured at both collection points. 
The doubling of breast cancer risk for pre-menopausal women consuming supplements 
containing low dose of vitamin C (1-60mg/d) in the supplement-only analyses supports 
earlier results found in chapter 8 which analysed data from the full phase 2 UKWCS 
dataset. This was despite a difference in calculating the average intake: the average 
supplement vitamin C intake used in this nested case-control was calculated over the 
total diary days, whereas the average used in the full dataset was calculated over the 
number of days taken. Possible reasons for the similar results were because diary 
recordings were used in both, and because a large proportion of these women in the 
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pooled nested case-control dataset were from the UKWCS (66%). Indeed, a significant 
association was found in the analysis using only UKWCS data, but not in the analyses 
combining EPIC-Norfolk and EPIC Oxford, though the latter may be due to low 
numbers involved. One reason why the result for total women consuming supplements 
containing low dose vitamin C in this analysis, and not in the previous analysis in 
chapter 8, is that pre-menopausal women made up a larger proportion of the total in 
this dataset than the full UKWCS phase 2 dataset. 
Pooling of the cohorts was necessary since none of the separate nested case-control 
studies was large enough to power the analysis to detect a significant moderate effect 
for total vitamin C intake (about 650 cases with five matched controls were needed to 
detect an OR of 1.4, as calculated in the methods chapter, section 4.7.7). Pooling 
individual participant data in this consortium had three other advantages. Firstly, it 
ensured that vitamin C intake from the whole consortium could be categorised into 
fifths; secondly, the variations in intake across the cohorts increase the power to detect 
smaller effect sizes,375 i.e. many women in EPIC-Oxford and UKWCS were vegetarians 
and/ or consumed supplements containing vitamin C compared to the other cohorts; 
thirdly, analysis and adjustment by covariates could be done in a uniform way.   
The study had a few caveats. Whilst the use of missing covariate categories may have 
grouped dissimilar individuals and introduced some bias, its effect on the adjusted 
results may be considered acceptable since the level of missing data was small, and 
confounding was judged to be weak. To account for the possible modulation of vitamin 
C on cancer development due to its the role in the regeneration of vitamin E, in the 
absorption of iron and in the Fenton reaction,76 sensitivity analysis adjustments were 
made for these dietary nutrients. Supplement intake data for these nutrients, however, 
was not available. The Danish studies, one of which found a positive association, 
controlled for both dietary and supplement intake of vitamin A and E.245 273 In the 
current study data were unavailable to adjust for family history of breast cancer which 
has been associated with high-dose vitamin C supplement use in the UK 1. Data were 
unavailable from all cohorts to exclude general supplement users from the dietary 
analysis; the different health behaviours of users may have influenced the results.27 
There was inadequate power to sub-analyse by HRT users, oestrogen receptor-
negative or pre-menopausal breast cancers to find moderate effects.  
Unfortunately, it was considered that the selection of some of the UKWCS controls was 
biased, in that they may have not been truly representative of the cohort, the 
population from which the cases were drawn, with respect to vitamin C exposure. This 
selection bias could have been minimised by selecting controls at random from the 
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whole cohort. However, the controls from the UKWCS which were coded using DINER, 
a system developed at Cambridge, were considered not to be a random selection since 
it was later found that they were more likely to be meat-eaters and less likely to be 
vegetarians than the cohort as a whole. It was assumed that, on average, the meat-
eaters would have consumed less vitamin C than vegetarians, and therefore controls 
were likely to have had lower vitamin C intake than the cohort on average. An 
artificially inflated difference in vitamin C intake between cases and controls could have 
attenuated any potential associations between breast cancer risk and vitamin C intake 
in the results. Therefore, for the manuscript accepted for publication which used the 
same dietary and total analysis methods used in this chapter,2 these 583 controls and 
the 144 matched cases were omitted from the dataset due to potential selection bias. 
However, their omission made little difference to the results, giving further support to 
the conclusion that vitamin C intake is not associated with breast cancer risk. 
Additionally, further inspection indicated that the vitamin C intake of these controls was, 
in fact, unlikely to be much different from the cohort as a whole; as seen in chapter 5, 
section 5.3.3, the vegetarians in the UKWCS on average consumed only 3% more 
vitamin C than non-vegetarians, the majority of whom were meat eaters. Given these 
facts, it was decided to include these cases and controls in the analyses for this 
chapter. 
This is the first time the relationship between breast cancer risk and vitamin C intake 
has been analysed using prospective data from food diaries. Diaries can capture 
detailed and accurate intake over a narrow period of days due to their open format, 
whereas FFQs aim to reflect intake over a much longer period, normally an estimated 
average of the previous 12 months. Repeated diary data collections may reduce their 
short-term limitations but were not undertaken for the whole consortium due to 
expense and time taken to administer, complete and analyse. The required 
commitment and awareness of intake may have also influenced participants’ 
consumption during diary recording. As discussed in section 5.4.4 of the evaluation 
chapter, when compared to FFQs, food diaries have shown stronger correlations with 
plasma vitamin C biomarkers in validity tests when collected in close temporal 
proximity. However this may reflect the short-term nature of both plasma vitamin C and 
diary data, particularly since correlations with biomarker levels re-measured several 
years later were similar for diaries and FFQs.346 347 370 Furthermore, other UK validation 
studies have shown similar associations between biomarkers and vitamin C estimated 
from FFQs and diaries. 294 338 Overall correlations between biomarkers and FFQs or 
diaries are generally weak to moderate.335 343 Since the absorption and storage of 
vitamin C is limited, particularly above 400mg/d,65 biomarkers are unlikely to reflect 
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dietary vitamin C intake well. Therefore it is difficult to assess objectively whether 
diaries or FFQs can rank individual intake sufficiently well in order to find associations 
between vitamin C and cancer risk. Given the limitations, results of vitamin C analyses 
from either FFQs and diaries need to be treated with some caution. Additional analysis 
could be undertaken using dietary vitamin C FFQ data from this UK Dietary Cohort 
Consortium dataset, to compare them with the diary dietary vitamin C results. 
Nevertheless, the dietary results using diary data in this chapter supports those 
reported in chapter 9 using FFQ recordings. 
To conclude, the supplement-only results support those found in chapter 8, that use of 
supplements containing low-dose vitamin C is associated with increased breast cancer 
risk, though as explained in chapter 8, the results may be due to the effects of other 
ingredients in supplements, or may be spurious. In relation to dietary or total vitamin C 
intake, the evidence to date from this and other prospective studies does not indicate 
either a beneficial or a detrimental effect of vitamin C intake on breast cancer risk.   
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CHAPTER 11  
11 Summary discussion 
The analyses in this thesis have used data from the UKWCS and other cohorts in the 
UK Dietary Cohort Consortium. These are some of the largest population-based 
prospective studies in the UK which were designed to assess associations between 
diet and chronic diseases. The majority of the analyses used previously unexploited 
supplement data to explore, for the first time, breast cancer risk in UK women in 
relation to:  
 any supplement use, including use of any supplements over two recording 
periods, roughly 4 years apart (chapter 7) 
 vitamin C contained in supplements, examining dose-response relationships, as 
well as the risk of taking supplements containing high, medium and low vitamin 
C content (chapter 8) 
 dietary vitamin C intake derived from FFQs for supplement users and non-
users; the latter sub-analysis provided a clearer picture of the relationship 
between breast cancer risk and dietary vitamin C intake without residual 
confounding by factors relating to supplement use. The use of restricted cubic 
spline models enabled non-linear relationships between vitamin C intake and 
breast cancer risk to be explored for the first time (chapter 9) 
 total vitamin C intake from both diet and supplements; this was examined 
prospectively for the first time using food diary records instead of FFQs (chapter 
10) 
The combination of these objectives ensured that vitamin C intake in relation to breast 
cancer risk in UK women had been thoroughly examined in this thesis. The first three 
objectives used data from the baseline or phase 2 of the UKWCS only, whilst the fourth 
objective used nested case-control data from the UKWCS and other UK studies, which 
were part of the UK Dietary Cohort Consortium. Data from the extensive supplement 
ingredient database and participant supplement use database at phase 2 of the 
UKWCS was used for the second objective. Additionally, a large number of vegetarian 
women consuming high levels of dietary vitamin C from fruit and vegetables were 
included in the baseline analysis. This provided a wide range of vitamin C intakes for 
analysis. Furthermore, women from baseline and phase 2 in the UKWCS were 
followed-up for cancer incidences for over 11 and 7 years respectively, which was 
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comparable to or better than most studies detailed in the literature review chapter in 
section 3.7.2. 
A major strength of these studies is that their prospective nature minimised reverse 
causality, recall bias and responder bias which can affect results of retrospective case-
control studies. Selection bias, however, may have been present in the nested case-
control analysis of total vitamin C, though this may have been minimal. Their large size 
increased the power of the analyses, particularly in the baseline and nested case-
control analyses which involved substantial numbers of cases. Additionally, the study 
questionnaires captured many important health and lifestyle factors which were 
potential confounders and were adjusted for in the analyses.  
The UKWCS, instigated through the World Cancer Research Fund, in general 
comprised of health conscious women. The results are therefore directly applicable to 
similar women, who would be interested to know how lifestyles choices could affect 
their breast cancer risk, and who may be prepared to alter their behaviours. The UK 
Dietary Cohort Consortium data produced results slightly more generalizable to the UK 
population as a whole, in addition to providing an opportunity to examine breast cancer 
risk in relation to total vitamin C intake recorded by diary data. 
In addition to the objectives listed above, the phase 2 UKWCS data provided an 
opportunity to determine, for the first time, whether UK women who have a history of 
breast cancer were more likely to use high dose vitamin C supplements. The results 
showed women who had a family history of breast cancer, or who self-reported having 
had breast cancer, were respectively 26% and 70% more likely to use vitamin C 
supplements of 1000mg/d or above, (chapter 6).1 Since these women were likely to 
have different health behaviours than others, women with a family history of breast 
cancer were adjusted for and/or excluded in breast cancer risk sensitivity analyses in 
this thesis. 
In relation to risk, the results showed there was no evidence of statistically significant 
associations between general supplement use, fruit and vegetable intake and vitamin 
C intakes per se and breast cancer incidence in the UK in any of the analyses reported 
in this thesis. Similarly, no associations were found after excluding all supplement 
users in the dietary vitamin C analysis; previously non-supplement users had been 
examined in only one other cohort.273 Moreover, the unique use of diary recorded data 
in dietary and total vitamin C analyses produced no evidence of associations with 
breast cancer risk. These results are inline with the majority of previous prospective 
studies from other countries reported in the 2007 WCRF review and the 2008 WCRF 
continuous update.7 169 As discussed in section 3.7 of the literature review chapter, the 
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inclusion of the results from more recently published studies in future meta-analyses 
are unlikely to produce a different conclusion from the 2007 WCRF review,14 244 270 273 
despite a significantly increased breast cancer risk with high vitamin C intake from 
supplements reported in 2008 by a large US study.270 Meta-analyses including these 
recent studies have not been done for this thesis since these are likely to be 
undertaken by the WCRF in their future continuous updates. Regardless, there was 
insufficient evidence from the UKWCS and other studies to support a U–shaped 
relationship between vitamin C intake and breast cancer risk, which at the start of this 
thesis had been hypothesised due to the potential of vitamin C to act as both an 
antioxidant and a pro-oxidant.  
The current study did, however, find a more than doubled increased risk for pre-
menopausal women taking supplements containing low dose vitamin C, up to and 
including 60mg/d (the EU RDA), compared to women not taking supplements 
containing vitamin C. Since there appears to be no biological rationale that this 
increased risk is specifically due to low vitamin C content, it was thought to be due to 
other ingredients in the supplements taken. However, in exploring the relationship with 
multivitamin supplements, which usually contain EU RDA amounts of vitamin C, no 
significant associations with breast cancer in the UKWCS were observed (although a 
non-significant increased risk of 50% for pre-menopausal women was found for daily 
users). Additionally, as seen in chapter 7, general supplement use was associated with 
a weak, but non-significant increased risk for pre-menopausal women. The significant 
finding may be spurious due to residual confounding, or possible inappropriate use of 
covariates or due to low numbers of pre-menopausal women involved. Alternatively 
multiple testing of sub-groups may have produced spurious significant associations by 
chance, though the pattern seen for pre-menopausal women does not support this. To 
avoid chance findings, lower p values for testing levels of statistical significance could 
have been used;298  the p-values, nevertheless, for the doubling in risk were very low 
(e.g. 0.004). Instead, the significant results may be specific to this group of cases in the 
UKWCS. Indeed, in a previous UKWCS analysis of pre-menopausal women another 
result was difficult to explain; vegetarians were found to have a significantly higher 
breast cancer risk than low meat consumers.82 Since few studies have examined use 
of supplements containing vitamin C in well-nourished pre-menopausal women more 
research is needed. The two studies which have assessed low level intakes of vitamin 
C from supplements included post-menopausal women only.270 273  
 
Although the UK cohorts were of high quality and large size, the possibility that null 
results have been found when a true association exists should not be ruled out entirely. 
Various reasons for null results have been suggested by Willet, which can be related to 
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the current findings.301 From the life-course perspective, vitamin C intake prior to breast 
tissue differentiation before first pregnancy may have a greater influence on breast 
cancer risk than intake in later life. Nevertheless, it is difficult to argue that midlife is not 
a critical period for susceptibility to the effects of vitamin C intake in relation to cancer 
development; midlife in general being the age when the women in these cohorts 
recorded intake. Considering the antioxidant theory, and given the potential 
accumulation of DNA damage caused by free radicals as we age, midlife appears to be 
a time when the antioxidant effects of vitamin C would be most beneficial in preventing 
cancer initiation. On the other hand, non-invasive cancer cells may be already present 
in many women at midlife, and these may be susceptible to further cancer progression 
by potentially detrimental effects of vitamin C discussed in chapter 2. Since vitamin C 
plays many roles in the body and interacts with other nutrients, any weak to moderate 
positive and negative effects these create in relation to cancer may balance out to 
produce a null effect overall. An additional reason for null results is vitamin C may only 
affect cancer risk in certain types of women and there may have been insufficient 
cases to power some of the sub-analyses undertaken to find statistically significant 
effects. Different mechanisms in the body are likely to dominate in certain sub-groups 
of pre- or post-menopausal women, for instance it is possible that vitamin C may have 
a differential effect with women who are overweight compared to those who are not; 
however this was not analysed in this thesis. Since subgroup analysis can produce 
significant associations by chance, they should be stated a priori or, as mentioned 
above, at least smaller p values should be used for statistical significance levels.  
 
Although there was considerable variation in vitamin C intake across the UKWCS, the 
women were well-nourished, meaning there may have been insufficient women with 
low vitamin C status to reveal a raised risk of breast cancer in such women, if one 
existed. Only 3% of women in the baseline analyses had dietary intakes below the EU 
RDA (60mg/d) and less than 1% had intakes below the UK RNI (40%). Furthermore, 
simple linear dose-response relationships may not have been apparent when 
calculating continuous estimates over a wide intake range, due to the limits of 
absorption, storage, etc of vitamin C at high intake levels. Nevertheless, the restricted 
cubic spline graphs did not show any significant relationships, despite excluding 
outliers that may have undue influence. Another reason for finding a null result is that, 
as discussed in chapters 5 and 10, the FFQ, and 4-d and 7-d diary methods in general 
may be too imprecise to measure vitamin C accurately. Although Bingham et al. (1987) 
suggested that 36 days of weighed food records are required to correctly classify 
vitamin C intake at an individual level,376 this is not practical, and besides participants 
are likely to change their eating habits to reduce the burden of recording. Repeat 
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measures over a period of years are needed to examine the effects of longer term 
intake, or fluctuations in intake. The largest fluctuations in nutrient intakes are likely to 
be due to supplements, but as seen in chapters 3 and 8, little research on this has 
been reported, and further research is needed. Finally, another limitation common to all 
the UKWCS results is that, since the cohort includes a high proportion of vegetarians, 
the results are not generalizable to the UK population, therefore absolute risk rates for 
the UK as a whole could not be calculated from the results. Sensitivity analyses could 
be undertaken to reweight the cohort by the percentage of vegetarians in the general 
population. In the 2004 NDNS survey 7% of women (and about 5% over the age of 35 
years) stated they were vegetarian,24 whereas at baseline in the UKWCS 28% stated 
they were vegetarian. However, a more accurate but pragmatic definition classified 
18% as vegetarian (those who ate meat or fish less than once a week).279 Previous 
analyses of the UKWCS, however, have found no substantial differences before or 
after weighting for vegetarians.  
Although adjustments were made for many confounding factors, one potential limitation 
was that no adjustment could be made for breast screening, since this information had 
not been gathered. Breast screening, which has been provided to over 50 year olds 
since the start of the UKWCS, could have been a confounding factor, particularly in the 
post-menopausal analyses. This was because breast screening was likely to pick up 
cases sooner and because health conscious women were more likely to attend 
screening as well as tending to have a higher vitamin C intake. Additionally, these 
women may have been more likely to have had a family history of breast cancer, and 
potentially had a higher risk of breast cancer themselves. Future analyses of other 
cohorts which have gathered screening information could control for this, though prior 
studies however, have not done so. It is possible that given the long length of follow-up 
of this cohort, and many prior studies, screening may not have detected substantially 
more cases. 
 
11.1 Ideas for future research 
11.1.1 UKWCS 
Further sensitivity analyses of the current data could be undertaken to observe the 
effects of excluding self-reported cancers in the baseline analyses, or the effects of 
excluding women with a family history of cancer, where this has not already been 
done. Additionally, sensitivity analyses could be undertaken to exclude women who 
developed breast cancer within two years, since some of these women may have 
suspected they had cancer and altered their diet before their diagnosis. Furthermore, 
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the interaction, seen in chapter 7, between general supplement use and socio-
economic status in relation to breast cancer could be explored further.  
Since total cancer incidence is available for the UKWCS, associations between this risk 
and vitamin C intake or multivitamin use could be examined. Although, there are too 
few women (861) who had prevalent breast cancer at baseline to examine risk of 
breast cancer reoccurrence, there is scope to examine changes in diet from baseline to 
phase 2 for the ~130 women who developed cancer between these data collections.  
Within phase 2 of the UKWCS there is a range of possibilities for examining risk of 
cancers or other diseases in relation to other supplements, whether this is from 
recordings by diary or questionnaire. Supplement types recorded by questionnaire, 
however, are limited to those displayed in Figure 2 in chapter 2, with fish oil (26.5%), 
evening primrose oil/ starflower oil (18.7%) and calcium (14.2%) being used by a 
relatively high percentage of women. Unfortunately, vitamin D supplement use, which 
has been the focus of more recent attention,377 has not been recorded by questionnaire 
in the UKWCS. Additionally, folic acid supplement use, which as discussed in chapter 8 
has been linked to an increased risk of cancer, was only recorded by 2.2% of women 
on the questionnaire which would result in insufficient cases to power analyses. 
Nevertheless, folic acid is present in many supplements, particularly multivitamins; 
therefore the amount of this or other nutrients such as vitamin D in supplements 
recorded by diary could be determined from the UKWCS participant supplement 
database. Further cleaning of this database would be needed, and ideally, these 
analyses should be delayed to ensure sufficient cancer cases have accumulated to 
power the analyses.  
Furthermore, breast cancer risks for UKWCS women who followed most of the eight 
WCRF cancer prevention guidelines, summarised at the front of the 2007 WCRF 
report,7 could be compared to those who did not. Similar research has been 
undertaken in a US cohort where a score of 0-2 was given for adherence to each of the 
four American Cancer Society prevention guidelines, and subjects with total scores of 
7-8 were compared to those with total scores of 0-2.378  
Although women at phase 2 who were at raised risk or high risk of breast cancer, 
according to the NICE guidelines, were excluded from some of the analyses in this 
thesis, they comprised such a small percentage of UKWCS (2.1% and 0.8% 
respectively) that breast cancer risk analyses for these women were not feasible. Also, 
there are too few of these women to undertake a nested case-control study.  
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11.1.2 Other 
As previously discussed, there is a need for more accurate methods of measuring 
dietary intake in order to examine relationships between diet and cancer risks. There is 
potential for cohort dietary data to be collected using innovative technologies in the 
future; for instance using on-line 24 hour recall questionnaires and FFQs, or using 
handheld devices such as the Smartphone with the ‘My Meal Mate’ application that is 
being trialled at the University of Leeds.379 These have facilities for participants to 
select foods and have the potential for data to be downloaded to an automatic coding 
system, which would reduce data collection and coding time, as well as coding errors. 
Additionally, the portability and convenience of the Smartphone has an added 
advantage that recordings can be done in real-time and not be reliant on memory.379 
Further work, however, may be needed on the application to ensure portion sizes are 
correctly recorded.379 It is expected to be less burdensome than paper diary methods, 
particularly for the younger generation, and therefore participants may be less likely to 
alter their normal intake and may be willing to produce many days of reporting 
necessary to correctly classify their nutrient intake, and to repeat these at future dates. 
In order to minimise costs, the recruitment of sufficient participants with their own 
personal Smartphones for a large cohort appears possible in the future since these 
phones are becoming widely used. Although this device may not be suitable to gather 
follow-up data for the women of the UKWCS, three quarters of whom will now be over 
the age of 60, it may be suitable for collecting data from their offspring, if required.  
Future research on other cohorts needs to take account of supplements, whether this 
is through sub-analysis by supplement users and non-users or, for nutrient analyses, 
by including nutrient intake from supplements. As discussed above more research is 
needed relating to supplement use in pre-menopausal women, and in particular use of 
supplements containing low dose vitamin C such as multivitamins. Vitamin C intake 
sub-analyses by HRT or by BMI should be undertaken in large cohorts to test for 
significant results found in the pooled EPIC study and the RCT previously mentioned.14 
255 Additionally, very few studies have sub-analysed by hormone receptor status of 
breast cancers,270 273 since these data have not been widely available, or there has 
been insufficient cases to power the analyses. In general, the prevalence of oestrogen 
receptor negative breast cancers may be less than 20%, and for triple negative breast 
cancers may be about 15%.380 Many women who develop the latter are carriers of 
BRCA1 gene faults,380 and little research has been done to identify whether lifestyle 
factors including diet could modify risks for these women, or others who are highly 
susceptible to breast cancer. Due to the small percentage of these women, nested 
case-control studies would be needed. A Korean case-control study reported breast 
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cancer risk was higher in women who were carriers of ATM (Ataxia telangiectasia 
mutated cells) and had low intakes of vitamin C or other antioxidants compared to 
those with high intake.272 Since intake in this study was measured after diagnosis of 
cancer, temporal bias cannot be ruled out. 
Genetic susceptibility to having low blood vitamin C levels could be researched with 
respect to breast cancer risk. A genetic variation (at the SLC23A1 gene locus) in 
coding for a sodium-dependent vitamin C active transporter which facilitates ascorbic 
acid transport across intestinal cell membranes has been associated with low plasma 
ascorbic acid levels.381 This genetic variant could be used as an instrumental variable 
within observational studies as a proxy for plasma vitamin C levels to determine the 
causal effect of lifetime variation in vitamin C concentrations on the risk of cancer and 
other chronic diseases.381 This ‘Mendelian Randomisation’ method has the added 
benefit of being free from confounding influences since potential confounders are 
naturally randomised between carriers and non-carriers of the genetic variant.382 
However, this method is limited by the need for very large sample sizes.382 
Nutrigenomics is a relatively new research discipline involving the study of genetic 
variations and their interactions with nutritional factors and subsequent associations 
with disease. Not only can genetic variation affect an individual’s processing of food, 
but constituents of food can also change the expression of genes, i.e. the phenotype, 
which may then impact on the development of disease. It may be some considerable 
time, however, before research evidence from nutrigenomics can be employed at an 
individual and commercial level due to the cost and time involved in the genotype-
phenotype-biomarker testing of individuals that would be necessary in order to provide 
tailored dietary advice. 
More research using larger cohorts, nested case-control studies or RCTs is needed in 
relation to vitamin C intake or supplement use and risk of cancer reoccurrence, 
especially since cancer survivors are more likely to use supplements, as seen in 
chapter 6. There has been controversy surrounding evidence of benefits of high dose 
vitamin C supplementation for prolonged cancer survival,87-89 indeed there is some 
evidence that antioxidants can potentially reduce the effectiveness of anti-cancer 
drugs.77 356 Patients, therefore, should be encouraged to discuss their supplement use 
with their doctors in order to avoid contraindications. More recently clinical trials using 
intravenous vitamin C, with or without chemotherapy have been undertaken (e.g. trial 
reference NCT00441207 and NCT01050621). Phase I results of a recent Canadian 
trial failed to demonstrate an effect on patients with advanced cancer.383  
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11.2 Public health issues 
The potential for antioxidants, contained in fruit and vegetables, to reduce the risk of 
cancers, was one of the original promoted benefits of the 5-A-day fruit and vegetable 
campaign. Despite the evidence in chapter 9 and in the 2007 second WCRF review,7 
that neither the increased intake of fruit and vegetables, nor dietary intake of vitamin C 
appear to reduce the risk of breast cancer, the public health message to consume high 
intakes of fruit and vegetables need not be changed since there is no convincing 
evidence of detrimental effects. Moreover, fruit and vegetable intake should be 
encouraged since there is evidence they reduce the risk of other cancers,7 as well as 
heart disease.384 Whether it is antioxidants and specifically vitamin C, or other bioactive 
chemicals in the fruit and vegetables that are beneficial in these cases is still unclear. 
The current results also suggest, along with some but not all previous studies reported 
in chapter 8, that there are no detrimental effects in relation to breast cancer risk from 
using high dose vitamin C supplements, meaning the current results do not support a 
need to restrict their sale to the general public. Furthermore, after reviewing evidence 
on any aspect of health, both the European Food Safety Authority and the UK Expert 
Group on Vitamins and Minerals currently believe there is insufficient data to set an 
upper limit for vitamin C.22 52 One reason why vitamin C may not have an effect on 
humans is that it is water-soluble and is readily excreted above levels of about 
400mg/d.65 Being water-soluble, though, does not preclude micronutrients from being 
toxic as there have been recommendations that other soluble micronutrients, such as 
folic acid, should be re-categorised as over-the-counter medicine because of concerns 
over toxicity.385 Vitamins are currently sold as dietary supplements where the onus in 
the US has been on the food authorities to prove supplements are unsafe, rather than 
manufacturers needing to provide evidence of their benefits and needing to obtain 
licences to sell them like drugs.385 In addition however, in Europe the EFSA has 
recently implemented regulations for approving or rejecting general health claims made 
on foods and supplements based on whether these claims are independently verified 
by research studies.21  
Indeed, as seen in chapters 8 and 10, no protective effects of taking high dose vitamin 
C, or any dose of vitamin C, were found in terms of breast cancer risk, which in general 
supports previous research from cohort studies discussed in chapter 8. Results, 
therefore, do not support the use of vitamin C supplements for reducing breast cancer 
risk. As reported in chapter 2 and chapter 6, as many as a third of UKWCS women 
used supplements containing vitamin C, and about 10% of women frequently took high 
dose vitamin C. Furthermore, chapter 6 reported that women with a family history of 
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breast cancer or personal history of breast cancer in the UK were more likely to 
frequently take high doses of 1000mg/d or above.1 Although the reasons these women 
took high dose supplements is unknown, it is possible they hoped they may reduce 
breast cancer risk. It appears, therefore, some women may be spending money and 
consuming supplements unnecessarily. Indeed, antioxidant supplements are sold in a 
multimillion pound worldwide industry. Although there are regulations to prevent 
specific health claims being stated explicitly, antioxidants are sold on the basis they 
reduce free radicals, which is widely believed, by the general public, to play a role in 
preventing chronic diseases including cancer. However, some researchers doubt 
antioxidants can provide this role and believe claims relating to them may be 
overstated.386 Indeed, the EFSA has recently reported that no evidence has been 
provided to them to establish that having antioxidant activity/content and/or antioxidant 
properties exerts beneficial physiological effects on humans.46 Any future restrictions 
on EU selling, however, would not prevent supplements being purchased outside the 
EU by UK residents via mail order. 
The 2007 WCRF report, nevertheless, judged there was convincing or probable 
evidence from prospective studies that some antioxidants are associated with some 
cancers (Appendix B).7 For instance, the antioxidant selenium was associated with a 
reduced risk of lung, stomach and prostate cancer,7 although more recent analyses 
from the SELECT trial do not support the latter.237 387 Furthermore, supplementing with 
low doses of antioxidants appears to reduce cancer risk or cancer mortality in people 
who may have low antioxidant status,17 for instance men,256 and people researched in 
remote parts of China who may consume insufficient nutrients via their diet.388 
Importantly, however, there has been convincing evidence that supplementation with 
the antioxidant β-carotene increases the risk of lung cancer in smokers.238  
As Bjekelakovic has pointed out, dietary supplementation has moved from preventing 
deficiencies to being used in attempts to promote wellness and prevent disease. He 
maintains consumers are being taking advantage of and are not getting value for 
money since supplementation cannot be recommended for preventative measures in 
well-nourished populations.389 Using a peer-reviewed Cochrane protocol, a systematic 
review and meta-analysis by Bjelakovic et al. (2007) of low-bias, primary and 
secondary prevention randomised trials of antioxidant supplements (published to 
October 2005) concluded that antioxidant supplements carotene and vitamin E, and 
also vitamin A may increase all-cause mortality.351 Vitamin C and selenium were found 
to have no effect on mortality. Several researchers, nevertheless, have questioned the 
Bjelakovic et al. (2007) results, for instance, because 405 out of 815 trials reviewed 
were excluded since no deaths occurred.390  
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The question remains: Should vitamins be considered as drugs?385 The evidence from 
this thesis for vitamin C does not support this consideration; however, the results 
indicate that more research evidence is needed on pre-menopausal supplement users 
to help answer this question. The current evidence, nevertheless, does not justify the 
widespread use of vitamin C supplements to reduce breast cancer risk. Indeed, the 
WCRF does not recommend supplements to prevent cancer and in 2009 issued a 
press release warning on high strength supplements in general.362 Whether the advice 
has been heard and acted upon is, as yet, unknown. 
The WCRF reported that a 2009 YouGov survey found media reporting of conflicting 
studies appears to have caused many people to ignore dietary advice relating to 
cancer risks, with 60% of people over the age of 55 years being cynical about dietary 
advice.15 Consequently, media reporting of more important results from reviews, meta-
analysis and large pooling studies are likely to be overlooked by the general public, in 
the midst of reports of many smaller less important results. Therefore, there may be a 
need for greater control over the types and amount of reporting by journalists, who may 
need some education in epidemiology. Additionally, academics should be encouraged 
to disseminate important work in popular press. Given the often inappropriate affect of 
the media, more government controls may be needed relating to the pricing, availability 
and production of food and supplements, in order to reduce the risk of cancer in 
general. Policy recommendations such as these have been detailed by the WCRF in 
their policy report.391 
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Appendix C.  
Search strategy for vitamin C and breast cancer 
OVID MEDLINE (Jan 2006 -June 2011) 
1. (vitamin$ adj5 c).ti,ab,sh. 
2. Ascorbate.ti,ab,sh. 
3. ascorbic acid.ti,ab,sh. 
4. exp Ascorbic acid/ 
5. or/1-4 
6. antioxidant*.ti,ab,sh. 
7. anti-oxidant*.ti,ab,sh. 
8. antioxidants/ 
9. or/6-8 
10. vitamin*.ti,ab. 
11. vitamins/ 
12. 10 or 11 
13. 9 and 12 
14. (micronutrient$ or nutrient$).ti,ab,sh. 
15. fruit$.ti,ab,sh. 
16. vegetable$.ti,ab,sh. 
17. 14 and 15 and 16 
18. 5 or 13 or 17 
19. exp breast neoplasms/ 
20. exp neoplasms, hormone-dependent/ 
21. (breast adj25 neoplasm$).ti,ab. 
22. (breast adj25 cancer$).ti,ab. 
23. (breast adj25 tumo$).ti,ab. 
24. (breast adj25 malign$).ti,ab. 
25. (breast adj25 carcinoma$).ti,ab. 
26. (breast adj25 adenocarcinoma$).ti,ab. 
27. or/19-26 
28. 18 and 27 
29. Food/ 
30. Diet/ 
31. Nutrition Surveys/ 
32. Dietary Supplements/ 
33. diet records/ 
34. (diet$ or intake$ or nutri$ or food$ or supplement$).ti,ab,sh. 
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35. or/29-34 
36. exp cohort studies/ 
37. exp prospective studies/ 
38. exp follow-up studies/ 
39. exp longitudinal studies/ 
40. exp diet surveys/ 
41. cohort$.ti,ab,sh. 
42. longitudinal$.ti,ab,sh. 
43. prospective$.ti,ab,sh. 
44. controlled clinical trial.pt. 
45. epidemiologic methods/ 
46. limit 45 to yr=1966-1989 
47. exp case-control studies/ 
48. (case$ and control$).tw. 
49. or/36-44,46-48 
50. "randomized controlled trial".pt. 
51. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab. 
52. (retraction of publication or retracted publication).pt. 
53. or/50-52 
54. (animals not humans).sh. 
55. ((comment or editorial or meta-analysis or practice-guideline or review or letter or 
journal correspondence) not "randomized controlled trial").pt. 
56. (random sampl$ or random digit$ or random effect$ or random survey or random 
regression).ti,ab. not "randomized controlled trial".pt. 
57. 53 not (54 or 55 or 56) 
58. (review or review,tutorial or review, academic).pt. 
59. (pooling or pooled or mantel haenszel).tw,sh. 
60. meta-analysis.pt. 
61. meta-analysis.sh. 
62. (meta-analys$ or meta analys$ or metaanalys$).tw,sh. 
63. (systematic$ adj5 review$).tw,sh. 
64. (systematic$ adj5 overview$).tw,sh. 
65. (quantitativ$ adj5 review$).tw,sh. 
66. (quantitativ$ adj5 overview$).tw,sh. 
67. (quantitativ$ adj5 synthesis$).tw,sh. 
68. (methodologic$ adj5 review$).tw,sh. 
69. (methodologic$ adj5 overview$).tw,sh. 
70. (integrative research review$ or research integration).tw. 
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71. or/58-70 
72. 49 or 57 or 71 
73. 28 and 35 and 72 
 
Note relating to search: it was possible that articles may have been missed which 
reported the analysis of vitamin C and breast cancer risk within the main body of the 
article but did not include the key search terms in the title, subject heading and 
abstract. To check this, a search was undertaken restricting key words to those 
indicating only cohorts (i.e. cohort, prospective, follow-up, longitudinal), dietary studies 
and breast cancer. Titles and abstracts for 303 articles were found and examined. Only 
four of these, over and above those found in the initial search appear to be potentially 
relevant; the full articles were retrieved but these did not meet the full inclusion criteria.   
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Appendix D.  
NICE guidelines used to identify women in the UKWCS who may be 
at raised risk or high risk of developing breast cancer 
The following NICE guidelines 319 were used to identify women in the UKWCS who may 
be at raised risk as those who met any of the following criteria: 
 One 1st degree relative and one 2nd degree relative diagnosed with breast 
cancer before average age 50 
 Two 1st degree relatives diagnosed with breast cancer before average age 50 
 Three or more 1st or 2nd degree relatives diagnosed with breast cancer at any 
age 
 One 1st degree male relative diagnosed with breast cancer at any age 
 One 1st or 2nd degree relative with ovarian cancer at any age and one 1st or 
2nd degree relative with breast cancer at any age (one should be a 1st degree 
relative) 
Note: First-degree relatives: mother; father; daughter; son; sister; brother. Second-
degree relatives: grandparent; grandchild; aunt; uncle; niece and nephew; half sister 
and half brother. 
 
The following NICE guidelines319 were used to identify women in the UKWCS who may 
be at high risk as those who met any of the following criteria: 
 Two 1st or 2nd degree relatives diagnosed with breast cancer before average 
age 50 
 Three 1st or 2nd degree relatives diagnosed before average age 60 
 Four relatives including one 1st degree relative diagnosed at any age 
Or one relative diagnosed with ovarian cancer at any age and on the same side of the 
family there is 
 One 1st (including relative with ovarian cancer) or one 2nd degree relative 
diagnosed with breast cancer before age 50 
 One additional relative diagnosed with ovarian cancer at any age 
 Two 1st or 2nd degree relatives diagnosed with breast cancer before average 
age 60 
Or a relative with bilateral breast cancer as follows 
 One 1st degree relative with cancer diagnosed in both breasts before average 
age 50 
 One 1st or 2nd degree relative diagnosed with bilateral breast cancer and one 
1st or 2nd degree relative diagnosed with breast cancer before average age 60 
Or one male breast cancer at any age and on the same side of the family there is 
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 One 1st or 2nd degree relative diagnosed with breast cancer before age 50 
 Two 1st or 2nd degree relatives diagnosed with breast cancer before average 
age 60 
 
Unfortunately the NICE guidelines could not be followed in some areas; therefore the 
categories are only estimates. From the UKWCS data it was impossible to determine 
whether aunts were from the mothers’ or the fathers’ side of the family. Additionally, 
there was no information on daughters or sons with breast cancer or any relatives with 
bilateral breast cancer in the UKWCS.  
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Appendix E.  
Poster and oral conference presentations by Jayne Hutchinson 
 
Symposium: University of Leeds LIGHT’s Postgraduate Symposium. 24 January 
2012 
Oral presentation: Vitamin C intake from diary recordings and risk of breast cancer in 
the UK Dietary Cohort Consortium 
(based on results from chapter 10) 
 
Conference: IEA World Conference of Epidemiology. Edinburgh, 7-10 August 
2011 
Poster: Use of Supplements containing vitamin C and breast cancer risk in the UK 
Women’s Cohort Study 
(based on results from chapter 8)  
Poster: Vitamin C intake from diary recordings and risk of breast cancer in the UK 
Dietary Cohort Consortium 
(based on results from chapter 10) 
Abstracts published in the Journal of Epidemiology and Community Health, August 
2011, Vol 65, supplement 1  
Conference: World Cancer Research Fund: Nutrition, Physical Activity and 
Cancer Prevention: Current Challenges, New Horizons.  London 12-13 September 
2010 
Poster: High dose vitamin C supplement use is associated with a personal and family 
history of cancer 
(based on chapter 6) 
 
Conference: University of Leeds Faculty of Medicine and Health Conference Day 
2009: Identifying the Importance and Impact of Your Research. Weetwood Hall, 
Leeds 4 November 2009 
Poster: Do women who take supplements have a greater risk of cancer? 
(awarded poster prize) 
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